{"523f21228dcf76a16291e8eeed0c2eb757723a2c": [["Influenza A (H1N1): outbreak management in a dialysis unit and clinical outcomes of infection in chronic hemodialysis patientsInfluenza A (H1N1): controle de surto em unidade de di\u00e1lise e desfechos cl\u00ednicos da infec\u00e7\u00e3o em pacientes em hemodi\u00e1lise cr\u00f4nica Introdu\u00e7\u00e3o: Pacientes em hemodi\u00e1lise (HD) cr\u00f4nica apresentam risco elevado para infec\u00e7\u00f5es.", [["Influenza A", "DISEASE", 0, 11], ["infection", "DISEASE", 84, 93], ["Influenza A", "DISEASE", 126, 137], ["Influenza A", "ORGANISM", 0, 11], ["patients", "ORGANISM", 118, 126], ["Influenza A", "ORGANISM", 126, 137], ["Influenza A (H1N1", "SPECIES", 0, 17], ["patients", "SPECIES", 118, 126], ["Influenza", "SPECIES", 126, 135], ["Influenza", "PROBLEM", 0, 9], ["outbreak management", "TREATMENT", 20, 39], ["a dialysis unit", "TREATMENT", 43, 58], ["infection", "PROBLEM", 84, 93], ["chronic hemodialysis patients", "TREATMENT", 97, 126], ["Influenza", "PROBLEM", 126, 135], ["infection", "OBSERVATION", 84, 93], ["chronic", "OBSERVATION_MODIFIER", 97, 104], ["hemodialysis", "OBSERVATION", 105, 117]]], ["O presente estudo descreve os desfechos cl\u00ednicos de pacientes em HD cr\u00f4nica com infec\u00e7\u00e3o pelo v\u00edrus influenza A (H1N1) e as estrat\u00e9gias adotadas para controlar um surto de influenza A numa unidade de di\u00e1lise.", [["influenza", "PROBLEM", 100, 109]]], ["M\u00e9todos: Doze (19,4%) de 62 pacientes em HD cr\u00f4nica e quatro (12,5%) de 32 funcion\u00e1rios desta unidade de di\u00e1lise apresentaram infec\u00e7\u00e3o pelo v\u00edrus H1N1.", [["pelo v\u00edrus H1N1", "ORGANISM", 135, 150], ["HD cr\u00f4nica e quatro", "TREATMENT", 41, 60], ["H1N1", "PROBLEM", 146, 150]]], ["A presen\u00e7a de infec\u00e7\u00e3o foi confirmada por rea\u00e7\u00e3o em cadeia da polimerase via transcriptase reversa (RT-PCR) em tempo real.", [["transcriptase reversa", "TEST", 77, 98]]], ["O percentual de obesidade foi mais elevado no grupo com infec\u00e7\u00e3o por H1N1 (41,5% vs. 4%, p<0,002).", [["H1N1", "PROBLEM", 69, 73]]], ["Os sintomas mais comuns foram febre (92%), tosse (92%) e rinorreia (83%).", [["Os sintomas", "TEST", 0, 11], ["tosse", "TEST", 43, 48]]], ["Os pacientes foram submetidos a tratamento antiviral com oseltamivir e medidas de controle (intensifica\u00e7\u00e3o das medidas de redu\u00e7\u00e3o de contato pelos funcion\u00e1rios da cl\u00ednica, quimioprofilaxia com antiviral para pacientes assintom\u00e1ticos em HD na mesma sala dos pacientes com infec\u00e7\u00e3o e afastamento de funcion\u00e1rios da cl\u00ednica com suspeita de infec\u00e7\u00e3o) para controlar a dissemina\u00e7\u00e3o da infec\u00e7\u00e3o pela unidade de di\u00e1lise.", [["na", "CHEMICAL", 239, 241], ["a tratamento antiviral com oseltamivir e medidas", "TREATMENT", 30, 78], ["quimioprofilaxia com antiviral para pacientes", "TREATMENT", 172, 217], ["HD na mesma sala dos pacientes com infec\u00e7\u00e3o e afastamento", "TREATMENT", 236, 293]]], ["Nenhum evoluiu para doen\u00e7a grave e as estrat\u00e9gias adotadas foram efetivas no controle do surto.ResumoPalavras-chave: Di\u00e1lise Renal; V\u00edrus da Influenza A; Surtos de Doen\u00e7as; Unidades Hospitalares de Hemodi\u00e1lise.ResumoIntroduction: Chronic hemodialysis (HD) patients are considered to be at high risk for infection.", [["infection", "DISEASE", 303, 312], ["patients", "ORGANISM", 256, 264], ["patients", "SPECIES", 256, 264], ["ResumoPalavras", "TEST", 95, 109], ["Chronic hemodialysis (HD)", "TREATMENT", 230, 255], ["infection", "PROBLEM", 303, 312], ["Renal", "ANATOMY", 125, 130], ["Chronic", "OBSERVATION_MODIFIER", 230, 237], ["hemodialysis", "OBSERVATION", 238, 250], ["infection", "OBSERVATION", 303, 312]]], ["Here, we describe the clinical outcomes of chronic HD patients with influenza A (H1N1) infection and the strategies adopted to control an outbreak of influenza A in a dialysis unit.", [["HD", "DISEASE", 51, 53], ["influenza A (H1N1) infection", "DISEASE", 68, 96], ["influenza A", "DISEASE", 150, 161], ["patients", "ORGANISM", 54, 62], ["influenza A (H1N1)", "ORGANISM", 68, 86], ["patients", "SPECIES", 54, 62], ["influenza A (H1N1", "SPECIES", 68, 85], ["chronic HD patients", "TREATMENT", 43, 62], ["influenza A (H1N1) infection", "PROBLEM", 68, 96], ["the strategies", "TREATMENT", 101, 115], ["influenza", "PROBLEM", 150, 159], ["a dialysis unit", "TREATMENT", 165, 180], ["chronic", "OBSERVATION_MODIFIER", 43, 50], ["influenza", "OBSERVATION", 150, 159]]], ["Methods: Among a total of 62 chronic HD patients, H1N1 infection was identified in 12 (19.4%) .", [["HD", "DISEASE", 37, 39], ["H1N1 infection", "DISEASE", 50, 64], ["patients", "ORGANISM", 40, 48], ["H1N1", "ORGANISM", 50, 54], ["patients", "SPECIES", 40, 48], ["chronic HD patients", "TREATMENT", 29, 48], ["H1N1 infection", "PROBLEM", 50, 64], ["infection", "OBSERVATION", 55, 64]]], ["Of the 32 staff members, four (12.5%) were found to be infected with the H1N1 virus.", [["H1N1 virus", "ORGANISM", 73, 83], ["H1N1 virus", "SPECIES", 73, 83], ["the H1N1 virus", "PROBLEM", 69, 83], ["infected", "OBSERVATION", 55, 63], ["H1N1", "OBSERVATION", 73, 77]]], ["Outcomes included symptoms at presentation, comorbidities, occurrence of hypoxemia, hospital admission, and clinical evaluation.", [["hypoxemia", "DISEASE", 73, 82], ["symptoms", "PROBLEM", 18, 26], ["comorbidities", "PROBLEM", 44, 57], ["hypoxemia", "PROBLEM", 73, 82], ["clinical evaluation", "TEST", 108, 127], ["hypoxemia", "OBSERVATION", 73, 82]]], ["Infection was confirmed by real-time reverse transcriptase polymerase chain reaction.", [["reverse transcriptase", "PROTEIN", 37, 58], ["Infection", "PROBLEM", 0, 9], ["reverse transcriptase polymerase chain reaction", "PROBLEM", 37, 84]]], ["Results: The 12 patients who had H1N1 infection did not differ significantly from the other 50 non-infected patients with respect to age, sex, dialysis vintage, dialysis modality, or proportion of comorbidities.", [["H1N1 infection", "DISEASE", 33, 47], ["non-infected", "DISEASE", 95, 107], ["patients", "ORGANISM", 16, 24], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 16, 24], ["patients", "SPECIES", 108, 116], ["H1N1 infection", "PROBLEM", 33, 47], ["dialysis vintage", "TREATMENT", 143, 159], ["dialysis modality", "TREATMENT", 161, 178], ["comorbidities", "PROBLEM", 197, 210], ["infection", "OBSERVATION", 38, 47]]], ["Obesity was higher in the H1N1-infected group (41.5 vs. 4%, p<0.002).", [["Obesity", "DISEASE", 0, 7], ["H1N1-infected", "DISEASE", 26, 39], ["Obesity", "PROBLEM", 0, 7], ["the H1N1", "PROBLEM", 22, 30], ["higher", "OBSERVATION_MODIFIER", 12, 18], ["H1N1", "OBSERVATION", 26, 30], ["infected", "OBSERVATION_MODIFIER", 31, 39]]], ["The most common symptoms were fever (92%), cough (92%), and rhinorrhea (83%).", [["fever", "DISEASE", 30, 35], ["cough", "DISEASE", 43, 48], ["rhinorrhea", "DISEASE", 60, 70], ["The most common symptoms", "PROBLEM", 0, 24], ["fever", "PROBLEM", 30, 35], ["cough", "PROBLEM", 43, 48], ["rhinorrhea", "PROBLEM", 60, 70], ["rhinorrhea", "OBSERVATION", 60, 70]]], ["Early empirical antiviral treatment with oseltamivir was started in symptomatic patients and infection control measures, including the intensification of contact-reduction measures by the staff members, antiviral chemoprophylaxis to asymptomatic patients undergoing HD in the same shift of infected patients, and dismiss of staff members suspected of being infected, were implemented to control the spread of infection in the dialysis unit.", [["oseltamivir", "CHEMICAL", 41, 52], ["infection", "DISEASE", 93, 102], ["infection", "DISEASE", 409, 418], ["oseltamivir", "CHEMICAL", 41, 52], ["oseltamivir", "SIMPLE_CHEMICAL", 41, 52], ["patients", "ORGANISM", 80, 88], ["patients", "ORGANISM", 246, 254], ["patients", "ORGANISM", 299, 307], ["patients", "SPECIES", 80, 88], ["patients", "SPECIES", 246, 254], ["patients", "SPECIES", 299, 307], ["Early empirical antiviral treatment", "TREATMENT", 0, 35], ["oseltamivir", "TREATMENT", 41, 52], ["infection control measures", "TREATMENT", 93, 119], ["contact-reduction measures", "TREATMENT", 154, 180], ["antiviral chemoprophylaxis", "TREATMENT", 203, 229], ["HD", "TREATMENT", 266, 268], ["infection", "PROBLEM", 409, 418], ["the dialysis unit", "TREATMENT", 422, 439], ["infection", "OBSERVATION", 93, 102], ["infected", "OBSERVATION", 290, 298], ["infected", "OBSERVATION", 357, 365], ["infection", "OBSERVATION", 409, 418]]], ["Conclusion:ResumoThe clinical course of infection with H1N1 in our patients was favorable.", [["infection", "DISEASE", 40, 49], ["H1N1", "DISEASE", 55, 59], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["infection", "PROBLEM", 40, 49], ["H1N1", "PROBLEM", 55, 59], ["infection", "OBSERVATION", 40, 49]]], ["None of the patients developed severe disease and the strategies adopted to control the outbreak were successful.IntRoductIonInfluenza A (H1N1) is associated high morbidity and mortality, particularly among elderly people, pregnant women, and patients with chronic diseases 1 .", [["chronic diseases", "DISEASE", 257, 273], ["patients", "ORGANISM", 12, 20], ["IntRoductIonInfluenza A (H1N1)", "ORGANISM", 113, 143], ["people", "ORGANISM", 215, 221], ["women", "ORGANISM", 232, 237], ["patients", "ORGANISM", 243, 251], ["patients", "SPECIES", 12, 20], ["people", "SPECIES", 215, 221], ["women", "SPECIES", 232, 237], ["patients", "SPECIES", 243, 251], ["IntRoductIonInfluenza A (H1N1)", "SPECIES", 113, 143], ["severe disease", "PROBLEM", 31, 45], ["the strategies", "TREATMENT", 50, 64], ["high morbidity", "PROBLEM", 158, 172], ["chronic diseases 1", "PROBLEM", 257, 275], ["severe", "OBSERVATION_MODIFIER", 31, 37], ["disease", "OBSERVATION", 38, 45], ["high", "OBSERVATION_MODIFIER", 158, 162], ["morbidity", "OBSERVATION", 163, 172], ["chronic", "OBSERVATION_MODIFIER", 257, 264], ["diseases", "OBSERVATION", 265, 273]]], ["Patients with end-stage renal disease (ESRD) are considered to be at high risk for H1N1 infection because of their altered immune status.", [["renal", "ANATOMY", 24, 29], ["end-stage renal disease", "DISEASE", 14, 37], ["ESRD", "DISEASE", 39, 43], ["infection", "DISEASE", 88, 97], ["Patients", "ORGANISM", 0, 8], ["renal", "ORGAN", 24, 29], ["Patients", "SPECIES", 0, 8], ["H1N1", "SPECIES", 83, 87], ["end-stage renal disease", "PROBLEM", 14, 37], ["ESRD", "PROBLEM", 39, 43], ["H1N1 infection", "PROBLEM", 83, 97], ["their altered immune status", "PROBLEM", 109, 136], ["-stage", "OBSERVATION_MODIFIER", 17, 23], ["renal", "ANATOMY", 24, 29], ["disease", "OBSERVATION", 30, 37], ["H1N1", "OBSERVATION", 83, 87]]], ["Immune dysfunction has complex and multifactorial causes including defects in complement activation, neutrophil function, B-cell and T-cell function 2,3 .", [["neutrophil", "ANATOMY", 101, 111], ["B-cell", "ANATOMY", 122, 128], ["T-cell", "ANATOMY", 133, 139], ["Immune dysfunction", "DISEASE", 0, 18], ["neutrophil", "CELL", 101, 111], ["B-cell", "CELL", 122, 128], ["T-cell", "CELL", 133, 139], ["Immune dysfunction", "PROBLEM", 0, 18], ["defects in complement activation", "PROBLEM", 67, 99], ["neutrophil function", "TEST", 101, 120], ["B-cell", "TEST", 122, 128], ["defects", "OBSERVATION", 67, 74], ["neutrophil function", "OBSERVATION", 101, 120]]], ["An additional risk factor is undergoing hemodialysis (HD) in concurrent sessions, which implies exposure to other patients and health care personnel, thus facilitating cross-contamination within the dialysis unit.", [["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["hemodialysis", "TREATMENT", 40, 52], ["HD", "TREATMENT", 54, 56], ["the dialysis unit", "TREATMENT", 195, 212]]], ["In addition, prolonged viral shedding in immunosuppressed individuals can increase the risk of viral transmission.", [["prolonged viral shedding in immunosuppressed individuals", "PROBLEM", 13, 69], ["viral transmission", "PROBLEM", 95, 113], ["prolonged", "OBSERVATION_MODIFIER", 13, 22], ["viral", "OBSERVATION_MODIFIER", 23, 28], ["viral transmission", "OBSERVATION", 95, 113]]], ["One study demonstrated that the rates of H1N1 influenza were significantly higher among patients on HD than among those on peritoneal dialysis 4 .", [["peritoneal", "ANATOMY", 123, 133], ["influenza", "DISEASE", 46, 55], ["H1N1 influenza", "ORGANISM", 41, 55], ["patients", "ORGANISM", 88, 96], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 123, 133], ["patients", "SPECIES", 88, 96], ["One study", "TEST", 0, 9], ["H1N1 influenza", "PROBLEM", 41, 55], ["HD", "TREATMENT", 100, 102], ["peritoneal dialysis", "TREATMENT", 123, 142], ["peritoneal", "ANATOMY", 123, 133], ["dialysis", "OBSERVATION", 134, 142]]], ["Moreover, the treatment of patients with influenza has a significant impact on outpatient services 5 .IntRoductIonThe clinical presentation of H1N1 infection can range from mild respiratory symptoms to acute respiratory insufficiency, and HD patients tend to present a greater number of clinical complications and to develop severe or life-threatening disease.", [["respiratory", "ANATOMY", 178, 189], ["respiratory", "ANATOMY", 208, 219], ["influenza", "DISEASE", 41, 50], ["H1N1 infection", "DISEASE", 143, 157], ["respiratory symptoms", "DISEASE", 178, 198], ["acute respiratory insufficiency", "DISEASE", 202, 233], ["patients", "ORGANISM", 27, 35], ["H1N1", "ORGANISM", 143, 147], ["patients", "ORGANISM", 242, 250], ["patients", "SPECIES", 27, 35], ["patients", "SPECIES", 242, 250], ["influenza", "PROBLEM", 41, 50], ["H1N1 infection", "PROBLEM", 143, 157], ["mild respiratory symptoms", "PROBLEM", 173, 198], ["acute respiratory insufficiency", "PROBLEM", 202, 233], ["HD", "TREATMENT", 239, 241], ["clinical complications", "PROBLEM", 287, 309], ["severe or life-threatening disease", "PROBLEM", 325, 359], ["mild", "OBSERVATION_MODIFIER", 173, 177], ["respiratory", "ANATOMY", 178, 189], ["acute", "OBSERVATION_MODIFIER", 202, 207], ["respiratory insufficiency", "OBSERVATION", 208, 233], ["severe", "OBSERVATION_MODIFIER", 325, 331], ["threatening disease", "OBSERVATION", 340, 359]]], ["Underlying chronic medical conditions such as diabetes mellitus, heart disease, and lung disease contribute to the high risk of influenza complications among HD patients 6 .IntRoductIonInfluenza outbreaks are usually seasonal, peaking during the winter in the southern hemisphere.", [["heart", "ANATOMY", 65, 70], ["lung", "ANATOMY", 84, 88], ["diabetes mellitus", "DISEASE", 46, 63], ["heart disease", "DISEASE", 65, 78], ["lung disease", "DISEASE", 84, 96], ["influenza complications", "DISEASE", 128, 151], ["heart", "ORGAN", 65, 70], ["lung", "ORGAN", 84, 88], ["patients", "ORGANISM", 161, 169], ["patients", "SPECIES", 161, 169], ["Underlying chronic medical conditions", "PROBLEM", 0, 37], ["diabetes mellitus", "PROBLEM", 46, 63], ["heart disease", "PROBLEM", 65, 78], ["lung disease", "PROBLEM", 84, 96], ["influenza complications", "PROBLEM", 128, 151], ["HD patients", "TREATMENT", 158, 169], ["IntRoductIonInfluenza outbreaks", "PROBLEM", 173, 204], ["chronic", "OBSERVATION_MODIFIER", 11, 18], ["heart", "ANATOMY", 65, 70], ["disease", "OBSERVATION", 71, 78], ["lung", "ANATOMY", 84, 88], ["disease", "OBSERVATION", 89, 96], ["influenza", "OBSERVATION", 128, 137], ["southern hemisphere", "ANATOMY", 260, 279]]], ["Although most of Brazil's territory lies in the tropics, more than 60% of the population, including from S\u00e3o Paulo state, lives in the subtropical area with mild to cold winters.", [["population", "OBSERVATION", 78, 88], ["subtropical", "ANATOMY_MODIFIER", 135, 146], ["area", "ANATOMY", 147, 151], ["mild", "OBSERVATION_MODIFIER", 157, 161]]], ["The cases of infection by H1N1 have been reported with an increasing frequency between the months of June and September.", [["infection", "DISEASE", 13, 22], ["H1N1", "DISEASE", 26, 30], ["H1N1", "ORGANISM", 26, 30], ["infection", "PROBLEM", 13, 22], ["H1N1", "PROBLEM", 26, 30], ["infection", "OBSERVATION", 13, 22], ["increasing", "OBSERVATION_MODIFIER", 58, 68]]], ["Influenza vaccination campaigns have been conducted annually, between the end of April and May.", [["Influenza", "DISEASE", 0, 9], ["Influenza vaccination campaigns", "TREATMENT", 0, 31]]], ["Compared to previous years, seasonal influenza activity commenced early in S\u00e3o Paulo during the 2016 year, before the vaccination campaign period.", [["influenza", "DISEASE", 37, 46], ["seasonal influenza activity", "PROBLEM", 28, 55], ["influenza activity", "OBSERVATION", 37, 55]]], ["In March 2016, a high number of cases of acute respiratory infection caused by H1N1 virus were reported in the city of S\u00e3o Paulo.", [["respiratory", "ANATOMY", 47, 58], ["respiratory infection", "DISEASE", 47, 68], ["H1N1 virus", "ORGANISM", 79, 89], ["H1N1 virus", "SPECIES", 79, 89], ["H1N1 virus", "SPECIES", 79, 89], ["acute respiratory infection", "PROBLEM", 41, 68], ["H1N1 virus", "PROBLEM", 79, 89], ["acute", "OBSERVATION_MODIFIER", 41, 46], ["respiratory", "ANATOMY", 47, 58], ["infection", "OBSERVATION", 59, 68], ["H1N1 virus", "OBSERVATION", 79, 89]]], ["At that time, we also witnessed an outbreak of H1N1 in our dialysis unit (outpatient setting).IntRoductIonThis study describes the clinical evolution of individuals infected with the H1N1 virus and discuss the management strategies that should be adopted to control an influenza outbreak in a dialysis unit.mAteRIAl And methodsBetween March and April 2016, we evaluated 16 individuals infected with the H1N1 virus -12 adult patients with ESRD receiving regular HD therapy and four staff members-during a H1N1 outbreak at the dialysis unit of S\u00edrio-Liban\u00eas Hospital, a private hospital in the city of S\u00e3o Paulo.", [["H1N1", "DISEASE", 47, 51], ["influenza", "DISEASE", 269, 278], ["unit.mAteRIAl", "CHEMICAL", 302, 315], ["ESRD", "DISEASE", 438, 442], ["H1N1", "DISEASE", 504, 508], ["individuals", "ORGANISM", 153, 164], ["individuals", "ORGANISM", 373, 384], ["H1N1 virus", "ORGANISM", 403, 413], ["patients", "ORGANISM", 424, 432], ["H1N1 virus", "SPECIES", 183, 193], ["H1N1 virus", "SPECIES", 403, 413], ["patients", "SPECIES", 424, 432], ["H1N1 virus", "SPECIES", 183, 193], ["H1N1 virus", "SPECIES", 403, 413], ["H1N1", "PROBLEM", 47, 51], ["IntRoductIonThis study", "TEST", 94, 116], ["individuals infected", "PROBLEM", 153, 173], ["the H1N1 virus", "PROBLEM", 179, 193], ["the management strategies", "TREATMENT", 206, 231], ["an influenza outbreak", "PROBLEM", 266, 287], ["a dialysis unit.mAteRIAl", "TREATMENT", 291, 315], ["the H1N1 virus", "TREATMENT", 399, 413], ["ESRD", "PROBLEM", 438, 442], ["regular HD therapy", "TREATMENT", 453, 471]]], ["At that time, the unit had 15 dialysis stations and served a total of 62 patients.", [["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["15 dialysis stations", "TREATMENT", 27, 47]]], ["Patients were on conventional HD (3 to 4 hours per session, three times a week) or intensified HD (nocturnal HD: 8 hours per session, three times a week or daily HD: 2-2.5 hours per session, five to six times a week).", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["conventional HD", "TREATMENT", 17, 32], ["intensified HD (nocturnal HD", "TREATMENT", 83, 111]]], ["Our dialysis unit did not have patients on peritoneal dialysis.mAteRIAl And methodsPatients and staff who had one or more symptoms resembling those of seasonal influenza, including fever (>37.4\u00b0C), cough, rhinorrhea or nasal congestion, body aches, sore throat, and headache were investigated for influenza.mAteRIAl And methodsThe diagnosis of H1N1 infection was confirmed by real-time RT-PCR (rRT-PCR) test using nasopharyngeal swab specimens, in accordance with guidelines from the Centers for Disease Control and Prevention 7 .", [["peritoneal", "ANATOMY", 43, 53], ["nasal", "ANATOMY", 219, 224], ["body", "ANATOMY", 237, 241], ["nasopharyngeal swab specimens", "ANATOMY", 414, 443], ["influenza", "DISEASE", 160, 169], ["fever", "DISEASE", 181, 186], ["cough", "DISEASE", 198, 203], ["rhinorrhea", "DISEASE", 205, 215], ["nasal congestion", "DISEASE", 219, 235], ["body aches", "DISEASE", 237, 247], ["sore throat", "DISEASE", 249, 260], ["headache", "DISEASE", 266, 274], ["influenza.mAteRIAl", "CHEMICAL", 297, 315], ["H1N1 infection", "DISEASE", 344, 358], ["patients", "ORGANISM", 31, 39], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 43, 53], ["Patients", "ORGANISM", 83, 91], ["nasal", "ORGANISM_SUBDIVISION", 219, 224], ["body", "ORGANISM_SUBDIVISION", 237, 241], ["aches", "ORGANISM_SUBDIVISION", 242, 247], ["H1N1", "ORGANISM", 344, 348], ["patients", "SPECIES", 31, 39], ["Patients", "SPECIES", 83, 91], ["peritoneal dialysis.mAteRIAl", "TREATMENT", 43, 71], ["more symptoms", "PROBLEM", 117, 130], ["seasonal influenza", "PROBLEM", 151, 169], ["fever", "PROBLEM", 181, 186], ["cough", "PROBLEM", 198, 203], ["rhinorrhea", "PROBLEM", 205, 215], ["nasal congestion", "PROBLEM", 219, 235], ["body aches", "PROBLEM", 237, 247], ["sore throat", "PROBLEM", 249, 260], ["headache", "PROBLEM", 266, 274], ["influenza.mAteRIAl", "PROBLEM", 297, 315], ["H1N1 infection", "PROBLEM", 344, 358], ["PCR", "TEST", 389, 392], ["rRT", "TEST", 394, 397], ["nasopharyngeal swab specimens", "TEST", 414, 443], ["Disease Control", "TREATMENT", 496, 511], ["peritoneal", "ANATOMY", 43, 53], ["influenza", "OBSERVATION", 160, 169], ["rhinorrhea", "OBSERVATION", 205, 215], ["nasal", "ANATOMY", 219, 224], ["congestion", "OBSERVATION", 225, 235], ["body aches", "ANATOMY", 237, 247], ["sore throat", "ANATOMY", 249, 260], ["H1N1", "OBSERVATION_MODIFIER", 344, 348], ["infection", "OBSERVATION", 349, 358]]], ["For all patients, the diagnosis and decisions regarding treatment, including the choice of antiviral therapy to be administered, were standardized and were made by the attending physician.", [["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["treatment", "TREATMENT", 56, 65], ["antiviral therapy", "TREATMENT", 91, 108]]], ["The following information was reviewed: symptoms at presentation, comorbidities, HD modality, occurrence of hypoxemia, laboratorial parameters, hospital admission, and clinical outcomes.mAteRIAl And methodsDuring the outbreak, four staff members developed flu-like symptoms and were diagnosed with influenza A. They were temporarily dismissed from the dialysis unit and were duly treated.", [["hypoxemia", "DISEASE", 108, 117], ["flu-like symptoms", "DISEASE", 256, 273], ["influenza A.", "DISEASE", 298, 310], ["symptoms", "PROBLEM", 40, 48], ["comorbidities", "PROBLEM", 66, 79], ["HD modality", "TREATMENT", 81, 92], ["hypoxemia", "PROBLEM", 108, 117], ["laboratorial parameters", "TEST", 119, 142], ["flu-like symptoms", "PROBLEM", 256, 273], ["influenza A.", "PROBLEM", 298, 310], ["the dialysis unit", "TREATMENT", 348, 365], ["hypoxemia", "OBSERVATION", 108, 117]]], ["This study was approved by the Research Ethics Committee of S\u00edrio-Liban\u00eas Hospital (HSL 2017-74).", [["This study", "TEST", 0, 10]]], ["Patient anonymity was guaranteed, and the requirement to obtain informed consent was waived because of the retrospective nature of the study.infectiOn cOntrOl measuresAfter the first case of H1N1 infection had been confirmed, the following strategies were implemented to control the spread of infection in the dialysis unit: all dialysis patients were required to wear a surgical mask before entering the dialysis room.", [["H1N1 infection", "DISEASE", 191, 205], ["infection", "DISEASE", 293, 302], ["H1N1", "ORGANISM", 191, 195], ["patients", "ORGANISM", 338, 346], ["Patient", "SPECIES", 0, 7], ["patients", "SPECIES", 338, 346], ["H1N1", "SPECIES", 191, 195], ["the study", "TEST", 131, 140], ["infectiOn cOntrOl measures", "TREATMENT", 141, 167], ["H1N1 infection", "PROBLEM", 191, 205], ["infection", "PROBLEM", 293, 302], ["all dialysis", "TREATMENT", 325, 337], ["a surgical mask", "TREATMENT", 369, 384], ["the dialysis room", "TREATMENT", 401, 418], ["infection", "OBSERVATION", 196, 205], ["infection", "OBSERVATION", 293, 302]]], ["The health care staff intensified the use of contact-reduction measures and standard precautions, including the use of surgical masks, non-sterile gloves, and hand hygiene with soap and water or alcohol-based hand sanitizer.", [["hand", "ANATOMY", 159, 163], ["hand", "ANATOMY", 209, 213], ["alcohol", "CHEMICAL", 195, 202], ["alcohol", "CHEMICAL", 195, 202], ["hand", "ORGANISM_SUBDIVISION", 159, 163], ["water", "SIMPLE_CHEMICAL", 186, 191], ["alcohol", "SIMPLE_CHEMICAL", 195, 202], ["hand", "ORGANISM_SUBDIVISION", 209, 213], ["contact-reduction measures", "TREATMENT", 45, 71], ["standard precautions", "TREATMENT", 76, 96], ["surgical masks", "TREATMENT", 119, 133], ["non-sterile gloves", "TREATMENT", 135, 153], ["soap", "TREATMENT", 177, 181]]], ["Early empirical antiviral treatment with oseltamivir was started in the patients and staff members who were suspected of being infected.", [["oseltamivir", "CHEMICAL", 41, 52], ["oseltamivir", "CHEMICAL", 41, 52], ["oseltamivir", "SIMPLE_CHEMICAL", 41, 52], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["Early empirical antiviral treatment", "TREATMENT", 0, 35], ["oseltamivir", "TREATMENT", 41, 52], ["antiviral treatment", "OBSERVATION", 16, 35], ["infected", "OBSERVATION", 127, 135]]], ["Antiviral chemoprophylaxis was offered to asymptomatic patients undergoing HD in the same shift of infected patients.", [["patients", "ORGANISM", 55, 63], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 55, 63], ["patients", "SPECIES", 108, 116], ["Antiviral chemoprophylaxis", "TREATMENT", 0, 26], ["HD", "TREATMENT", 75, 77], ["infected", "OBSERVATION", 99, 107]]], ["All patients and staff members were immediately vaccinated with the 2016 influenza vaccine, regardless of their vaccination status.", [["influenza", "DISEASE", 73, 82], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["the 2016 influenza vaccine", "TREATMENT", 64, 90]]], ["The staff members suspected of being infected were removed from the dialysis unit for a 7-day period.", [["the dialysis unit", "TREATMENT", 64, 81], ["infected", "OBSERVATION", 37, 45]]], ["Precautionary measures were maintained for 7 days after symptom onset or for at least 24 h after the symptoms had resolved, whichever was longer.antiviral therapy and chemOprOphylaxisThe H1N1-infected patients were treated with an initial oral dose of 75 mg of oseltamivir followed by 30 mg after each HD session.", [["oral", "ANATOMY", 239, 243], ["H1N1-infected", "DISEASE", 187, 200], ["oseltamivir", "CHEMICAL", 261, 272], ["oseltamivir", "CHEMICAL", 261, 272], ["H1N1", "ORGANISM", 187, 191], ["patients", "ORGANISM", 201, 209], ["oral", "ORGANISM_SUBDIVISION", 239, 243], ["oseltamivir", "SIMPLE_CHEMICAL", 261, 272], ["patients", "SPECIES", 201, 209], ["Precautionary measures", "TREATMENT", 0, 22], ["the symptoms", "PROBLEM", 97, 109], ["antiviral therapy", "TREATMENT", 145, 162], ["chemOprOphylaxis", "TREATMENT", 167, 183], ["The H1N1", "PROBLEM", 183, 191], ["oseltamivir", "TREATMENT", 261, 272], ["each HD session", "TREATMENT", 297, 312], ["H1N1", "OBSERVATION", 187, 191], ["infected", "OBSERVATION_MODIFIER", 192, 200]]], ["Patients on daily dialysis received oseltamivir daily after HD session.", [["oseltamivir", "CHEMICAL", 36, 47], ["oseltamivir", "CHEMICAL", 36, 47], ["Patients", "ORGANISM", 0, 8], ["oseltamivir", "SIMPLE_CHEMICAL", 36, 47], ["Patients", "SPECIES", 0, 8], ["daily dialysis", "TREATMENT", 12, 26], ["oseltamivir", "TREATMENT", 36, 47], ["HD session", "TREATMENT", 60, 70]]], ["The treatment was initiated as soon as possible after the onset of symptoms (if necessary, even before infection had been confirmed by real-time RT-PCR).", [["infection", "DISEASE", 103, 112], ["The treatment", "TREATMENT", 0, 13], ["symptoms", "PROBLEM", 67, 75], ["infection", "PROBLEM", 103, 112]]], ["Antiviral chemoprophylaxis with oseltamivir (30 mg) was administered after each HD session for a 7-day period.", [["oseltamivir", "CHEMICAL", 32, 43], ["oseltamivir", "CHEMICAL", 32, 43], ["oseltamivir", "SIMPLE_CHEMICAL", 32, 43], ["Antiviral chemoprophylaxis", "TREATMENT", 0, 26], ["oseltamivir", "TREATMENT", 32, 43], ["each HD session", "TREATMENT", 75, 90]]], ["Staff members infected with H1N1 were also treated with oseltamivir for a 5-day period.statistical analysisContinuous variables are reported as mean (\u00b1 SD) or median (interquartile range), as appropriate, whereas categorical variables are presented as frequency (%).", [["H1N1", "DISEASE", 28, 32], ["oseltamivir", "CHEMICAL", 56, 67], ["oseltamivir", "CHEMICAL", 56, 67], ["H1N1", "ORGANISM", 28, 32], ["oseltamivir", "SIMPLE_CHEMICAL", 56, 67], ["H1N1", "PROBLEM", 28, 32], ["oseltamivir", "TREATMENT", 56, 67], ["statistical analysis", "TEST", 87, 107]]], ["Differences in variable distributions between two groups were analyzed using the nonparametric Mann-Whitney U test (continuous variables), or Fisher's exact test (categorical variables), as the distributions of all variables were not normal.", [["the nonparametric Mann-Whitney U test", "TEST", 77, 114], ["Fisher's exact test", "TEST", 142, 161], ["variable", "OBSERVATION_MODIFIER", 15, 23], ["distributions", "OBSERVATION_MODIFIER", 24, 37], ["normal", "OBSERVATION", 234, 240]]], ["All statistical analyses were performed with SPSS Statistics software package (version 18.0, IBM Corporation, USA).", [["All statistical analyses", "TEST", 0, 24]]], ["Two-sided p-values <0.05 were considered statistically significant.ResultsAmong a total of 62 chronic HD patients in our dialysis unit, H1N1 infection was identified in 12 (19.4%).", [["HD", "DISEASE", 102, 104], ["infection", "DISEASE", 141, 150], ["patients", "ORGANISM", 105, 113], ["H1N1", "ORGANISM", 136, 140], ["patients", "SPECIES", 105, 113], ["Two-sided p-values", "TEST", 0, 18], ["chronic HD patients", "TREATMENT", 94, 113], ["our dialysis unit", "TREATMENT", 117, 134], ["H1N1 infection", "PROBLEM", 136, 150], ["sided", "ANATOMY_MODIFIER", 4, 9], ["chronic", "OBSERVATION_MODIFIER", 94, 101], ["H1N1", "OBSERVATION_MODIFIER", 136, 140], ["infection", "OBSERVATION", 141, 150]]], ["Of the 32 staff members working in the dialysis unit, four (12.5%) were found to be infected with the H1N1 virus.", [["H1N1 virus", "ORGANISM", 102, 112], ["H1N1 virus", "SPECIES", 102, 112], ["the H1N1 virus", "PROBLEM", 98, 112], ["infected", "OBSERVATION", 84, 92], ["H1N1", "OBSERVATION", 102, 106]]], ["Table 1 shows the demographic and clinical characteristics of the patients.", [["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74]]], ["The 12 patients who had H1N1 infection did not differ significantly from the other 50 non-infected patients with respect to median age, sex, mean time on dialysis, or dialysis modality.", [["H1N1 infection", "DISEASE", 24, 38], ["non-infected", "DISEASE", 86, 98], ["patients", "ORGANISM", 7, 15], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 7, 15], ["patients", "SPECIES", 99, 107], ["H1N1 infection", "PROBLEM", 24, 38], ["dialysis", "TREATMENT", 154, 162], ["dialysis modality", "TREATMENT", 167, 184], ["infection", "OBSERVATION", 29, 38]]], ["The proportion of comorbidities was similar, except for obesity (body mass index >30 kg/ m 2 ), that was higher in the H1N1-infected group than in the non-infected group (41.5 vs. 4%, p<0.002).", [["body", "ANATOMY", 65, 69], ["obesity", "DISEASE", 56, 63], ["H1N1-infected", "DISEASE", 119, 132], ["body", "ORGANISM_SUBDIVISION", 65, 69], ["comorbidities", "PROBLEM", 18, 31], ["obesity", "PROBLEM", 56, 63], ["body mass index", "TEST", 65, 80], ["the H1N1", "PROBLEM", 115, 123], ["comorbidities", "OBSERVATION", 18, 31], ["obesity", "OBSERVATION", 56, 63], ["higher", "OBSERVATION_MODIFIER", 105, 111], ["H1N1", "OBSERVATION", 119, 123], ["infected", "OBSERVATION_MODIFIER", 124, 132]]], ["Although five H1N1-infected patients (41.5%) were obese, none were morbidly obese.ResultsAmong the HD-infected patients, symptom onset occurred between March 21 and April 11, 2016.", [["H1N1-infected", "DISEASE", 14, 27], ["HD-infected", "DISEASE", 99, 110], ["patients", "ORGANISM", 28, 36], ["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 28, 36], ["patients", "SPECIES", 111, 119], ["obese", "PROBLEM", 50, 55], ["morbidly obese", "PROBLEM", 67, 81], ["symptom", "PROBLEM", 121, 128], ["infected", "OBSERVATION_MODIFIER", 19, 27], ["obese", "OBSERVATION", 50, 55], ["obese", "OBSERVATION", 76, 81], ["infected", "OBSERVATION", 102, 110]]], ["The presenting symptoms are summarized in Table 2 .", [["The presenting symptoms", "PROBLEM", 0, 23]]], ["The most common symptoms were cough and fever.", [["cough", "DISEASE", 30, 35], ["fever", "DISEASE", 40, 45], ["The most common symptoms", "PROBLEM", 0, 24], ["cough", "PROBLEM", 30, 35], ["fever", "PROBLEM", 40, 45], ["cough", "OBSERVATION", 30, 35], ["fever", "OBSERVATION", 40, 45]]], ["Of the 12 patients, eleven (92%) had low-grade fever and, one patient (8%) was afebrile.", [["fever", "DISEASE", 47, 52], ["patients", "ORGANISM", 10, 18], ["patient", "ORGANISM", 62, 69], ["patients", "SPECIES", 10, 18], ["patient", "SPECIES", 62, 69], ["low-grade fever", "PROBLEM", 37, 52], ["afebrile", "PROBLEM", 79, 87], ["fever", "OBSERVATION", 47, 52]]], ["Gastrointestinal symptoms (diarrhea, nausea, and vomiting) were observed in only one patient.", [["Gastrointestinal", "ANATOMY", 0, 16], ["Gastrointestinal symptoms", "DISEASE", 0, 25], ["diarrhea", "DISEASE", 27, 35], ["nausea", "DISEASE", 37, 43], ["vomiting", "DISEASE", 49, 57], ["Gastrointestinal", "ORGAN", 0, 16], ["patient", "ORGANISM", 85, 92], ["patient", "SPECIES", 85, 92], ["Gastrointestinal symptoms", "PROBLEM", 0, 25], ["diarrhea", "PROBLEM", 27, 35], ["nausea", "PROBLEM", 37, 43], ["vomiting", "PROBLEM", 49, 57]]], ["The estimated median time from symptom onset to initiation of antiviral treatment was 2 days.", [["symptom", "PROBLEM", 31, 38], ["antiviral treatment", "TREATMENT", 62, 81], ["median", "OBSERVATION_MODIFIER", 14, 20]]], ["The diagnosis of H1N1 infection was confirmed by realtime RT-PCR of nasopharyngeal swab samples in ten of the 12 symptomatic patients (two patients refused sample collection).", [["nasopharyngeal swab samples", "ANATOMY", 68, 95], ["H1N1 infection", "DISEASE", 17, 31], ["H1N1", "ORGANISM", 17, 21], ["nasopharyngeal swab samples", "CANCER", 68, 95], ["patients", "ORGANISM", 125, 133], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 125, 133], ["patients", "SPECIES", 139, 147], ["H1N1 infection", "PROBLEM", 17, 31], ["realtime RT-PCR", "TEST", 49, 64], ["nasopharyngeal swab samples", "TEST", 68, 95], ["sample collection", "TEST", 156, 173], ["H1N1", "OBSERVATION_MODIFIER", 17, 21], ["infection", "OBSERVATION", 22, 31], ["nasopharyngeal", "ANATOMY", 68, 82]]], ["All but one of the patients received empiric antiviral treatment within the first 48 h after symptom onset, before the test results were available.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["empiric antiviral treatment", "TREATMENT", 37, 64], ["symptom onset", "PROBLEM", 93, 106], ["the test", "TEST", 115, 123]]], ["The duration of treatment with oseltamivir was 5 days, except one patient who was treated for seven days at medical discretion.", [["oseltamivir", "CHEMICAL", 31, 42], ["oseltamivir", "CHEMICAL", 31, 42], ["oseltamivir", "SIMPLE_CHEMICAL", 31, 42], ["patient", "ORGANISM", 66, 73], ["patient", "SPECIES", 66, 73], ["treatment", "TREATMENT", 16, 25], ["oseltamivir", "TREATMENT", 31, 42]]], ["None of the patients experienced adverse events related to the use of oseltamivir.", [["oseltamivir", "CHEMICAL", 70, 81], ["oseltamivir", "CHEMICAL", 70, 81], ["patients", "ORGANISM", 12, 20], ["oseltamivir", "SIMPLE_CHEMICAL", 70, 81], ["patients", "SPECIES", 12, 20], ["adverse events", "PROBLEM", 33, 47], ["oseltamivir", "TREATMENT", 70, 81]]], ["The total white blood cells count was similar in the two groups.", [["white blood cells", "ANATOMY", 10, 27], ["white blood cells", "CELL", 10, 27], ["The total white blood cells count", "TEST", 0, 33], ["total", "OBSERVATION_MODIFIER", 4, 9]]], ["The infected patients had C-reactive protein (CRP) significantly higher while the lymphocytes count and serum albumin were significantly lower compared with non-infected patients.", [["lymphocytes", "ANATOMY", 82, 93], ["serum", "ANATOMY", 104, 109], ["patients", "ORGANISM", 13, 21], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 26, 44], ["CRP", "GENE_OR_GENE_PRODUCT", 46, 49], ["lymphocytes", "CELL", 82, 93], ["serum", "ORGANISM_SUBSTANCE", 104, 109], ["albumin", "GENE_OR_GENE_PRODUCT", 110, 117], ["patients", "ORGANISM", 170, 178], ["C-reactive protein", "PROTEIN", 26, 44], ["CRP", "PROTEIN", 46, 49], ["lymphocytes", "CELL_TYPE", 82, 93], ["serum albumin", "PROTEIN", 104, 117], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 170, 178], ["C-reactive protein", "PROBLEM", 26, 44], ["CRP", "TEST", 46, 49], ["the lymphocytes count", "TEST", 78, 99], ["serum albumin", "TEST", 104, 117], ["infected", "OBSERVATION_MODIFIER", 4, 12], ["-reactive protein", "OBSERVATION", 27, 44]]], ["The influenza vaccination rate (2015) was similar between infected patients (75%) and non-infected patients (76%).", [["influenza", "DISEASE", 4, 13], ["patients", "ORGANISM", 67, 75], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 67, 75], ["patients", "SPECIES", 99, 107], ["The influenza vaccination rate", "TEST", 0, 30]]], ["Of the 12 H1N1-infected patients, three (25%) were hospitalized, each for a period of 4 days.ResultsThe reasons for hospitalization were: exacerbation of chronic asthma; severe gastrointestinal symptoms, and an elderly patient with COPD.", [["gastrointestinal", "ANATOMY", 177, 193], ["H1N1-infected", "DISEASE", 10, 23], ["asthma", "DISEASE", 162, 168], ["gastrointestinal symptoms", "DISEASE", 177, 202], ["COPD", "DISEASE", 232, 236], ["patients", "ORGANISM", 24, 32], ["gastrointestinal", "ORGAN", 177, 193], ["patient", "ORGANISM", 219, 226], ["patients", "SPECIES", 24, 32], ["patient", "SPECIES", 219, 226], ["exacerbation", "PROBLEM", 138, 150], ["chronic asthma", "PROBLEM", 154, 168], ["severe gastrointestinal symptoms", "PROBLEM", 170, 202], ["COPD", "PROBLEM", 232, 236], ["infected", "OBSERVATION_MODIFIER", 15, 23], ["chronic", "OBSERVATION_MODIFIER", 154, 161], ["asthma", "OBSERVATION", 162, 168], ["severe", "OBSERVATION_MODIFIER", 170, 176], ["gastrointestinal", "ANATOMY", 177, 193], ["COPD", "OBSERVATION", 232, 236]]], ["At admission, all patients underwent a computed tomography scan of the chest, which showed no evidence of pulmonary infiltrate in all cases.", [["chest", "ANATOMY", 71, 76], ["pulmonary", "ANATOMY", 106, 115], ["patients", "ORGANISM", 18, 26], ["chest", "ORGAN", 71, 76], ["pulmonary", "ORGAN", 106, 115], ["patients", "SPECIES", 18, 26], ["a computed tomography scan of the chest", "TEST", 37, 76], ["pulmonary infiltrate in all cases", "PROBLEM", 106, 139], ["chest", "ANATOMY", 71, 76], ["no evidence of", "UNCERTAINTY", 91, 105], ["pulmonary", "ANATOMY", 106, 115], ["infiltrate", "OBSERVATION", 116, 126]]], ["Neither of the hospitalized patients presented hypoxemia or required admission to the intensive care unit (ICU).", [["hypoxemia", "DISEASE", 47, 56], ["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["hypoxemia", "PROBLEM", 47, 56], ["hypoxemia", "OBSERVATION", 47, 56]]], ["Complete recovery was observed in all H1N1-infected patients.ResultsThe number of individuals infected in the period of outbreak and their distribution among the dialysis shifts are presented in Figure 1 .", [["H1N1-infected", "DISEASE", 38, 51], ["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["outbreak", "PROBLEM", 120, 128], ["the dialysis shifts", "TREATMENT", 158, 177], ["infected", "OBSERVATION", 43, 51], ["infected", "OBSERVATION_MODIFIER", 94, 102], ["dialysis shifts", "OBSERVATION", 162, 177]]], ["The first case of the influenza A outbreak in our dialysis unit was admitted on March 21, 2016.", [["influenza A", "DISEASE", 22, 33], ["the influenza", "PROBLEM", 18, 31]]], ["That patient was placed under respiratory precautions as soon as the influenza symptoms were known to the staff physician.", [["respiratory", "ANATOMY", 30, 41], ["influenza", "DISEASE", 69, 78], ["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12], ["respiratory precautions", "TREATMENT", 30, 53], ["the influenza symptoms", "PROBLEM", 65, 87]]], ["The second confirmed case was in a staff member (a receptionist) who was removed from the dialysis unit as soon as the infection was suspected.", [["infection", "DISEASE", 119, 128], ["the dialysis unit", "TREATMENT", 86, 103], ["the infection", "PROBLEM", 115, 128], ["infection", "OBSERVATION", 119, 128]]], ["On March 25, infection was confirmed in a second patient who was on the same dialysis schedule (second shift) as the first infected patient, constituting an outbreak in the unit and leading to prompt implementation of infection control measures.", [["infection", "DISEASE", 13, 22], ["infection", "DISEASE", 218, 227], ["patient", "ORGANISM", 49, 56], ["patient", "ORGANISM", 132, 139], ["patient", "SPECIES", 49, 56], ["patient", "SPECIES", 132, 139], ["infection", "PROBLEM", 13, 22], ["the same dialysis schedule", "TREATMENT", 68, 94], ["infection control measures", "TREATMENT", 218, 244], ["infection", "OBSERVATION", 13, 22], ["infected", "OBSERVATION", 123, 131], ["infection", "OBSERVATION", 218, 227]]], ["Other six infected patients were identified between March 26 and 28.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["six", "OBSERVATION_MODIFIER", 6, 9], ["infected", "OBSERVATION", 10, 18]]], ["Of the 12 H1N1-infected patients, ten (83%) occurred in the same dialysis room: nine (75%), including the first case, during the second HD shift, and one in a subsequent HD shift (third shift).", [["H1N1-infected", "DISEASE", 10, 23], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["the second HD shift", "TREATMENT", 125, 144], ["a subsequent HD shift", "TREATMENT", 157, 178], ["infected", "OBSERVATION_MODIFIER", 15, 23]]], ["The two remaining patients were on the morning HD schedule (first shift).", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["the morning HD schedule", "TREATMENT", 35, 58]]], ["The analysis of the clinical background of the second shift patients was not significantly different compared to those patients on HD in the other shifts ( Table 3) .ResultsThe four H1N1-infected staff members were one receptionist, one nurse, and two nurse technicians.", [["H1N1-infected", "DISEASE", 182, 195], ["patients", "ORGANISM", 60, 68], ["patients", "ORGANISM", 119, 127], ["staff", "ORGANISM", 196, 201], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 119, 127], ["The analysis", "TEST", 0, 12], ["HD", "TREATMENT", 131, 133], ["significantly different", "OBSERVATION_MODIFIER", 77, 100]]], ["Infection with the H1N1 virus was confirmed by real-time RT-PCR in only three (75.0%); no samples for PCR was collected from one staff member.", [["samples", "ANATOMY", 90, 97], ["H1N1 virus", "ORGANISM", 19, 29], ["samples", "CANCER", 90, 97], ["H1N1 virus", "SPECIES", 19, 29], ["H1N1 virus", "SPECIES", 19, 29], ["Infection", "PROBLEM", 0, 9], ["the H1N1 virus", "PROBLEM", 15, 29], ["PCR", "TEST", 60, 63], ["PCR", "TEST", 102, 105]]], ["All of the infected individuals received the recommended treatment with oseltamivir.ResultsThe 2016 seasonal influenza vaccine was offered in advance to all patients under treatment at the dialysis unit during the outbreak.", [["oseltamivir", "CHEMICAL", 72, 83], ["oseltamivir", "CHEMICAL", 72, 83], ["individuals", "ORGANISM", 20, 31], ["oseltamivir", "SIMPLE_CHEMICAL", 72, 83], ["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 157, 165], ["the infected individuals", "PROBLEM", 7, 31], ["oseltamivir", "TREATMENT", 72, 83], ["seasonal influenza vaccine", "TREATMENT", 100, 126], ["treatment", "TREATMENT", 172, 181], ["the dialysis unit", "TREATMENT", 185, 202], ["infected", "OBSERVATION", 11, 19]]], ["All staff members were required to be vaccinated.dIscussIonIn this study, we have described the clinical course of documented H1N1 infection in 12 HD patients and the infection control measures implemented during an outbreak in a dialysis unit.", [["H1N1 infection", "DISEASE", 126, 140], ["infection", "DISEASE", 167, 176], ["patients", "ORGANISM", 150, 158], ["patients", "SPECIES", 150, 158], ["this study", "TEST", 62, 72], ["H1N1 infection", "PROBLEM", 126, 140], ["12 HD patients", "TREATMENT", 144, 158], ["the infection control measures", "TREATMENT", 163, 193], ["a dialysis unit", "TREATMENT", 228, 243], ["H1N1", "OBSERVATION_MODIFIER", 126, 130], ["infection", "OBSERVATION", 131, 140], ["infection", "OBSERVATION", 167, 176]]], ["There is a paucity of data regarding H1N1 infection in HD patients.", [["infection", "DISEASE", 42, 51], ["HD", "DISEASE", 55, 57], ["H1N1", "ORGANISM", 37, 41], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["H1N1 infection", "PROBLEM", 37, 51], ["HD patients", "TREATMENT", 55, 66], ["infection", "OBSERVATION", 42, 51]]], ["Although case series related to the 2009 H1N1 pandemic have reported a relatively severe clinical course of infection in the dialysis population 8-9 , we observed an apparently milder evolution.", [["H1N1 pandemic", "DISEASE", 41, 54], ["infection", "DISEASE", 108, 117], ["infection", "PROBLEM", 108, 117], ["the dialysis population", "TREATMENT", 121, 144], ["severe", "OBSERVATION_MODIFIER", 82, 88], ["infection", "OBSERVATION", 108, 117], ["milder", "OBSERVATION_MODIFIER", 177, 183], ["evolution", "OBSERVATION_MODIFIER", 184, 193]]], ["None of our patients presented severe disease, developed hypoxemia, or required ICU admission, and all recovered completely.dIscussIonThe real-time RT-PCR used in our study is currently the most sensitive and specific diagnostic test for influenza, results becoming available 4-6 h after specimen submission.", [["specimen", "ANATOMY", 288, 296], ["hypoxemia", "DISEASE", 57, 66], ["influenza", "DISEASE", 238, 247], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["severe disease", "PROBLEM", 31, 45], ["hypoxemia", "PROBLEM", 57, 66], ["our study", "TEST", 163, 172], ["influenza", "PROBLEM", 238, 247], ["specimen submission", "TEST", 288, 307], ["severe", "OBSERVATION_MODIFIER", 31, 37], ["disease", "OBSERVATION", 38, 45], ["hypoxemia", "OBSERVATION", 57, 66]]], ["In our analysis, two (16%) of the patients with flu-like symptoms presented nasopharyngeal swab samples that tested negative by real-time RT-PCR.", [["nasopharyngeal swab samples", "ANATOMY", 76, 103], ["flu", "DISEASE", 48, 51], ["patients", "ORGANISM", 34, 42], ["nasopharyngeal swab samples", "CANCER", 76, 103], ["patients", "SPECIES", 34, 42], ["our analysis", "TEST", 3, 15], ["flu-like symptoms", "PROBLEM", 48, 65], ["nasopharyngeal swab samples", "TEST", 76, 103], ["nasopharyngeal", "ANATOMY", 76, 90]]], ["However, these two patients were considered infected based on their clinical symptoms and on the fact that those symptoms appeared during an influenza outbreak.", [["influenza", "DISEASE", 141, 150], ["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["infected", "PROBLEM", 44, 52], ["their clinical symptoms", "PROBLEM", 62, 85], ["those symptoms", "PROBLEM", 107, 121], ["an influenza outbreak", "PROBLEM", 138, 159], ["infected", "OBSERVATION", 44, 52]]], ["In another study, 19% of patients with detectable H1N1 viral RNA in bronchoscopy samples had previously tested negative for the virus in upper respiratory tract samples 10 .", [["samples", "ANATOMY", 81, 88], ["upper respiratory tract samples", "ANATOMY", 137, 168], ["patients", "ORGANISM", 25, 33], ["bronchoscopy samples", "CANCER", 68, 88], ["H1N1 viral RNA", "RNA", 50, 64], ["patients", "SPECIES", 25, 33], ["another study", "TEST", 3, 16], ["detectable H1N1 viral RNA", "PROBLEM", 39, 64], ["bronchoscopy samples", "TEST", 68, 88], ["the virus in upper respiratory tract samples", "PROBLEM", 124, 168], ["upper", "ANATOMY_MODIFIER", 137, 142], ["respiratory tract", "ANATOMY", 143, 160]]], ["Therefore, negative results in single respiratory specimens do not rule out H1N1 infection and the collection of multiple respiratory specimens is recommended when the level of clinical suspicion is high.", [["respiratory specimens", "ANATOMY", 38, 59], ["respiratory specimens", "ANATOMY", 122, 143], ["infection", "DISEASE", 81, 90], ["single respiratory specimens", "TEST", 31, 59], ["H1N1 infection", "PROBLEM", 76, 90], ["multiple respiratory specimens", "TEST", 113, 143], ["clinical suspicion", "TEST", 177, 195], ["infection", "OBSERVATION", 81, 90]]], ["The two patients who refused to have nasopharyngeal swab samples collected to test RT-PCR were both febrile and presented with the appropriate clinical syndrome and epidemiologic exposure.dIscussIonIn the present study, the hospital admission rate was 25%, higher than the 1-7% estimated for the general population of H1N1-infected individuals 11 .", [["nasopharyngeal swab samples", "ANATOMY", 37, 64], ["febrile", "DISEASE", 100, 107], ["H1N1-infected", "DISEASE", 318, 331], ["patients", "ORGANISM", 8, 16], ["nasopharyngeal swab samples", "CANCER", 37, 64], ["H1N1", "ORGANISM", 318, 322], ["patients", "SPECIES", 8, 16], ["nasopharyngeal swab samples", "TEST", 37, 64], ["test RT-PCR", "TEST", 78, 89], ["febrile", "PROBLEM", 100, 107], ["the appropriate clinical syndrome", "PROBLEM", 127, 160], ["the hospital admission rate", "TEST", 220, 247], ["H1N1", "PROBLEM", 318, 322], ["infected individuals", "PROBLEM", 323, 343], ["H1N1", "OBSERVATION", 318, 322], ["infected", "OBSERVATION", 323, 331]]], ["In a previous multicenter study involving 306 chronic dialysis patients infected with the 2009 H1N1 virus, a hospital admission rate of 34% was reported 9 .", [["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["H1N1 virus", "SPECIES", 95, 105], ["2009 H1N1 virus", "SPECIES", 90, 105], ["a previous multicenter study", "TEST", 3, 31], ["chronic dialysis", "TREATMENT", 46, 62], ["a hospital admission rate", "TEST", 107, 132], ["chronic", "OBSERVATION_MODIFIER", 46, 53], ["dialysis", "OBSERVATION", 54, 62]]], ["In our study, the hospital admissions were due to complications of comorbid medical conditions.", [["our study", "TEST", 3, 12], ["comorbid medical conditions", "PROBLEM", 67, 94]]], ["Two hospitalized patients had diabetes and cardiovascular disease and one had chronic obstructive pulmonary disease.", [["cardiovascular", "ANATOMY", 43, 57], ["pulmonary", "ANATOMY", 98, 107], ["diabetes", "DISEASE", 30, 38], ["cardiovascular disease", "DISEASE", 43, 65], ["chronic obstructive pulmonary disease", "DISEASE", 78, 115], ["patients", "ORGANISM", 17, 25], ["pulmonary", "ORGAN", 98, 107], ["patients", "SPECIES", 17, 25], ["diabetes", "PROBLEM", 30, 38], ["cardiovascular disease", "PROBLEM", 43, 65], ["chronic obstructive pulmonary disease", "PROBLEM", 78, 115], ["diabetes", "OBSERVATION", 30, 38], ["cardiovascular", "ANATOMY", 43, 57], ["disease", "OBSERVATION", 58, 65], ["chronic", "OBSERVATION_MODIFIER", 78, 85], ["obstructive", "OBSERVATION_MODIFIER", 86, 97], ["pulmonary", "ANATOMY", 98, 107], ["disease", "OBSERVATION", 108, 115]]], ["Patients with chronic kidney disease are at a higher risk for hospitalization as a consequence of the comorbid conditions frequently associated with the primary renal disease 12, 13 .dIscussIonIn the above mentioned multicenter study, the authors reported that the incidence of pneumonia was 22.5% 9 , whereas we observed no case of pneumonia in our analysis.", [["kidney", "ANATOMY", 22, 28], ["renal", "ANATOMY", 161, 166], ["chronic kidney disease", "DISEASE", 14, 36], ["primary renal disease", "DISEASE", 153, 174], ["pneumonia", "DISEASE", 278, 287], ["pneumonia", "DISEASE", 333, 342], ["Patients", "ORGANISM", 0, 8], ["kidney", "ORGAN", 22, 28], ["renal", "ORGAN", 161, 166], ["Patients", "SPECIES", 0, 8], ["chronic kidney disease", "PROBLEM", 14, 36], ["the comorbid conditions", "PROBLEM", 98, 121], ["the primary renal disease", "PROBLEM", 149, 174], ["multicenter study", "TEST", 216, 233], ["pneumonia", "PROBLEM", 278, 287], ["pneumonia", "PROBLEM", 333, 342], ["our analysis", "TEST", 346, 358], ["chronic", "OBSERVATION_MODIFIER", 14, 21], ["kidney", "ANATOMY", 22, 28], ["disease", "OBSERVATION", 29, 36], ["renal", "ANATOMY", 161, 166], ["disease", "OBSERVATION", 167, 174], ["pneumonia", "OBSERVATION", 278, 287], ["no case of", "UNCERTAINTY", 322, 332], ["pneumonia", "OBSERVATION", 333, 342]]], ["Similarly, two previous case series of H1N1-infected chronic HD patients in China 8 and Korea 4 reported the incidence of pneumonia to be 100% and 17%, respectively.", [["H1N1-infected chronic HD", "DISEASE", 39, 63], ["pneumonia", "DISEASE", 122, 131], ["H1N1", "ORGANISM", 39, 43], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["H1N1", "PROBLEM", 39, 43], ["infected chronic HD patients", "TREATMENT", 44, 72], ["pneumonia", "PROBLEM", 122, 131], ["infected", "OBSERVATION_MODIFIER", 44, 52], ["chronic", "OBSERVATION_MODIFIER", 53, 60], ["HD", "OBSERVATION", 61, 63], ["pneumonia", "OBSERVATION", 122, 131]]], ["These discrepancies might be partly attributable to differences among the studies in terms of the characteristics of study populations, as well as the fact that the above studies refer to the first year of H1N1 infection with less immunized population.", [["infection", "DISEASE", 211, 220], ["H1N1", "ORGANISM", 206, 210], ["the studies", "TEST", 70, 81], ["the above studies", "TEST", 161, 178], ["H1N1 infection", "PROBLEM", 206, 220], ["infection", "OBSERVATION", 211, 220]]], ["The low incidence of complications in our study can be explained by the high rate of patients previously vaccinated 78.3% received the 2014-2015 vaccine), early diagnosis, and prompt antiviral treatment.dIscussIonIn all but one of the patients in our study population, antiviral treatment was started before the laboratory test results had been made available.", [["patients", "ORGANISM", 85, 93], ["patients", "ORGANISM", 235, 243], ["patients", "SPECIES", 85, 93], ["patients", "SPECIES", 235, 243], ["our study", "TEST", 38, 47], ["prompt antiviral treatment", "TREATMENT", 176, 202], ["antiviral treatment", "TREATMENT", 269, 288], ["the laboratory test", "TEST", 308, 327], ["low", "OBSERVATION_MODIFIER", 4, 7], ["complications", "OBSERVATION", 21, 34]]], ["Decisions regarding antiviral treatment should not await laboratory confirmation, and patients presenting with progressive illness should be treated empirically as soon as possible.", [["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["antiviral treatment", "TREATMENT", 20, 39], ["laboratory confirmation", "TEST", 57, 80], ["progressive illness", "PROBLEM", 111, 130], ["progressive", "OBSERVATION_MODIFIER", 111, 122], ["illness", "OBSERVATION", 123, 130]]], ["In the general population of H1N1infected individuals, early treatment with oseltamivir can reduce the duration of hospitalization and the risk of progression to severe disease requiring ICU admission or resulting in death 14 .dIscussIonThe dose of oseltamivir used for treatment and prophylaxis in our center was directed by the recommended dose for patients with ESRD receiving HD 15 .", [["oseltamivir", "CHEMICAL", 76, 87], ["death", "DISEASE", 217, 222], ["oseltamivir", "CHEMICAL", 249, 260], ["ESRD", "DISEASE", 365, 369], ["oseltamivir", "CHEMICAL", 76, 87], ["oseltamivir", "CHEMICAL", 249, 260], ["individuals", "ORGANISM", 42, 53], ["oseltamivir", "SIMPLE_CHEMICAL", 76, 87], ["oseltamivir", "SIMPLE_CHEMICAL", 249, 260], ["patients", "ORGANISM", 351, 359], ["patients", "SPECIES", 351, 359], ["H1N1infected individuals", "PROBLEM", 29, 53], ["oseltamivir", "TREATMENT", 76, 87], ["severe disease", "PROBLEM", 162, 176], ["death", "PROBLEM", 217, 222], ["oseltamivir", "TREATMENT", 249, 260], ["treatment", "TREATMENT", 270, 279], ["prophylaxis", "TREATMENT", 284, 295], ["ESRD", "PROBLEM", 365, 369], ["HD", "TREATMENT", 380, 382], ["severe", "OBSERVATION_MODIFIER", 162, 168], ["disease", "OBSERVATION", 169, 176]]], ["Although the ideal regimen for treating influenza in these patients is uncertain, pharmacokinetics studies showed that a 30 mg dose of oseltamivir given after HD sessions, provides sufficient exposure to allow safe and effective anti-influenza treatment and prophylaxis 16, 17 .dIscussIonVaccination continues to be the best way to prevent influenza illness.", [["influenza", "DISEASE", 40, 49], ["oseltamivir", "CHEMICAL", 135, 146], ["influenza illness", "DISEASE", 340, 357], ["oseltamivir", "CHEMICAL", 135, 146], ["patients", "ORGANISM", 59, 67], ["oseltamivir", "SIMPLE_CHEMICAL", 135, 146], ["patients", "SPECIES", 59, 67], ["the ideal regimen", "TREATMENT", 9, 26], ["influenza", "PROBLEM", 40, 49], ["pharmacokinetics studies", "TEST", 82, 106], ["oseltamivir", "TREATMENT", 135, 146], ["HD sessions", "TREATMENT", 159, 170], ["safe and effective anti-influenza treatment", "TREATMENT", 210, 253], ["prophylaxis", "TREATMENT", 258, 269], ["influenza illness", "PROBLEM", 340, 357], ["influenza", "OBSERVATION", 340, 349]]], ["However, previous studies have reported reduced vaccine efficacy in HD patients.", [["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["previous studies", "TEST", 9, 25], ["reduced vaccine efficacy", "PROBLEM", 40, 64], ["HD patients", "TREATMENT", 68, 79]]], ["Crespo et al, showed that a single dose of the influenza A H1N1/2009 vaccine was associated with a low serum-conversion rate of 33% in this population 18 .", [["serum", "ANATOMY", 103, 108], ["influenza A H1N1", "ORGANISM", 47, 63], ["serum", "ORGANISM_SUBSTANCE", 103, 108], ["influenza A H1N1", "SPECIES", 47, 63], ["A H1N1/2009", "SPECIES", 57, 68], ["the influenza", "PROBLEM", 43, 56]]], ["Despite the controversy regarding the efficacy of influenza vaccine among patients on dialysis 19-20 , a 2-year analysis of Medicare claims for dialysis patients showed that vaccination significantly reduced the risk of all-cause hospitalizations and deaths associated with influenza 21 .dIscussIonIn addition, we administered chemoprophylaxis with oseltamivir to all patients undergoing HD in the same room of infected patients to contain the spread of the virus.", [["influenza", "DISEASE", 50, 59], ["deaths", "DISEASE", 251, 257], ["oseltamivir", "CHEMICAL", 349, 360], ["oseltamivir", "CHEMICAL", 349, 360], ["patients", "ORGANISM", 74, 82], ["patients", "ORGANISM", 153, 161], ["oseltamivir", "SIMPLE_CHEMICAL", 349, 360], ["patients", "ORGANISM", 368, 376], ["patients", "ORGANISM", 420, 428], ["patients", "SPECIES", 74, 82], ["patients", "SPECIES", 153, 161], ["patients", "SPECIES", 368, 376], ["patients", "SPECIES", 420, 428], ["influenza vaccine", "TREATMENT", 50, 67], ["dialysis", "TREATMENT", 86, 94], ["dialysis", "TREATMENT", 144, 152], ["vaccination", "TREATMENT", 174, 185], ["influenza", "PROBLEM", 274, 283], ["chemoprophylaxis", "TREATMENT", 327, 343], ["oseltamivir", "TREATMENT", 349, 360], ["HD", "TREATMENT", 388, 390], ["the virus", "PROBLEM", 454, 463], ["infected", "OBSERVATION", 411, 419]]], ["Chemoprophylaxis has been recommended to control influenza in populations at high risk of complications and where vaccine efficacy is reduced, particularly across individual outbreaks 22.", [["influenza", "DISEASE", 49, 58], ["Chemoprophylaxis", "TREATMENT", 0, 16], ["influenza", "PROBLEM", 49, 58], ["complications", "PROBLEM", 90, 103], ["vaccine efficacy", "TREATMENT", 114, 130], ["complications", "OBSERVATION", 90, 103]]], ["Chemoprophylaxis with antiviral provides an immediate and immune-independent intervention to prevent seasonal influenza-related illness.", [["influenza", "DISEASE", 110, 119], ["illness", "DISEASE", 128, 135], ["Chemoprophylaxis", "TREATMENT", 0, 16], ["antiviral", "TREATMENT", 22, 31], ["immune-independent intervention", "TREATMENT", 58, 89], ["seasonal influenza", "PROBLEM", 101, 119], ["influenza", "OBSERVATION", 110, 119]]], ["We did not offer chemoprophylaxis to the staff member once all of them were previously vaccinated and were removed from dialysis as soon as they presented any flu symptom.dIscussIonThe mechanisms of person-to-person transmission of H1N1 virus appear to be similar to those of seasonal influenza 6 , but we were unable to determine the relative contributions of each transmission route (droplet, aerosol, or contact) in our patients.", [["influenza", "DISEASE", 285, 294], ["H1N1 virus", "ORGANISM", 232, 242], ["patients", "ORGANISM", 423, 431], ["person", "SPECIES", 199, 205], ["person", "SPECIES", 209, 215], ["H1N1 virus", "SPECIES", 232, 242], ["patients", "SPECIES", 423, 431], ["H1N1 virus", "SPECIES", 232, 242], ["chemoprophylaxis", "TREATMENT", 17, 33], ["dialysis", "TREATMENT", 120, 128], ["H1N1 virus", "PROBLEM", 232, 242], ["seasonal influenza", "PROBLEM", 276, 294]]], ["Epidemiologic analyses support patient-to-patient transmission, however, this does not rule out viral transmission from infected health care personal.", [["patient", "ORGANISM", 31, 38], ["patient", "ORGANISM", 42, 49], ["patient", "SPECIES", 31, 38], ["patient", "SPECIES", 42, 49], ["Epidemiologic analyses", "TEST", 0, 22], ["viral transmission", "PROBLEM", 96, 114]]], ["The four staff members diagnosed with H1N1 had contact with patients undergoing HD in the second shift.", [["H1N1", "DISEASE", 38, 42], ["H1N1", "ORGANISM", 38, 42], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["H1N1", "PROBLEM", 38, 42], ["HD", "TREATMENT", 80, 82]]], ["In addition to standardized data collection, viral RNA sequencing should be performed when possible to enable the understanding of transmission events 23 .dIscussIonIt is an important fact that the majority of influenza infections were spreading in the same room.", [["influenza infections", "DISEASE", 210, 230], ["standardized data collection", "TEST", 15, 43], ["viral RNA sequencing", "TEST", 45, 65], ["influenza infections", "PROBLEM", 210, 230], ["influenza", "OBSERVATION", 210, 219]]], ["A risk factor for the spread of viruses in dialysis units is the practice of HD in concurrent sessions in a single space, which is inherently associated with exposure to other HD patients and health care staff 5 .dIscussIonIn our dialysis center, we have one dialysis room specific for isolating patients with transmissible diseases, nevertheless, it is not feasible to isolate infected patients in other rooms during the HD sessions.", [["transmissible diseases", "DISEASE", 310, 332], ["patients", "ORGANISM", 179, 187], ["patients", "ORGANISM", 296, 304], ["patients", "ORGANISM", 387, 395], ["patients", "SPECIES", 179, 187], ["patients", "SPECIES", 296, 304], ["patients", "SPECIES", 387, 395], ["A risk factor", "PROBLEM", 0, 13], ["viruses in dialysis units", "TREATMENT", 32, 57], ["HD", "TREATMENT", 77, 79], ["transmissible diseases", "PROBLEM", 310, 332], ["the HD sessions", "TREATMENT", 418, 433], ["viruses", "OBSERVATION", 32, 39]]], ["The strength of this study remains in the fact that although patients were treated in the same dialysis room, the infectious outbreak was controlled successfully.", [["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["this study", "TEST", 16, 26], ["the infectious outbreak", "PROBLEM", 110, 133], ["infectious", "OBSERVATION", 114, 124]]], ["After the infection-control interventions were implemented, the illness was diagnosed in four patients.", [["infection", "DISEASE", 10, 19], ["illness", "DISEASE", 64, 71], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["the infection", "PROBLEM", 6, 19], ["control interventions", "TREATMENT", 20, 41], ["infection", "OBSERVATION", 10, 19]]], ["The two cases restricted to the first shift had no contact with other infected patients, and is possible that the infection had come from the community.dIscussIonOur study has several limitations.", [["infection", "DISEASE", 114, 123], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["the infection", "PROBLEM", 110, 123], ["IonOur study", "TEST", 159, 171], ["infection", "OBSERVATION", 114, 123]]], ["Because this was a retrospective analysis, we may have missed clinical information not documented.", [["a retrospective analysis", "TEST", 17, 41]]], ["We also may have missed patients with asymptomatic infection because RT-PCR was collected only when patients were symptomatic.", [["infection", "DISEASE", 51, 60], ["patients", "ORGANISM", 24, 32], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 100, 108], ["asymptomatic infection", "PROBLEM", 38, 60], ["RT-PCR", "TEST", 69, 75], ["symptomatic", "PROBLEM", 114, 125], ["infection", "OBSERVATION", 51, 60]]], ["Chest radiograph was not available for all patients.", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["Chest radiograph", "TEST", 0, 16]]], ["However, all patients recovered completely and hypoxemia was not documented in any patient.dIscussIonThe control of the outbreak observed in the present study supports the use of the infection control measures implemented.", [["hypoxemia", "DISEASE", 47, 56], ["infection", "DISEASE", 183, 192], ["patients", "ORGANISM", 13, 21], ["patient", "ORGANISM", 83, 90], ["patients", "SPECIES", 13, 21], ["patient", "SPECIES", 83, 90], ["hypoxemia", "PROBLEM", 47, 56], ["the outbreak", "PROBLEM", 116, 128], ["the infection control measures", "TREATMENT", 179, 209], ["hypoxemia", "OBSERVATION", 47, 56], ["infection", "OBSERVATION", 183, 192]]], ["In periods during which H1N1 virus circulates in a dialysis unit, it is likely that cases of flu-like illness represent H1N1 infection, and the initiation of antiviral therapy in suspected cases should not be delayed to wait for a definitive diagnosis based on laboratory tests.", [["flu-like illness", "DISEASE", 93, 109], ["H1N1 infection", "DISEASE", 120, 134], ["H1N1 virus", "ORGANISM", 24, 34], ["H1N1", "ORGANISM", 120, 124], ["H1N1 virus", "SPECIES", 24, 34], ["H1N1 virus", "PROBLEM", 24, 34], ["a dialysis unit", "TREATMENT", 49, 64], ["flu", "PROBLEM", 93, 96], ["illness", "PROBLEM", 102, 109], ["H1N1 infection", "PROBLEM", 120, 134], ["antiviral therapy", "TREATMENT", 158, 175], ["laboratory tests", "TEST", 261, 277], ["is likely", "UNCERTAINTY", 69, 78], ["flu", "OBSERVATION", 93, 96], ["H1N1", "OBSERVATION_MODIFIER", 120, 124], ["infection", "OBSERVATION", 125, 134]]], ["In such contexts, other infection control measures, such as the use of surgical masks by patients, their contacts, and dialysis unit staff members, together with antiviral chemoprophylaxis to asymptomatic patients undergoing hemodialysis in the same room, should be implemented and could help control the outbreak.dIscussIonIn conclusion, the clinical evolution of infection with the H1N1 virus was favorable.", [["infection", "DISEASE", 24, 33], ["infection", "DISEASE", 365, 374], ["patients", "ORGANISM", 89, 97], ["patients", "ORGANISM", 205, 213], ["H1N1 virus", "ORGANISM", 384, 394], ["patients", "SPECIES", 89, 97], ["patients", "SPECIES", 205, 213], ["H1N1 virus", "SPECIES", 384, 394], ["other infection control measures", "PROBLEM", 18, 50], ["surgical masks", "TREATMENT", 71, 85], ["antiviral chemoprophylaxis", "TREATMENT", 162, 188], ["hemodialysis", "TREATMENT", 225, 237], ["infection", "PROBLEM", 365, 374], ["the H1N1 virus", "PROBLEM", 380, 394], ["infection", "OBSERVATION", 24, 33], ["infection", "OBSERVATION", 365, 374]]], ["None of the patients developed severe disease, and the outbreak was successfully controlled.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["severe disease", "PROBLEM", 31, 45], ["the outbreak", "PROBLEM", 51, 63], ["severe", "OBSERVATION_MODIFIER", 31, 37], ["disease", "OBSERVATION", 38, 45]]]], "ea5ebe3d67f7df0138bb09da922de33767fb04da": [["Some enterprises begin with a type 1 strategy and are then infiltrated by what might be called a creeping type 2 strategy.", [["a type 1 strategy", "TREATMENT", 28, 45], ["a creeping type 2 strategy", "TREATMENT", 95, 121]]], ["One reason is that a type 2 strategy has the most immediate appeal, especially when setting fundable goals and trying to maintain organizational status quo.IntroductionAn example of a creeping type 2 strategy is provided by the Ranger program to photograph the moon in the early days of the US space program.", [["a type 2 strategy", "TREATMENT", 19, 36], ["a creeping type 2 strategy", "TREATMENT", 182, 208]]], ["Although the details differed for the different failures [1] , one can summarize the failures as the products of deficient systems integration, unrealistic testing conditions and haste.", [["the different failures", "PROBLEM", 34, 56], ["the failures", "PROBLEM", 81, 93], ["deficient systems integration", "PROBLEM", 113, 142], ["unrealistic testing conditions", "TEST", 144, 174], ["haste", "TEST", 179, 184]]], ["The deficiency in systems integration is basically a synonym for a creeping type 2 strategy.", [["The deficiency in systems integration", "PROBLEM", 0, 37], ["a synonym", "TREATMENT", 51, 60], ["a creeping type 2 strategy", "TREATMENT", 65, 91], ["deficiency", "OBSERVATION", 4, 14]]], ["Haste and lack of real-world orientation are corollary to a type 2 strategy.", [["Haste", "TEST", 0, 5]]], ["Better adherence to a type 1 strategy yielded more success with the initially-believed-beyond-reach, 9 year targeted Apollo program [2, 3] ; people walked on the moon ahead of schedule [3, 4] .", [["people", "ORGANISM", 141, 147], ["people", "SPECIES", 141, 147]]], ["Closer to the current topic is a non-specialist critique of research on curing metastatic cancer.", [["metastatic cancer", "ANATOMY", 79, 96], ["cancer", "DISEASE", 90, 96], ["metastatic cancer", "CANCER", 79, 96], ["metastatic cancer", "PROBLEM", 79, 96], ["metastatic", "OBSERVATION_MODIFIER", 79, 89], ["cancer", "OBSERVATION", 90, 96]]], ["In brief, this discussion outlines a creeping type 2 strategy in that field [5] .IntroductionThe central point here is that the situation is analogous for developing vaccines for pandemic viruses.", [["a creeping type 2 strategy", "TREATMENT", 35, 61], ["developing vaccines", "TREATMENT", 155, 174], ["pandemic viruses", "PROBLEM", 179, 195], ["central", "ANATOMY_MODIFIER", 97, 104]]], ["That is to say, as discussed in more detail below, vaccine-producing efforts have the highest chance of success via disciplined use of a type 1 strategy.", [["vaccine", "TREATMENT", 51, 58], ["a type 1 strategy", "TREATMENT", 135, 152]]], ["The overall objective is a safe, mass-produced, emerging virus-targeted vaccine on 2-4 week notice.", [["mass", "PROBLEM", 33, 37], ["emerging virus", "PROBLEM", 48, 62], ["targeted vaccine", "TREATMENT", 63, 79], ["mass", "OBSERVATION", 33, 37]]], ["I also present an alternative type 1 strategy option.IntroductionFor the main type 1 strategy option, the following are the initial subsidiary objectives for the overall objective.", [["an alternative type 1 strategy option", "TREATMENT", 15, 52]]], ["(1) Start with a platform based on live viruses that infect bacteria, but not humans (bacteriophages, or phages [6, 7] ).", [["humans", "ORGANISM", 78, 84], ["humans", "SPECIES", 78, 84], ["humans", "SPECIES", 78, 84], ["a platform", "TREATMENT", 15, 25], ["live viruses", "PROBLEM", 35, 47], ["infect bacteria", "PROBLEM", 53, 68]]], ["(2) Isolate phages (to be called pathogen homologs) that resemble and provide antigenic context for membrane-covered, pathogenic RNA viruses; coronavirus-phage homologs might be found if the search is correctly done.", [["membrane", "ANATOMY", 100, 108], ["membrane", "CELLULAR_COMPONENT", 100, 108], ["coronavirus-phage", "ORGANISM", 142, 159], ["coronavirus-phage homologs", "DNA", 142, 168], ["Isolate phages", "TREATMENT", 4, 18], ["pathogenic RNA viruses", "PROBLEM", 118, 140], ["coronavirus-phage homologs", "TREATMENT", 142, 168], ["RNA viruses", "OBSERVATION", 129, 140]]], ["(3) Upon isolating a pathogenic virus, evolve its phage homolog to bind neutralizing antibodies to the pathogenic virus.", [["neutralizing antibodies", "PROTEIN", 72, 95], ["a pathogenic virus", "PROBLEM", 19, 37], ["its phage homolog", "TREATMENT", 46, 63], ["the pathogenic virus", "PROBLEM", 99, 119], ["pathogenic virus", "OBSERVATION", 21, 37], ["pathogenic virus", "OBSERVATION", 103, 119]]], ["(4) Vaccinate with the evolved phage homolog by generating a local, non-hazardous infection with the phage host and then curing the infection by propagating the phage in the artificially infecting host.Large-Scale Vaccine Production and UseThe last subsidiary objective of any strategy is mass vaccine production.", [["infection", "DISEASE", 82, 91], ["infection", "DISEASE", 132, 141], ["Vaccinate", "TREATMENT", 4, 13], ["a local, non-hazardous infection", "PROBLEM", 59, 91], ["the phage host", "TREATMENT", 97, 111], ["the infection", "PROBLEM", 128, 141], ["Large-Scale Vaccine Production", "TREATMENT", 202, 232], ["mass vaccine production", "PROBLEM", 289, 312], ["infection", "OBSERVATION", 82, 91], ["infection", "OBSERVATION", 132, 141], ["-Scale", "OBSERVATION_MODIFIER", 207, 213], ["mass", "OBSERVATION", 289, 293]]], ["Live vaccines are the most easily adapted to meet this requirement because their constituents propagate post-vaccination.", [["Live vaccines", "TREATMENT", 0, 13]]], ["Smallpox vaccine [8] and the Sabin [9] and Koprowski [10] polio vaccines are examples; the Salk inactivated virus vaccine was the first vaccine for polio [11] .", [["Sabin", "ORGANISM", 29, 34], ["Koprowski [10] polio", "ORGANISM", 43, 63], ["Salk inactivated virus", "ORGANISM", 91, 113], ["Salk inactivated virus", "SPECIES", 91, 113], ["Smallpox vaccine", "TREATMENT", 0, 16], ["the Sabin [9] and Koprowski [10] polio vaccines", "TREATMENT", 25, 72], ["the Salk inactivated virus vaccine", "TREATMENT", 87, 121]]], ["Indeed, most currently approved anti-viral vaccines are either attenuated, live virus vaccines or inactivated virus vaccines [12] [13] [14] [15] .", [["[12] [13] [14] [15]", "SIMPLE_CHEMICAL", 125, 144], ["anti-viral vaccines", "TREATMENT", 32, 51], ["attenuated", "PROBLEM", 63, 73], ["live virus vaccines", "TREATMENT", 75, 94], ["inactivated virus vaccines", "TREATMENT", 98, 124]]], ["In the case of phages, a single preparation typically has over 10 13 phage particles (sometimes over 10 14 ) when the phages have been propagated, concentrated and purified from a 15 L lysate.", [["a 15 L lysate", "TREATMENT", 178, 191]]], ["This is more than enough to vaccinate everyone in the world with a 1000 phage dose, if the phages can be made to propagate post-vaccination.", [["a 1000 phage dose", "TREATMENT", 65, 82], ["the phages", "TREATMENT", 87, 97]]], ["Bulk-purifying phages by ultracentrifugation takes approximately two days.Large-Scale Vaccine Production and UseTo achieve post-vaccination phage propagation, we have to give the phages a bacterial host.", [["Bulk-purifying phages", "TREATMENT", 0, 21], ["Large-Scale Vaccine Production", "TREATMENT", 74, 104], ["UseTo achieve post-vaccination phage propagation", "TREATMENT", 109, 157], ["a bacterial host", "TREATMENT", 186, 202], ["purifying phages", "OBSERVATION", 5, 21], ["-Scale", "OBSERVATION_MODIFIER", 79, 85]]], ["One way to do this is to start an intra-dermal infection with the bacterial host.", [["infection", "DISEASE", 47, 56], ["an intra-dermal infection", "PROBLEM", 31, 56], ["the bacterial host", "PROBLEM", 62, 80], ["infection", "OBSERVATION", 47, 56], ["bacterial host", "OBSERVATION", 66, 80]]], ["Then, cure the infection by infecting the bacterial host with the antigenic phage.", [["infection", "DISEASE", 15, 24], ["the infection", "PROBLEM", 11, 24], ["the antigenic phage", "TREATMENT", 62, 81], ["infection", "OBSERVATION", 15, 24], ["bacterial host", "OBSERVATION", 42, 56]]], ["This is upside-down phage therapy so to speak.", [["upside-down phage therapy", "TREATMENT", 8, 33]]], ["The phages will multiply until either the bacteria are gone or until immune systems prevent further multiplication.", [["The phages", "TREATMENT", 0, 10], ["the bacteria", "PROBLEM", 38, 50], ["immune systems", "PROBLEM", 69, 83], ["further multiplication", "PROBLEM", 92, 114]]], ["Thus, the characteristics of the bacterial host are key components of this platform.", [["the bacterial host", "PROBLEM", 29, 47], ["bacterial host", "OBSERVATION", 33, 47]]], ["The host must not itself become a problematic pathogen, yet it must continue to propagate enough to yield enough phages to stimulate innate and adaptive immune systems to produce immunity to the phage and, by homology, immunity to the virus that is causing the problem in the first place.Large-Scale Vaccine Production and UseIndeed, this proposed procedure is not all that far from the procedure of a smallpox vaccination and might leave a similar scar.", [["scar", "ANATOMY", 449, 453], ["smallpox", "DISEASE", 402, 410], ["scar", "PATHOLOGICAL_FORMATION", 449, 453], ["a problematic pathogen", "PROBLEM", 32, 54], ["adaptive immune systems", "TREATMENT", 144, 167], ["the virus", "PROBLEM", 231, 240], ["Large-Scale Vaccine Production", "TREATMENT", 288, 318], ["this proposed procedure", "TREATMENT", 334, 357], ["the procedure", "TREATMENT", 383, 396], ["a smallpox vaccination", "TREATMENT", 400, 422], ["a similar scar", "PROBLEM", 439, 453], ["-Scale", "OBSERVATION_MODIFIER", 293, 299], ["similar", "OBSERVATION_MODIFIER", 441, 448], ["scar", "OBSERVATION", 449, 453]]], ["Some of us can still see scars from smallpox vaccination.", [["smallpox", "DISEASE", 36, 44], ["scars", "PATHOLOGICAL_FORMATION", 25, 30], ["scars", "PROBLEM", 25, 30], ["smallpox vaccination", "TREATMENT", 36, 56], ["scars", "OBSERVATION", 25, 30]]], ["The main difference is that the replicating phage antigen needs externally supplied host cells in order to produce immunity.Large-Scale Vaccine Production and UseWithout going into details concerning live vaccine production via eukaryotic viruses, I think it reasonable to assume that eukaryotic virus production is more difficult, more expensive and less rapid than the production of phages.", [["cells", "ANATOMY", 89, 94], ["phage antigen", "GENE_OR_GENE_PRODUCT", 44, 57], ["host cells", "CELL", 84, 94], ["replicating phage antigen", "PROTEIN", 32, 57], ["externally supplied host cells", "CELL_TYPE", 64, 94], ["the replicating phage antigen", "TREATMENT", 28, 57], ["Large-Scale Vaccine Production", "TREATMENT", 124, 154], ["eukaryotic virus production", "PROBLEM", 285, 312], ["main", "OBSERVATION_MODIFIER", 4, 8], ["difference", "OBSERVATION_MODIFIER", 9, 19], ["phage", "OBSERVATION_MODIFIER", 44, 49], ["host cells", "OBSERVATION", 84, 94], ["-Scale", "OBSERVATION_MODIFIER", 129, 135], ["virus", "OBSERVATION", 296, 301]]], ["Further, there are fewer safety concerns with phages.Evolving Phages to Bind Antibodies that Neutralize a Viral PathogenTo understand the principle of how this type of evolution might be achieved, I use the following analogy.", [["Bind Antibodies", "PROTEIN", 72, 87], ["Evolving Phages", "PROBLEM", 53, 68], ["Bind Antibodies", "TREATMENT", 72, 87], ["fewer", "OBSERVATION_MODIFIER", 19, 24]]], ["Suppose one wanted to maximize the speed of the non-mechanized elevation of a person to a ledge 10 feet high.", [["person", "SPECIES", 78, 84]]], ["Jumping that high is out of the question, no matter how many tries are made.", [["high", "OBSERVATION_MODIFIER", 13, 17]]], ["The situation with phages is analogous, as we found when evolving phage T3 to propagate in 0.9 M NaCl.", [["NaCl", "CHEMICAL", 97, 101], ["NaCl", "CHEMICAL", 97, 101]]], ["Parenthetically, this NaCl concentration is so high that, in Petri plates, our only indication of host growth was the observation of plaques of our step-evolved phage.", [["plaques", "ANATOMY", 133, 140], ["NaCl", "CHEMICAL", 22, 26], ["NaCl", "CHEMICAL", 22, 26], ["NaCl", "SIMPLE_CHEMICAL", 22, 26], ["this NaCl concentration", "TREATMENT", 17, 40], ["host growth", "PROBLEM", 98, 109], ["plaques", "PROBLEM", 133, 140]]], ["It is not intended to indicate the complexity of what is proposed below.Evolving Phages to Bind Antibodies that Neutralize a Viral PathogenThus, the basic idea is to build the foundation by step-evolving phages to react with the neutralizing antibodies of the target pathogen.", [["Viral PathogenThus", "DISEASE", 125, 143], ["Bind Antibodies", "PROTEIN", 91, 106], ["neutralizing antibodies", "PROTEIN", 229, 252], ["Evolving Phages", "PROBLEM", 72, 87], ["Bind Antibodies", "TEST", 91, 106], ["a Viral PathogenThus", "PROBLEM", 123, 143], ["the neutralizing antibodies", "TREATMENT", 225, 252], ["the target pathogen", "PROBLEM", 256, 275]]], ["I assume here that the antibodies are already in hand.", [["hand", "ANATOMY", 49, 53], ["hand", "ORGANISM_SUBDIVISION", 49, 53], ["antibodies", "PROTEIN", 23, 33], ["the antibodies", "PROBLEM", 19, 33]]], ["That, in turn, can be done by antibody-selecting phage homologs for each of the multiple known and potential pathogens isolated from the environment.", [["selecting phage homologs", "TREATMENT", 39, 63], ["potential pathogens", "PROBLEM", 99, 118]]], ["For example, an antibody-selected SARS-CoV-1 phage homolog might serve as the starting point for an antibody-selected SARS-CoV-2 phage homolog.", [["SARS-CoV-1", "ORGANISM", 34, 44], ["SARS-CoV-2 phage homolog", "GENE_OR_GENE_PRODUCT", 118, 142], ["SARS-CoV-1 phage homolog", "DNA", 34, 58], ["SARS-CoV-2 phage homolog", "DNA", 118, 142], ["SARS-CoV-1", "SPECIES", 34, 44], ["an antibody", "TEST", 13, 24], ["CoV-1 phage homolog", "TREATMENT", 39, 58], ["an antibody", "TEST", 97, 108]]], ["That is to say, some of the inter-pandemic activity would be devoted to improving vaccines to current pathogens.", [["current pathogens", "PROBLEM", 94, 111]]], ["Recommendations to do this have already been made, in the context of other vaccine-generating options [14] .Evolving Phages to Bind Antibodies that Neutralize a Viral PathogenSeveral procedures exist for performing the antibody-selection of phages.", [["Bind Antibodies", "PROTEIN", 127, 142], ["other vaccine", "TREATMENT", 69, 82], ["Evolving Phages", "PROBLEM", 108, 123], ["Bind Antibodies", "TREATMENT", 127, 142], ["a Viral PathogenSeveral procedures", "TREATMENT", 159, 193], ["the antibody", "TEST", 215, 227]]], ["Affinity, antigen-loaded columns are already used via chromatography to select antibody-displaying phages for antibodies with increased affinity to antigen [17, 18] .", [["antibody", "PROTEIN", 79, 87], ["antibodies", "PROTEIN", 110, 120], ["antigen-loaded columns", "TREATMENT", 10, 32], ["chromatography", "TEST", 54, 68], ["antibody", "TEST", 79, 87], ["antibodies", "PROBLEM", 110, 120], ["increased affinity", "PROBLEM", 126, 144], ["antigen", "TEST", 148, 155]]], ["Using this procedure, while reversing the role of antibody and antigen (antibody bound to the column), is one way to antibody-select phages.", [["antibody and antigen", "PROTEIN", 50, 70], ["antibody", "PROTEIN", 72, 80], ["antibody", "PROTEIN", 117, 125], ["this procedure", "TREATMENT", 6, 20], ["antibody", "TEST", 50, 58]]], ["An independent approach is indicated by the fact that antibody-generated phage multimers are observed as discrete, more origin-proximal-than-monomeric-phage bands after reacting phages with antiserum and performing native gel electrophoresis [19] .", [["antiserum", "ORGANISM_SUBSTANCE", 190, 199], ["antibody-generated phage multimers", "PROTEIN", 54, 88], ["antibody", "TEST", 54, 62], ["monomeric-phage bands", "TREATMENT", 141, 162], ["antiserum", "TREATMENT", 190, 199], ["performing native gel electrophoresis", "TREATMENT", 204, 241], ["proximal", "ANATOMY_MODIFIER", 127, 135]]], ["Selecting phages near or at the origin is an alternative selection of antibody-reactive phage.", [["antibody", "PROTEIN", 70, 78], ["Selecting phages", "TREATMENT", 0, 16], ["reactive phage", "OBSERVATION", 79, 93]]], ["The same is the case for phages that are in the void volume after molecular sieve chromatography.", [["phages", "TREATMENT", 25, 31], ["molecular sieve chromatography", "TEST", 66, 96], ["sieve chromatography", "OBSERVATION", 76, 96]]], ["Selecting rapidly sedimenting phages after rate zonal centrifugation in a sucrose density gradient is yet another procedure.Evolving Phages to Bind Antibodies that Neutralize a Viral PathogenThen arises the question of which phage to use at the beginning.", [["sucrose", "CHEMICAL", 74, 81], ["sucrose", "CHEMICAL", 74, 81], ["sucrose", "SIMPLE_CHEMICAL", 74, 81], ["Bind Antibodies", "PROTEIN", 143, 158], ["Selecting rapidly sedimenting phages", "TREATMENT", 0, 36], ["rate zonal centrifugation", "TREATMENT", 43, 68], ["a sucrose density gradient", "TREATMENT", 72, 98], ["another procedure", "TREATMENT", 106, 123], ["Evolving Phages", "PROBLEM", 124, 139], ["Bind Antibodies", "TREATMENT", 143, 158], ["a Viral PathogenThen", "PROBLEM", 175, 195], ["rapidly", "OBSERVATION_MODIFIER", 10, 17], ["sedimenting phages", "OBSERVATION", 18, 36], ["sucrose density", "OBSERVATION_MODIFIER", 74, 89]]], ["In theory, any stable phage could be used as a starting point.", [["any stable phage", "TREATMENT", 11, 27], ["stable", "OBSERVATION_MODIFIER", 15, 21], ["phage", "OBSERVATION", 22, 27]]], ["Time to objective might be decreased by using a phage displaying a peptide from the spike protein (or other protruding protein) of a potential target virus.", [["spike protein", "PROTEIN", 84, 97], ["protruding protein", "PROTEIN", 108, 126], ["a phage", "TREATMENT", 46, 53], ["a peptide", "PROBLEM", 65, 74], ["the spike protein", "PROBLEM", 80, 97], ["other protruding protein", "PROBLEM", 102, 126], ["a potential target virus", "PROBLEM", 131, 155], ["target virus", "OBSERVATION", 143, 155]]], ["However, current efforts to human-engineer improved antigens for anti-RNA virus vaccines have shown that neutralizing antibodies typically react with viral proteins that are in states that are context dependent and unstable [12, 13, 15, 20] .", [["human", "ORGANISM", 28, 33], ["anti-RNA virus", "ORGANISM", 65, 79], ["neutralizing antibodies", "PROTEIN", 105, 128], ["viral proteins", "PROTEIN", 150, 164], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 28, 33], ["anti-RNA virus vaccines", "TREATMENT", 65, 88], ["neutralizing antibodies", "PROBLEM", 105, 128], ["viral proteins", "PROBLEM", 150, 164], ["unstable", "OBSERVATION_MODIFIER", 215, 223]]], ["The context includes assembly with other viral proteins, which results in the use of artificial scaffolds in structural vaccinology [12] .", [["viral proteins", "PROTEIN", 41, 55], ["other viral proteins", "PROBLEM", 35, 55], ["artificial scaffolds", "TREATMENT", 85, 105]]], ["Much work has been devoted to stabilizing protein antigens in \"appropriate\" states and masking epitopes that interfere with the epitope that reacts with neutralizing antibody [12, 13, 15, 20] .", [["protein antigens", "PROTEIN", 42, 58], ["epitopes", "PROTEIN", 95, 103], ["neutralizing antibody", "PROTEIN", 153, 174], ["stabilizing protein antigens", "PROBLEM", 30, 58], ["masking epitopes", "PROBLEM", 87, 103], ["neutralizing antibody", "TEST", 153, 174]]], ["RNA viruses have evolved sophistication to the point that they make most accessible the epitopes that change the most rapidly [20] .", [["epitopes", "PROTEIN", 88, 96], ["RNA viruses", "PROBLEM", 0, 11], ["viruses", "OBSERVATION", 4, 11]]], ["The context also includes embedding in a lipid bilayer membrane [12] [13] [14] [15] .", [["lipid bilayer membrane", "ANATOMY", 41, 63], ["a lipid bilayer membrane", "TEST", 39, 63]]], ["The context dependence of neutralizing antibody antigenicity leads to the conclusion that, in practice, the best starting point is a phage structurally homologous to the known or anticipated pathogenic virus.Evolving Phages to Bind Antibodies that Neutralize a Viral PathogenI take the liberty of responding here to the obvious objection that no membrane-covered, single-stranded RNA phage has ever been isolated [21] and that the pandemic viruses include influenza, Zika-type and coronaviruses, all in this category.", [["membrane", "ANATOMY", 346, 354], ["influenza", "DISEASE", 456, 465], ["Zika-type and coronaviruses", "DISEASE", 467, 494], ["membrane", "CELLULAR_COMPONENT", 346, 354], ["Zika-type", "ORGANISM", 467, 476], ["coronaviruses", "ORGANISM", 481, 494], ["Bind Antibodies", "PROTEIN", 227, 242], ["neutralizing antibody antigenicity", "PROBLEM", 26, 60], ["a phage structurally homologous", "PROBLEM", 131, 162], ["anticipated pathogenic virus", "PROBLEM", 179, 207], ["Evolving Phages", "PROBLEM", 208, 223], ["Bind Antibodies", "TREATMENT", 227, 242], ["a Viral PathogenI", "TREATMENT", 259, 276], ["membrane", "PROBLEM", 346, 354], ["single-stranded RNA phage", "TREATMENT", 364, 389], ["the pandemic viruses", "PROBLEM", 427, 447], ["influenza", "PROBLEM", 456, 465], ["Zika", "PROBLEM", 467, 471], ["coronaviruses", "PROBLEM", 481, 494], ["dependence", "OBSERVATION_MODIFIER", 12, 22], ["neutralizing", "OBSERVATION_MODIFIER", 26, 38], ["antibody antigenicity", "OBSERVATION", 39, 60], ["pathogenic virus", "OBSERVATION", 191, 207]]], ["Membrane-covered, double-stranded RNA phages have been isolated [21] .", [["Membrane", "ANATOMY", 0, 8], ["Membrane", "CELLULAR_COMPONENT", 0, 8], ["double-stranded RNA phages", "DNA", 18, 44], ["Membrane", "TEST", 0, 8], ["double-stranded RNA phages", "TREATMENT", 18, 44]]], ["Already shown is that membrane-coated DNA phages are dramatically under-isolated with the current most popular isolation procedures.", [["membrane", "ANATOMY", 22, 30], ["membrane", "CELLULAR_COMPONENT", 22, 30], ["DNA", "CELLULAR_COMPONENT", 38, 41], ["membrane-coated DNA phages", "TREATMENT", 22, 48], ["popular isolation procedures", "TREATMENT", 103, 131]]], ["Chloroform treatment is a major culprit [22] .", [["Chloroform", "CHEMICAL", 0, 10], ["Chloroform", "CHEMICAL", 0, 10], ["Chloroform", "SIMPLE_CHEMICAL", 0, 10], ["Chloroform treatment", "TREATMENT", 0, 20]]], ["I note that some propagating, bacteriolytic particles are, structurally, far from the phages isolated in the past; an example is phage 904phi4-5 in [23] .Evolving Phages to Bind Antibodies that Neutralize a Viral PathogenThe underlying thesis for this section is that genetic selection is the most reliable way to achieve the systems engineering needed to achieve appropriate antigens for needed vaccines.", [["[23]", "SIMPLE_CHEMICAL", 148, 152], ["Bind Antibodies", "PROTEIN", 173, 188], ["some propagating, bacteriolytic particles", "PROBLEM", 12, 53], ["Evolving Phages", "PROBLEM", 154, 169], ["Bind Antibodies", "TREATMENT", 173, 188], ["a Viral Pathogen", "PROBLEM", 205, 221], ["this section", "TREATMENT", 247, 259], ["needed vaccines", "TREATMENT", 389, 404], ["bacteriolytic particles", "OBSERVATION", 30, 53]]], ["When performed with phages, genetic selection is also rapid to the point that human engineering, even if enough was known to do it reliably, would probably not be as rapid.Isolating Phage Homologs to Disease-Causing VirusesMy preferred procedural advance for rapidly and unbiasedly isolating phages has already been described [24, 25] .", [["human", "ORGANISM", 78, 83], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 78, 83], ["phages", "TREATMENT", 20, 26], ["genetic selection", "TEST", 28, 45], ["VirusesMy", "PROBLEM", 216, 225], ["unbiasedly isolating phages", "TREATMENT", 271, 298]]], ["In brief, the phage isolation techniques include both initial isolation and subsequent propagation in a gel.", [["the phage isolation techniques", "TREATMENT", 10, 40], ["both initial isolation", "TREATMENT", 49, 71], ["subsequent propagation in a gel", "TREATMENT", 76, 107]]], ["All transfers are done with a needle.", [["a needle", "TREATMENT", 28, 36]]], ["No liquid culture is involved.", [["liquid culture", "TEST", 3, 17], ["liquid culture", "OBSERVATION", 3, 17]]], ["One advantage of a procedure of this type is that dry environmental samples (often in a powdered state) are used, thereby increasing the probability that the phages isolated can be dried for transport.", [["samples", "ANATOMY", 68, 75], ["a procedure", "TREATMENT", 17, 28], ["dry environmental samples", "PROBLEM", 50, 75], ["the phages", "TREATMENT", 154, 164]]], ["Presumably, further development of these procedures is possible.Isolating Phage Homologs to Disease-Causing VirusesOrganization and inter-laboratory coordination will be a key feature of any effort, whatever procedures are used for phage isolation.", [["these procedures", "TREATMENT", 35, 51], ["Disease", "PROBLEM", 92, 99], ["VirusesOrganization", "PROBLEM", 108, 127], ["phage isolation", "TREATMENT", 232, 247]]], ["The reason is that the phage collection will be large enough so that computerization will be needed for access to both data and the phages themselves.", [["the phage collection", "PROBLEM", 19, 39]]], ["Organization begins with a naming system that makes impossible the giving of the same name to two different phages [24, 25] .SafetyAny therapeutic use of phages begins with two advantages in the area of safety.", [["phages", "TREATMENT", 154, 160], ["therapeutic", "OBSERVATION_MODIFIER", 135, 146]]], ["(1) Although phage uptake into human cells occurs, no evidence exists that phages replicate in human cells [26] [27] [28] .", [["cells", "ANATOMY", 37, 42], ["cells", "ANATOMY", 101, 106], ["human", "ORGANISM", 31, 36], ["cells", "CELL", 37, 42], ["human", "ORGANISM", 95, 100], ["cells", "CELL", 101, 106], ["human cells", "CELL_TYPE", 31, 42], ["human cells", "CELL_TYPE", 95, 106], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 95, 100], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 95, 100], ["phage uptake into human cells", "PROBLEM", 13, 42], ["human cells", "OBSERVATION", 31, 42], ["no evidence exists", "UNCERTAINTY", 51, 69]]], ["For example, phages use transcription and translation signals that are different from those of eukaryotic cells.", [["cells", "ANATOMY", 106, 111], ["cells", "CELL", 106, 111], ["eukaryotic cells", "CELL_TYPE", 95, 111], ["translation signals", "TEST", 42, 61], ["eukaryotic cells", "OBSERVATION", 95, 111]]], ["(2) The experience with phage therapy of infectious disease is that the phage particles themselves are never found to have negative effects in humans [29, 30] .", [["infectious disease", "DISEASE", 41, 59], ["humans", "ORGANISM", 143, 149], ["humans", "SPECIES", 143, 149], ["humans", "SPECIES", 143, 149], ["phage therapy", "TREATMENT", 24, 37], ["infectious disease", "PROBLEM", 41, 59]]], ["Perhaps the greatest danger is the induction of non-neutralizing antibodies that aggravate an infection.", [["infection", "DISEASE", 94, 103], ["non-neutralizing antibodies", "PROTEIN", 48, 75], ["non-neutralizing antibodies", "PROBLEM", 48, 75], ["an infection", "PROBLEM", 91, 103], ["greatest", "OBSERVATION_MODIFIER", 12, 20], ["infection", "OBSERVATION", 94, 103]]], ["This is one explanation of vaccine aggravation of dengue fever, a phenomenon preferentially encountered with young recipients of dengue fever vaccine [31, 32] .", [["dengue fever", "DISEASE", 50, 62], ["dengue fever", "DISEASE", 129, 141], ["vaccine aggravation", "PROBLEM", 27, 46], ["dengue fever", "PROBLEM", 50, 62], ["a phenomenon", "PROBLEM", 64, 76], ["dengue fever vaccine", "TREATMENT", 129, 149], ["one explanation of", "UNCERTAINTY", 8, 26]]], ["However, selection against induction of non-neutralizing antibodies occurs when the phage is selected for binding to neutralizing antibody.SafetyOne cannot be so sanguine about any vaccine that has either eukaryotic RNA or eukaryotic DNA with transcription and translation signals.", [["SafetyOne", "CHEMICAL", 139, 148], ["DNA", "CELLULAR_COMPONENT", 234, 237], ["non-neutralizing antibodies", "PROTEIN", 40, 67], ["neutralizing antibody", "PROTEIN", 117, 138], ["eukaryotic RNA", "RNA", 205, 219], ["eukaryotic DNA", "DNA", 223, 237], ["non-neutralizing antibodies", "TREATMENT", 40, 67], ["the phage", "TREATMENT", 80, 89], ["neutralizing antibody", "TEST", 117, 138], ["any vaccine", "TREATMENT", 177, 188], ["translation signals", "TEST", 261, 280]]], ["DNA vaccines are the more serious concern because of possible chromosome insertions [13] .", [["chromosome", "ANATOMY", 62, 72], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["chromosome", "CELLULAR_COMPONENT", 62, 72], ["chromosome insertions", "DNA", 62, 83], ["DNA vaccines", "TREATMENT", 0, 12], ["chromosome insertions", "PROBLEM", 62, 83]]], ["In the case of an un-encapsulated RNA vaccine, a secondary concern is destruction of the vaccine by RNases [13] .", [["an un-encapsulated RNA vaccine", "TREATMENT", 15, 45], ["destruction of the vaccine", "PROBLEM", 70, 96]]], ["Assuming that eukaryotic DNA and RNA vaccines will always have to be safety tested, they are not likely to meet the 2-4 week constraint that is imposed by a novel, rapidly spreading pandemic virus.", [["DNA", "CELLULAR_COMPONENT", 25, 28], ["eukaryotic DNA", "DNA", 14, 28], ["eukaryotic DNA", "TREATMENT", 14, 28], ["RNA vaccines", "TREATMENT", 33, 45], ["rapidly spreading pandemic virus", "PROBLEM", 164, 196], ["eukaryotic DNA", "OBSERVATION", 14, 28]]], ["Many years are likely to be required to test for cancer-generating chromosomal alterations.", [["cancer", "ANATOMY", 49, 55], ["chromosomal", "ANATOMY", 67, 78], ["cancer", "DISEASE", 49, 55], ["cancer", "CANCER", 49, 55], ["chromosomal", "CELLULAR_COMPONENT", 67, 78], ["cancer", "PROBLEM", 49, 55], ["chromosomal alterations", "PROBLEM", 67, 90], ["chromosomal alterations", "OBSERVATION", 67, 90]]], ["A non-specialist observer reasonably concludes that DNA and RNA vaccines, when viewed in the context of our overall objective, are examples of type 2 strategy options.", [["DNA", "CELLULAR_COMPONENT", 52, 55], ["DNA and RNA vaccines", "TREATMENT", 52, 72], ["type 2 strategy options", "TREATMENT", 143, 166]]], ["Furthermore, in spite of a~27 year history [33] , no DNA vaccine has ever been FDA approved for use with humans [13, 34] .", [["DNA", "CELLULAR_COMPONENT", 53, 56], ["humans", "ORGANISM", 105, 111], ["humans", "SPECIES", 105, 111], ["humans", "SPECIES", 105, 111], ["DNA vaccine", "TREATMENT", 53, 64]]], ["Pathogen homolog RNA phage vaccines, on the other hand, would have an a priori and reasonable projection (not certainty) of safety.", [["Pathogen homolog", "GENE_OR_GENE_PRODUCT", 0, 16], ["Pathogen homolog RNA phage vaccines", "TREATMENT", 0, 35]]], ["Even some DNA phage vaccines might eventually be placed in this category.SafetyThe importance of this latter characteristic becomes apparent when one intellectually removes the blinders that human emotion places on us.", [["DNA", "CELLULAR_COMPONENT", 10, 13], ["human", "ORGANISM", 191, 196], ["human", "SPECIES", 191, 196], ["human", "SPECIES", 191, 196], ["some DNA phage vaccines", "TREATMENT", 5, 28]]], ["Specifically, SARS-CoV-2 is not as deadly as SARS-CoV-1.", [["SARS", "DISEASE", 14, 18], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 14, 24], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 45, 55], ["SARS-CoV", "SPECIES", 14, 22], ["SARS-CoV-1", "SPECIES", 45, 55], ["SARS", "PROBLEM", 14, 18]]], ["The problem is that SARS-CoV-2 transmits more actively and does so on inanimate surfaces, although I have not yet seen a claim that SARS-CoV-2 can transmit on dust particles.", [["SARS", "DISEASE", 20, 24], ["SARS", "DISEASE", 132, 136], ["SARS-CoV-2", "ORGANISM", 20, 30], ["SARS", "PROBLEM", 20, 24]]], ["Can a virus transmit even more actively than SARS-CoV-2?", [["SARS", "DISEASE", 45, 49], ["SARS-CoV-2", "ORGANISM", 45, 55], ["SARS-CoV", "SPECIES", 45, 53], ["a virus transmit", "PROBLEM", 4, 20], ["CoV", "TEST", 50, 53]]], ["First, in the real world, one of the best sources of phages is dry soil around horse watering troughs (our circumstantial observations).", [["horse", "ORGANISM_SUBDIVISION", 79, 84], ["horse", "SPECIES", 79, 84], ["phages", "PROBLEM", 53, 59], ["dry soil", "PROBLEM", 63, 71]]], ["This soil typically resembles a powder and would be easily dispersed as dust in the atmosphere by wind.", [["a powder", "TREATMENT", 30, 38]]], ["If so, the thought part of this experiment tells us that eukaryotic viruses can also evolve to survive on dust particles.", [["eukaryotic viruses", "PROBLEM", 57, 75], ["viruses", "OBSERVATION", 68, 75]]], ["Similar, more dramatic dust-generating effects occur in deserts.", [["more", "OBSERVATION_MODIFIER", 9, 13], ["dramatic", "OBSERVATION_MODIFIER", 14, 22], ["dust", "OBSERVATION", 23, 27], ["generating effects", "OBSERVATION", 28, 46], ["deserts", "OBSERVATION_MODIFIER", 56, 63]]], ["We were apparently lucky that the MERS coronavirus [35] did not create greater problems than it did via transmission on sand particles, given that it originated in Saudi Arabia.SafetyCan more active transmission be accompanied by higher virulence?", [["MERS coronavirus", "ORGANISM", 34, 50], ["MERS coronavirus", "SPECIES", 34, 50], ["the MERS coronavirus", "PROBLEM", 30, 50], ["higher virulence", "PROBLEM", 230, 246], ["higher", "OBSERVATION_MODIFIER", 230, 236], ["virulence", "OBSERVATION", 237, 246]]], ["Either way, I think that the case for vaccine development speed, and therefore the case for vaccines with a priori, rational expectation of safety, needs no further justification.", [["vaccines", "TREATMENT", 92, 100]]], ["Otherwise, we would already have a vaccine and we would not be told that we have to wait over a year for one.", [["a vaccine", "TREATMENT", 33, 42]]], ["My use of this time constraint is closely connected to the real world of both mass fatalities and economic collapse-both of which are now beginning and can be compounded by criminal misuse of SARS-CoV-2.", [["fatalities", "DISEASE", 83, 93], ["SARS", "DISEASE", 192, 196], ["SARS-CoV-2", "ORGANISM", 192, 202], ["SARS-CoV", "SPECIES", 192, 200], ["both mass fatalities", "PROBLEM", 73, 93], ["economic collapse", "PROBLEM", 98, 115], ["mass", "OBSERVATION", 78, 82], ["economic", "OBSERVATION_MODIFIER", 98, 106], ["collapse", "OBSERVATION", 107, 115]]], ["That is to say, realistic conditions are not being currently used for testing vaccine strategies.", [["testing vaccine strategies", "TREATMENT", 70, 96]]], ["(1) \"Most people would rather fail conventionally than succeed unconventionally.\" (2) When the tide goes out, you discover who is swimming naked.\"", [["people", "ORGANISM", 10, 16], ["people", "SPECIES", 10, 16]]], ["The tide is going out.Perspective and an AlternativeThe preferred option for anti-viral vaccine response depends, to some extent, on the history and agenda of the responder.", [["anti-viral vaccine response", "TREATMENT", 77, 104]]], ["Indeed, the phage isolation aspect overlaps the author's previous proposals for resolving current crises in the therapy of multi-drug-resistant bacterial infections [36] and metastatic cancer [37] .", [["metastatic cancer", "ANATOMY", 174, 191], ["bacterial infections", "DISEASE", 144, 164], ["cancer", "DISEASE", 185, 191], ["metastatic cancer", "CANCER", 174, 191], ["the phage isolation", "TREATMENT", 8, 27], ["resolving current crises", "PROBLEM", 80, 104], ["the therapy", "TREATMENT", 108, 119], ["multi-drug-resistant bacterial infections", "PROBLEM", 123, 164], ["metastatic cancer", "PROBLEM", 174, 191], ["bacterial", "OBSERVATION_MODIFIER", 144, 153], ["infections", "OBSERVATION", 154, 164], ["metastatic", "OBSERVATION_MODIFIER", 174, 184], ["cancer", "OBSERVATION", 185, 191]]], ["Investigation of natural phage bioengineering has produced a framework for understanding and curing neurodegenerative diseases [38] .", [["neurodegenerative diseases", "DISEASE", 100, 126], ["natural phage bioengineering", "TREATMENT", 17, 45], ["neurodegenerative diseases", "PROBLEM", 100, 126], ["natural phage", "OBSERVATION", 17, 30]]], ["The underlying thesis is the following: make use of the systems engineering of perhaps two billion years of phage evolution.Perspective and an AlternativeGiven that the platforms presented here for the above type 1 strategy option are not (and may never be) built, I present an alternative to this option.", [["this option", "TREATMENT", 293, 304]]], ["The alternative option is a live eukaryotic virus vaccine of atypical type.", [["a live eukaryotic virus vaccine", "TREATMENT", 26, 57]]], ["Given that eukaryotic viruses have doubling times much greater than those of phages (2-5 min for typical coliphages), meeting this objective implies that a live virus vaccine has to be already present in the environment.Perspective and an AlternativeThat this presence is a realistic expectation was shown by Pasteur's demonstration of the absence, for all practical purposes, of spontaneous generation of microbes [39] .", [["coliphages", "CANCER", 105, 115], ["eukaryotic viruses", "PROBLEM", 11, 29], ["typical coliphages", "PROBLEM", 97, 115], ["a live virus vaccine", "TREATMENT", 154, 174], ["spontaneous generation of microbes", "PROBLEM", 380, 414], ["viruses", "OBSERVATION", 22, 29]]], ["Thus, any emerging pathogenic virus has ancestors.", [["any emerging pathogenic virus", "PROBLEM", 6, 35]]], ["Given the emerging pathogen character, most ancestors do not have the pathogenicity of the current pathogen.", [["the current pathogen", "PROBLEM", 87, 107]]], ["However, at least some ancestors are likely to have sufficient antigenic overlap to act as live vaccines.", [["live vaccines", "TREATMENT", 91, 104]]], ["That use of such ancestor vaccines can work has been shown via finding that porcine respiratory coronavirus infection of pigs immunizes naturally against the more dangerous transmissible gastroenteritis coronavirus [40] .", [["respiratory coronavirus infection", "DISEASE", 84, 117], ["gastroenteritis coronavirus", "DISEASE", 187, 214], ["porcine", "ORGANISM", 76, 83], ["respiratory coronavirus", "ORGANISM", 84, 107], ["pigs", "ORGANISM", 121, 125], ["porcine respiratory coronavirus", "SPECIES", 76, 107], ["pigs", "SPECIES", 121, 125], ["transmissible gastroenteritis coronavirus", "SPECIES", 173, 214], ["porcine respiratory coronavirus", "SPECIES", 76, 107], ["pigs", "SPECIES", 121, 125], ["gastroenteritis coronavirus", "SPECIES", 187, 214], ["such ancestor vaccines", "TREATMENT", 12, 34], ["porcine respiratory coronavirus infection", "PROBLEM", 76, 117], ["the more dangerous transmissible gastroenteritis coronavirus", "PROBLEM", 154, 214]]], ["Further, the original smallpox vaccine was also of this type [8] .Perspective and an AlternativeThus, the first platform for this alternate type 1 strategy option is a library of live viruses in each of the classes that also contain viral pathogens.", [["the original smallpox vaccine", "TREATMENT", 9, 38], ["this alternate type 1 strategy option", "TREATMENT", 125, 162], ["viral pathogens", "PROBLEM", 233, 248], ["viral pathogens", "OBSERVATION", 233, 248]]], ["Recommendation to build this platform has already been made for other reasons [14] .Perspective and an AlternativeThe second platform is enough interpreted data so that both pathogenicity and antigenicity of any potential live vaccine strain can be predicted from the base sequence of its genome.", [["genome", "CELLULAR_COMPONENT", 289, 295], ["both pathogenicity", "PROBLEM", 169, 187], ["any potential live vaccine strain", "PROBLEM", 208, 241]]], ["This platform is not here at present and is faced with significant difficulties.", [["significant difficulties", "PROBLEM", 55, 79], ["significant", "OBSERVATION_MODIFIER", 55, 66], ["difficulties", "OBSERVATION", 67, 79]]], ["For example, even though the SARS-CoV-1 spike protein (i.e., the protein that makes the initial contact with a cellular receptor) is structurally homologous to the SARS-CoV-2 spike protein, neutralizing antibodies to the SARS-CoV-1 spike protein do not react with the SARS-CoV-2 spike protein [41] .", [["cellular", "ANATOMY", 111, 119], ["SARS", "DISEASE", 29, 33], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 29, 39], ["cellular", "CELL", 111, 119], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 164, 174], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 221, 231], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 268, 278], ["SARS-CoV-1 spike protein", "PROTEIN", 29, 53], ["cellular receptor", "PROTEIN", 111, 128], ["SARS-CoV-2 spike protein", "PROTEIN", 164, 188], ["neutralizing antibodies", "PROTEIN", 190, 213], ["SARS-CoV-1 spike protein", "PROTEIN", 221, 245], ["SARS-CoV-2 spike protein", "PROTEIN", 268, 292], ["SARS-CoV-1", "SPECIES", 221, 231], ["the SARS", "TEST", 25, 33], ["CoV", "TEST", 34, 37], ["spike protein", "TEST", 40, 53], ["the protein", "TEST", 61, 72], ["a cellular receptor", "TREATMENT", 109, 128], ["the SARS", "TEST", 160, 168], ["CoV", "TEST", 169, 172], ["spike protein", "TEST", 175, 188], ["neutralizing antibodies", "TEST", 190, 213], ["the SARS", "TEST", 217, 225], ["CoV", "TEST", 226, 229], ["spike protein", "TEST", 232, 245], ["the SARS", "TEST", 264, 272], ["CoV", "TEST", 273, 276], ["spike protein", "TEST", 279, 292]]], ["One of the reasons for building/sequencing/interpreting an extensive library of phages is to assist interpretation of the sequences of eukaryotes and their viruses.Perspective and an AlternativeThe decision to make use of fast-tracked live vaccines would presumably depend on the state of the pandemic being faced.", [["fast-tracked live vaccines", "TREATMENT", 222, 248]]], ["As a thought experiment, imagine that (1) you are 80 years old today, (2) a fast-tracked live-virus vaccine has been developed for SARS-CoV-2 and (3) a reasonable projection is that you have a 1/100 chance of being seriously ill from the vaccine.", [["SARS-CoV", "SPECIES", 131, 139], ["a fast-tracked live-virus vaccine", "TREATMENT", 74, 107], ["SARS", "PROBLEM", 131, 135], ["the vaccine", "TREATMENT", 234, 245]]], ["The bias toward or against vaccination would depend on the projection for how socio-political measures will go in the future.", [["vaccination", "TREATMENT", 27, 38]]], ["As the economy progressively pressures the easing of these measures, I suspect that the bias for most people will progressively become toward vaccination.Perspective and an AlternativeThe real world of \"needed research\" can be (and, in my opinion, is) different from the world of \"fundable research\".", [["people", "ORGANISM", 102, 108], ["people", "SPECIES", 102, 108], ["pressures", "OBSERVATION_MODIFIER", 29, 38]]], ["The experience with generating polio virus vaccines [42] suggests that non-specialist scientific influence will be needed to manage the conditions described in this paragraph.", [["polio virus", "ORGANISM", 31, 42], ["polio virus", "SPECIES", 31, 42], ["generating polio virus vaccines", "TREATMENT", 20, 51], ["the conditions", "PROBLEM", 132, 146]]], ["The \"silver lining\" is that the recent crisis might help make improvements in research on therapies for diseases other than pandemic virus infections.A Note for DoubtersThe following examples will, perhaps, convince those who are doubters of the value of a type 1 strategy.", [["silver", "CHEMICAL", 5, 11], ["pandemic virus infections", "DISEASE", 124, 149], ["silver", "CHEMICAL", 5, 11], ["the recent crisis", "PROBLEM", 28, 45], ["therapies", "TREATMENT", 90, 99], ["diseases", "PROBLEM", 104, 112], ["pandemic virus infections", "PROBLEM", 124, 149], ["silver lining", "OBSERVATION_MODIFIER", 5, 18]]], ["Paul Ehrlich used a type 1 strategy to plough through compounds until he found the first usable antibiotic, Salvarsan (reviewed in [43] ).", [["a type 1 strategy", "TREATMENT", 18, 35]]], ["Schatz and Waksman did the same during the discovery of streptomycin [44] .", [["Schatz", "CHEMICAL", 0, 6], ["streptomycin", "CHEMICAL", 56, 68], ["streptomycin", "CHEMICAL", 56, 68], ["streptomycin", "SIMPLE_CHEMICAL", 56, 68], ["Schatz", "TREATMENT", 0, 6], ["streptomycin", "TREATMENT", 56, 68]]], ["Early anti-cancer drug discovery was a repeat performance (reviewed in [5] ).A Note for DoubtersFurthermore, the current situation with SARS-CoV-2 has been described as analogous to war [45] .", [["SARS", "DISEASE", 136, 140], ["a repeat performance", "TEST", 37, 57]]], ["Of course, in this war, everyone is on the same side, whether or not apparent.", [["course", "OBSERVATION_MODIFIER", 3, 9]]], ["Given its historical closeness, I also compare the poorly coordinated, low-training, take-the-easy-path, ultimately disastrous type 2 strategy of the US at the beginning of the Battle of the Bulge with the initially-thought-impossible-to-execute, focused, rapid, highly coordinated, successful type 1 strategy used by the highly trained, highly motivated US third army at the end of the Battle of the Bulge [47] .", [["the US", "TEST", 146, 152], ["the Bulge", "PROBLEM", 187, 196], ["successful type 1 strategy", "TREATMENT", 283, 309], ["disastrous", "OBSERVATION", 116, 126], ["Bulge", "OBSERVATION", 191, 196], ["Bulge", "OBSERVATION", 401, 406]]], ["Let us hope that, in the contest with SARS-CoV-2, the outcome for people resembles the latter US outcome.", [["SARS", "DISEASE", 38, 42], ["CoV-2", "ORGANISM", 43, 48], ["people", "ORGANISM", 66, 72], ["people", "SPECIES", 66, 72], ["SARS-CoV", "SPECIES", 38, 46]]]], "52da582d52fe94db1ad926067dbdcb8c13fcdd8e": [["IntroductionHepatitis A virus is a picornavirus and is the only known member of the genus hepatovirus.", [["Hepatitis A virus", "DISEASE", 12, 29], ["picornavirus", "DISEASE", 35, 47], ["Hepatitis A virus", "ORGANISM", 12, 29], ["hepatovirus", "CANCER", 90, 101], ["Hepatitis A virus", "SPECIES", 12, 29], ["Hepatitis A virus", "SPECIES", 12, 29], ["Hepatitis A virus", "PROBLEM", 12, 29], ["a picornavirus", "PROBLEM", 33, 47], ["Hepatitis", "OBSERVATION", 12, 21], ["virus", "OBSERVATION", 24, 29], ["genus hepatovirus", "ANATOMY", 84, 101]]], ["It is the major causative agent for infectious hepatitis worldwide and is easily disseminated by person to person contact as well as via contaminated foods and water, due to its resistance to environmental factors such as heat, low pH, etc. (Siegl et al., 1984; Gust, 1988) .", [["infectious hepatitis", "DISEASE", 36, 56], ["person", "SPECIES", 97, 103], ["person", "SPECIES", 107, 113], ["infectious hepatitis", "PROBLEM", 36, 56], ["heat, low pH", "PROBLEM", 222, 234], ["infectious", "OBSERVATION_MODIFIER", 36, 46], ["hepatitis", "OBSERVATION", 47, 56], ["low pH", "OBSERVATION_MODIFIER", 228, 234]]], ["Most of the known HAV strains establish a slowly replicating and non-cytopathogenic persistent infection in permissive cells in vitro (Provost and Hillemen, 1979; Flehmig, 1980; Binn et al., 1984; Vallbracht et al., 1984) .", [["cells", "ANATOMY", 119, 124], ["infection", "DISEASE", 95, 104], ["HAV strains", "ORGANISM", 18, 29], ["cells", "CELL", 119, 124], ["permissive cells", "CELL_TYPE", 108, 124], ["HAV", "SPECIES", 18, 21], ["the known HAV strains", "PROBLEM", 8, 29], ["non-cytopathogenic persistent infection", "PROBLEM", 65, 104], ["persistent", "OBSERVATION_MODIFIER", 84, 94], ["infection", "OBSERVATION", 95, 104], ["permissive cells", "OBSERVATION", 108, 124]]], ["This is in contrast to in vivo infection, where persistence is restricted to a few weeks (Lemon, 1985; Vallbracht et al., 1989) , although sporadic cases of chronic infection have been reported (Fagan et al., 1990; Inoue et al., 1996) .", [["infection", "DISEASE", 31, 40], ["chronic infection", "DISEASE", 157, 174], ["vivo infection", "PROBLEM", 26, 40], ["chronic infection", "PROBLEM", 157, 174], ["infection", "OBSERVATION", 31, 40], ["chronic", "OBSERVATION_MODIFIER", 157, 164], ["infection", "OBSERVATION", 165, 174]]], ["Several laboratories have isolated rapidly replicating cytopathogenic (cp) strains that produce visible morphological changes primarily in continuous cell lines of monkey kidney origin (Divizia et al., 1986; Venuti et al., 1986; Anderson, 1987; Cromeans et al., 1987; Nasser and Metcalf, 1987; Zhang et al., 1995; Brack et al., 1998) .", [["cell lines", "ANATOMY", 150, 160], ["kidney", "ANATOMY", 171, 177], ["cell lines", "CELL", 150, 160], ["monkey", "ORGANISM", 164, 170], ["kidney", "ORGAN", 171, 177], ["continuous cell lines", "CELL_LINE", 139, 160], ["Several laboratories", "TEST", 0, 20], ["cytopathogenic (cp) strains", "PROBLEM", 55, 82], ["visible morphological changes", "PROBLEM", 96, 125], ["rapidly", "OBSERVATION_MODIFIER", 35, 42], ["replicating", "OBSERVATION_MODIFIER", 43, 54], ["cytopathogenic", "OBSERVATION_MODIFIER", 55, 69], ["visible", "OBSERVATION_MODIFIER", 96, 103], ["morphological changes", "OBSERVATION", 104, 125], ["continuous cell lines", "OBSERVATION", 139, 160], ["kidney", "ANATOMY", 171, 177], ["origin", "ANATOMY_MODIFIER", 178, 184]]], ["The mechanism of the cytopathogenic effect (cpe) produced by the rapidly replicating HAV strains has been intensely investigated during the past few years to understand why wild type (wt) and cell culture adapted (cc) strains replicate slowly and are unable to induce cpe in these cell lines.", [["cell", "ANATOMY", 192, 196], ["cell lines", "ANATOMY", 281, 291], ["HAV strains", "ORGANISM", 85, 96], ["cell", "CELL", 192, 196], ["cell lines", "CELL", 281, 291], ["cpe", "PROTEIN", 268, 271], ["cell lines", "CELL_LINE", 281, 291], ["HAV", "SPECIES", 85, 88], ["the cytopathogenic effect", "PROBLEM", 17, 42], ["the rapidly replicating HAV strains", "PROBLEM", 61, 96], ["cell culture", "TEST", 192, 204], ["cytopathogenic effect", "OBSERVATION", 21, 42], ["cell lines", "OBSERVATION", 281, 291]]], ["These studies have revealed that the genome of the cpe-inducing (cp) strains contain point mutations, compared to the wt strains from which they were derived, scattered throughout the genome, as well as a 14-bp repeat in the 5 non-translated region (NTR), which harbors the internal ribosomal entry site or IRES (Lemon et al., 1991; Brack et al., 1998) .", [["ribosomal", "ANATOMY", 283, 292], ["cpe-inducing (cp) strains", "ORGANISM", 51, 76], ["NTR", "GENE_OR_GENE_PRODUCT", 250, 253], ["ribosomal", "CELLULAR_COMPONENT", 283, 292], ["14-bp repeat", "DNA", 205, 217], ["5 non-translated region", "DNA", 225, 248], ["NTR", "DNA", 250, 253], ["internal ribosomal entry site", "DNA", 274, 303], ["IRES", "DNA", 307, 311], ["These studies", "TEST", 0, 13], ["the cpe-inducing (cp) strains", "PROBLEM", 47, 76], ["point mutations", "PROBLEM", 85, 100], ["the wt strains", "PROBLEM", 114, 128], ["bp repeat", "TEST", 208, 217], ["scattered", "OBSERVATION_MODIFIER", 159, 168], ["internal ribosomal", "ANATOMY", 274, 292], ["entry site", "OBSERVATION", 293, 303]]], ["The biological significance of these mutations for the rapid replication phenotype of the cp strains is not completely understood.", [["these mutations", "PROBLEM", 31, 46], ["the cp strains", "PROBLEM", 86, 100]]], ["Experiments with chimeric viral genomes containing mutated regions of cp strains on a genetic background of cc strains suggested an effect of these mutations on the expression of the viral genome, possibly due to altered interaction of the mutated genomes with cellular proteins that either positively or negatively regulate viral gene expression Whetter et al., 1994; Zhang et al., 1995; Funkhouser et al., 1999; Yi et al., 2000) .", [["cellular", "ANATOMY", 261, 269], ["cp strains", "ORGANISM", 70, 80], ["cellular", "CELL", 261, 269], ["chimeric viral genomes", "DNA", 17, 39], ["viral genome", "DNA", 183, 195], ["mutated genomes", "DNA", 240, 255], ["cellular proteins", "PROTEIN", 261, 278], ["chimeric viral genomes", "PROBLEM", 17, 39], ["cp strains", "PROBLEM", 70, 80], ["cc strains", "PROBLEM", 108, 118], ["these mutations", "PROBLEM", 142, 157], ["the viral genome", "PROBLEM", 179, 195], ["cellular proteins", "PROBLEM", 261, 278], ["viral genome", "OBSERVATION", 183, 195]]], ["However, the view that HAV IRES is inefficient compared to other picornaviruses is not universally accepted (Jia et al., 1996; Graff and Ehrenfeld, 1998; Gauss-M\u00fcller and Kusov, 2002) .IntroductionWe have recently reported that in the permissive monkey kidney cell line FrhK4 infection with the cp strain HM175 18f (hereafter referred to as 18f) resulted in degradation of ribosomal RNAs (rRNAs), whereas viral genomic RNA was not degraded.", [["kidney cell line", "ANATOMY", 253, 269], ["ribosomal", "ANATOMY", 373, 382], ["infection", "DISEASE", 276, 285], ["HM175 18f", "CHEMICAL", 305, 314], ["HAV", "ORGANISM", 23, 26], ["monkey", "ORGANISM", 246, 252], ["kidney cell line FrhK4", "CELL", 253, 275], ["rRNAs", "CELLULAR_COMPONENT", 389, 394], ["HAV IRES", "DNA", 23, 31], ["permissive monkey kidney cell line", "CELL_LINE", 235, 269], ["HM175 18f", "DNA", 305, 314], ["18f", "DNA", 341, 344], ["ribosomal RNAs", "RNA", 373, 387], ["rRNAs", "RNA", 389, 394], ["viral genomic RNA", "RNA", 405, 422], ["HAV", "SPECIES", 23, 26], ["HAV IRES", "PROBLEM", 23, 31], ["FrhK4 infection", "PROBLEM", 270, 285], ["the cp strain", "PROBLEM", 291, 304], ["ribosomal RNAs (rRNAs)", "PROBLEM", 373, 395], ["viral genomic RNA", "PROBLEM", 405, 422], ["kidney", "ANATOMY", 253, 259], ["cell line", "OBSERVATION", 260, 269], ["infection", "OBSERVATION", 276, 285], ["ribosomal RNAs", "OBSERVATION", 373, 387], ["genomic RNA", "OBSERVATION", 411, 422]]], ["In contrast, the parental cc strain did not cause such degradation either after an acute infection or extended persistent infection (Kulka et al., 2003) .", [["infection", "DISEASE", 89, 98], ["infection", "DISEASE", 122, 131], ["the parental cc strain", "PROBLEM", 13, 35], ["such degradation", "PROBLEM", 50, 66], ["an acute infection", "PROBLEM", 80, 98], ["extended persistent infection", "PROBLEM", 102, 131], ["acute", "OBSERVATION_MODIFIER", 83, 88], ["infection", "OBSERVATION", 89, 98], ["persistent", "OBSERVATION_MODIFIER", 111, 121], ["infection", "OBSERVATION", 122, 131]]], ["Based on the pattern of rRNA degradation in intact ribosomes, we suggested that the 18f virus activates the interferon (IFN) controlled 2 -5 oligoadenylic acid-dependent RNase L pathway (for recent reviews, see Stark et al., 1998; Barber, 2001; Sen, 2001) .", [["ribosomes", "ANATOMY", 51, 60], ["acid-", "CHEMICAL", 155, 160], ["rRNA", "CELLULAR_COMPONENT", 24, 28], ["ribosomes", "CELLULAR_COMPONENT", 51, 60], ["18f virus", "ORGANISM", 84, 93], ["interferon", "GENE_OR_GENE_PRODUCT", 108, 118], ["RNase L", "GENE_OR_GENE_PRODUCT", 170, 177], ["interferon (IFN) controlled 2 -5 oligoadenylic acid-dependent RNase L", "PROTEIN", 108, 177], ["18f virus", "SPECIES", 84, 93], ["rRNA degradation", "PROBLEM", 24, 40], ["the 18f virus", "TREATMENT", 80, 93], ["the interferon (IFN)", "TREATMENT", 104, 124], ["rRNA degradation", "OBSERVATION", 24, 40], ["intact ribosomes", "OBSERVATION", 44, 60]]], ["Since this pathway is essentially an antiviral mechanism mounted by cells in defense against viral infection, the usurpation of this pathway by the 18f virus could be a mechanism employed by this virus to reduce competition from cellular mRNAs for the host protein synthetic machinery.", [["cells", "ANATOMY", 68, 73], ["cellular", "ANATOMY", 229, 237], ["viral infection", "DISEASE", 93, 108], ["cells", "CELL", 68, 73], ["18f virus", "ORGANISM", 148, 157], ["cellular", "CELL", 229, 237], ["cellular mRNAs", "RNA", 229, 243], ["viral infection", "PROBLEM", 93, 108], ["the 18f virus", "PROBLEM", 144, 157], ["this virus", "PROBLEM", 191, 201], ["cellular mRNAs", "TREATMENT", 229, 243], ["antiviral", "OBSERVATION", 37, 46], ["viral", "OBSERVATION_MODIFIER", 93, 98], ["infection", "OBSERVATION", 99, 108]]], ["This virus lacks an active 2A protease (Schultheiss et al., 1994; Harmon et al., 1995) capable of degrading either eIF-4G or other cellular translation factors required for translation of capped cellular mRNAs, therefore, the importance of such an RNA degradative mechanism cannot be overstated.IntroductionThe activation of the RNase L pathway is controlled by IFN (Stark et al., 1998; Barber, 2001; Sen, 2001) through the induction of 2 -5 oligoadenylate synthetase (2 -5 OAS), which synthesizes 2 -5 oligoadenylic acid or 2-5A, the proximal activator of the RNase L from ATP, in the presence of double stranded RNA (dsRNA).", [["cellular", "ANATOMY", 131, 139], ["cellular", "ANATOMY", 195, 203], ["2 -5 oligoadenylate", "CHEMICAL", 437, 456], ["2 -5 OAS", "CHEMICAL", 469, 477], ["2 -5 oligoadenylic acid", "CHEMICAL", 498, 521], ["ATP", "CHEMICAL", 574, 577], ["2 -5 oligoadenylic acid", "CHEMICAL", 498, 521], ["ATP", "CHEMICAL", 574, 577], ["eIF-4G", "GENE_OR_GENE_PRODUCT", 115, 121], ["cellular", "CELL", 131, 139], ["cellular", "CELL", 195, 203], ["RNase L", "GENE_OR_GENE_PRODUCT", 329, 336], ["IFN", "GENE_OR_GENE_PRODUCT", 362, 365], ["2 -5 oligoadenylate synthetase", "SIMPLE_CHEMICAL", 437, 467], ["2 -5 OAS", "SIMPLE_CHEMICAL", 469, 477], ["2 -5 oligoadenylic acid", "SIMPLE_CHEMICAL", 498, 521], ["2-5A", "SIMPLE_CHEMICAL", 525, 529], ["RNase L", "GENE_OR_GENE_PRODUCT", 561, 568], ["ATP", "SIMPLE_CHEMICAL", 574, 577], ["2A protease", "PROTEIN", 27, 38], ["eIF-4G", "PROTEIN", 115, 121], ["cellular translation factors", "PROTEIN", 131, 159], ["capped cellular mRNAs", "RNA", 188, 209], ["RNase L", "PROTEIN", 329, 336], ["IFN", "PROTEIN", 362, 365], ["oligoadenylate synthetase", "PROTEIN", 442, 467], ["OAS", "PROTEIN", 474, 477], ["RNase L", "PROTEIN", 561, 568], ["double stranded RNA", "RNA", 598, 617], ["This virus", "PROBLEM", 0, 10], ["other cellular translation factors", "PROBLEM", 125, 159], ["capped cellular mRNAs", "PROBLEM", 188, 209], ["an RNA degradative mechanism", "TREATMENT", 245, 273], ["the RNase L pathway", "TREATMENT", 325, 344], ["the induction of 2 -5 oligoadenylate synthetase", "TREATMENT", 420, 467], ["ATP", "PROBLEM", 574, 577], ["double stranded RNA (dsRNA", "PROBLEM", 598, 624], ["active", "OBSERVATION_MODIFIER", 20, 26], ["cellular mRNAs", "OBSERVATION", 195, 209], ["double", "OBSERVATION_MODIFIER", 598, 604], ["stranded RNA", "OBSERVATION", 605, 617]]], ["Overexpression of RNase L has been shown to inhibit the growth of diverse RNA viruses (Zhou et al., 1998) .", [["RNase L", "GENE_OR_GENE_PRODUCT", 18, 25], ["RNase L", "PROTEIN", 18, 25], ["Overexpression of RNase L", "PROBLEM", 0, 25], ["diverse RNA viruses", "PROBLEM", 66, 85], ["RNase L", "OBSERVATION_MODIFIER", 18, 25], ["growth", "OBSERVATION_MODIFIER", 56, 62], ["RNA viruses", "OBSERVATION", 74, 85]]], ["Whether HAV infection can induce synthesis of type I IFN (IFN \u2423/\u2424) in cultured cells or intact organisms and consequently activate the 2 -5 OAS/RNase L pathway remains unclear.", [["cells", "ANATOMY", 79, 84], ["HAV infection", "DISEASE", 8, 21], ["HAV", "ORGANISM", 8, 11], ["type I IFN", "GENE_OR_GENE_PRODUCT", 46, 56], ["IFN \u2423/\u2424", "GENE_OR_GENE_PRODUCT", 58, 65], ["cells", "CELL", 79, 84], ["OAS", "GENE_OR_GENE_PRODUCT", 140, 143], ["RNase L", "GENE_OR_GENE_PRODUCT", 144, 151], ["type I IFN", "PROTEIN", 46, 56], ["IFN \u2423/\u2424", "PROTEIN", 58, 65], ["cultured cells", "CELL_LINE", 70, 84], ["OAS", "PROTEIN", 140, 143], ["RNase L", "PROTEIN", 144, 151], ["HAV", "SPECIES", 8, 11], ["HAV infection", "PROBLEM", 8, 21], ["type I IFN (IFN \u2423/\u2424", "PROBLEM", 46, 65], ["cultured cells", "PROBLEM", 70, 84], ["intact organisms", "PROBLEM", 88, 104], ["RNase L pathway", "TEST", 144, 159], ["infection", "OBSERVATION", 12, 21]]], ["Cell cultures persistently infected with culture-adapted HAV do not induce type 1 IFN, and the replication of the virus in persistently infected cells remains sensitive to exogenously added IFN (Vallbracht et al., 1985; Brack et al., 2002) .", [["Cell cultures", "ANATOMY", 0, 13], ["cells", "ANATOMY", 145, 150], ["Cell cultures", "CELL", 0, 13], ["HAV", "ORGANISM", 57, 60], ["type 1 IFN", "GENE_OR_GENE_PRODUCT", 75, 85], ["cells", "CELL", 145, 150], ["type 1 IFN", "PROTEIN", 75, 85], ["persistently infected cells", "CELL_TYPE", 123, 150], ["IFN", "PROTEIN", 190, 193], ["HAV", "SPECIES", 57, 60], ["Cell cultures", "TEST", 0, 13], ["culture", "TEST", 41, 48], ["type 1 IFN", "PROBLEM", 75, 85], ["the virus", "PROBLEM", 110, 119], ["persistently infected cells", "PROBLEM", 123, 150], ["infected cells", "OBSERVATION", 136, 150]]], ["Acute infection with cc or cp strains of HAV did not cause induction of IFN \u2423/\u2424 mRNA transcription and cc strains also blocked IFN mRNA transcription and secretion of IFN in response to dsRNA in FrhK4 and MRC-5 cells (Brack et al., 2002) .", [["FrhK4", "ANATOMY", 195, 200], ["MRC-5 cells", "ANATOMY", 205, 216], ["infection", "DISEASE", 6, 15], ["HAV", "DISEASE", 41, 44], ["HAV", "ORGANISM", 41, 44], ["IFN \u2423", "GENE_OR_GENE_PRODUCT", 72, 77], ["\u2424", "GENE_OR_GENE_PRODUCT", 78, 79], ["IFN", "GENE_OR_GENE_PRODUCT", 127, 130], ["IFN", "GENE_OR_GENE_PRODUCT", 167, 170], ["FrhK4", "CELL", 195, 200], ["MRC-5 cells", "CELL", 205, 216], ["IFN \u2423/\u2424 mRNA", "RNA", 72, 84], ["IFN mRNA", "RNA", 127, 135], ["IFN", "PROTEIN", 167, 170], ["FrhK4", "CELL_LINE", 195, 200], ["MRC-5 cells", "CELL_LINE", 205, 216], ["HAV", "SPECIES", 41, 44], ["Acute infection", "PROBLEM", 0, 15], ["cc or cp strains of HAV", "PROBLEM", 21, 44], ["IFN", "TREATMENT", 72, 75], ["mRNA transcription", "TREATMENT", 80, 98], ["cc strains", "PROBLEM", 103, 113], ["IFN mRNA transcription", "TREATMENT", 127, 149], ["secretion of IFN", "PROBLEM", 154, 170], ["dsRNA", "TEST", 186, 191], ["FrhK4", "TEST", 195, 200], ["MRC", "TEST", 205, 208], ["infection", "OBSERVATION", 6, 15]]], ["Exogenous IFN inhibited virus replication when added either before or after exposure to virus in a dose dependent manner in PLC/PRF/5 cells (Crance et al., 1995) .", [["PLC/PRF/5 cells", "ANATOMY", 124, 139], ["IFN", "CHEMICAL", 10, 13], ["IFN", "GENE_OR_GENE_PRODUCT", 10, 13], ["PLC/PRF/5 cells", "CELL", 124, 139], ["IFN", "PROTEIN", 10, 13], ["PLC/PRF/5 cells", "CELL_LINE", 124, 139], ["Exogenous IFN inhibited virus replication", "TREATMENT", 0, 41], ["virus", "TREATMENT", 88, 93], ["PLC/PRF/5 cells", "TREATMENT", 124, 139]]], ["Inhibi-tion of virus replication in the above study also showed a strong dependence on the multiplicity of infection (moi).", [["infection", "DISEASE", 107, 116], ["virus replication", "TREATMENT", 15, 32], ["the above study", "TEST", 36, 51], ["infection", "PROBLEM", 107, 116], ["virus replication", "OBSERVATION", 15, 32], ["strong", "OBSERVATION_MODIFIER", 66, 72], ["dependence", "OBSERVATION_MODIFIER", 73, 83], ["infection", "OBSERVATION", 107, 116]]], ["A significant increase in the activity of the IFN-induced 2 -5 OAS was observed following IFN treatment, suggesting that the RNase L pathway may be involved in the inhibition of virus replication (Crance et al., 1995) .", [["IFN", "CHEMICAL", 90, 93], ["IFN", "GENE_OR_GENE_PRODUCT", 46, 49], ["IFN", "GENE_OR_GENE_PRODUCT", 90, 93], ["RNase L", "GENE_OR_GENE_PRODUCT", 125, 132], ["IFN", "PROTEIN", 46, 49], ["OAS", "PROTEIN", 63, 66], ["IFN", "PROTEIN", 90, 93], ["RNase L", "PROTEIN", 125, 132], ["A significant increase", "PROBLEM", 0, 22], ["the IFN", "TREATMENT", 42, 49], ["IFN treatment", "TREATMENT", 90, 103], ["the RNase L pathway", "PROBLEM", 121, 140], ["virus replication", "TREATMENT", 178, 195], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["increase", "OBSERVATION_MODIFIER", 14, 22], ["activity", "OBSERVATION_MODIFIER", 30, 38]]], ["Constitutive expression of 2 -5 OAS results in the inhibition of picornavirus replication (Chebath et al., 1987) , and ectopic expression and activation of RNase L induces apoptosis in animal cells (Diaz-Guerra et al., 1997; Castelli et al., 1998) .IntroductionThe goal of this investigation was to study the role of the IFN -regulated 2-5A activated RNase L on RNA degradation and apoptosis in 18f infected cells.Cells and virusesFrhK4 monkey kidney cell line was a kind gift of Dr. G. Kaplan (FDA, Center for Biologics Evaluation and Research, Bethesda, MD).", [["cells", "ANATOMY", 192, 197], ["cells", "ANATOMY", 408, 413], ["Cells", "ANATOMY", 414, 419], ["kidney cell line", "ANATOMY", 444, 460], ["picornavirus", "ORGANISM", 65, 77], ["RNase L", "GENE_OR_GENE_PRODUCT", 156, 163], ["cells", "CELL", 192, 197], ["IFN", "GENE_OR_GENE_PRODUCT", 321, 324], ["2-5A", "GENE_OR_GENE_PRODUCT", 336, 340], ["RNase L", "GENE_OR_GENE_PRODUCT", 351, 358], ["cells", "CELL", 408, 413], ["Cells", "CELL", 414, 419], ["FrhK4 monkey", "CELL", 431, 443], ["kidney cell line", "CELL", 444, 460], ["OAS", "PROTEIN", 32, 35], ["RNase L", "PROTEIN", 156, 163], ["animal cells", "CELL_TYPE", 185, 197], ["IFN -regulated 2-5A activated RNase L", "PROTEIN", 321, 358], ["18f infected cells", "CELL_LINE", 395, 413], ["FrhK4 monkey kidney cell line", "CELL_LINE", 431, 460], ["monkey", "SPECIES", 437, 443], ["picornavirus replication", "TREATMENT", 65, 89], ["ectopic expression", "PROBLEM", 119, 137], ["RNase L induces apoptosis", "PROBLEM", 156, 181], ["this investigation", "TEST", 273, 291], ["the IFN", "TREATMENT", 317, 324], ["RNA degradation", "TREATMENT", 362, 377], ["apoptosis in 18f infected cells", "PROBLEM", 382, 413], ["Cells", "TEST", 414, 419], ["viruses", "PROBLEM", 424, 431], ["Biologics Evaluation", "TEST", 511, 531], ["infected cells", "OBSERVATION", 399, 413], ["viruses", "OBSERVATION", 424, 431], ["kidney", "ANATOMY", 444, 450], ["cell line", "OBSERVATION", 451, 460]]], ["The cells were grown in Eagles Minimal Essential Medium (EMEM) containing 5% heat inactivated fetal bovine serum (FBS), MEM non-essential amino acids and sodium pyruvate (all from Invitrogen, Carlsbad, CA), with routine weekly sub-culturing.", [["cells", "ANATOMY", 4, 9], ["fetal bovine serum", "ANATOMY", 94, 112], ["FBS", "ANATOMY", 114, 117], ["amino acids", "CHEMICAL", 138, 149], ["sodium pyruvate", "CHEMICAL", 154, 169], ["amino acids", "CHEMICAL", 138, 149], ["sodium pyruvate", "CHEMICAL", 154, 169], ["cells", "CELL", 4, 9], ["bovine", "ORGANISM", 100, 106], ["serum", "ORGANISM_SUBSTANCE", 107, 112], ["FBS", "ORGANISM_SUBSTANCE", 114, 117], ["MEM non-essential", "SIMPLE_CHEMICAL", 120, 137], ["amino acids", "AMINO_ACID", 138, 149], ["sodium pyruvate", "SIMPLE_CHEMICAL", 154, 169], ["bovine", "SPECIES", 100, 106], ["bovine", "SPECIES", 100, 106], ["5% heat inactivated fetal bovine serum (FBS", "PROBLEM", 74, 117], ["MEM non-essential amino acids", "TEST", 120, 149], ["sodium pyruvate", "PROBLEM", 154, 169], ["Invitrogen", "TEST", 180, 190], ["routine weekly sub-culturing", "TREATMENT", 212, 240], ["Eagles", "OBSERVATION_MODIFIER", 24, 30], ["Minimal", "OBSERVATION_MODIFIER", 31, 38], ["Essential", "OBSERVATION_MODIFIER", 39, 48], ["Medium", "OBSERVATION_MODIFIER", 49, 55]]], ["Under these conditions the cells increase about 20-fold in 6-7 days.", [["cells", "ANATOMY", 27, 32], ["cells", "CELL", 27, 32]]], ["The cell line is contact inhibited and can be kept in growth medium or maintenance medium (1% FBS) for several weeks without degeneration of the monolayer.", [["cell line", "ANATOMY", 4, 13], ["FBS", "ANATOMY", 94, 97], ["monolayer", "ANATOMY", 145, 154], ["cell line", "CELL", 4, 13], ["FBS", "ORGANISM_SUBSTANCE", 94, 97], ["monolayer", "CELL", 145, 154], ["cell line", "CELL_LINE", 4, 13], ["The cell line", "TREATMENT", 0, 13], ["maintenance medium (1% FBS", "TREATMENT", 71, 97], ["degeneration of the monolayer", "PROBLEM", 125, 154], ["cell line", "OBSERVATION", 4, 13], ["degeneration", "OBSERVATION", 125, 137]]], ["HAV strains HM175/18f (cytopathogenic in FrhK4 cells) and HM175/clone1 (non-cytopathogenic in FrhK4 cells) were obtained from ATCC.", [["FrhK4 cells", "ANATOMY", 41, 52], ["HM175/clone1", "ANATOMY", 58, 70], ["FrhK4 cells", "ANATOMY", 94, 105], ["ATCC", "ANATOMY", 126, 130], ["HAV", "ORGANISM", 0, 3], ["18f", "GENE_OR_GENE_PRODUCT", 18, 21], ["FrhK4 cells", "CELL", 41, 52], ["HM175/clone1", "CELL", 58, 70], ["FrhK4 cells", "CELL", 94, 105], ["ATCC", "CELL", 126, 130], ["FrhK4 cells", "CELL_LINE", 41, 52], ["HM175/clone1 (non-cytopathogenic in FrhK4 cells", "CELL_LINE", 58, 105], ["HAV", "SPECIES", 0, 3], ["ATCC", "SPECIES", 126, 130], ["HAV strains", "TEST", 0, 11], ["cytopathogenic in FrhK4 cells", "TEST", 23, 52], ["HM175", "TEST", 58, 63], ["clone1", "TEST", 64, 70], ["non-cytopathogenic in FrhK4 cells", "PROBLEM", 72, 105]]], ["Viruses were grown in FrhK4 cells.", [["FrhK4 cells", "ANATOMY", 22, 33], ["FrhK4 cells", "CELL", 22, 33], ["FrhK4 cells", "CELL_LINE", 22, 33], ["Viruses", "PROBLEM", 0, 7], ["FrhK4 cells", "OBSERVATION", 22, 33]]], ["Virus stocks were prepared as described before (Kulka et al., 2003) .", [["Virus", "ORGANISM", 0, 5], ["Virus stocks", "TREATMENT", 0, 12]]], ["18f was titered by plaque assay, while clone 1 virus was titered by EIA in 96-well plates as described previously (Goswami et al., 2002) using the HAVAB EIA Diagnostic Kit (Abbott Laboratories, Abbott Park, IL).", [["plaque", "ANATOMY", 19, 25], ["18f", "SIMPLE_CHEMICAL", 0, 3], ["clone 1 virus", "ORGANISM", 39, 52], ["IL", "GENE_OR_GENE_PRODUCT", 207, 209], ["clone 1 virus", "SPECIES", 39, 52], ["clone 1 virus", "PROBLEM", 39, 52], ["EIA", "TEST", 68, 71], ["plaque", "OBSERVATION", 19, 25]]], ["Human IFN-\u2424 and the pancaspase inhibitor Z-VAD-FMK were obtained from Sigma (St. Louis, MO).Virus infection for RNA isolationConfluent cultures of FrhK4 cells in 75 cm 2 flasks (5\u00d710 6 cells) were infected with a multiplicity of infection (moi) of 5 pfu/cell of 18f or 15 TCID 50 /cell of clone 1 in 1.5 ml of MEM containing 1% heat inactivated FBS or were mock infected.", [["Confluent cultures", "ANATOMY", 125, 143], ["FrhK4 cells", "ANATOMY", 147, 158], ["5\u00d710 6 cells", "ANATOMY", 178, 190], ["cell", "ANATOMY", 254, 258], ["cell", "ANATOMY", 281, 285], ["FBS", "ANATOMY", 345, 348], ["Z-VAD-FMK", "CHEMICAL", 41, 50], ["Virus infection", "DISEASE", 92, 107], ["infection", "DISEASE", 229, 238], ["MEM", "CHEMICAL", 310, 313], ["Z-VAD-FMK", "CHEMICAL", 41, 50], ["Human", "ORGANISM", 0, 5], ["IFN-\u2424", "GENE_OR_GENE_PRODUCT", 6, 11], ["pancaspase", "GENE_OR_GENE_PRODUCT", 20, 30], ["Z-VAD-FMK", "SIMPLE_CHEMICAL", 41, 50], ["St. Louis, MO", "ORGANISM", 77, 90], ["Virus", "ORGANISM", 92, 97], ["FrhK4 cells", "CELL", 147, 158], ["cells", "CELL", 185, 190], ["cell", "CELL", 254, 258], ["cell", "CELL", 281, 285], ["FBS", "ORGANISM_SUBSTANCE", 345, 348], ["IFN", "PROTEIN", 6, 9], ["FrhK4 cells", "CELL_LINE", 147, 158], ["Human", "SPECIES", 0, 5], ["Human IFN", "TEST", 0, 9], ["the pancaspase inhibitor", "TREATMENT", 16, 40], ["Virus infection", "PROBLEM", 92, 107], ["RNA isolation", "TEST", 112, 125], ["Confluent cultures", "TEST", 125, 143], ["FrhK4 cells", "TEST", 147, 158], ["flasks", "TEST", 170, 176], ["infection", "PROBLEM", 229, 238], ["clone", "TEST", 289, 294], ["1% heat inactivated FBS", "TREATMENT", 325, 348], ["infection", "OBSERVATION", 98, 107], ["Confluent", "OBSERVATION_MODIFIER", 125, 134], ["75 cm", "OBSERVATION_MODIFIER", 162, 167], ["infection", "OBSERVATION", 229, 238]]], ["After 2 h of adsorption, 13.5 ml of the same medium was added to each flask and incubation continued until the desired time of harvest.", [["incubation", "TREATMENT", 80, 90], ["harvest", "TREATMENT", 127, 134], ["harvest", "OBSERVATION", 127, 134]]], ["Cells were harvested by scraping, centrifuged to remove medium, and the pellets washed once with PBS (Ca 2+ and Mg 2+ free) and stored frozen at \u221270 \u2022 C or used immediately.", [["Cells", "ANATOMY", 0, 5], ["Ca", "CHEMICAL", 102, 104], ["Mg", "CHEMICAL", 112, 114], ["Ca 2+", "CHEMICAL", 102, 107], ["Mg 2+", "CHEMICAL", 112, 117], ["Cells", "CELL", 0, 5], ["Ca 2+", "SIMPLE_CHEMICAL", 102, 107], ["Mg 2+", "SIMPLE_CHEMICAL", 112, 117], ["the pellets", "TREATMENT", 68, 79], ["PBS", "TEST", 97, 100], ["Ca", "TEST", 102, 104], ["Mg", "TEST", 112, 114]]], ["RNA isolation was carried out as previously described (Kulka et al., 2003) .Persistent infection with HM175/clone 1A persistent infection of FrhK4 cells with clone 1 virus was established as described (Kulka et al., 2003) .", [["FrhK4 cells", "ANATOMY", 141, 152], ["infection", "DISEASE", 87, 96], ["infection", "DISEASE", 128, 137], ["clone 1A", "ORGANISM", 108, 116], ["FrhK4 cells", "CELL", 141, 152], ["clone 1 virus", "ORGANISM", 158, 171], ["HM175", "PROTEIN", 102, 107], ["FrhK4 cells", "CELL_LINE", 141, 152], ["clone 1 virus", "SPECIES", 158, 171], ["RNA isolation", "TEST", 0, 13], ["Persistent infection", "PROBLEM", 76, 96], ["HM175", "TREATMENT", 102, 107], ["persistent infection of FrhK4 cells", "PROBLEM", 117, 152], ["clone 1 virus", "PROBLEM", 158, 171], ["infection", "OBSERVATION", 87, 96], ["persistent", "OBSERVATION_MODIFIER", 117, 127], ["infection", "OBSERVATION", 128, 137], ["FrhK4 cells", "OBSERVATION", 141, 152]]], ["The cells were maintained by routine subculturing in the same manner as for normal FrhK4 cells.", [["cells", "ANATOMY", 4, 9], ["FrhK4 cells", "ANATOMY", 83, 94], ["cells", "CELL", 4, 9], ["FrhK4 cells", "CELL", 83, 94], ["FrhK4 cells", "CELL_LINE", 83, 94], ["routine subculturing", "TEST", 29, 49], ["FrhK4 cells", "OBSERVATION", 83, 94]]], ["To monitor virus replication, cells were periodically seeded into 12-well plates along with uninfected cells, and viral antigen in methanol fixed cells measured by the HAVAB EIA procedure (Goswami et al., 2002; Kulka et al., 2003) .", [["cells", "ANATOMY", 30, 35], ["cells", "ANATOMY", 103, 108], ["cells", "ANATOMY", 146, 151], ["methanol", "CHEMICAL", 131, 139], ["cells", "CELL", 30, 35], ["cells", "CELL", 103, 108], ["methanol", "SIMPLE_CHEMICAL", 131, 139], ["cells", "CELL", 146, 151], ["uninfected cells", "CELL_TYPE", 92, 108], ["viral antigen", "PROTEIN", 114, 127], ["methanol fixed cells", "CELL_TYPE", 131, 151], ["virus replication", "TREATMENT", 11, 28], ["uninfected cells", "PROBLEM", 92, 108], ["viral antigen", "TEST", 114, 127], ["methanol fixed cells", "TREATMENT", 131, 151], ["uninfected cells", "OBSERVATION", 92, 108]]], ["All experiments with this cell line (hereafter referred to as clone 1) were carried out between 6 months and 1 year of routine subculture.Isolation of cytoplasmic RNA and DNA and gel analysisCell pellets of uninfected or virus infected cells were resuspended in 10 mM Tris-HCl, 20 mM EDTA, pH 8.0 and lysed by the addition of Triton X-100 to 0.5% (Brack et al., 1998) .", [["cell line", "ANATOMY", 26, 35], ["cytoplasmic", "ANATOMY", 151, 162], ["Cell", "ANATOMY", 191, 195], ["cells", "ANATOMY", 236, 241], ["Tris-HCl", "CHEMICAL", 268, 276], ["Triton X-100", "CHEMICAL", 326, 338], ["Tris-HCl", "CHEMICAL", 268, 276], ["EDTA", "CHEMICAL", 284, 288], ["cell line", "CELL", 26, 35], ["cytoplasmic", "ORGANISM_SUBSTANCE", 151, 162], ["DNA", "CELLULAR_COMPONENT", 171, 174], ["Cell", "CELL", 191, 195], ["cells", "CELL", 236, 241], ["Tris-HCl", "SIMPLE_CHEMICAL", 268, 276], ["EDTA", "SIMPLE_CHEMICAL", 284, 288], ["Triton X-100", "SIMPLE_CHEMICAL", 326, 338], ["cell line", "CELL_LINE", 26, 35], ["clone 1", "CELL_LINE", 62, 69], ["cytoplasmic RNA", "RNA", 151, 166], ["virus infected cells", "CELL_TYPE", 221, 241], ["this cell line", "TREATMENT", 21, 35], ["cytoplasmic RNA", "TREATMENT", 151, 166], ["DNA and gel analysis", "TEST", 171, 191], ["Cell pellets", "TEST", 191, 203], ["uninfected or virus infected cells", "PROBLEM", 207, 241], ["pH", "TEST", 290, 292], ["Triton X", "TREATMENT", 326, 334], ["cytoplasmic RNA", "OBSERVATION", 151, 166]]], ["Cell lysates were kept on ice for 20 min with intermittent vortex mixing, followed by centrifugation at 12,000 \u00d7 g for 10 min.", [["Cell lysates", "ANATOMY", 0, 12], ["Cell lysates", "CELL", 0, 12], ["Cell lysates", "TEST", 0, 12], ["intermittent vortex mixing", "TREATMENT", 46, 72]]], ["The supernatant was carefully removed and digested with proteinase K (0.1 mg/ml) in the presence of 0.5% SDS.", [["supernatant", "ANATOMY", 4, 15], ["K", "CHEMICAL", 67, 68], ["SDS", "CHEMICAL", 105, 108], ["proteinase K", "GENE_OR_GENE_PRODUCT", 56, 68], ["The supernatant", "TREATMENT", 0, 15], ["proteinase K", "TREATMENT", 56, 68]]], ["The digest was extracted with an equal volume of phenol:chloroform:isoamyl alcohol (PCIA), and the aqueous phase removed to a fresh tube.", [["phenol:chloroform:isoamyl alcohol", "CHEMICAL", 49, 82], ["PCIA", "CHEMICAL", 84, 88], ["phenol", "CHEMICAL", 49, 55], ["chloroform", "CHEMICAL", 56, 66], ["isoamyl alcohol", "CHEMICAL", 67, 82], ["PCIA", "CHEMICAL", 84, 88], ["phenol", "SIMPLE_CHEMICAL", 49, 55], ["chloroform", "SIMPLE_CHEMICAL", 56, 66], ["isoamyl alcohol", "SIMPLE_CHEMICAL", 67, 82], ["PCIA", "SIMPLE_CHEMICAL", 84, 88], ["tube", "TISSUE", 132, 136], ["the aqueous phase", "TREATMENT", 95, 112], ["a fresh tube", "TREATMENT", 124, 136], ["fresh tube", "OBSERVATION", 126, 136]]], ["Nucleic acids were precipitated by the addition of sodium acetate to 0.3 M and 2.5 volume of ethanol.", [["sodium acetate", "CHEMICAL", 51, 65], ["ethanol", "CHEMICAL", 93, 100], ["sodium acetate", "CHEMICAL", 51, 65], ["ethanol", "CHEMICAL", 93, 100], ["Nucleic acids", "SIMPLE_CHEMICAL", 0, 13], ["sodium acetate", "SIMPLE_CHEMICAL", 51, 65], ["ethanol", "SIMPLE_CHEMICAL", 93, 100], ["Nucleic acids", "TEST", 0, 13], ["sodium acetate", "TREATMENT", 51, 65], ["ethanol", "TREATMENT", 93, 100], ["acids", "OBSERVATION", 8, 13]]], ["The precipitates were collected by centrifugation, washed once with 70% ethanol, dried and dissolved in RNase/DNase free water.", [["ethanol", "CHEMICAL", 72, 79], ["ethanol", "CHEMICAL", 72, 79], ["ethanol", "SIMPLE_CHEMICAL", 72, 79], ["RNase", "GENE_OR_GENE_PRODUCT", 104, 109], ["DNase", "GENE_OR_GENE_PRODUCT", 110, 115], ["RNase", "PROTEIN", 104, 109], ["DNase", "PROTEIN", 110, 115], ["70% ethanol", "TREATMENT", 68, 79], ["RNase/DNase free water", "TREATMENT", 104, 126]]], ["Nucleic acids were quantitated by A 260 measurement.", [["Nucleic acids", "SIMPLE_CHEMICAL", 0, 13], ["Nucleic acids", "TEST", 0, 13]]], ["Equal amounts of sample were incubated at 37 \u2022 C for 15 min in 15 l TE with or without 50 U of cloned RNase 1 (Ambion, Austin, TX), and analyzed by 1% agarose gel electrophoresis in TBE.Denaturing agarose gel electrophoresisDenaturing agarose gel electrophoresis was performed as described before (Kulka et al., 2003; Chomczynski and Mackey, 1992) .", [["sample", "ANATOMY", 17, 23], ["RNase 1", "GENE_OR_GENE_PRODUCT", 102, 109], ["Ambion", "ORGANISM", 111, 117], ["agarose", "SIMPLE_CHEMICAL", 151, 158], ["agarose", "SIMPLE_CHEMICAL", 197, 204], ["agarose", "SIMPLE_CHEMICAL", 235, 242], ["RNase 1", "PROTEIN", 102, 109], ["TBE", "SPECIES", 182, 185], ["cloned RNase", "TREATMENT", 95, 107], ["TX", "TREATMENT", 127, 129], ["1% agarose gel electrophoresis", "TREATMENT", 148, 178], ["Denaturing agarose gel electrophoresis", "TREATMENT", 186, 224], ["Denaturing agarose gel electrophoresis", "TEST", 224, 262], ["amounts", "OBSERVATION_MODIFIER", 6, 13]]], ["The gel was photographed under UV light.TUNEL assayThe induction of apoptosis was investigated by the incorporation of biotin labeled deoxyribonucleotides and detection of biotin incorporation according to the manufacturer's instructions (DeadEnd colorimetric TUNEL system, Promega).", [["biotin", "CHEMICAL", 119, 125], ["biotin", "CHEMICAL", 172, 178], ["biotin", "CHEMICAL", 119, 125], ["deoxyribonucleotides", "CHEMICAL", 134, 154], ["biotin", "CHEMICAL", 172, 178], ["biotin", "SIMPLE_CHEMICAL", 119, 125], ["deoxyribonucleotides", "SIMPLE_CHEMICAL", 134, 154], ["biotin", "SIMPLE_CHEMICAL", 172, 178], ["The gel", "TREATMENT", 0, 7], ["TUNEL assay", "TEST", 40, 51], ["apoptosis", "PROBLEM", 68, 77], ["biotin labeled deoxyribonucleotides", "TREATMENT", 119, 154], ["biotin incorporation", "TREATMENT", 172, 192], ["UV light", "OBSERVATION", 31, 39]]], ["Cells were seeded in four well chamber slides, and infected at confluency with 18f at 5 pfu/cell.", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 92, 96], ["Cells", "CELL", 0, 5], ["cell", "CELL", 92, 96], ["Cells", "TEST", 0, 5], ["infected", "OBSERVATION_MODIFIER", 51, 59]]], ["Cells were fixed for TUNEL assay at 48 h pi.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["TUNEL assay", "TEST", 21, 32]]], ["Persistently infected cells were seeded in four well chamber slides, and processed when the monolayers reached confluence.", [["cells", "ANATOMY", 22, 27], ["monolayers", "ANATOMY", 92, 102], ["cells", "CELL", 22, 27], ["monolayers", "CELL", 92, 102], ["Persistently infected cells", "PROBLEM", 0, 27], ["infected cells", "OBSERVATION", 13, 27]]], ["Viral antigen-positive cells were displayed by immunohistochemistry, using an antibody to VP1 (Kulka et al., 2003) .", [["cells", "ANATOMY", 23, 28], ["Viral antigen-positive cells", "CELL_TYPE", 0, 28], ["VP1", "PROTEIN", 90, 93], ["Viral antigen", "TEST", 0, 13], ["immunohistochemistry", "TEST", 47, 67], ["an antibody", "TEST", 75, 86], ["VP1", "TEST", 90, 93], ["positive cells", "OBSERVATION", 14, 28]]], ["Briefly, cells were fixed in buffered formalin, permeabilized with 0.1% Tween 20 in PBS, and reacted with 1:200 dilution of rabbit anti-VP1 antibody in PBS containing 1% nonfat dry milk (Nadala and Loh, 1990) .", [["cells", "ANATOMY", 9, 14], ["formalin", "CHEMICAL", 38, 46], ["formalin", "CHEMICAL", 38, 46], ["Tween 20", "CHEMICAL", 72, 80], ["cells", "CELL", 9, 14], ["formalin", "SIMPLE_CHEMICAL", 38, 46], ["PBS", "SIMPLE_CHEMICAL", 84, 87], ["rabbit", "ORGANISM", 124, 130], ["anti-VP1", "GENE_OR_GENE_PRODUCT", 131, 139], ["milk", "ORGANISM_SUBSTANCE", 181, 185], ["rabbit anti-VP1 antibody", "PROTEIN", 124, 148], ["rabbit", "SPECIES", 124, 130], ["rabbit", "SPECIES", 124, 130], ["rabbit anti-VP1 antibody in PBS", "TREATMENT", 124, 155]]], ["After several washes with PBS containing 0.1% Tween 20, the cells were incubated with HRP labeled anti-rabbit IgG diluted in 1% non-fat dry milk.", [["cells", "ANATOMY", 60, 65], ["milk", "ANATOMY", 140, 144], ["Tween 20", "CHEMICAL", 46, 54], ["cells", "CELL", 60, 65], ["HRP", "SIMPLE_CHEMICAL", 86, 89], ["milk", "ORGANISM_SUBSTANCE", 140, 144], ["HRP labeled anti-rabbit IgG", "PROTEIN", 86, 113], ["anti-rabbit", "SPECIES", 98, 109], ["anti-rabbit", "SPECIES", 98, 109], ["PBS", "TREATMENT", 26, 29], ["HRP labeled anti-rabbit IgG", "TREATMENT", 86, 113]]], ["Following several washes to remove unbound antibody, color was developed using CN-DAB substrate (Pierce Chemical Co.).Reverse transcription-PCRTotal cytoplasmic RNAs were digested with RNase free DNase (Promega) in the presence of RNasin RNase inhibitor followed by PCIA extraction and ethanol precipitation, as above, to remove any contaminating DNA.", [["cytoplasmic", "ANATOMY", 149, 160], ["PCIA", "CHEMICAL", 266, 270], ["ethanol", "CHEMICAL", 286, 293], ["DAB", "CHEMICAL", 82, 85], ["ethanol", "CHEMICAL", 286, 293], ["CN-DAB", "SIMPLE_CHEMICAL", 79, 85], ["cytoplasmic", "ORGANISM_SUBSTANCE", 149, 160], ["RNase", "GENE_OR_GENE_PRODUCT", 185, 190], ["DNase", "GENE_OR_GENE_PRODUCT", 196, 201], ["RNasin RNase", "GENE_OR_GENE_PRODUCT", 231, 243], ["PCIA", "SIMPLE_CHEMICAL", 266, 270], ["ethanol", "SIMPLE_CHEMICAL", 286, 293], ["DNA", "CELLULAR_COMPONENT", 347, 350], ["unbound antibody", "PROTEIN", 35, 51], ["CN", "PROTEIN", 79, 81], ["PCRTotal cytoplasmic RNAs", "RNA", 140, 165], ["RNase", "PROTEIN", 185, 190], ["DNase", "PROTEIN", 196, 201], ["several washes", "TREATMENT", 10, 24], ["unbound antibody", "TEST", 35, 51], ["Reverse transcription", "TREATMENT", 118, 139], ["PCRTotal cytoplasmic RNAs", "PROBLEM", 140, 165], ["RNase free DNase (Promega", "TREATMENT", 185, 210], ["RNasin RNase inhibitor", "TREATMENT", 231, 253], ["PCIA extraction", "TREATMENT", 266, 281], ["ethanol precipitation", "TREATMENT", 286, 307], ["any contaminating DNA", "PROBLEM", 329, 350], ["cytoplasmic RNAs", "OBSERVATION", 149, 165]]], ["RNA samples (2 g) each were reverse transcribed using AMV reverse transcriptase in a total volume of 20 l using 1 g oligo(dT) 15 as primer as described previously (Goswami et al., 1994) .", [["samples", "ANATOMY", 4, 11], ["AMV", "ORGANISM", 54, 57], ["AMV reverse transcriptase", "PROTEIN", 54, 79], ["RNA samples", "TEST", 0, 11], ["AMV reverse transcriptase", "TREATMENT", 54, 79], ["a total volume", "TREATMENT", 83, 97], ["1 g oligo(dT)", "TREATMENT", 112, 125]]], ["IFN-\u2424 mRNA was amplified using the primer pairs 5 ACCAACAAGTGTCTCCTCCA3 (sense) and 5 GAGGTAACCTGTAAGTCTGT3 (antisense), with an annealing temperature of 60 \u2022 C. This primer pair amplifies a 552-bp fragment (Brack et al., 2002) .", [["IFN-\u2424", "GENE_OR_GENE_PRODUCT", 0, 5], ["GAGGTAACCTGTAAGTCTGT3", "GENE_OR_GENE_PRODUCT", 86, 107], ["IFN-\u2424 mRNA", "RNA", 0, 10], ["primer pair", "DNA", 167, 178], ["552-bp fragment", "DNA", 191, 206], ["mRNA", "TREATMENT", 6, 10], ["the primer pairs 5 ACCAACAAGTGTCTCCTCCA3 (sense)", "TREATMENT", 31, 79], ["an annealing temperature", "TEST", 126, 150]]], ["Amplification of the p40/46 and the p69/71 forms of 2 -5 OAS were carried out with the primers p40/46 sense (5 GAAGCCTGTCAAAGAGAGAG3 ) and p40/46 antisense (5 TGTGTTTTCATGCTCCCTCG3 ) which amplifies a 424-bp fragment (nucleotides 382-806), p69/71 sense (5 CAATCAGCGAGGCCAGTAATC3 ), and p69/71 antisense (5 CTTGACGATTTTGTGCCGCTC3 ), which amplifies a 447-bp fragment (nucleotides 872-1318), with annealing at 56 and 59 \u2022 C, respectively (Takahashi et al., 2002) .", [["p40/46", "GENE_OR_GENE_PRODUCT", 21, 27], ["p69/71", "GENE_OR_GENE_PRODUCT", 36, 42], ["p69/71", "GENE_OR_GENE_PRODUCT", 286, 292], ["p40/46", "DNA", 21, 27], ["primers p40/46 sense", "DNA", 87, 107], ["p40/46 antisense", "DNA", 139, 155], ["424-bp fragment", "DNA", 201, 216], ["nucleotides 382-806", "DNA", 218, 237], ["p69/71 sense", "DNA", 240, 252], ["p69/71 antisense", "DNA", 286, 302], ["447-bp fragment", "DNA", 350, 365], ["nucleotides 872-1318", "DNA", 367, 387], ["the primers", "TEST", 83, 94], ["antisense (5 TGTGTTTTCATGCTCCCTCG3 )", "TREATMENT", 146, 182], ["a 424-bp fragment (nucleotides", "TREATMENT", 199, 229], ["bp fragment", "TEST", 354, 365], ["nucleotides", "TEST", 367, 378], ["annealing", "TEST", 395, 404]]], ["To amplify RNase L mRNA, the following primers were synthesized based on the sequence of human RNase L (GenBank accession number NM 021133): RNase L sense (5 AGATGAGGAAACTAAGGACCTC3 ), and RNase L antisense (5 GAGGTTTGTTTGGACTGTGGG3 ), which amplifies a 512-bp fragment (nucleotides 1768-2279).", [["nucleotides 1768-2279", "CHEMICAL", 271, 292], ["RNase L", "GENE_OR_GENE_PRODUCT", 11, 18], ["human", "ORGANISM", 89, 94], ["RNase L", "GENE_OR_GENE_PRODUCT", 95, 102], ["RNase L sense (5 AGATGAGGAAACTAAGGACCTC3", "GENE_OR_GENE_PRODUCT", 141, 181], ["RNase L antisense", "GENE_OR_GENE_PRODUCT", 189, 206], ["RNase L mRNA", "RNA", 11, 23], ["human RNase L", "DNA", 89, 102], ["RNase L antisense", "DNA", 189, 206], ["512-bp fragment", "DNA", 254, 269], ["nucleotides 1768-2279", "DNA", 271, 292], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 89, 94], ["RNase L mRNA", "TREATMENT", 11, 23], ["RNase L sense (5 AGATGAGGAAACTAAGGACCTC3 )", "TREATMENT", 141, 183], ["RNase L antisense (5 GAGGTTTGTTTGGACTGTGGG3 )", "TREATMENT", 189, 234], ["a 512-bp fragment", "TREATMENT", 252, 269], ["nucleotides", "TEST", 271, 282], ["RNase L mRNA", "OBSERVATION_MODIFIER", 11, 23]]], ["The annealing temperature was 60 \u2022 C. \u2425-Actin mRNA levels were used to normalize the RT-PCR signal generated by the other mRNAs.", [["\u2425-Actin", "GENE_OR_GENE_PRODUCT", 38, 45], ["mRNAs", "RNA", 122, 127], ["The annealing temperature", "TEST", 0, 25], ["C. \u2425-Actin mRNA levels", "TEST", 35, 57], ["the RT-PCR signal", "TEST", 81, 98]]], ["The primers for \u2425-actin were 5 AAGTACCCCATTGAGCATGGC3 (sense) and 5 CACAGCTTCTCCTTGATGTCGC3 (antisense).", [["\u2425-actin", "GENE_OR_GENE_PRODUCT", 16, 23], ["\u2425-actin", "DNA", 16, 23], ["The primers", "TREATMENT", 0, 11], ["\u2425-actin were 5 AAGTACCCCATTGAGCATGGC3 (sense)", "TREATMENT", 16, 61], ["5 CACAGCTTCTCCTTGATGTCGC3 (antisense)", "TREATMENT", 66, 103]]], ["The annealing temperature was 60 \u2022 C. Viral RNA in total or cytoplasmic RNA samples were amplified using primers 5 CCGTTTGCCTAGGCTATAGGCTA3 (sense) and 5 CAGCTCCATGCTAATCATGGAGT3 (antisense).", [["cytoplasmic", "ANATOMY", 60, 71], ["samples", "ANATOMY", 76, 83], ["cytoplasmic", "ORGANISM_SUBSTANCE", 60, 71], ["Viral RNA", "RNA", 38, 47], ["cytoplasmic RNA samples", "RNA", 60, 83], ["The annealing temperature", "TEST", 0, 25], ["cytoplasmic RNA samples", "TEST", 60, 83], ["primers 5 CCGTTTGCCTAGGCTATAGGCTA3 (sense)", "TREATMENT", 105, 147], ["5 CAGCTCCATGCTAATCATGGAGT3 (antisense", "TREATMENT", 152, 189], ["Viral RNA", "OBSERVATION", 38, 47]]], ["This primer pair is directed to the 5 end of the HAV genome and can differentiate between the genomes of 18f and clone 1 strains of HAV based on the presence of an additional 14 bases in the 5 NTR of the 18f genome (Goswami et al., 2002; Kulka et al., 2003) .", [["HAV", "DISEASE", 132, 135], ["HAV", "ORGANISM", 49, 52], ["clone 1 strains", "ORGANISM", 113, 128], ["HAV", "ORGANISM", 132, 135], ["NTR", "GENE_OR_GENE_PRODUCT", 193, 196], ["primer pair", "DNA", 5, 16], ["5 end", "DNA", 36, 41], ["HAV genome", "DNA", 49, 59], ["5 NTR", "DNA", 191, 196], ["18f genome", "DNA", 204, 214], ["HAV", "SPECIES", 49, 52], ["HAV", "SPECIES", 132, 135], ["HAV", "PROBLEM", 132, 135]]], ["All PCR amplifications were carried out in a total volume of 50 l, and contained 2-5 l of the cDNA pool, 2.5 mM MgCl 2 , 200 M of each deoxynucleoside triphosphate, 50 pmol of each primer, and 2 U of Taq DNA polymerase (Promega) for 30-35 cycles.Virus infection and Z-VAD-FMK treatment for protein extractionFrhK4 cells were mock infected or infected with 5 pfu/cell of 18f, 15 TCID 50 /cell of clone 1 or 5 pfu/cell of coxsackievirus B1 (CBV1) in MEM containing 1% heat inactivated FBS.", [["FrhK4 cells", "ANATOMY", 308, 319], ["cell", "ANATOMY", 362, 366], ["cell", "ANATOMY", 387, 391], ["cell", "ANATOMY", 412, 416], ["FBS", "ANATOMY", 483, 486], ["MgCl", "CHEMICAL", 112, 116], ["deoxynucleoside triphosphate", "CHEMICAL", 135, 163], ["Virus infection", "DISEASE", 246, 261], ["Z-VAD-FMK", "CHEMICAL", 266, 275], ["MgCl", "CHEMICAL", 112, 116], ["deoxynucleoside triphosphate", "CHEMICAL", 135, 163], ["deoxynucleoside triphosphate", "SIMPLE_CHEMICAL", 135, 163], ["Taq", "GENE_OR_GENE_PRODUCT", 200, 203], ["DNA", "CELLULAR_COMPONENT", 204, 207], ["Virus", "ORGANISM", 246, 251], ["FrhK4 cells", "CELL", 308, 319], ["cell", "CELL", 362, 366], ["cell", "CELL", 387, 391], ["clone", "CELL", 395, 400], ["cell", "CELL", 412, 416], ["coxsackievirus B1", "ORGANISM", 420, 437], ["CBV1", "ORGANISM", 439, 443], ["FBS", "ORGANISM_SUBSTANCE", 483, 486], ["Taq DNA polymerase", "PROTEIN", 200, 218], ["FrhK4 cells", "CELL_LINE", 308, 319], ["CBV1", "SPECIES", 439, 443], ["All PCR amplifications", "TEST", 0, 22], ["the cDNA pool", "TREATMENT", 90, 103], ["each deoxynucleoside triphosphate", "TREATMENT", 130, 163], ["Taq DNA polymerase", "TREATMENT", 200, 218], ["Promega", "TEST", 220, 227], ["Virus infection", "PROBLEM", 246, 261], ["Z-VAD", "TREATMENT", 266, 271], ["FMK treatment", "TREATMENT", 272, 285], ["protein extraction", "TREATMENT", 290, 308], ["clone", "TEST", 395, 400], ["coxsackievirus B1", "TEST", 420, 437], ["1% heat inactivated FBS", "TREATMENT", 463, 486], ["infection", "OBSERVATION", 252, 261]]], ["After 2 h adsorption period, medium was added to each flask and incubation continued for the indicated time period.", [["incubation", "TREATMENT", 64, 74]]], ["For infected cultures treated with Z-VAD-FMK, the virus adsorption media was removed prior to the addition of MEM/1% FBS containing 0-50 M inhibitor and subsequently incubated for 48 h.", [["cultures", "ANATOMY", 13, 21], ["FBS", "ANATOMY", 117, 120], ["Z-VAD-FMK", "CHEMICAL", 35, 44], ["MEM", "CHEMICAL", 110, 113], ["FBS", "CHEMICAL", 117, 120], ["Z-VAD-FMK", "CHEMICAL", 35, 44], ["cultures", "CELL", 13, 21], ["Z-VAD-FMK", "SIMPLE_CHEMICAL", 35, 44], ["FBS", "ORGANISM_SUBSTANCE", 117, 120], ["infected cultures", "TEST", 4, 21], ["Z-VAD", "TREATMENT", 35, 40], ["FMK", "TREATMENT", 41, 44], ["the virus adsorption media", "TREATMENT", 46, 72], ["MEM/1% FBS", "TREATMENT", 110, 120]]], ["At the indicated times post-treatment, cell culture monolayers were scraped into their media and pelleted by centrifugation (1500 \u00d7 g, 4 \u2022 C).", [["cell culture monolayers", "ANATOMY", 39, 62], ["cell culture monolayers", "CELL", 39, 62], ["cell culture monolayers", "CELL_LINE", 39, 62], ["treatment", "TREATMENT", 28, 37], ["cell culture monolayers", "TEST", 39, 62]]], ["Cell extracts were prepared and the protein content estimated as described previously (Kulka et al., 2003) .Western blot analysisEqual concentrations of each protein extract were adjusted to equivalent volumes in denaturing sample buffer and heated at 95 \u2022 C for 5-10 min and subjected to SDS-PAGE under reducing conditions, followed by electrophoretic transfer onto nitrocellulose membranes in transfer buffer containing methanol.", [["Cell extracts", "ANATOMY", 0, 13], ["membranes", "ANATOMY", 382, 391], ["methanol", "CHEMICAL", 422, 430], ["nitrocellulose", "CHEMICAL", 367, 381], ["methanol", "CHEMICAL", 422, 430], ["Cell extracts", "ORGANISM_SUBSTANCE", 0, 13], ["methanol", "SIMPLE_CHEMICAL", 422, 430], ["Cell extracts", "TEST", 0, 13], ["the protein content", "TEST", 32, 51], ["blot analysis", "TEST", 116, 129], ["each protein extract", "TREATMENT", 153, 173], ["denaturing sample buffer", "TREATMENT", 213, 237], ["nitrocellulose membranes", "TREATMENT", 367, 391], ["methanol", "TREATMENT", 422, 430]]], ["The membranes were blocked with TBS-T (Tris buffered saline/0.1% Tween 20) containing 5% nonfat dried milk (NFDM) for 90 min at room temperature (rt) and washed four times with TBS-T.", [["membranes", "ANATOMY", 4, 13], ["milk", "ANATOMY", 102, 106], ["NFDM", "CHEMICAL", 108, 112], ["Tween 20", "CHEMICAL", 65, 73], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["TBS-T", "SIMPLE_CHEMICAL", 32, 37], ["Tris buffered saline", "SIMPLE_CHEMICAL", 39, 59], ["Tween 20", "SIMPLE_CHEMICAL", 65, 73], ["milk", "ORGANISM_SUBSTANCE", 102, 106], ["TBS-T (Tris buffered saline", "TREATMENT", 32, 59]]], ["Membranes were incubated either overnight at 4 \u2022 C or 1 h at rt with primary antibody diluted in TBS-T containing either 5% BSA or 5% NFDM.", [["Membranes", "ANATOMY", 0, 9], ["BSA", "CHEMICAL", 124, 127], ["NFDM", "CHEMICAL", 134, 138], ["Membranes", "ORGANISM_SUBSTANCE", 0, 9], ["BSA", "SIMPLE_CHEMICAL", 124, 127], ["NFDM", "SIMPLE_CHEMICAL", 134, 138], ["primary antibody", "PROTEIN", 69, 85], ["primary antibody", "TEST", 69, 85], ["TBS", "TEST", 97, 100], ["5% NFDM", "PROBLEM", 131, 138]]], ["Primary antibodies were used that recognize (i) STAT1 (phosphorylation state independent) or STAT1 phosphorylated on tyrosine at position 701 (Cell Signaling Technologies), used at a 1:1200 dilution (5% BSA) for incubation overnight at 4 \u2022 C; (ii) full length/large (cleaved) fragment caspase-3 (Cell Signaling Technologies), used at a 1:1200 dilution (5% NFDM) for overnight incubation at 4 \u2022 C; (iii) full length/large (cleaved) fragment PARP (Sigma), used at a 1:2000 dilution (5% BSA) for 1 h incubation at rt, and (iv) \u2424-actin (Sigma), used at a 1:1000 dilution (5% NFDM) for 1 h incubation at rt.", [["Cell", "ANATOMY", 143, 147], ["Cell", "ANATOMY", 296, 300], ["tyrosine", "CHEMICAL", 117, 125], ["tyrosine", "CHEMICAL", 117, 125], ["STAT1", "GENE_OR_GENE_PRODUCT", 48, 53], ["STAT1", "GENE_OR_GENE_PRODUCT", 93, 98], ["tyrosine", "AMINO_ACID", 117, 125], ["caspase-3", "GENE_OR_GENE_PRODUCT", 285, 294], ["Cell", "CELL", 296, 300], ["PARP", "GENE_OR_GENE_PRODUCT", 440, 444], ["antibodies", "PROTEIN", 8, 18], ["STAT1", "PROTEIN", 48, 53], ["phosphorylation state", "PROTEIN", 55, 76], ["STAT1", "PROTEIN", 93, 98], ["position 701", "PROTEIN", 129, 141], ["PARP", "PROTEIN", 440, 444], ["Primary antibodies", "TREATMENT", 0, 18], ["STAT1 phosphorylated", "PROBLEM", 93, 113], ["full length/large (cleaved) fragment caspase", "TREATMENT", 248, 292], ["large (cleaved) fragment PARP", "PROBLEM", 415, 444], ["a 1:2000 dilution", "TREATMENT", 462, 479], ["large", "OBSERVATION_MODIFIER", 260, 265], ["large", "OBSERVATION_MODIFIER", 415, 420]]], ["Secondary antibody-HRP conjugates (Pierce-Endogen) were used at a 1:30,000 dilution.", [["HRP conjugates", "SIMPLE_CHEMICAL", 19, 33], ["Pierce-Endogen", "SIMPLE_CHEMICAL", 35, 49], ["Secondary antibody", "TEST", 0, 18], ["HRP conjugates", "TREATMENT", 19, 33], ["Pierce-Endogen)", "TREATMENT", 35, 50]]], ["All other steps including detection were performed as previously described (Kulka et al., 2003) .Viral replication assayConfluent cultures of FrhK4 cells in 12-well plates were infected with 18f at 0.2, 1, or 5 pfu/cell, as described previously.", [["Confluent cultures", "ANATOMY", 120, 138], ["FrhK4 cells", "ANATOMY", 142, 153], ["cell", "ANATOMY", 215, 219], ["Confluent cultures", "CELL", 120, 138], ["FrhK4 cells", "CELL", 142, 153], ["cell", "CELL", 215, 219], ["FrhK4 cells", "CELL_LINE", 142, 153], ["Viral replication assay", "TEST", 97, 120], ["Confluent cultures", "TEST", 120, 138], ["FrhK4 cells", "TEST", 142, 153], ["Confluent", "OBSERVATION_MODIFIER", 120, 129]]], ["Replication of virus was assessed by the level of viral antigen in each well as described before using the HAVAB EIA kit (Goswami et al., 2002; Kulka et al., 2003) .Virus replication and apoptosis in infected cellsPrevious investigations have demonstrated that a cp strain of HAV, HAVcyt/HB1.1, derived from the cc strain HM175, induced apoptosis in 2-5% of the cells by 120 h post-infection (pi), increasing to 37.5% by 14 days pi (Brack et al., 1998) .", [["cells", "ANATOMY", 209, 214], ["cells", "ANATOMY", 362, 367], ["HM175", "CHEMICAL", 322, 327], ["infection", "DISEASE", 382, 391], ["Virus", "ORGANISM", 165, 170], ["cells", "CELL", 209, 214], ["HAV", "ORGANISM", 276, 279], ["HAVcyt", "GENE_OR_GENE_PRODUCT", 281, 287], ["HB1.1", "GENE_OR_GENE_PRODUCT", 288, 293], ["cc strain", "ORGANISM", 312, 321], ["HM175", "ORGANISM", 322, 327], ["cells", "CELL", 362, 367], ["viral antigen", "PROTEIN", 50, 63], ["infected cells", "CELL_TYPE", 200, 214], ["HAV", "SPECIES", 276, 279], ["Replication of virus", "PROBLEM", 0, 20], ["Virus replication", "TREATMENT", 165, 182], ["apoptosis in infected cells", "PROBLEM", 187, 214], ["Previous investigations", "TEST", 214, 237], ["a cp strain of HAV", "PROBLEM", 261, 279], ["HAVcyt", "TEST", 281, 287], ["HB1.1", "PROBLEM", 288, 293], ["the cc strain", "TEST", 308, 321], ["induced apoptosis", "PROBLEM", 329, 346], ["infection", "PROBLEM", 382, 391], ["virus", "OBSERVATION", 15, 20], ["apoptosis", "OBSERVATION_MODIFIER", 187, 196], ["infected cells", "OBSERVATION", 200, 214], ["infection", "OBSERVATION", 382, 391]]], ["Similar slowly developing cpe and apoptosis were reported in cells infected with another cp strain, HM175/24a (Gosert et al., 2000) .", [["cells", "ANATOMY", 61, 66], ["cells", "CELL", 61, 66], ["Similar slowly developing cpe", "PROBLEM", 0, 29], ["apoptosis", "PROBLEM", 34, 43], ["another cp strain", "PROBLEM", 81, 98], ["slowly", "OBSERVATION_MODIFIER", 8, 14], ["developing", "OBSERVATION_MODIFIER", 15, 25], ["cpe", "OBSERVATION", 26, 29], ["apoptosis", "OBSERVATION_MODIFIER", 34, 43]]], ["In contrast, cells infected with the 18f strain develop extensive cpe in approximately 15% of the cells by 48 h, and an almost total cpe is observed by 96 h (Kulka et al., 2003) .", [["cells", "ANATOMY", 13, 18], ["cells", "ANATOMY", 98, 103], ["cells", "CELL", 13, 18], ["18f strain", "ORGANISM", 37, 47], ["cells", "CELL", 98, 103], ["extensive cpe", "PROBLEM", 56, 69], ["an almost total cpe", "PROBLEM", 117, 136], ["extensive", "OBSERVATION_MODIFIER", 56, 65], ["cpe", "OBSERVATION_MODIFIER", 66, 69], ["total", "OBSERVATION_MODIFIER", 127, 132], ["cpe", "OBSERVATION", 133, 136]]], ["Using a colorimetric TUNEL assay at 48 h pi we investigated whether cpe induced by the 18f strain is a result of apoptosis (Fig. 1) .", [["cpe", "GENE_OR_GENE_PRODUCT", 68, 71], ["18f", "GENE_OR_GENE_PRODUCT", 87, 90], ["a colorimetric TUNEL assay", "TEST", 6, 32], ["cpe", "PROBLEM", 68, 71], ["the 18f strain", "PROBLEM", 83, 97], ["apoptosis", "PROBLEM", 113, 122], ["apoptosis", "OBSERVATION", 113, 122]]], ["TUNEL positive cells were present in the 18f infected monolayers, whereas positively stained cells were only occasionally observed in the absence of virus infection.", [["cells", "ANATOMY", 15, 20], ["monolayers", "ANATOMY", 54, 64], ["cells", "ANATOMY", 93, 98], ["infection", "DISEASE", 155, 164], ["cells", "CELL", 15, 20], ["monolayers", "CELL", 54, 64], ["cells", "CELL", 93, 98], ["positively stained cells", "CELL_TYPE", 74, 98], ["TUNEL positive cells", "PROBLEM", 0, 20], ["positively stained cells", "PROBLEM", 74, 98], ["virus infection", "PROBLEM", 149, 164], ["positive cells", "OBSERVATION", 6, 20], ["infected monolayers", "OBSERVATION_MODIFIER", 45, 64], ["stained cells", "OBSERVATION", 85, 98], ["virus", "OBSERVATION_MODIFIER", 149, 154], ["infection", "OBSERVATION", 155, 164]]], ["Persistently infected clone 1 cells at 35 days or 330 days pi also showed an occasional positively stained cell.", [["clone 1 cells", "ANATOMY", 22, 35], ["cell", "ANATOMY", 107, 111], ["clone 1 cells", "CELL", 22, 35], ["cell", "CELL", 107, 111], ["Persistently infected clone 1 cells", "CELL_LINE", 0, 35], ["Persistently infected clone 1 cells", "PROBLEM", 0, 35], ["an occasional positively stained cell", "PROBLEM", 74, 111], ["infected", "OBSERVATION_MODIFIER", 13, 21], ["clone 1 cells", "OBSERVATION", 22, 35], ["occasional", "OBSERVATION_MODIFIER", 77, 87], ["positively", "OBSERVATION_MODIFIER", 88, 98], ["stained cell", "OBSERVATION", 99, 111]]], ["The culture remained viable, however, and 18f like cpe was not observed until more than a year of weekly passages.", [["The culture", "TEST", 0, 11], ["18f like cpe", "PROBLEM", 42, 54]]], ["Immunohistochemical staining was performed on the persistently infected clone 1 cells to determine if the persistently infected status of these cells is due to the lack of actively replicating virus in a majority of the cell population (Fig. 2) .", [["clone 1 cells", "ANATOMY", 72, 85], ["cells", "ANATOMY", 144, 149], ["cell", "ANATOMY", 220, 224], ["clone 1 cells", "CELL", 72, 85], ["cells", "CELL", 144, 149], ["cell population", "CELL", 220, 235], ["persistently infected clone 1 cells", "CELL_LINE", 50, 85], ["Immunohistochemical staining", "TEST", 0, 28], ["the persistently infected clone 1 cells", "PROBLEM", 46, 85], ["the persistently infected status of these cells", "PROBLEM", 102, 149], ["actively replicating virus", "PROBLEM", 172, 198], ["persistently", "OBSERVATION_MODIFIER", 106, 118], ["infected", "OBSERVATION", 119, 127], ["virus", "OBSERVATION", 193, 198], ["cell population", "OBSERVATION", 220, 235]]], ["Almost all of the cells showed positive staining for viral antigen.", [["cells", "ANATOMY", 18, 23], ["cells", "CELL", 18, 23], ["viral antigen", "GENE_OR_GENE_PRODUCT", 53, 66], ["viral antigen", "PROTEIN", 53, 66], ["positive staining", "PROBLEM", 31, 48], ["viral antigen", "PROBLEM", 53, 66], ["positive staining", "OBSERVATION", 31, 48]]], ["In addition, replication of the virus as measured by EIA confirmed the presence of actively replicating virus (data not shown).", [["the virus", "PROBLEM", 28, 37], ["EIA", "TEST", 53, 56], ["actively replicating virus", "PROBLEM", 83, 109], ["virus", "OBSERVATION", 104, 109]]], ["Taken together, these results show that the 18f strain causes apoptosis in infected cells much earlier than cells infected with other cp strains, and that the lack of apoptosis in persistently infected cells is not due to lack of active virus replication.RNA degradation occurs prior to apoptotic DNA fragmentationWe have previously shown that rRNA degradation is dependent upon replication of 18f, since treatments that inhibited replication also resulted in inhibition of rRNA degradation.", [["cells", "ANATOMY", 84, 89], ["cells", "ANATOMY", 108, 113], ["cells", "ANATOMY", 202, 207], ["18f", "GENE_OR_GENE_PRODUCT", 44, 47], ["cells", "CELL", 84, 89], ["cells", "CELL", 108, 113], ["cp strains", "ORGANISM", 134, 144], ["cells", "CELL", 202, 207], ["DNA", "CELLULAR_COMPONENT", 297, 300], ["rRNA", "CELLULAR_COMPONENT", 344, 348], ["18f", "GENE_OR_GENE_PRODUCT", 394, 397], ["rRNA", "CELLULAR_COMPONENT", 474, 478], ["infected cells", "CELL_TYPE", 75, 89], ["persistently infected cells", "CELL_TYPE", 180, 207], ["18f", "DNA", 394, 397], ["the 18f strain", "PROBLEM", 40, 54], ["apoptosis", "PROBLEM", 62, 71], ["infected cells", "PROBLEM", 75, 89], ["other cp strains", "PROBLEM", 128, 144], ["apoptosis", "PROBLEM", 167, 176], ["persistently infected cells", "PROBLEM", 180, 207], ["active virus replication", "PROBLEM", 230, 254], ["RNA degradation", "PROBLEM", 255, 270], ["apoptotic DNA fragmentation", "PROBLEM", 287, 314], ["rRNA degradation", "PROBLEM", 344, 360], ["treatments", "TREATMENT", 405, 415], ["rRNA degradation", "PROBLEM", 474, 490], ["infected cells", "OBSERVATION", 75, 89], ["apoptosis", "OBSERVATION", 167, 176], ["persistently", "OBSERVATION_MODIFIER", 180, 192], ["infected cells", "OBSERVATION", 193, 207], ["active", "OBSERVATION_MODIFIER", 230, 236], ["virus", "OBSERVATION", 237, 242], ["apoptotic DNA fragmentation", "OBSERVATION", 287, 314], ["rRNA degradation", "OBSERVATION", 344, 360], ["dependent", "OBSERVATION_MODIFIER", 364, 373], ["rRNA degradation", "OBSERVATION", 474, 490]]], ["However, certain cell lines are sensitive to perturbation of cellular macromolecule synthesis and can be driven to apoptotic cell death by treatment with metabolic inhibitors.", [["cell lines", "ANATOMY", 17, 27], ["cellular", "ANATOMY", 61, 69], ["cell", "ANATOMY", 125, 129], ["death", "DISEASE", 130, 135], ["cell lines", "CELL", 17, 27], ["cellular", "CELL", 61, 69], ["cell", "CELL", 125, 129], ["cell lines", "CELL_LINE", 17, 27], ["certain cell lines", "PROBLEM", 9, 27], ["cellular macromolecule synthesis", "TREATMENT", 61, 93], ["apoptotic cell death", "TREATMENT", 115, 135], ["metabolic inhibitors", "TREATMENT", 154, 174], ["cell lines", "OBSERVATION", 17, 27], ["cellular macromolecule synthesis", "OBSERVATION", 61, 93], ["apoptotic cell", "OBSERVATION", 115, 129]]], ["In such instances, apoptosis causes 28S rRNA fragmentation (Houge et al., 1995) .", [["28S", "CELLULAR_COMPONENT", 36, 39], ["rRNA", "CELLULAR_COMPONENT", 40, 44], ["apoptosis", "PROBLEM", 19, 28], ["28S rRNA fragmentation", "PROBLEM", 36, 58], ["28S rRNA", "OBSERVATION", 36, 44], ["fragmentation", "OBSERVATION_MODIFIER", 45, 58]]], ["Therefore, to determine whether rRNA degradation is a cause, or the effect of apoptosis in 18f infection, it was necessary to establish the temporal sequence of these two events.", [["infection", "DISEASE", 95, 104], ["rRNA", "CELLULAR_COMPONENT", 32, 36], ["rRNA degradation", "PROBLEM", 32, 48], ["apoptosis", "PROBLEM", 78, 87], ["18f infection", "PROBLEM", 91, 104]]], ["FrhK4 cells were infected with 18f and total nucleic acids from the cytoplasm were prepared at different times as described in Section 2.", [["FrhK4 cells", "ANATOMY", 0, 11], ["cytoplasm", "ANATOMY", 68, 77], ["nucleic acids", "CHEMICAL", 45, 58], ["FrhK4 cells", "CELL", 0, 11], ["cytoplasm", "ORGANISM_SUBSTANCE", 68, 77], ["FrhK4 cells", "CELL_LINE", 0, 11], ["18f", "PROTEIN", 31, 34], ["FrhK4 cells", "PROBLEM", 0, 11], ["total nucleic acids", "TEST", 39, 58]]], ["As control, cytoplasmic nucleic acids were also isolated from mock infected cells and persistently infected (clone 1) cells.", [["cytoplasmic", "ANATOMY", 12, 23], ["cells", "ANATOMY", 76, 81], ["clone 1) cells", "ANATOMY", 109, 123], ["nucleic acids", "CHEMICAL", 24, 37], ["cytoplasmic", "ORGANISM_SUBSTANCE", 12, 23], ["nucleic acids", "AMINO_ACID", 24, 37], ["cells", "CELL", 76, 81], ["clone 1", "CELL", 109, 116], ["cells", "CELL", 118, 123], ["cytoplasmic nucleic acids", "PROTEIN", 12, 37], ["mock infected cells", "CELL_TYPE", 62, 81], ["persistently infected (clone 1) cells", "CELL_LINE", 86, 123], ["cytoplasmic nucleic acids", "TEST", 12, 37], ["mock infected cells", "PROBLEM", 62, 81], ["persistently infected (clone 1) cells", "PROBLEM", 86, 123], ["nucleic acids", "OBSERVATION", 24, 37]]], ["Nucleic acids were analyzed by agarose gel electrophoresis before and after digestion with RNase 1 (Fig. 3) .", [["Nucleic acids", "SIMPLE_CHEMICAL", 0, 13], ["agarose", "SIMPLE_CHEMICAL", 31, 38], ["RNase 1", "GENE_OR_GENE_PRODUCT", 91, 98], ["RNase 1", "PROTEIN", 91, 98], ["Nucleic acids", "TREATMENT", 0, 13], ["agarose gel electrophoresis", "TEST", 31, 58], ["RNase", "TEST", 91, 96]]], ["Degradation of the 28S and 18S molecules into discrete products was Fig. 1 .", [["28S", "CELLULAR_COMPONENT", 19, 22], ["28S and 18S molecules", "PROTEIN", 19, 40], ["Degradation of the 28S", "PROBLEM", 0, 22], ["discrete", "OBSERVATION_MODIFIER", 46, 54], ["products", "OBSERVATION_MODIFIER", 55, 63], ["Fig", "OBSERVATION_MODIFIER", 68, 71]]], ["Rapid induction of apoptosis in 18f infected FrhK4 cells.", [["FrhK4 cells", "ANATOMY", 45, 56], ["FrhK4 cells", "CELL", 45, 56], ["18f infected FrhK4 cells", "CELL_LINE", 32, 56], ["apoptosis", "PROBLEM", 19, 28], ["infected FrhK4 cells", "PROBLEM", 36, 56], ["apoptosis", "OBSERVATION_MODIFIER", 19, 28], ["FrhK4 cells", "OBSERVATION", 45, 56]]], ["Confluent cultures of FrhK4 cells were mock infected or infected with the cytopathic 18f strain of HAV.", [["Confluent cultures", "ANATOMY", 0, 18], ["FrhK4 cells", "ANATOMY", 22, 33], ["HAV", "DISEASE", 99, 102], ["Confluent cultures", "CELL", 0, 18], ["FrhK4 cells", "CELL", 22, 33], ["HAV", "ORGANISM", 99, 102], ["FrhK4 cells", "CELL_LINE", 22, 33], ["HAV", "SPECIES", 99, 102], ["Confluent cultures", "TEST", 0, 18], ["FrhK4 cells", "PROBLEM", 22, 33], ["HAV", "PROBLEM", 99, 102], ["cultures", "OBSERVATION_MODIFIER", 10, 18], ["FrhK4 cells", "OBSERVATION", 22, 33], ["cytopathic", "OBSERVATION_MODIFIER", 74, 84]]], ["Cells were processed for the detection of TUNEL positive cells at 48 h pi as described in Section 2.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 57, 62], ["Cells", "CELL", 0, 5], ["cells", "CELL", 57, 62], ["TUNEL positive cells", "CELL_LINE", 42, 62], ["the detection", "TEST", 25, 38], ["TUNEL positive cells", "PROBLEM", 42, 62], ["TUNEL positive cells", "OBSERVATION", 42, 62]]], ["Persistently infected cultures following infection by the non-cytopathic HM175 (clone 1) strain of HAV were established as described in Section 2.", [["cultures", "ANATOMY", 22, 30], ["infection", "DISEASE", 41, 50], ["HAV", "DISEASE", 99, 102], ["cultures", "CELL", 22, 30], ["clone 1", "ORGANISM", 80, 87], ["HAV", "ORGANISM", 99, 102], ["HAV", "SPECIES", 99, 102], ["Persistently infected cultures", "PROBLEM", 0, 30], ["infection", "PROBLEM", 41, 50], ["HAV", "PROBLEM", 99, 102], ["infected", "OBSERVATION_MODIFIER", 13, 21], ["cultures", "OBSERVATION_MODIFIER", 22, 30], ["infection", "OBSERVATION", 41, 50]]], ["Cells were processed for TUNEL positive cells at 35 days or 330 days post infection. evident at 24 h pi, and by 72 h pi very little intact rRNAs could be detected.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 40, 45], ["rRNAs", "ANATOMY", 139, 144], ["infection", "DISEASE", 74, 83], ["Cells", "CELL", 0, 5], ["cells", "CELL", 40, 45], ["rRNAs", "CELLULAR_COMPONENT", 139, 144], ["TUNEL positive cells", "CELL_LINE", 25, 45], ["intact rRNAs", "RNA", 132, 144], ["TUNEL positive cells", "PROBLEM", 25, 45], ["infection", "PROBLEM", 74, 83], ["very little intact rRNAs", "PROBLEM", 120, 144], ["positive cells", "OBSERVATION", 31, 45], ["infection", "OBSERVATION", 74, 83], ["rRNAs", "OBSERVATION", 139, 144]]], ["The appearance of apoptotic DNA laddering in the cytoplasm could be detected following elimination of rRNAs from total nucleic acid preparations by RNase 1 and clearly lagged behind rRNA degradation as a result of 18f infection (Fig. 3, Panel A) .", [["cytoplasm", "ANATOMY", 49, 58], ["nucleic acid", "CHEMICAL", 119, 131], ["infection", "DISEASE", 218, 227], ["DNA", "CELLULAR_COMPONENT", 28, 31], ["cytoplasm", "ORGANISM_SUBSTANCE", 49, 58], ["RNase 1", "GENE_OR_GENE_PRODUCT", 148, 155], ["rRNA", "CELLULAR_COMPONENT", 182, 186], ["rRNAs", "RNA", 102, 107], ["RNase 1", "PROTEIN", 148, 155], ["apoptotic DNA laddering", "PROBLEM", 18, 41], ["rRNAs", "PROBLEM", 102, 107], ["total nucleic acid preparations", "TREATMENT", 113, 144], ["rRNA degradation", "PROBLEM", 182, 198], ["18f infection", "PROBLEM", 214, 227], ["apoptotic DNA laddering", "OBSERVATION", 18, 41], ["infection", "OBSERVATION", 218, 227]]], ["Neither mock infected cells nor persistently infected (clone 1) cells showed any evidence of RNA or DNA degradation (Fig. 3, Panel B) .", [["cells", "ANATOMY", 22, 27], ["clone 1) cells", "ANATOMY", 55, 69], ["cells", "CELL", 22, 27], ["clone 1", "CELL", 55, 62], ["cells", "CELL", 64, 69], ["DNA", "CELLULAR_COMPONENT", 100, 103], ["mock infected cells", "CELL_TYPE", 8, 27], ["Neither mock infected cells", "PROBLEM", 0, 27], ["persistently infected", "PROBLEM", 32, 53], ["clone 1) cells", "TEST", 55, 69], ["RNA", "PROBLEM", 93, 96], ["DNA degradation", "PROBLEM", 100, 115], ["infected cells", "OBSERVATION", 13, 27], ["persistently", "OBSERVATION_MODIFIER", 32, 44], ["infected", "OBSERVATION", 45, 53], ["any evidence of", "UNCERTAINTY", 77, 92], ["RNA", "OBSERVATION", 93, 96]]], ["No evidence of RNA or DNA degradation could be seen in nucleic acid preparations from cells infected with 18f virus, at 6 or 12 h pi (data not shown).", [["cells", "ANATOMY", 86, 91], ["nucleic acid", "CHEMICAL", 55, 67], ["DNA", "CELLULAR_COMPONENT", 22, 25], ["nucleic acid", "SIMPLE_CHEMICAL", 55, 67], ["cells", "CELL", 86, 91], ["18f virus", "ORGANISM", 106, 115], ["18f virus", "SPECIES", 106, 115], ["RNA", "PROBLEM", 15, 18], ["DNA degradation", "PROBLEM", 22, 37], ["nucleic acid preparations", "TREATMENT", 55, 80], ["18f virus", "TREATMENT", 106, 115], ["evidence of", "UNCERTAINTY", 3, 14], ["RNA", "OBSERVATION", 15, 18]]], ["The data indicate that rRNA degradation in 18f infected cells occurs prior to apoptosis, and is not a consequence of apoptosis or DNA fragmentation.Caspase is activated in 18f infected cellsPrevious studies have shown that rRNA degradation in cells over-expressing the IFN regulated 2-5A activated RNase L results in apoptosis due to activation of caspase 3 (Rusch et al., 2000) .", [["cells", "ANATOMY", 56, 61], ["cells", "ANATOMY", 185, 190], ["cells", "ANATOMY", 243, 248], ["rRNA", "CELLULAR_COMPONENT", 23, 27], ["cells", "CELL", 56, 61], ["DNA", "CELLULAR_COMPONENT", 130, 133], ["Caspase", "GENE_OR_GENE_PRODUCT", 148, 155], ["cells", "CELL", 185, 190], ["rRNA", "CELLULAR_COMPONENT", 223, 227], ["cells", "CELL", 243, 248], ["IFN", "GENE_OR_GENE_PRODUCT", 269, 272], ["2-5A", "GENE_OR_GENE_PRODUCT", 283, 287], ["RNase L", "GENE_OR_GENE_PRODUCT", 298, 305], ["caspase 3", "GENE_OR_GENE_PRODUCT", 348, 357], ["18f infected cells", "CELL_LINE", 43, 61], ["Caspase", "PROTEIN", 148, 155], ["18f infected cells", "CELL_LINE", 172, 190], ["IFN regulated 2-5A activated RNase L", "PROTEIN", 269, 305], ["caspase 3", "PROTEIN", 348, 357], ["The data", "TEST", 0, 8], ["rRNA degradation", "PROBLEM", 23, 39], ["18f infected cells", "PROBLEM", 43, 61], ["apoptosis", "PROBLEM", 78, 87], ["apoptosis", "PROBLEM", 117, 126], ["DNA fragmentation", "PROBLEM", 130, 147], ["Caspase", "TREATMENT", 148, 155], ["Previous studies", "TEST", 190, 206], ["rRNA degradation in cells", "PROBLEM", 223, 248], ["apoptosis", "PROBLEM", 317, 326], ["activation of caspase", "TREATMENT", 334, 355], ["rRNA degradation", "OBSERVATION", 23, 39], ["infected cells", "OBSERVATION", 47, 61], ["not a consequence of", "UNCERTAINTY", 96, 116], ["apoptosis", "OBSERVATION", 117, 126], ["DNA fragmentation", "OBSERVATION", 130, 147], ["infected cells", "OBSERVATION", 176, 190], ["rRNA degradation", "OBSERVATION", 223, 239]]], ["Caspase 3 is the terminal enzyme in the caspase cascade, and activation of caspase 3 by upstream caspases occurs due to proteolytic cleavage (for a review, see Roulston et al., 1999) .", [["Caspase 3", "GENE_OR_GENE_PRODUCT", 0, 9], ["caspase", "GENE_OR_GENE_PRODUCT", 40, 47], ["caspase 3", "GENE_OR_GENE_PRODUCT", 75, 84], ["caspases", "GENE_OR_GENE_PRODUCT", 97, 105], ["Caspase 3", "PROTEIN", 0, 9], ["terminal enzyme", "PROTEIN", 17, 32], ["caspase 3", "PROTEIN", 75, 84], ["upstream caspases", "PROTEIN", 88, 105], ["Caspase", "TREATMENT", 0, 7], ["the terminal enzyme", "TREATMENT", 13, 32], ["the caspase cascade", "TREATMENT", 36, 55], ["caspase", "TREATMENT", 75, 82], ["upstream caspases", "TREATMENT", 88, 105], ["proteolytic cleavage", "PROBLEM", 120, 140]]], ["To investigate if a similar activation of caspase 3 takes place due to infection with the 18f virus, we investigated caspase 3 activation by western blotting experiments (Fig. 4) .", [["infection", "DISEASE", 71, 80], ["caspase 3", "GENE_OR_GENE_PRODUCT", 42, 51], ["18f virus", "ORGANISM", 90, 99], ["caspase 3", "GENE_OR_GENE_PRODUCT", 117, 126], ["caspase 3", "PROTEIN", 42, 51], ["caspase 3", "PROTEIN", 117, 126], ["18f virus", "SPECIES", 90, 99], ["caspase", "TREATMENT", 42, 49], ["infection", "PROBLEM", 71, 80], ["the 18f virus", "TREATMENT", 86, 99], ["caspase 3 activation", "TREATMENT", 117, 137], ["infection", "OBSERVATION", 71, 80]]], ["Proteolytic cleavage of caspase 3 could be detected in 18f infected cells at 48 h pi, which coincided with the appearance of a DNA ladder in the cytoplasm (compare Fig. 3 , Panel A with Fig. 4, Panel A) .", [["cells", "ANATOMY", 68, 73], ["cytoplasm", "ANATOMY", 145, 154], ["caspase 3", "GENE_OR_GENE_PRODUCT", 24, 33], ["cells", "CELL", 68, 73], ["DNA", "CELLULAR_COMPONENT", 127, 130], ["cytoplasm", "ORGANISM_SUBSTANCE", 145, 154], ["caspase 3", "PROTEIN", 24, 33], ["18f infected cells", "CELL_LINE", 55, 73], ["Proteolytic cleavage of caspase", "TREATMENT", 0, 31], ["a DNA ladder", "PROBLEM", 125, 137]]], ["Proteolysis of caspase 3 was not detectable at earlier times, nor in persistently infected (clone 1) cells (Fig. 4, Panel A) , confirming that caspase activation follows rRNA degradation (Fig. 3) .", [["clone 1) cells", "ANATOMY", 92, 106], ["caspase 3", "GENE_OR_GENE_PRODUCT", 15, 24], ["cells", "CELL", 101, 106], ["caspase", "GENE_OR_GENE_PRODUCT", 143, 150], ["caspase 3", "PROTEIN", 15, 24], ["clone 1) cells", "CELL_LINE", 92, 106], ["caspase", "PROTEIN", 143, 150], ["caspase", "TEST", 15, 22], ["persistently infected (clone 1) cells", "PROBLEM", 69, 106], ["caspase activation", "PROBLEM", 143, 161], ["rRNA degradation", "PROBLEM", 170, 186], ["infected", "OBSERVATION", 82, 90]]], ["Activation of caspase 3 was accompanied by the degradation of PARP-1 (poly ADP-ribose polymerase 1), a target for caspase 3 during the apoptotic response (Kaufmann et al., 1993) .", [["poly ADP-ribose", "CHEMICAL", 70, 85], ["poly ADP-ribose", "CHEMICAL", 70, 85], ["caspase 3", "GENE_OR_GENE_PRODUCT", 14, 23], ["PARP-1", "GENE_OR_GENE_PRODUCT", 62, 68], ["poly ADP-ribose polymerase 1", "GENE_OR_GENE_PRODUCT", 70, 98], ["caspase 3", "GENE_OR_GENE_PRODUCT", 114, 123], ["caspase 3", "PROTEIN", 14, 23], ["PARP-1", "PROTEIN", 62, 68], ["poly ADP-ribose polymerase 1", "PROTEIN", 70, 98], ["caspase 3", "PROTEIN", 114, 123], ["caspase", "TREATMENT", 14, 21], ["PARP", "TEST", 62, 66], ["poly ADP-ribose polymerase", "TREATMENT", 70, 96], ["caspase", "TREATMENT", 114, 121]]], ["Cleavage of PARP-1 was evident at 48 h pi and coincided with the appearance of activated caspase 3; PARP was no longer detectable in 18f infected cells at 72 h pi (Fig. 4, Panel B) .", [["cells", "ANATOMY", 146, 151], ["PARP-1", "GENE_OR_GENE_PRODUCT", 12, 18], ["caspase 3", "GENE_OR_GENE_PRODUCT", 89, 98], ["PARP", "GENE_OR_GENE_PRODUCT", 100, 104], ["cells", "CELL", 146, 151], ["PARP-1", "PROTEIN", 12, 18], ["caspase 3", "PROTEIN", 89, 98], ["PARP", "PROTEIN", 100, 104], ["18f infected cells", "CELL_LINE", 133, 151], ["PARP", "TEST", 12, 16], ["activated caspase", "TREATMENT", 79, 96], ["PARP", "PROBLEM", 100, 104], ["no longer", "UNCERTAINTY", 109, 118], ["infected cells", "OBSERVATION", 137, 151]]], ["Commensurate with the lack of caspase activation or RNA degradation, there was no cleavage of PARP in persistently infected cells.Effects of caspase inhibitor Z-VAD-FMKHaving shown the proteolytic activation of caspase 3 in 18f infected cells, it was of interest to determine if apoptotic DNA degradation was a consequence of caspase activity.", [["cells", "ANATOMY", 124, 129], ["cells", "ANATOMY", 237, 242], ["Z-VAD-FMKHaving", "CHEMICAL", 159, 174], ["Z-VAD-FMKHaving", "CHEMICAL", 159, 174], ["caspase", "GENE_OR_GENE_PRODUCT", 30, 37], ["PARP", "GENE_OR_GENE_PRODUCT", 94, 98], ["cells", "CELL", 124, 129], ["caspase", "GENE_OR_GENE_PRODUCT", 141, 148], ["Z-VAD-FMKHaving", "SIMPLE_CHEMICAL", 159, 174], ["caspase 3", "GENE_OR_GENE_PRODUCT", 211, 220], ["cells", "CELL", 237, 242], ["DNA", "CELLULAR_COMPONENT", 289, 292], ["caspase", "GENE_OR_GENE_PRODUCT", 326, 333], ["caspase", "PROTEIN", 30, 37], ["PARP", "PROTEIN", 94, 98], ["persistently infected cells", "CELL_TYPE", 102, 129], ["caspase 3", "PROTEIN", 211, 220], ["18f infected cells", "CELL_LINE", 224, 242], ["caspase", "PROTEIN", 326, 333], ["caspase activation", "PROBLEM", 30, 48], ["RNA degradation", "PROBLEM", 52, 67], ["PARP", "PROBLEM", 94, 98], ["persistently infected cells", "PROBLEM", 102, 129], ["caspase inhibitor Z", "TREATMENT", 141, 160], ["VAD", "TREATMENT", 161, 164], ["FMKHaving", "TREATMENT", 165, 174], ["the proteolytic activation of caspase", "TREATMENT", 181, 218], ["infected cells", "PROBLEM", 228, 242], ["apoptotic DNA degradation", "PROBLEM", 279, 304], ["caspase activity", "TREATMENT", 326, 342], ["no cleavage", "UNCERTAINTY", 79, 90], ["persistently", "OBSERVATION_MODIFIER", 102, 114], ["infected cells", "OBSERVATION", 115, 129]]], ["FrhK4 cells were infected with 18f and then treated with different concentrations of the caspase inhibitor Z-VAD-FMK for 48 h.", [["FrhK4 cells", "ANATOMY", 0, 11], ["Z-VAD-FMK", "CHEMICAL", 107, 116], ["Z-VAD-FMK", "CHEMICAL", 107, 116], ["FrhK4 cells", "CELL", 0, 11], ["caspase", "GENE_OR_GENE_PRODUCT", 89, 96], ["Z-VAD-FMK", "SIMPLE_CHEMICAL", 107, 116], ["FrhK4 cells", "CELL_LINE", 0, 11], ["FrhK4 cells", "PROBLEM", 0, 11], ["the caspase inhibitor Z", "TREATMENT", 85, 108]]], ["Cultures were processed for the analysis of caspase activation by western blotting as described in Section 2.", [["caspase", "GENE_OR_GENE_PRODUCT", 44, 51], ["caspase", "PROTEIN", 44, 51], ["Cultures", "TEST", 0, 8], ["the analysis", "TEST", 28, 40], ["caspase activation", "TREATMENT", 44, 62]]], ["Caspase activation was prevented in a dose dependent manner by treatment with Z-VAD-FMK (Fig. 5 ).", [["Z-VAD-FMK", "CHEMICAL", 78, 87], ["Z-VAD-FMK", "CHEMICAL", 78, 87], ["Caspase", "GENE_OR_GENE_PRODUCT", 0, 7], ["Z-VAD-FMK", "SIMPLE_CHEMICAL", 78, 87], ["Caspase", "PROTEIN", 0, 7], ["Caspase activation", "TREATMENT", 0, 18], ["a dose dependent manner", "TREATMENT", 36, 59], ["Z-VAD-FMK", "TREATMENT", 78, 87]]], ["Significant inhibition of caspase activation was achieved with 25 M Z-VAD-FMK, and complete inhibition was observed at 50 M of the inhibitor.", [["Z-VAD-FMK", "CHEMICAL", 68, 77], ["Z-VAD-FMK", "CHEMICAL", 68, 77], ["caspase", "GENE_OR_GENE_PRODUCT", 26, 33], ["Z-VAD-FMK", "SIMPLE_CHEMICAL", 68, 77], ["caspase", "PROTEIN", 26, 33], ["caspase activation", "TREATMENT", 26, 44], ["25 M Z-VAD-FMK", "TREATMENT", 63, 77], ["the inhibitor", "TREATMENT", 127, 140], ["caspase activation", "OBSERVATION", 26, 44]]], ["RNA and DNA analyses by agarose gel electrophoresis in the cytoplasm of 18f infected cells were carried out to establish a connection between caspase activation and apoptotic DNA laddering (Fig. 6) .", [["cytoplasm", "ANATOMY", 59, 68], ["cells", "ANATOMY", 85, 90], ["DNA", "CELLULAR_COMPONENT", 8, 11], ["agarose", "SIMPLE_CHEMICAL", 24, 31], ["cytoplasm", "ORGANISM_SUBSTANCE", 59, 68], ["cells", "CELL", 85, 90], ["caspase", "GENE_OR_GENE_PRODUCT", 142, 149], ["DNA", "CELLULAR_COMPONENT", 175, 178], ["18f infected cells", "CELL_LINE", 72, 90], ["caspase", "PROTEIN", 142, 149], ["RNA and DNA analyses", "TEST", 0, 20], ["agarose gel electrophoresis", "TEST", 24, 51], ["infected cells", "PROBLEM", 76, 90], ["caspase activation", "TREATMENT", 142, 160], ["apoptotic DNA laddering", "TREATMENT", 165, 188], ["infected cells", "OBSERVATION", 76, 90]]], ["Treatment of 18f infected cells with 50 M Z-VAD-FMK did not prevent rRNA degradation (Panel A).", [["cells", "ANATOMY", 26, 31], ["Z-VAD-FMK", "CHEMICAL", 42, 51], ["Z-VAD-FMK", "CHEMICAL", 42, 51], ["cells", "CELL", 26, 31], ["Z-VAD-FMK", "SIMPLE_CHEMICAL", 42, 51], ["18f infected cells", "CELL_LINE", 13, 31], ["18f infected cells", "PROBLEM", 13, 31], ["rRNA degradation", "PROBLEM", 68, 84]]], ["The appearance of apoptotic DNA laddering in the cytoplasm was completely prevented (Panel B).", [["cytoplasm", "ANATOMY", 49, 58], ["DNA", "CELLULAR_COMPONENT", 28, 31], ["cytoplasm", "ORGANISM_SUBSTANCE", 49, 58], ["apoptotic DNA laddering", "PROBLEM", 18, 41], ["apoptotic DNA laddering", "OBSERVATION", 18, 41]]], ["These results show that rRNA degradation is independent of caspase induced DNA degradation, Fig. 5 .", [["rRNA", "CELLULAR_COMPONENT", 24, 28], ["caspase", "GENE_OR_GENE_PRODUCT", 59, 66], ["DNA", "CELLULAR_COMPONENT", 75, 78], ["caspase", "PROTEIN", 59, 66], ["rRNA degradation", "PROBLEM", 24, 40], ["caspase induced DNA degradation", "PROBLEM", 59, 90]]], ["Effect of the caspase inhibitor Z-VAD-FMK on proteolytic activation of caspase 3 in response to 18f infection.", [["Z-VAD-FMK", "CHEMICAL", 32, 41], ["infection", "DISEASE", 100, 109], ["Z-VAD-FMK", "CHEMICAL", 32, 41], ["caspase", "GENE_OR_GENE_PRODUCT", 14, 21], ["Z-VAD-FMK", "SIMPLE_CHEMICAL", 32, 41], ["caspase 3", "GENE_OR_GENE_PRODUCT", 71, 80], ["18f", "GENE_OR_GENE_PRODUCT", 96, 99], ["caspase 3", "PROTEIN", 71, 80], ["the caspase inhibitor Z", "TREATMENT", 10, 33], ["VAD", "TREATMENT", 34, 37], ["proteolytic activation of caspase", "TREATMENT", 45, 78], ["18f infection", "PROBLEM", 96, 109], ["infection", "OBSERVATION", 100, 109]]], ["Cells were infected with 18f (5 pfu/cell), and incubated in growth medium containing 0-50 M of the inhibitor for 48 h, prior to protein extraction.", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 36, 40], ["Cells", "CELL", 0, 5], ["cell", "CELL", 36, 40], ["the inhibitor", "TREATMENT", 95, 108], ["protein extraction", "TREATMENT", 128, 146]]], ["Electrophoresis, transfer, and immunodetection with antibody against caspase 3 were performed as described in Section 2.", [["antibody against caspase 3", "GENE_OR_GENE_PRODUCT", 52, 78], ["caspase 3", "PROTEIN", 69, 78], ["Electrophoresis", "TEST", 0, 15], ["immunodetection", "TEST", 31, 46], ["caspase", "TEST", 69, 76]]], ["The lane marked M contains protein extracts from mock infected cells harvested and processed 48 h following mock infection in the absence of inhibitor.", [["extracts", "ANATOMY", 35, 43], ["cells", "ANATOMY", 63, 68], ["infection", "DISEASE", 113, 122], ["extracts", "ORGANISM_SUBSTANCE", 35, 43], ["cells", "CELL", 63, 68], ["mock infected cells", "CELL_TYPE", 49, 68], ["protein extracts", "TREATMENT", 27, 43], ["mock infected cells", "TREATMENT", 49, 68], ["mock infection", "PROBLEM", 108, 122], ["inhibitor", "TREATMENT", 141, 150], ["protein extracts", "OBSERVATION_MODIFIER", 27, 43], ["infected cells harvested", "OBSERVATION", 54, 78], ["infection", "OBSERVATION", 113, 122]]], ["Effect of Z-VAD-FMK on rRNA degradation and apoptotic DNA laddering in the cytoplasm of infected cells.", [["cytoplasm", "ANATOMY", 75, 84], ["cells", "ANATOMY", 97, 102], ["Z-VAD-FMK", "CHEMICAL", 10, 19], ["Z-VAD-FMK", "CHEMICAL", 10, 19], ["Z-VAD-FMK", "SIMPLE_CHEMICAL", 10, 19], ["rRNA", "CELLULAR_COMPONENT", 23, 27], ["DNA", "CELLULAR_COMPONENT", 54, 57], ["cytoplasm", "ORGANISM_SUBSTANCE", 75, 84], ["cells", "CELL", 97, 102], ["Z-VAD", "PROTEIN", 10, 15], ["FMK", "PROTEIN", 16, 19], ["infected cells", "CELL_TYPE", 88, 102], ["Z-VAD", "TEST", 10, 15], ["FMK", "PROBLEM", 16, 19], ["rRNA degradation", "PROBLEM", 23, 39], ["apoptotic DNA laddering", "PROBLEM", 44, 67], ["infected cells", "PROBLEM", 88, 102], ["apoptotic DNA", "OBSERVATION", 44, 57], ["cytoplasm", "OBSERVATION_MODIFIER", 75, 84], ["infected cells", "OBSERVATION", 88, 102]]], ["Cells were infected with 18f (5 or 0.5 pfu/cell) or mock infected, and further incubated in growth medium containing 50 M Z-VAD-FMK for 48 h, prior to isolation of total cytoplasmic nucleic acids.", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 43, 47], ["cytoplasmic", "ANATOMY", 170, 181], ["Z-VAD-FMK", "CHEMICAL", 122, 131], ["nucleic acids", "CHEMICAL", 182, 195], ["Z-VAD-FMK", "CHEMICAL", 122, 131], ["Cells", "CELL", 0, 5], ["cell", "CELL", 43, 47], ["Z-VAD-FMK", "SIMPLE_CHEMICAL", 122, 131], ["cytoplasmic", "ORGANISM_SUBSTANCE", 170, 181], ["nucleic acids", "AMINO_ACID", 182, 195], ["mock infected", "PROBLEM", 52, 65], ["total cytoplasmic nucleic acids", "TREATMENT", 164, 195], ["infected", "OBSERVATION", 57, 65], ["nucleic acids", "OBSERVATION", 182, 195]]], ["Samples were separated in an 1% agarose gel before (A) or after (B) digestion with RNase 1. and is not a consequence of apoptosis due to perturbation of cellular macromolecule synthesis as a result of virus infection.", [["Samples", "ANATOMY", 0, 7], ["cellular", "ANATOMY", 153, 161], ["infection", "DISEASE", 207, 216], ["agarose", "SIMPLE_CHEMICAL", 32, 39], ["RNase 1", "GENE_OR_GENE_PRODUCT", 83, 90], ["cellular", "CELL", 153, 161], ["RNase 1", "PROTEIN", 83, 90], ["Samples", "TEST", 0, 7], ["an 1% agarose gel", "TREATMENT", 26, 43], ["apoptosis", "PROBLEM", 120, 129], ["cellular macromolecule synthesis", "PROBLEM", 153, 185], ["virus infection", "PROBLEM", 201, 216], ["not a consequence", "UNCERTAINTY", 99, 116], ["apoptosis", "OBSERVATION", 120, 129], ["cellular macromolecule synthesis", "OBSERVATION", 153, 185], ["virus", "OBSERVATION_MODIFIER", 201, 206], ["infection", "OBSERVATION", 207, 216]]], ["We have previously shown that despite rRNA degradation, cellular protein synthesis remains unaffected in 18f infected cells between 48 and 72 h pi (Kulka et al., 2003) .", [["cellular", "ANATOMY", 56, 64], ["cells", "ANATOMY", 118, 123], ["rRNA", "CELLULAR_COMPONENT", 38, 42], ["cellular", "CELL", 56, 64], ["cells", "CELL", 118, 123], ["18f infected cells", "CELL_LINE", 105, 123], ["rRNA degradation", "PROBLEM", 38, 54], ["cellular protein synthesis", "TEST", 56, 82]]], ["In agreement with the lack of effect of Z-VAD-FMK on rRNA degradation which requires replication of the virus (Kulka et al., 2003) , virus replication was not inhibited by treatment with this compound (Table 1) .Effect of interferon pretreatment on RNA degradationRibosomal RNA degradation is one of the three antiviral mechanisms controlled by IFN.", [["Z-VAD-FMK", "CHEMICAL", 40, 49], ["Z-VAD-FMK", "CHEMICAL", 40, 49], ["Z-VAD-FMK", "SIMPLE_CHEMICAL", 40, 49], ["rRNA", "CELLULAR_COMPONENT", 53, 57], ["interferon", "GENE_OR_GENE_PRODUCT", 222, 232], ["IFN", "GENE_OR_GENE_PRODUCT", 345, 348], ["FMK", "PROTEIN", 46, 49], ["interferon", "PROTEIN", 222, 232], ["IFN", "PROTEIN", 345, 348], ["Z-VAD", "TREATMENT", 40, 45], ["rRNA degradation", "PROBLEM", 53, 69], ["the virus", "TREATMENT", 100, 109], ["virus replication", "TREATMENT", 133, 150], ["interferon pretreatment", "TREATMENT", 222, 245], ["RNA degradationRibosomal RNA degradation", "PROBLEM", 249, 289], ["interferon", "OBSERVATION", 222, 232]]], ["It is brought about by the activation of a latent ribonuclease RNase L by 2-5A, and requires IFN treatment of cells prior to virus infection Fig. 7 .", [["cells", "ANATOMY", 110, 115], ["infection", "DISEASE", 131, 140], ["RNase L", "GENE_OR_GENE_PRODUCT", 63, 70], ["2-5A", "GENE_OR_GENE_PRODUCT", 74, 78], ["IFN", "GENE_OR_GENE_PRODUCT", 93, 96], ["cells", "CELL", 110, 115], ["latent ribonuclease RNase L", "PROTEIN", 43, 70], ["IFN", "PROTEIN", 93, 96], ["a latent ribonuclease RNase L", "TREATMENT", 41, 70], ["IFN treatment of cells", "TREATMENT", 93, 115], ["virus infection Fig", "PROBLEM", 125, 144]]], ["Effect of IFN on rRNA degradation and DNA ladder formation in response to 18f infection.", [["IFN", "CHEMICAL", 10, 13], ["infection", "DISEASE", 78, 87], ["IFN", "GENE_OR_GENE_PRODUCT", 10, 13], ["rRNA", "CELLULAR_COMPONENT", 17, 21], ["DNA", "CELLULAR_COMPONENT", 38, 41], ["IFN", "PROTEIN", 10, 13], ["IFN", "PROBLEM", 10, 13], ["rRNA degradation", "PROBLEM", 17, 33], ["DNA ladder formation", "PROBLEM", 38, 58], ["18f infection", "PROBLEM", 74, 87], ["infection", "OBSERVATION", 78, 87]]], ["Cells were either pretreated with 500 U/ml IFN-\u2424 for 24 h (24 h pre) before infection or treated with IFN following virus infection (2 h post).", [["Cells", "ANATOMY", 0, 5], ["infection", "DISEASE", 76, 85], ["IFN", "CHEMICAL", 102, 105], ["infection", "DISEASE", 122, 131], ["Cells", "CELL", 0, 5], ["IFN-\u2424", "GENE_OR_GENE_PRODUCT", 43, 48], ["IFN", "GENE_OR_GENE_PRODUCT", 102, 105], ["IFN", "PROTEIN", 43, 46], ["IFN", "PROTEIN", 102, 105], ["IFN", "TREATMENT", 43, 46], ["infection", "PROBLEM", 76, 85], ["IFN", "TREATMENT", 102, 105], ["virus infection", "PROBLEM", 116, 131], ["infection", "OBSERVATION", 76, 85]]], ["At 48 h pi, cytoplasmic nucleic acids were isolated as described in Section 2 and analyzed by agarose gel electrophoresis before (A) or after (B) treatment with RNase 1 to assess RNA or DNA degradation.", [["cytoplasmic", "ANATOMY", 12, 23], ["nucleic acids", "CHEMICAL", 24, 37], ["cytoplasmic", "ORGANISM_SUBSTANCE", 12, 23], ["nucleic acids", "AMINO_ACID", 24, 37], ["agarose", "SIMPLE_CHEMICAL", 94, 101], ["RNase 1", "GENE_OR_GENE_PRODUCT", 161, 168], ["DNA", "CELLULAR_COMPONENT", 186, 189], ["RNase 1", "PROTEIN", 161, 168], ["cytoplasmic nucleic acids", "TEST", 12, 37], ["agarose gel electrophoresis", "TEST", 94, 121], ["B) treatment", "TREATMENT", 143, 155], ["RNase", "TREATMENT", 161, 166], ["RNA", "PROBLEM", 179, 182], ["DNA degradation", "PROBLEM", 186, 201], ["nucleic acids", "OBSERVATION", 24, 37]]], ["The bracketed areas indicate the position of the degradation products of 28S and 18S rRNA.", [["28S", "CELLULAR_COMPONENT", 73, 76], ["18S", "GENE_OR_GENE_PRODUCT", 81, 84], ["rRNA", "CELLULAR_COMPONENT", 85, 89], ["28S and 18S rRNA", "RNA", 73, 89], ["the degradation products", "TREATMENT", 45, 69], ["18S rRNA", "PROBLEM", 81, 89], ["position", "OBSERVATION_MODIFIER", 33, 41], ["18S rRNA", "OBSERVATION", 81, 89]]], ["In contrast, RNA degradation or apoptosis induced by 18f did not require IFN pretreatment of the cells (Figs.", [["cells", "ANATOMY", 97, 102], ["IFN", "CHEMICAL", 73, 76], ["IFN", "GENE_OR_GENE_PRODUCT", 73, 76], ["cells", "CELL", 97, 102], ["IFN", "PROTEIN", 73, 76], ["RNA degradation", "PROBLEM", 13, 28], ["apoptosis", "PROBLEM", 32, 41], ["IFN pretreatment", "TREATMENT", 73, 89]]], ["To investigate whether IFN is involved in 18f induced rRNA degradation and apoptosis, cells were pretreated with 500 U/ml IFN-\u2424 (human) for 24 h, prior to exposure to 18f virus at a moi of 1 or 0.2 pfu/cell.", [["cells", "ANATOMY", 86, 91], ["cell", "ANATOMY", 202, 206], ["IFN", "GENE_OR_GENE_PRODUCT", 23, 26], ["18f", "SIMPLE_CHEMICAL", 42, 45], ["rRNA", "CELLULAR_COMPONENT", 54, 58], ["cells", "CELL", 86, 91], ["IFN-\u2424", "GENE_OR_GENE_PRODUCT", 122, 127], ["human", "ORGANISM", 129, 134], ["18f virus", "ORGANISM", 167, 176], ["cell", "CELL", 202, 206], ["IFN", "PROTEIN", 23, 26], ["18f", "PROTEIN", 42, 45], ["IFN", "PROTEIN", 122, 125], ["human", "SPECIES", 129, 134], ["human", "SPECIES", 129, 134], ["IFN", "PROBLEM", 23, 26], ["rRNA degradation", "PROBLEM", 54, 70], ["apoptosis", "PROBLEM", 75, 84], ["18f virus", "PROBLEM", 167, 176]]], ["DNA and RNA from the cytoplasm of infected cells were analyzed at 48 h pi as described in Section 2 (Fig. 7) .", [["cytoplasm", "ANATOMY", 21, 30], ["cells", "ANATOMY", 43, 48], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["cytoplasm", "ORGANISM_SUBSTANCE", 21, 30], ["cells", "CELL", 43, 48], ["infected cells", "CELL_TYPE", 34, 48], ["DNA", "PROBLEM", 0, 3], ["RNA", "PROBLEM", 8, 11], ["infected cells", "PROBLEM", 34, 48], ["RNA", "OBSERVATION_MODIFIER", 8, 11], ["cytoplasm", "OBSERVATION_MODIFIER", 21, 30], ["infected cells", "OBSERVATION", 34, 48]]], ["Pretreatment with IFN had a modest inhibitory effect on both rRNA degradation and apoptotic DNA degradation, particularly at low moi.", [["IFN", "CHEMICAL", 18, 21], ["IFN", "GENE_OR_GENE_PRODUCT", 18, 21], ["DNA", "CELLULAR_COMPONENT", 92, 95], ["IFN", "PROTEIN", 18, 21], ["IFN", "TREATMENT", 18, 21], ["a modest inhibitory effect", "PROBLEM", 26, 52], ["both rRNA degradation", "PROBLEM", 56, 77], ["apoptotic DNA degradation", "PROBLEM", 82, 107], ["rRNA degradation", "OBSERVATION", 61, 77], ["apoptotic DNA degradation", "OBSERVATION", 82, 107]]], ["When IFN was added to the cells following the 2 h virus absorption period, neither RNA degradation nor DNA laddering was affected by IFN treatment (Fig. 7) .", [["cells", "ANATOMY", 26, 31], ["IFN", "CHEMICAL", 5, 8], ["IFN", "CHEMICAL", 133, 136], ["IFN", "GENE_OR_GENE_PRODUCT", 5, 8], ["cells", "CELL", 26, 31], ["DNA", "CELLULAR_COMPONENT", 103, 106], ["IFN", "GENE_OR_GENE_PRODUCT", 133, 136], ["IFN", "PROTEIN", 5, 8], ["IFN", "PROTEIN", 133, 136], ["IFN", "TREATMENT", 5, 8], ["the 2 h virus absorption period", "TREATMENT", 42, 73], ["neither RNA degradation", "PROBLEM", 75, 98], ["DNA laddering", "PROBLEM", 103, 116], ["IFN treatment", "TREATMENT", 133, 146]]], ["IFN treatment had a significant growth inhibitory effect on 18f only at low moi (0.2 pfu/cell) infection (Table 1) , and had no effect on virus replication in clone 1 cells over a 72 h treatment period (data not shown).", [["cell", "ANATOMY", 89, 93], ["clone 1 cells", "ANATOMY", 159, 172], ["IFN", "CHEMICAL", 0, 3], ["infection", "DISEASE", 95, 104], ["18f", "SIMPLE_CHEMICAL", 60, 63], ["cell", "CELL", 89, 93], ["clone 1 cells", "CELL", 159, 172], ["IFN", "PROTEIN", 0, 3], ["clone 1 cells", "CELL_LINE", 159, 172], ["IFN treatment", "TREATMENT", 0, 13], ["a significant growth inhibitory effect", "PROBLEM", 18, 56], ["infection", "PROBLEM", 95, 104], ["virus replication", "TREATMENT", 138, 155], ["significant", "OBSERVATION_MODIFIER", 20, 31], ["growth", "OBSERVATION_MODIFIER", 32, 38], ["infection", "OBSERVATION", 95, 104], ["no", "UNCERTAINTY", 125, 127]]], ["Thus, the involvement of the canonical IFN regulated 2-5A system seemed unlikely.", [["IFN", "GENE_OR_GENE_PRODUCT", 39, 42], ["canonical IFN regulated 2-5A", "PROTEIN", 29, 57]]], ["The relatively slow replication of even the 18f strain might allow the infected cells to synthesize and excrete IFN, however, which may stimulate the 2-5A pathway in neighboring uninfected cells causing RNA degradation.", [["cells", "ANATOMY", 80, 85], ["cells", "ANATOMY", 189, 194], ["18f", "GENE_OR_GENE_PRODUCT", 44, 47], ["cells", "CELL", 80, 85], ["IFN", "GENE_OR_GENE_PRODUCT", 112, 115], ["A", "GENE_OR_GENE_PRODUCT", 153, 154], ["cells", "CELL", 189, 194], ["infected cells", "CELL_TYPE", 71, 85], ["IFN", "PROTEIN", 112, 115], ["neighboring uninfected cells", "CELL_TYPE", 166, 194], ["the 18f strain", "TREATMENT", 40, 54], ["the infected cells", "PROBLEM", 67, 85], ["RNA degradation", "PROBLEM", 203, 218], ["slow", "OBSERVATION_MODIFIER", 15, 19], ["infected cells", "OBSERVATION", 71, 85], ["uninfected cells", "OBSERVATION", 178, 194], ["RNA degradation", "OBSERVATION", 203, 218]]], ["First, the level of IFN, 2 -5 OAS and RNase L mRNAs were investigated by RT-PCR to determine if any of these RNAs were induced following virus infection (Fig. 8) .Effect of interferon pretreatment on RNA degradationIn agreement with previous reports that HAV infection does not induce IFN, we did not observe significant induction of IFN message up to 24 h pi with 18f virus (Fig. 8, Panel A) .", [["infection", "DISEASE", 143, 152], ["HAV infection", "DISEASE", 255, 268], ["IFN", "GENE_OR_GENE_PRODUCT", 20, 23], ["2 -5 OAS", "GENE_OR_GENE_PRODUCT", 25, 33], ["RNase L", "GENE_OR_GENE_PRODUCT", 38, 45], ["interferon", "GENE_OR_GENE_PRODUCT", 173, 183], ["HAV", "ORGANISM", 255, 258], ["IFN", "GENE_OR_GENE_PRODUCT", 285, 288], ["IFN", "GENE_OR_GENE_PRODUCT", 334, 337], ["18f virus", "ORGANISM", 365, 374], ["IFN, 2 -5 OAS and RNase L mRNAs", "RNA", 20, 51], ["interferon", "PROTEIN", 173, 183], ["IFN", "PROTEIN", 285, 288], ["IFN", "PROTEIN", 334, 337], ["HAV", "SPECIES", 255, 258], ["IFN", "TEST", 20, 23], ["RNase L mRNAs", "TREATMENT", 38, 51], ["RT-PCR", "TEST", 73, 79], ["these RNAs", "PROBLEM", 103, 113], ["virus infection", "PROBLEM", 137, 152], ["interferon pretreatment", "TREATMENT", 173, 196], ["HAV infection", "PROBLEM", 255, 268], ["IFN message", "TREATMENT", 334, 345], ["infection", "OBSERVATION", 259, 268]]], ["RT-PCR amplification of selected cellular and viral mRNAs.", [["cellular", "ANATOMY", 33, 41], ["cellular", "CELL", 33, 41], ["cellular and viral mRNAs", "RNA", 33, 57], ["RT-PCR amplification", "TEST", 0, 20], ["selected cellular and viral mRNAs", "PROBLEM", 24, 57], ["cellular", "OBSERVATION_MODIFIER", 33, 41], ["viral mRNAs", "OBSERVATION", 46, 57]]], ["Two microgram of RNA isolated from virus infected, IFN-\u2424, or dsRNA treated cells were reverse transcribed in a volume of 20 l using oligo(dT) 15 as primer as described in Section 2.", [["cells", "ANATOMY", 75, 80], ["IFN-\u2424", "GENE_OR_GENE_PRODUCT", 51, 56], ["cells", "CELL", 75, 80], ["IFN", "PROTEIN", 51, 54], ["dsRNA treated cells", "CELL_LINE", 61, 80], ["RNA", "PROBLEM", 17, 20], ["virus infected", "PROBLEM", 35, 49], ["IFN", "TEST", 51, 54], ["\u2424", "PROBLEM", 55, 56], ["dsRNA treated cells", "TREATMENT", 61, 80], ["a volume", "TEST", 109, 117], ["oligo(dT)", "TREATMENT", 132, 141], ["RNA isolated", "OBSERVATION_MODIFIER", 17, 29]]], ["Five microliter of each RT reaction was amplified for 35 cycles with sense and antisense primers for IFN-\u2424 (A), 2 -5 OAS (B), \u2425-actin (C), RNase L (D), or HAV genomic RNA (E) as described in Section 2, and 15 l PCR reactions were analyzed by 1% agarose gel electrophoresis.", [["IFN-\u2424", "GENE_OR_GENE_PRODUCT", 101, 106], ["A", "GENE_OR_GENE_PRODUCT", 108, 109], ["2 -5 OAS", "SIMPLE_CHEMICAL", 112, 120], ["B", "GENE_OR_GENE_PRODUCT", 122, 123], ["\u2425-actin (C)", "GENE_OR_GENE_PRODUCT", 126, 137], ["RNase L", "GENE_OR_GENE_PRODUCT", 139, 146], ["D", "GENE_OR_GENE_PRODUCT", 148, 149], ["HAV", "ORGANISM", 155, 158], ["agarose", "SIMPLE_CHEMICAL", 245, 252], ["IFN", "PROTEIN", 101, 104], ["OAS", "PROTEIN", 117, 120], ["B", "PROTEIN", 122, 123], ["\u2425-actin", "PROTEIN", 126, 133], ["C", "PROTEIN", 135, 136], ["RNase L", "PROTEIN", 139, 146], ["D", "PROTEIN", 148, 149], ["HAV genomic RNA", "RNA", 155, 170], ["HAV", "SPECIES", 155, 158], ["each RT reaction", "TREATMENT", 19, 35], ["antisense primers", "TEST", 79, 96], ["IFN", "TEST", 101, 104], ["\u2425-actin (C), RNase L (D)", "PROBLEM", 126, 150], ["HAV genomic RNA", "PROBLEM", 155, 170], ["15 l PCR reactions", "TEST", 206, 224], ["agarose gel electrophoresis", "TEST", 245, 272]]], ["RNA from uninfected cells (UI) and cells transfected in the absence of dsRNA (Trfn.", [["cells", "ANATOMY", 20, 25], ["cells", "ANATOMY", 35, 40], ["cells", "CELL", 20, 25], ["UI", "CELL", 27, 29], ["cells", "CELL", 35, 40], ["Trfn", "GENE_OR_GENE_PRODUCT", 78, 82], ["RNA", "RNA", 0, 3], ["uninfected cells", "CELL_TYPE", 9, 25], ["Trfn", "DNA", 78, 82], ["RNA from uninfected cells", "PROBLEM", 0, 25], ["UI", "TEST", 27, 29], ["cells", "PROBLEM", 35, 40], ["dsRNA", "PROBLEM", 71, 76], ["uninfected cells", "OBSERVATION", 9, 25], ["dsRNA", "OBSERVATION", 71, 76]]], ["Control) were included in the RT-PCR analyses.", [["the RT-PCR analyses", "TEST", 26, 45]]], ["Takahashi et al. (2002) successfully demonstrated the application of RT-PCR for the detection of mRNAs, which encode the 2 -5 OAS isoforms that synthesize the biologically active forms of 2-5A.", [["mRNAs", "RNA", 97, 102], ["OAS isoforms", "PROTEIN", 126, 138], ["RT-PCR", "TREATMENT", 69, 75]]], ["Using these primers, we determined that the mRNAs for either the p69/71 form (Fig. 8, Panel B) or the p40/46 form (data not shown) of 2 -5 OAS was not induced following virus infection.", [["infection", "DISEASE", 175, 184], ["p69/71", "GENE_OR_GENE_PRODUCT", 65, 71], ["Panel B", "GENE_OR_GENE_PRODUCT", 86, 93], ["p40/46", "GENE_OR_GENE_PRODUCT", 102, 108], ["mRNAs", "RNA", 44, 49], ["p69/71 form", "PROTEIN", 65, 76], ["Panel B", "PROTEIN", 86, 93], ["p40/46 form", "PROTEIN", 102, 113], ["OAS", "PROTEIN", 139, 142], ["these primers", "TEST", 6, 19], ["the mRNAs", "TEST", 40, 49], ["virus infection", "PROBLEM", 169, 184]]], ["Treatment of the cells with 500 U/ml IFN-\u2424 induced the message for the 69/71 form (Panel B), but not the 40/46 form, although the primer pair is capable of amplifying this mRNA from both mouse and human cells (data not shown).", [["cells", "ANATOMY", 17, 22], ["cells", "ANATOMY", 203, 208], ["IFN", "CHEMICAL", 37, 40], ["cells", "CELL", 17, 22], ["IFN-\u2424", "GENE_OR_GENE_PRODUCT", 37, 42], ["mouse", "ORGANISM", 187, 192], ["human", "ORGANISM", 197, 202], ["cells", "CELL", 203, 208], ["IFN", "PROTEIN", 37, 40], ["69/71 form", "RNA", 71, 81], ["40/46 form", "RNA", 105, 115], ["mRNA", "RNA", 172, 176], ["mouse and human cells", "CELL_TYPE", 187, 208], ["mouse", "SPECIES", 187, 192], ["human", "SPECIES", 197, 202], ["mouse", "SPECIES", 187, 192], ["human", "SPECIES", 197, 202], ["IFN", "TREATMENT", 37, 40]]], ["Thus, the FrhK4 cells are competent to mount an IFN response by inducing the 69/71 form of 2 -5 OAS.", [["FrhK4 cells", "ANATOMY", 10, 21], ["FrhK4 cells", "CELL", 10, 21], ["IFN", "GENE_OR_GENE_PRODUCT", 48, 51], ["FrhK4 cells", "CELL_LINE", 10, 21], ["IFN", "PROTEIN", 48, 51], ["the FrhK4 cells", "TREATMENT", 6, 21]]], ["RT-PCR experiments with primers for RNase L, on the other hand, revealed that this mRNA was present in cells constitutively, with some increase in the level of this mRNA following virus infection (Panel D).", [["cells", "ANATOMY", 103, 108], ["infection", "DISEASE", 186, 195], ["RNase L", "GENE_OR_GENE_PRODUCT", 36, 43], ["cells", "CELL", 103, 108], ["RNase L", "PROTEIN", 36, 43], ["mRNA", "RNA", 83, 87], ["mRNA", "RNA", 165, 169], ["RT-PCR experiments", "TEST", 0, 18], ["primers", "TREATMENT", 24, 31], ["RNase L", "TREATMENT", 36, 43], ["this mRNA", "PROBLEM", 78, 87], ["this mRNA", "PROBLEM", 160, 169], ["virus infection", "PROBLEM", 180, 195], ["some", "OBSERVATION_MODIFIER", 130, 134], ["increase", "OBSERVATION_MODIFIER", 135, 143]]], ["To ascertain that both the 18f and clone 1 cells were actively replicat- Fig. 9 .", [["clone 1 cells", "ANATOMY", 35, 48], ["clone 1 cells", "CELL", 35, 48], ["18f and clone 1 cells", "CELL_LINE", 27, 48], ["clone 1 cells", "TREATMENT", 35, 48]]], ["STAT 1 phosphorylation in response to virus infection and/or IFN-\u2424 treatment.", [["infection", "DISEASE", 44, 53], ["STAT 1", "GENE_OR_GENE_PRODUCT", 0, 6], ["IFN-\u2424", "GENE_OR_GENE_PRODUCT", 61, 66], ["STAT 1", "PROTEIN", 0, 6], ["IFN", "PROTEIN", 61, 64], ["STAT 1 phosphorylation", "TREATMENT", 0, 22], ["virus infection", "PROBLEM", 38, 53], ["IFN-\u2424 treatment", "TREATMENT", 61, 76]]], ["(A) FrhK4 cells were treated with IFN-\u2424 for 1 or 4 h prior to total protein extraction.", [["FrhK4 cells", "ANATOMY", 4, 15], ["IFN", "CHEMICAL", 34, 37], ["FrhK4 cells", "CELL", 4, 15], ["IFN-\u2424", "GENE_OR_GENE_PRODUCT", 34, 39], ["FrhK4 cells", "CELL_LINE", 4, 15], ["IFN", "PROTEIN", 34, 37], ["FrhK4 cells", "PROBLEM", 4, 15], ["IFN", "TREATMENT", 34, 37], ["total protein extraction", "TREATMENT", 62, 86]]], ["(B) FrhK4 cells were mock infected (M), infected with 18f for various times, or infected with coxsackie B1 (CBV1) prior to protein extraction.", [["FrhK4 cells", "ANATOMY", 4, 15], ["B) FrhK4 cells", "CELL", 1, 15], ["coxsackie B1", "ORGANISM", 94, 106], ["CBV1", "ORGANISM", 108, 112], ["FrhK4 cells", "CELL_LINE", 4, 15], ["coxsackie B1", "PROTEIN", 94, 106], ["CBV1", "SPECIES", 108, 112], ["FrhK4 cells", "PROBLEM", 4, 15], ["coxsackie B1 (CBV1", "TREATMENT", 94, 112], ["protein extraction", "TREATMENT", 123, 141]]], ["(C) FrhK4 cells were infected with 2 pfu/cell 18f for 2 h followed by the addition of growth medium.", [["FrhK4 cells", "ANATOMY", 4, 15], ["cell", "ANATOMY", 41, 45], ["FrhK4 cells", "CELL", 4, 15], ["cell 18f", "CELL", 41, 49], ["FrhK4 cells", "CELL_LINE", 4, 15], ["FrhK4 cells", "PROBLEM", 4, 15], ["growth medium", "TREATMENT", 86, 99], ["growth medium", "OBSERVATION", 86, 99]]], ["After 24 h, cells were treated with 500 U/ml IFN-\u2424 in growth medium.", [["cells", "ANATOMY", 12, 17], ["IFN", "CHEMICAL", 45, 48], ["cells", "CELL", 12, 17], ["IFN-\u2424", "SIMPLE_CHEMICAL", 45, 50], ["IFN", "PROTEIN", 45, 48], ["IFN", "TREATMENT", 45, 48], ["growth medium", "OBSERVATION_MODIFIER", 54, 67]]], ["NT means not treated with IFN-\u2424.", [["IFN", "CHEMICAL", 26, 29], ["IFN", "PROTEIN", 26, 29], ["IFN", "TREATMENT", 26, 29]]], ["Proteins were extracted after 2 or 4 h of IFN treatment.", [["IFN", "CHEMICAL", 42, 45], ["IFN", "PROTEIN", 42, 45], ["IFN treatment", "TREATMENT", 42, 55]]], ["Clone 1 cells were used at 330d pi.", [["Clone 1 cells", "ANATOMY", 0, 13], ["Clone 1 cells", "CELL", 0, 13], ["Clone 1 cells", "CELL_LINE", 0, 13], ["Clone 1 cells", "TREATMENT", 0, 13]]], ["Western blotting with an antibody to unphosphorylated STAT 1 (anti-STAT), phosphorylated STAT 1 (anti-STAT-P), or actin was performed as described in Section 2.Effect of interferon pretreatment on RNA degradationing virus, viral genomic RNA was amplified using primers directed to the 5 NTR (Panel E).", [["STAT 1", "GENE_OR_GENE_PRODUCT", 54, 60], ["anti-", "GENE_OR_GENE_PRODUCT", 62, 67], ["STAT", "GENE_OR_GENE_PRODUCT", 67, 71], ["STAT 1", "GENE_OR_GENE_PRODUCT", 89, 95], ["anti-STAT-P", "GENE_OR_GENE_PRODUCT", 97, 108], ["actin", "GENE_OR_GENE_PRODUCT", 114, 119], ["interferon", "GENE_OR_GENE_PRODUCT", 170, 180], ["NTR", "GENE_OR_GENE_PRODUCT", 287, 290], ["unphosphorylated STAT 1", "PROTEIN", 37, 60], ["STAT", "PROTEIN", 67, 71], ["phosphorylated STAT 1", "PROTEIN", 74, 95], ["anti", "PROTEIN", 97, 101], ["STAT", "PROTEIN", 102, 106], ["P", "PROTEIN", 107, 108], ["actin", "PROTEIN", 114, 119], ["interferon", "PROTEIN", 170, 180], ["viral genomic RNA", "RNA", 223, 240], ["5 NTR", "DNA", 285, 290], ["Panel E", "DNA", 292, 299], ["an antibody", "TEST", 22, 33], ["unphosphorylated STAT", "TEST", 37, 58], ["phosphorylated STAT", "TEST", 74, 93], ["interferon pretreatment", "TREATMENT", 170, 193], ["RNA degradationing virus", "PROBLEM", 197, 221], ["viral genomic RNA", "PROBLEM", 223, 240], ["primers", "TREATMENT", 261, 268], ["interferon", "OBSERVATION", 170, 180], ["genomic RNA", "OBSERVATION", 229, 240]]], ["The results clearly show the presence of undiminished amount of viral genome in clone 1 cells after several months of cultivation, with no indication that the virus has acquired the 14 base repeat present in the genome of 18f and other cp strains (Brack et al., 1998; Zhang et al., 1995) .Effect of interferon pretreatment on RNA degradationSecond, we determined whether STAT 1 phosphorylation occurs following virus infection.", [["clone 1 cells", "ANATOMY", 80, 93], ["infection", "DISEASE", 417, 426], ["clone 1 cells", "CELL", 80, 93], ["interferon", "GENE_OR_GENE_PRODUCT", 299, 309], ["STAT 1", "GENE_OR_GENE_PRODUCT", 371, 377], ["viral genome", "DNA", 64, 76], ["clone 1 cells", "CELL_LINE", 80, 93], ["14 base repeat", "DNA", 182, 196], ["interferon", "PROTEIN", 299, 309], ["STAT 1", "PROTEIN", 371, 377], ["viral genome in clone 1 cells", "PROBLEM", 64, 93], ["cultivation", "TREATMENT", 118, 129], ["the virus", "PROBLEM", 155, 164], ["other cp strains", "PROBLEM", 230, 246], ["interferon pretreatment", "TREATMENT", 299, 322], ["STAT 1 phosphorylation", "TREATMENT", 371, 393], ["virus infection", "PROBLEM", 411, 426], ["undiminished", "OBSERVATION_MODIFIER", 41, 53], ["amount", "OBSERVATION_MODIFIER", 54, 60], ["viral genome", "OBSERVATION", 64, 76], ["no indication", "UNCERTAINTY", 136, 149], ["interferon", "OBSERVATION", 299, 309]]], ["Phosphorylation of STAT1 on Y701 is indicative of the activation of the JAK-STAT pathway, and is a prerequisite for the transcriptional induction of ISGs by IFN (for a review, see Stark et al., 1998) .", [["STAT1", "GENE_OR_GENE_PRODUCT", 19, 24], ["Y701", "AMINO_ACID", 28, 32], ["JAK", "GENE_OR_GENE_PRODUCT", 72, 75], ["STAT", "GENE_OR_GENE_PRODUCT", 76, 80], ["ISGs", "GENE_OR_GENE_PRODUCT", 149, 153], ["IFN", "GENE_OR_GENE_PRODUCT", 157, 160], ["STAT1", "PROTEIN", 19, 24], ["JAK", "PROTEIN", 72, 75], ["STAT", "PROTEIN", 76, 80], ["ISGs", "DNA", 149, 153], ["IFN", "PROTEIN", 157, 160], ["indicative of", "UNCERTAINTY", 36, 49]]], ["To investigate if this signaling pathway is activated following viral infection due to synthesis of low levels of IFN, phosphorylation of STAT1 was investigated by immunoblot analysis (Fig. 9) .", [["viral infection", "DISEASE", 64, 79], ["IFN", "GENE_OR_GENE_PRODUCT", 114, 117], ["STAT1", "GENE_OR_GENE_PRODUCT", 138, 143], ["IFN", "PROTEIN", 114, 117], ["STAT1", "PROTEIN", 138, 143], ["this signaling pathway", "PROBLEM", 18, 40], ["viral infection", "PROBLEM", 64, 79], ["synthesis of low levels of IFN", "PROBLEM", 87, 117], ["phosphorylation of STAT1", "TREATMENT", 119, 143], ["immunoblot analysis", "TEST", 164, 183], ["low levels", "OBSERVATION_MODIFIER", 100, 110]]], ["In IFN treated FrhK4 cells, STAT1 phosphorylation was observed as early as 10 min post-treatment (data not shown), and the peak level of phosphorylation was detected at 1 h post-treatment (Panel A).", [["FrhK4 cells", "ANATOMY", 15, 26], ["FrhK4 cells", "CELL", 15, 26], ["STAT1", "GENE_OR_GENE_PRODUCT", 28, 33], ["IFN treated FrhK4 cells", "CELL_LINE", 3, 26], ["STAT1", "PROTEIN", 28, 33], ["IFN treated FrhK4 cells", "TREATMENT", 3, 26], ["STAT1 phosphorylation", "TREATMENT", 28, 49], ["the peak level", "TEST", 119, 133], ["phosphorylation", "TEST", 137, 152]]], ["These results confirm that FrhK4 cells are capable of responding to IFN (Panel A).", [["FrhK4 cells", "ANATOMY", 27, 38], ["FrhK4 cells", "CELL", 27, 38], ["IFN", "GENE_OR_GENE_PRODUCT", 68, 71], ["FrhK4 cells", "CELL_LINE", 27, 38], ["IFN", "PROTEIN", 68, 71], ["Panel A", "PROTEIN", 73, 80], ["FrhK4 cells", "PROBLEM", 27, 38]]], ["However, no phosphorylation was detectable following infection with 18f, up to 24 h pi (Panel B), when rRNA degradation is occurring.", [["infection", "DISEASE", 53, 62], ["rRNA", "CELLULAR_COMPONENT", 103, 107], ["phosphorylation", "PROBLEM", 12, 27], ["infection", "PROBLEM", 53, 62], ["rRNA degradation", "PROBLEM", 103, 119], ["no", "UNCERTAINTY", 9, 11]]], ["Previously, we followed STAT 1 phosphorylation for up to 72 h pi and found no evidence of activation of this pathway (Kulka et al., 2003) .", [["STAT 1", "GENE_OR_GENE_PRODUCT", 24, 30], ["STAT 1", "PROTEIN", 24, 30], ["no evidence of", "UNCERTAINTY", 75, 89]]], ["Surprisingly, cells infected with the 18f virus for 24 h showed diminished phosphorylation of STAT 1 when treated with IFN, compared to uninfected or clone 1 cells treated with IFN (Panel C).", [["cells", "ANATOMY", 14, 19], ["clone 1 cells", "ANATOMY", 150, 163], ["cells", "CELL", 14, 19], ["18f virus", "ORGANISM", 38, 47], ["STAT 1", "GENE_OR_GENE_PRODUCT", 94, 100], ["IFN", "GENE_OR_GENE_PRODUCT", 119, 122], ["clone 1 cells", "CELL", 150, 163], ["STAT 1", "PROTEIN", 94, 100], ["IFN", "PROTEIN", 119, 122], ["clone 1 cells", "CELL_LINE", 150, 163], ["IFN", "PROTEIN", 177, 180], ["18f virus", "SPECIES", 38, 47], ["the 18f virus", "TREATMENT", 34, 47], ["diminished phosphorylation of STAT", "PROBLEM", 64, 98], ["IFN", "TREATMENT", 119, 122], ["IFN (Panel C", "TREATMENT", 177, 189]]], ["Thus, the cp strains of HAV not only interfere with the induction of IFN by dsRNA (Brack et al., 2002) , but can also interfere with IFN signaling.", [["HAV", "ORGANISM", 24, 27], ["IFN", "GENE_OR_GENE_PRODUCT", 69, 72], ["IFN", "GENE_OR_GENE_PRODUCT", 133, 136], ["IFN", "PROTEIN", 69, 72], ["IFN", "PROTEIN", 133, 136], ["HAV", "SPECIES", 24, 27], ["the cp strains of HAV", "PROBLEM", 6, 27], ["IFN", "TREATMENT", 69, 72], ["IFN signaling", "PROBLEM", 133, 146]]], ["Similarly, coxsackievirus B1, a fast-replicating picornavirus that induces similar RNA degradation in FrhK4 cells, did not induce phosphorylation of STAT1 (Panel B).", [["FrhK4 cells", "ANATOMY", 102, 113], ["coxsackievirus B1", "ORGANISM", 11, 28], ["picornavirus", "ORGANISM", 49, 61], ["FrhK4 cells", "CELL", 102, 113], ["STAT1", "GENE_OR_GENE_PRODUCT", 149, 154], ["Panel B", "GENE_OR_GENE_PRODUCT", 156, 163], ["FrhK4 cells", "CELL_LINE", 102, 113], ["STAT1", "PROTEIN", 149, 154], ["Panel B", "PROTEIN", 156, 163], ["coxsackievirus B1", "SPECIES", 11, 28], ["coxsackievirus B1", "PROBLEM", 11, 28], ["a fast-replicating picornavirus", "PROBLEM", 30, 61], ["similar RNA degradation in FrhK4 cells", "PROBLEM", 75, 113], ["coxsackievirus", "OBSERVATION", 11, 25], ["picornavirus", "OBSERVATION", 49, 61], ["RNA degradation", "OBSERVATION", 83, 98]]], ["The data clearly suggest the existence of a virus inducible, 2-5A independent RNA degradative pathway that is activated by 18f infection in the apparent absence of IFN induction of 2 -5 OAS.DiscussionIn this study, we report a novel pathway for rRNA degradation in cytopathogenic hepatitis A virus infected cells.", [["cells", "ANATOMY", 307, 312], ["infection", "DISEASE", 127, 136], ["hepatitis A virus infected", "DISEASE", 280, 306], ["2-5A", "GENE_OR_GENE_PRODUCT", 61, 65], ["18f", "GENE_OR_GENE_PRODUCT", 123, 126], ["IFN", "GENE_OR_GENE_PRODUCT", 164, 167], ["rRNA", "CELLULAR_COMPONENT", 245, 249], ["cytopathogenic hepatitis A virus", "ORGANISM", 265, 297], ["cells", "CELL", 307, 312], ["IFN", "PROTEIN", 164, 167], ["cytopathogenic hepatitis A virus infected cells", "CELL_LINE", 265, 312], ["hepatitis A virus", "SPECIES", 280, 297], ["hepatitis A virus", "SPECIES", 280, 297], ["a virus inducible", "PROBLEM", 42, 59], ["18f infection", "PROBLEM", 123, 136], ["IFN induction", "TREATMENT", 164, 177], ["this study", "TEST", 203, 213], ["rRNA degradation", "PROBLEM", 245, 261], ["cytopathogenic hepatitis A virus infected cells", "PROBLEM", 265, 312], ["infection", "OBSERVATION", 127, 136], ["cytopathogenic hepatitis", "OBSERVATION", 265, 289], ["virus infected cells", "OBSERVATION", 292, 312]]], ["The observed cleavage of both species of rRNA suggests that this phenomenon is different from the cleavage of 28S rRNA in mouse hepatitis A virus (a coronavirus) infected cells (Banerjee et al., 2000) .", [["cells", "ANATOMY", 171, 176], ["hepatitis A", "DISEASE", 128, 139], ["coronavirus) infected", "DISEASE", 149, 170], ["rRNA", "CELLULAR_COMPONENT", 41, 45], ["28S", "CELLULAR_COMPONENT", 110, 113], ["rRNA", "CELLULAR_COMPONENT", 114, 118], ["mouse", "ORGANISM", 122, 127], ["hepatitis A virus", "ORGANISM", 128, 145], ["coronavirus", "ORGANISM", 149, 160], ["cells", "CELL", 171, 176], ["28S rRNA", "RNA", 110, 118], ["mouse", "SPECIES", 122, 127], ["hepatitis A virus", "SPECIES", 128, 145], ["mouse hepatitis A virus", "SPECIES", 122, 145], ["both species of rRNA", "PROBLEM", 25, 45], ["this phenomenon", "PROBLEM", 60, 75], ["the cleavage of 28S rRNA", "PROBLEM", 94, 118], ["mouse hepatitis A virus", "PROBLEM", 122, 145], ["a coronavirus) infected cells", "PROBLEM", 147, 176], ["both species", "OBSERVATION", 25, 37], ["different", "OBSERVATION_MODIFIER", 79, 88], ["28S rRNA", "OBSERVATION", 110, 118], ["mouse hepatitis", "OBSERVATION", 122, 137]]], ["We have also shown that the virus induced rRNA cleavage is not a consequence of apoptosis, as has been reported to occur as a result of perturbation of cellular macromolecular synthesis (Houge and D\u00f8skeland, 1996) .", [["cellular", "ANATOMY", 152, 160], ["rRNA", "CELLULAR_COMPONENT", 42, 46], ["cellular", "CELL", 152, 160], ["the virus induced rRNA cleavage", "PROBLEM", 24, 55], ["apoptosis", "PROBLEM", 80, 89], ["cellular macromolecular synthesis", "PROBLEM", 152, 185], ["not a consequence", "UNCERTAINTY", 59, 76], ["apoptosis", "OBSERVATION", 80, 89], ["cellular", "OBSERVATION_MODIFIER", 152, 160], ["macromolecular synthesis", "OBSERVATION", 161, 185]]], ["In a previous study, we have shown that the cleavage of rRNAs is also accompanied by a reduction in the levels of some cellular mRNAs, while viral RNA was not significantly affected (Kulka et al., 2003) .", [["cellular", "ANATOMY", 119, 127], ["rRNAs", "CELLULAR_COMPONENT", 56, 61], ["cellular", "CELL", 119, 127], ["rRNAs", "RNA", 56, 61], ["cellular mRNAs", "RNA", 119, 133], ["viral RNA", "RNA", 141, 150], ["a previous study", "TEST", 3, 19], ["the cleavage of rRNAs", "PROBLEM", 40, 61], ["a reduction", "PROBLEM", 85, 96], ["some cellular mRNAs", "PROBLEM", 114, 133], ["viral RNA", "PROBLEM", 141, 150], ["rRNAs", "OBSERVATION", 56, 61], ["reduction", "OBSERVATION_MODIFIER", 87, 96], ["some", "OBSERVATION_MODIFIER", 114, 118], ["cellular mRNAs", "OBSERVATION", 119, 133]]], ["The appearance of specific sizes of rRNA degradation products is reminiscent of IFN regulated 2-5A activated RNase L. The activation of this pathway, which is part of the cellular defense against viral infection, requires prior exposure of cells to IFN (Stark et al., 1998; Barber, 2001; Sen, 2001) .", [["cellular", "ANATOMY", 171, 179], ["cells", "ANATOMY", 240, 245], ["viral infection", "DISEASE", 196, 211], ["IFN", "GENE_OR_GENE_PRODUCT", 80, 83], ["2-5A", "GENE_OR_GENE_PRODUCT", 94, 98], ["RNase L.", "GENE_OR_GENE_PRODUCT", 109, 117], ["cellular", "CELL", 171, 179], ["cells", "CELL", 240, 245], ["IFN", "GENE_OR_GENE_PRODUCT", 249, 252], ["rRNA degradation products", "PROTEIN", 36, 61], ["IFN regulated 2-5A activated RNase L.", "PROTEIN", 80, 117], ["IFN", "PROTEIN", 249, 252], ["rRNA degradation products", "PROBLEM", 36, 61], ["viral infection", "PROBLEM", 196, 211], ["specific", "OBSERVATION_MODIFIER", 18, 26], ["sizes", "OBSERVATION_MODIFIER", 27, 32], ["rRNA degradation", "OBSERVATION", 36, 52], ["cellular defense", "OBSERVATION", 171, 187], ["viral", "OBSERVATION_MODIFIER", 196, 201], ["infection", "OBSERVATION", 202, 211]]], ["RNA degradation during 18f infection, however, occurs without prior treatment of the cells with IFN.", [["cells", "ANATOMY", 85, 90], ["infection", "DISEASE", 27, 36], ["cells", "CELL", 85, 90], ["IFN", "GENE_OR_GENE_PRODUCT", 96, 99], ["IFN", "PROTEIN", 96, 99], ["RNA degradation", "PROBLEM", 0, 15], ["18f infection", "PROBLEM", 23, 36], ["IFN", "PROBLEM", 96, 99], ["infection", "OBSERVATION", 27, 36]]], ["It is conceivable that a slowly replicating virus such as HAV could induce production of low levels of IFN to activate the 2-5A pathway in surrounding uninfected cells.", [["cells", "ANATOMY", 162, 167], ["HAV", "DISEASE", 58, 61], ["HAV", "ORGANISM", 58, 61], ["IFN", "GENE_OR_GENE_PRODUCT", 103, 106], ["2-5A", "GENE_OR_GENE_PRODUCT", 123, 127], ["cells", "CELL", 162, 167], ["IFN", "PROTEIN", 103, 106], ["uninfected cells", "CELL_TYPE", 151, 167], ["HAV", "SPECIES", 58, 61], ["a slowly replicating virus", "PROBLEM", 23, 49], ["HAV", "PROBLEM", 58, 61], ["low levels of IFN", "PROBLEM", 89, 106], ["slowly", "OBSERVATION_MODIFIER", 25, 31], ["virus", "OBSERVATION", 44, 49], ["low levels", "OBSERVATION_MODIFIER", 89, 99], ["uninfected cells", "OBSERVATION", 151, 167]]], ["We showed that this is not the case, since the JAK/STAT pathway was not activated following virus infection, even though IFN-\u2424 mRNA was marginally induced in 18f and clone 1 infected cells.", [["cells", "ANATOMY", 183, 188], ["infection", "DISEASE", 98, 107], ["JAK", "GENE_OR_GENE_PRODUCT", 47, 50], ["STAT", "GENE_OR_GENE_PRODUCT", 51, 55], ["IFN-\u2424", "GENE_OR_GENE_PRODUCT", 121, 126], ["clone 1", "CELL", 166, 173], ["cells", "CELL", 183, 188], ["JAK", "PROTEIN", 47, 50], ["STAT", "PROTEIN", 51, 55], ["IFN-\u2424 mRNA", "RNA", 121, 131], ["18f and clone 1 infected cells", "CELL_LINE", 158, 188], ["the JAK/STAT pathway", "TEST", 43, 63], ["virus infection", "PROBLEM", 92, 107], ["IFN", "TEST", 121, 124], ["mRNA", "TEST", 127, 131], ["clone 1 infected cells", "PROBLEM", 166, 188], ["infected cells", "OBSERVATION", 174, 188]]], ["These results make it unlikely that the canonical 2-5A dependent RNA degradation pathway is activated during 18f infection.", [["infection", "DISEASE", 113, 122], ["2-5A", "GENE_OR_GENE_PRODUCT", 50, 54], ["the canonical 2-5A dependent RNA degradation pathway", "PROBLEM", 36, 88], ["18f infection", "PROBLEM", 109, 122], ["infection", "OBSERVATION", 113, 122]]], ["We also showed that RNA is not degraded in persistently infected cells despite the presence of comparable levels of viral RNA and antigens (proteins).", [["cells", "ANATOMY", 65, 70], ["cells", "CELL", 65, 70], ["persistently infected cells", "CELL_TYPE", 43, 70], ["viral RNA", "RNA", 116, 125], ["antigens", "PROTEIN", 130, 138], ["RNA", "PROBLEM", 20, 23], ["persistently infected cells", "PROBLEM", 43, 70], ["viral RNA", "PROBLEM", 116, 125], ["RNA", "OBSERVATION", 20, 23], ["infected cells", "OBSERVATION", 56, 70], ["viral RNA", "OBSERVATION", 116, 125]]], ["Our results complement the results of Brack et al. (2002) and Vallbracht et al. (1984) , that IFN-\u2424 does not play a major role in HAV infection.DiscussionThe RNase L enzyme is one member of a multi-component system for RNA degradation, consisting of IFN, 2 -5 OAS (the enzyme that synthesizes 2-5A from ATP in the presence of dsRNA), and the latent endoribonuclease RNase L. RNase L is generally present in most cells and may function in situations other than virus infections, particularly during differentiation, apoptosis, hormonal regulation, chronic fatigue syndrome, and certain types of prostate cancer (for a review, see Silverman, 2003) .", [["cells", "ANATOMY", 412, 417], ["prostate cancer", "ANATOMY", 594, 609], ["HAV infection", "DISEASE", 130, 143], ["2-5A", "CHEMICAL", 293, 297], ["ATP", "CHEMICAL", 303, 306], ["infections", "DISEASE", 466, 476], ["chronic fatigue syndrome", "DISEASE", 547, 571], ["prostate cancer", "DISEASE", 594, 609], ["ATP", "CHEMICAL", 303, 306], ["IFN-\u2424", "GENE_OR_GENE_PRODUCT", 94, 99], ["HAV", "ORGANISM", 130, 133], ["RNase L", "GENE_OR_GENE_PRODUCT", 158, 165], ["IFN", "GENE_OR_GENE_PRODUCT", 250, 253], ["2 -5 OAS", "SIMPLE_CHEMICAL", 255, 263], ["2-5A", "SIMPLE_CHEMICAL", 293, 297], ["ATP", "SIMPLE_CHEMICAL", 303, 306], ["RNase L. RNase L", "GENE_OR_GENE_PRODUCT", 366, 382], ["cells", "CELL", 412, 417], ["prostate cancer", "CANCER", 594, 609], ["IFN", "PROTEIN", 94, 97], ["\u2424", "PROTEIN", 98, 99], ["RNase L enzyme", "PROTEIN", 158, 172], ["IFN", "PROTEIN", 250, 253], ["OAS", "PROTEIN", 260, 263], ["enzyme", "PROTEIN", 269, 275], ["latent endoribonuclease", "PROTEIN", 342, 365], ["RNase", "PROTEIN", 366, 371], ["RNase L", "PROTEIN", 375, 382], ["HAV", "SPECIES", 130, 133], ["HAV infection", "PROBLEM", 130, 143], ["The RNase L enzyme", "TEST", 154, 172], ["RNA degradation", "PROBLEM", 219, 234], ["IFN", "PROBLEM", 250, 253], ["the enzyme", "TEST", 265, 275], ["dsRNA", "PROBLEM", 326, 331], ["the latent endoribonuclease RNase L. RNase L", "PROBLEM", 338, 382], ["virus infections", "PROBLEM", 460, 476], ["apoptosis", "PROBLEM", 515, 524], ["hormonal regulation", "TREATMENT", 526, 545], ["chronic fatigue syndrome", "PROBLEM", 547, 571], ["prostate cancer", "PROBLEM", 594, 609], ["infection", "OBSERVATION", 134, 143], ["dsRNA", "OBSERVATION", 326, 331], ["RNase L", "OBSERVATION_MODIFIER", 375, 382], ["most cells", "OBSERVATION_MODIFIER", 407, 417], ["chronic", "OBSERVATION_MODIFIER", 547, 554], ["fatigue syndrome", "OBSERVATION", 555, 571], ["prostate", "ANATOMY", 594, 602], ["cancer", "OBSERVATION", 603, 609]]], ["RNase L levels are usually unaffected by virus infection or IFN treatment, but it is activated only in the presence of the proximal activator 2-5A, a series of unique 2 -5 phosphodiester linked oligoadenylic acid molecules.", [["infection", "DISEASE", 47, 56], ["IFN", "CHEMICAL", 60, 63], ["oligoadenylic acid", "CHEMICAL", 194, 212], ["phosphodiester", "CHEMICAL", 172, 186], ["oligoadenylic acid", "CHEMICAL", 194, 212], ["RNase L", "GENE_OR_GENE_PRODUCT", 0, 7], ["IFN", "GENE_OR_GENE_PRODUCT", 60, 63], ["2-5A", "GENE_OR_GENE_PRODUCT", 142, 146], ["2 -5 phosphodiester linked oligoadenylic acid", "SIMPLE_CHEMICAL", 167, 212], ["RNase L", "PROTEIN", 0, 7], ["IFN", "PROTEIN", 60, 63], ["proximal activator 2-5A", "PROTEIN", 123, 146], ["oligoadenylic acid molecules", "PROTEIN", 194, 222], ["RNase L levels", "TEST", 0, 14], ["virus infection", "PROBLEM", 41, 56], ["IFN treatment", "TREATMENT", 60, 73], ["5 phosphodiester linked oligoadenylic acid molecules", "PROBLEM", 170, 222], ["virus", "OBSERVATION_MODIFIER", 41, 46], ["infection", "OBSERVATION", 47, 56], ["proximal", "ANATOMY_MODIFIER", 123, 131], ["acid molecules", "OBSERVATION", 208, 222]]], ["The synthesis of 2-5A is dependent upon the induction of the enzyme 2 -5 OAS which is activated by dsRNA or other activator molecules such as the hepatitis C virus core protein (Naganuma et al., 2000) .", [["2-5A", "CHEMICAL", 17, 21], ["hepatitis C", "DISEASE", 146, 157], ["2-5A", "SIMPLE_CHEMICAL", 17, 21], ["hepatitis C virus", "ORGANISM", 146, 163], ["enzyme 2 -5 OAS", "PROTEIN", 61, 76], ["activator molecules", "PROTEIN", 114, 133], ["hepatitis C virus core protein", "PROTEIN", 146, 176], ["hepatitis C virus", "SPECIES", 146, 163], ["hepatitis C virus", "SPECIES", 146, 163], ["the enzyme", "TEST", 57, 67], ["dsRNA", "PROBLEM", 99, 104], ["other activator molecules", "PROBLEM", 108, 133], ["the hepatitis C virus core protein", "PROBLEM", 142, 176]]], ["We showed that 2 -5 OAS was not induced in 18f infected cells, despite the occurrence of massive RNA degradation.", [["cells", "ANATOMY", 56, 61], ["cells", "CELL", 56, 61], ["18f infected cells", "CELL_LINE", 43, 61], ["18f infected cells", "PROBLEM", 43, 61], ["massive RNA degradation", "PROBLEM", 89, 112], ["infected cells", "OBSERVATION", 47, 61], ["massive", "OBSERVATION_MODIFIER", 89, 96], ["RNA degradation", "OBSERVATION", 97, 112]]], ["We also showed that the failure to detect 2 -5 OAS mRNA was not due to a failure of the RT-PCR protocol or the genetic background of the FrhK4 cells, since treatment of this cell line with IFN-\u2424 resulted in an induction of the 69/71 form of 2 -5 OAS mRNA.", [["FrhK4 cells", "ANATOMY", 137, 148], ["cell line", "ANATOMY", 174, 183], ["IFN", "CHEMICAL", 189, 192], ["FrhK4 cells", "CELL", 137, 148], ["cell line", "CELL", 174, 183], ["IFN-\u2424", "GENE_OR_GENE_PRODUCT", 189, 194], ["OAS", "GENE_OR_GENE_PRODUCT", 246, 249], ["OAS mRNA", "RNA", 47, 55], ["FrhK4 cells", "CELL_LINE", 137, 148], ["IFN", "PROTEIN", 189, 192], ["69/71 form", "RNA", 227, 237], ["2 -5 OAS mRNA", "RNA", 241, 254], ["the failure", "PROBLEM", 20, 31], ["a failure", "PROBLEM", 71, 80], ["the RT-PCR protocol", "TREATMENT", 84, 103], ["the FrhK4 cells", "PROBLEM", 133, 148], ["this cell line", "TREATMENT", 169, 183], ["IFN", "TEST", 189, 192], ["an induction", "TEST", 207, 219], ["failure", "OBSERVATION", 24, 31], ["cell line", "OBSERVATION", 174, 183]]], ["We also showed that the mRNA for RNase L was present in both virus infected and uninfected cells, with some increase in the level of its mRNA following virus infection.", [["cells", "ANATOMY", 91, 96], ["infection", "DISEASE", 158, 167], ["RNase L", "GENE_OR_GENE_PRODUCT", 33, 40], ["cells", "CELL", 91, 96], ["mRNA", "RNA", 24, 28], ["RNase L", "PROTEIN", 33, 40], ["uninfected cells", "CELL_TYPE", 80, 96], ["mRNA", "RNA", 137, 141], ["RNase L", "PROBLEM", 33, 40], ["both virus infected and uninfected cells", "PROBLEM", 56, 96], ["virus infection", "PROBLEM", 152, 167], ["both virus", "ANATOMY", 56, 66], ["uninfected cells", "OBSERVATION", 80, 96], ["some", "OBSERVATION_MODIFIER", 103, 107], ["increase", "OBSERVATION_MODIFIER", 108, 116], ["virus infection", "OBSERVATION", 152, 167]]], ["We conclude that either RNase L may be activated by factors other than 2-5A, or that the enzyme responsible for RNA degradation is a novel RNase specifically induced or activated in 18f and coxsackievirus infected cells.", [["cells", "ANATOMY", 214, 219], ["RNase L", "GENE_OR_GENE_PRODUCT", 24, 31], ["2-5A", "GENE_OR_GENE_PRODUCT", 71, 75], ["RNase", "GENE_OR_GENE_PRODUCT", 139, 144], ["coxsackievirus", "ORGANISM", 190, 204], ["cells", "CELL", 214, 219], ["RNase L", "PROTEIN", 24, 31], ["RNase", "PROTEIN", 139, 144], ["18f and coxsackievirus infected cells", "CELL_LINE", 182, 219], ["RNase L", "TREATMENT", 24, 31], ["the enzyme", "TEST", 85, 95], ["RNA degradation", "PROBLEM", 112, 127], ["a novel RNase", "PROBLEM", 131, 144], ["coxsackievirus infected cells", "PROBLEM", 190, 219], ["infected cells", "OBSERVATION", 205, 219]]], ["In this regard, IFN treatment has been shown to stimulate the expression of a second ribonuclease, identified as ISG20 (Nguyen et al., 2001) .", [["IFN", "CHEMICAL", 16, 19], ["IFN", "GENE_OR_GENE_PRODUCT", 16, 19], ["ribonuclease", "GENE_OR_GENE_PRODUCT", 85, 97], ["ISG20", "GENE_OR_GENE_PRODUCT", 113, 118], ["IFN", "PROTEIN", 16, 19], ["ribonuclease", "PROTEIN", 85, 97], ["ISG20", "PROTEIN", 113, 118], ["IFN treatment", "TREATMENT", 16, 29], ["a second ribonuclease", "TREATMENT", 76, 97]]], ["However, this enzyme is an exonuclease, and the negative effect of IFN treatment on 18f-induced RNA degradation (Fig. 7) argues against the role of this enzyme.DiscussionUnlike most picornaviruses, persistent infection is the norm rather than the exception for HAV, at least in vitro in tissue culture cells.", [["tissue culture cells", "ANATOMY", 287, 307], ["IFN", "CHEMICAL", 67, 70], ["18f", "CHEMICAL", 84, 87], ["infection", "DISEASE", 209, 218], ["HAV", "DISEASE", 261, 264], ["IFN", "GENE_OR_GENE_PRODUCT", 67, 70], ["18f", "SIMPLE_CHEMICAL", 84, 87], ["HAV", "ORGANISM", 261, 264], ["tissue culture cells", "CELL", 287, 307], ["exonuclease", "PROTEIN", 27, 38], ["IFN", "PROTEIN", 67, 70], ["enzyme", "PROTEIN", 153, 159], ["tissue culture cells", "CELL_LINE", 287, 307], ["HAV", "SPECIES", 261, 264], ["this enzyme", "TEST", 9, 20], ["an exonuclease", "TEST", 24, 38], ["IFN treatment", "TREATMENT", 67, 80], ["induced RNA degradation", "PROBLEM", 88, 111], ["this enzyme", "TEST", 148, 159], ["most picornaviruses", "PROBLEM", 177, 196], ["persistent infection", "PROBLEM", 198, 218], ["HAV", "PROBLEM", 261, 264], ["persistent", "OBSERVATION_MODIFIER", 198, 208], ["infection", "OBSERVATION", 209, 218], ["tissue", "ANATOMY", 287, 293], ["culture cells", "OBSERVATION", 294, 307]]], ["Persistent infection by most cc strains of HAV has been suggested to be the result of inefficient translation initiation from its IRES (Whetter et al., 1994; Funkhouser et al., 1999; Yi et al., 2000) .", [["infection", "DISEASE", 11, 20], ["HAV", "DISEASE", 43, 46], ["HAV", "ORGANISM", 43, 46], ["IRES", "DNA", 130, 134], ["HAV", "SPECIES", 43, 46], ["Persistent infection", "PROBLEM", 0, 20], ["most cc strains of HAV", "PROBLEM", 24, 46], ["infection", "OBSERVATION", 11, 20], ["most cc strains", "OBSERVATION_MODIFIER", 24, 39]]], ["Recent results suggest that HAV IRES is as efficient as the IRES of other picornaviruses in initiating translation, and the switch from translation to negative strand synthesis is the rate-limiting step in HAV replication (Gauss-M\u00fcller and Kusov, 2002) .", [["HAV", "ORGANISM", 28, 31], ["HAV", "ORGANISM", 206, 209], ["HAV IRES", "DNA", 28, 36], ["IRES", "DNA", 60, 64], ["HAV", "SPECIES", 28, 31], ["HAV", "SPECIES", 206, 209], ["HAV IRES", "PROBLEM", 28, 36], ["other picornaviruses", "PROBLEM", 68, 88], ["strand synthesis", "TREATMENT", 160, 176], ["the rate", "TEST", 180, 188]]], ["It has also been suggested that the slow replication (even the replication of cp strains are slow compared to other picornaviruses) of HAV is a result of down regulation of its replication by the virus itself by unknown mechanisms (De Chastonay and Siegl, 1987) .", [["HAV", "DISEASE", 135, 138], ["HAV", "ORGANISM", 135, 138], ["HAV", "SPECIES", 135, 138], ["the slow replication", "PROBLEM", 32, 52], ["cp strains", "PROBLEM", 78, 88], ["HAV", "PROBLEM", 135, 138], ["slow", "OBSERVATION_MODIFIER", 36, 40], ["replication", "OBSERVATION", 41, 52]]], ["In the discussion of slow replication of HAV, the lack of a functional 2A protease has often been overlooked.", [["HAV", "DISEASE", 41, 44], ["HAV", "ORGANISM", 41, 44], ["2A protease", "PROTEIN", 71, 82], ["HAV", "SPECIES", 41, 44], ["HAV", "PROBLEM", 41, 44], ["a functional 2A protease", "PROBLEM", 58, 82]]], ["Picornaviral 2A protease is responsible for promoting cap-independent translation by inactivating eIF4G, and possibly other translation factors (Ziegler et al., 1995; Kerekatte et al., 1999) .", [["Picornaviral 2A", "GENE_OR_GENE_PRODUCT", 0, 15], ["cap", "GENE_OR_GENE_PRODUCT", 54, 57], ["eIF4G", "GENE_OR_GENE_PRODUCT", 98, 103], ["Picornaviral 2A protease", "PROTEIN", 0, 24], ["eIF4G", "PROTEIN", 98, 103], ["translation factors", "PROTEIN", 124, 143], ["Picornaviral 2A protease", "TREATMENT", 0, 24]]], ["2A protease is also a strong inducer of apoptosis when expressed ectopically (Goldstaub et al., 2000) .", [["2A", "GENE_OR_GENE_PRODUCT", 0, 2], ["2A protease", "PROTEIN", 0, 11], ["2A protease", "TREATMENT", 0, 11], ["apoptosis", "PROBLEM", 40, 49], ["apoptosis", "OBSERVATION", 40, 49]]], ["In the absence of a functional 2A protease, HAV viral RNA has to compete with cellular mRNAs for the host cell translation machinery.", [["cellular", "ANATOMY", 78, 86], ["cell", "ANATOMY", 106, 110], ["HAV viral", "ORGANISM", 44, 53], ["cellular", "CELL", 78, 86], ["cell", "CELL", 106, 110], ["2A protease", "PROTEIN", 31, 42], ["HAV viral RNA", "RNA", 44, 57], ["cellular mRNAs", "RNA", 78, 92], ["HAV", "SPECIES", 44, 47], ["a functional 2A protease", "TREATMENT", 18, 42], ["HAV viral RNA", "PROBLEM", 44, 57], ["cellular mRNAs", "TREATMENT", 78, 92], ["host cell", "OBSERVATION", 101, 110]]], ["We suggest that induction of an RNase activity may partially compensate for the absence of an active 2A protease, by reducing competition from cellular mRNAs and contributing to the rapid replication phenotype of 18f and possibly other cp strains of HAV.DiscussionApoptosis is generally thought to be a host defense response to virus infection (for a review, see Barber, 2001) .", [["cellular", "ANATOMY", 143, 151], ["HAV", "DISEASE", 250, 253], ["DiscussionApoptosis", "DISEASE", 254, 273], ["infection", "DISEASE", 334, 343], ["RNase", "GENE_OR_GENE_PRODUCT", 32, 37], ["cellular", "CELL", 143, 151], ["18f", "GENE_OR_GENE_PRODUCT", 213, 216], ["HAV", "ORGANISM", 250, 253], ["RNase", "PROTEIN", 32, 37], ["2A protease", "PROTEIN", 101, 112], ["cellular mRNAs", "RNA", 143, 157], ["HAV", "SPECIES", 250, 253], ["an RNase activity", "TREATMENT", 29, 46], ["an active 2A protease", "PROBLEM", 91, 112], ["cellular mRNAs", "PROBLEM", 143, 157], ["the rapid replication phenotype of 18f", "PROBLEM", 178, 216], ["other cp strains of HAV", "PROBLEM", 230, 253], ["virus infection", "PROBLEM", 328, 343], ["cellular mRNAs", "OBSERVATION", 143, 157], ["generally thought to be", "UNCERTAINTY", 277, 300]]], ["Premature induction of apoptosis results in abortive virus replication.", [["Premature induction of apoptosis", "PROBLEM", 0, 32], ["abortive virus replication", "TREATMENT", 44, 70]]], ["However, a late induction of apoptosis might favor the virus by allowing it to evade the host immune system.", [["apoptosis", "PROBLEM", 29, 38], ["the virus", "PROBLEM", 51, 60]]], ["Many viruses have thus evolved mechanisms to delay the onset of an apoptotic response (Roulston et al., 1999) .", [["Many viruses", "PROBLEM", 0, 12], ["viruses", "OBSERVATION", 5, 12], ["apoptotic response", "OBSERVATION", 67, 85]]], ["Similarly, induction of IFN mediated antiviral pathways is a defensive response of the host to virus infection, and many viruses have evolved mechanisms to block the induction of IFN mediated antiviral pathways (for reviews, see Barber, 2001; Sen, 2001) .", [["infection", "DISEASE", 101, 110], ["IFN", "GENE_OR_GENE_PRODUCT", 24, 27], ["IFN", "GENE_OR_GENE_PRODUCT", 179, 182], ["IFN", "PROTEIN", 24, 27], ["IFN", "PROTEIN", 179, 182], ["IFN mediated antiviral pathways", "TREATMENT", 24, 55], ["the host to virus infection", "PROBLEM", 83, 110], ["many viruses", "PROBLEM", 116, 128], ["IFN mediated antiviral pathways", "TREATMENT", 179, 210]]], ["It is therefore not surprising that the two major IFN mediated antiviral pathways, namely the 2-5A/RNase L pathway and the dsRNA activated PKR pathway, are also mediators of apoptosis.DiscussionAmong the picornaviruses, HAV is unique in its slow replication in permissive cells, and also in its ability to initiate and maintain a persistent infection.", [["cells", "ANATOMY", 272, 277], ["HAV", "DISEASE", 220, 223], ["infection", "DISEASE", 341, 350], ["IFN", "GENE_OR_GENE_PRODUCT", 50, 53], ["2-5A", "GENE_OR_GENE_PRODUCT", 94, 98], ["RNase L", "GENE_OR_GENE_PRODUCT", 99, 106], ["PKR", "GENE_OR_GENE_PRODUCT", 139, 142], ["picornaviruses", "ORGANISM", 204, 218], ["HAV", "ORGANISM", 220, 223], ["cells", "CELL", 272, 277], ["IFN", "PROTEIN", 50, 53], ["RNase L", "PROTEIN", 99, 106], ["PKR", "PROTEIN", 139, 142], ["permissive cells", "CELL_TYPE", 261, 277], ["HAV", "SPECIES", 220, 223], ["5A/RNase L pathway", "TREATMENT", 96, 114], ["the dsRNA activated PKR pathway", "TEST", 119, 150], ["apoptosis", "PROBLEM", 174, 183], ["the picornaviruses", "PROBLEM", 200, 218], ["a persistent infection", "PROBLEM", 328, 350], ["apoptosis", "OBSERVATION", 174, 183], ["permissive cells", "OBSERVATION", 261, 277], ["persistent", "OBSERVATION_MODIFIER", 330, 340], ["infection", "OBSERVATION", 341, 350]]], ["Persistent infection is known for other picornaviruses, but usually requires restriction of virus replication and gene expression, through the use of inhibitors in cultured cells and presumably the host IFN regulated system or the immune system in the intact organism (Agol et al., 2000) .", [["cells", "ANATOMY", 173, 178], ["immune system", "ANATOMY", 231, 244], ["infection", "DISEASE", 11, 20], ["cells", "CELL", 173, 178], ["cultured cells", "CELL_LINE", 164, 178], ["IFN", "PROTEIN", 203, 206], ["Persistent infection", "PROBLEM", 0, 20], ["other picornaviruses", "PROBLEM", 34, 54], ["virus replication", "TREATMENT", 92, 109], ["gene expression", "TREATMENT", 114, 129], ["inhibitors in cultured cells", "TREATMENT", 150, 178], ["the host IFN regulated system", "PROBLEM", 194, 223], ["infection", "OBSERVATION", 11, 20], ["picornaviruses", "OBSERVATION", 40, 54]]], ["Moreover, cp strains of HAV kill cells by apoptosis in cell culture, while in the whole organism, a role for apoptosis in the destruction of infected cells, or evading the host immune response is uncertain.", [["cells", "ANATOMY", 33, 38], ["cell culture", "ANATOMY", 55, 67], ["cells", "ANATOMY", 150, 155], ["HAV", "ORGANISM", 24, 27], ["cells", "CELL", 33, 38], ["cell culture", "CELL", 55, 67], ["cells", "CELL", 150, 155], ["infected cells", "CELL_TYPE", 141, 155], ["HAV", "SPECIES", 24, 27], ["cp strains", "PROBLEM", 10, 20], ["HAV kill cells", "PROBLEM", 24, 38], ["apoptosis in cell culture", "TEST", 42, 67], ["apoptosis", "PROBLEM", 109, 118], ["the destruction of infected cells", "PROBLEM", 122, 155], ["infected cells", "OBSERVATION", 141, 155], ["host immune response", "OBSERVATION", 172, 192]]], ["The late depletion of PARP-1 clearly indicates that HAV is capable of avoiding the induction of necrosis in infected cells and evade a host immune response.DiscussionIn conclusion, we present evidence that unlike some other picornaviruses, notably encephalomyocarditis (EMC) virus, HAV is relatively insensitive to the antiviral effect of IFN.", [["cells", "ANATOMY", 117, 122], ["necrosis", "DISEASE", 96, 104], ["encephalomyocarditis", "DISEASE", 248, 268], ["EMC", "DISEASE", 270, 273], ["HAV", "DISEASE", 282, 285], ["IFN", "CHEMICAL", 339, 342], ["PARP-1", "GENE_OR_GENE_PRODUCT", 22, 28], ["HAV", "ORGANISM", 52, 55], ["cells", "CELL", 117, 122], ["encephalomyocarditis (EMC) virus", "ORGANISM", 248, 280], ["HAV", "ORGANISM", 282, 285], ["IFN", "GENE_OR_GENE_PRODUCT", 339, 342], ["PARP-1", "PROTEIN", 22, 28], ["infected cells", "CELL_TYPE", 108, 122], ["IFN", "PROTEIN", 339, 342], ["HAV", "SPECIES", 52, 55], ["HAV", "SPECIES", 282, 285], ["PARP", "TEST", 22, 26], ["necrosis in infected cells", "PROBLEM", 96, 122], ["some other picornaviruses", "PROBLEM", 213, 238], ["encephalomyocarditis (EMC) virus", "PROBLEM", 248, 280], ["HAV", "PROBLEM", 282, 285], ["the antiviral effect of IFN", "TREATMENT", 315, 342], ["late", "OBSERVATION_MODIFIER", 4, 8], ["depletion", "OBSERVATION", 9, 18], ["necrosis", "OBSERVATION", 96, 104], ["infected cells", "OBSERVATION", 108, 122], ["picornaviruses", "OBSERVATION", 224, 238], ["encephalomyocarditis", "OBSERVATION", 248, 268]]], ["Furthermore, the degradation of rRNA in HAV 18f infected cells occurs in the absence of 2 -5 OAS, the key enzyme that regulates the 2-5A/RNase L antiviral pathway.", [["cells", "ANATOMY", 57, 62], ["rRNA", "CELLULAR_COMPONENT", 32, 36], ["HAV 18f", "ORGANISM", 40, 47], ["cells", "CELL", 57, 62], ["OAS", "GENE_OR_GENE_PRODUCT", 93, 96], ["2-5A", "GENE_OR_GENE_PRODUCT", 132, 136], ["RNase L", "GENE_OR_GENE_PRODUCT", 137, 144], ["HAV 18f infected cells", "CELL_LINE", 40, 62], ["OAS", "PROTEIN", 93, 96], ["RNase L", "PROTEIN", 137, 144], ["HAV 18f", "SPECIES", 40, 47], ["the degradation of rRNA", "PROBLEM", 13, 36], ["HAV 18f infected cells", "PROBLEM", 40, 62], ["the key enzyme", "TEST", 98, 112], ["RNase L antiviral pathway", "TREATMENT", 137, 162], ["infected cells", "OBSERVATION", 48, 62]]], ["The 18f virus is able to suppress the expression of ISGs including 2 -5 OAS by interfering with JAK/STAT signaling by an unknown mechanism, and it utilizes the degradation of RNA as a means to augment its replication and subsequently induce apoptosis in the host cell.", [["cell", "ANATOMY", 263, 267], ["18f virus", "ORGANISM", 4, 13], ["OAS", "GENE_OR_GENE_PRODUCT", 72, 75], ["JAK", "GENE_OR_GENE_PRODUCT", 96, 99], ["STAT", "GENE_OR_GENE_PRODUCT", 100, 104], ["host cell", "CELL", 258, 267], ["ISGs", "DNA", 52, 56], ["JAK", "PROTEIN", 96, 99], ["STAT", "PROTEIN", 100, 104], ["host cell", "CELL_TYPE", 258, 267], ["18f virus", "SPECIES", 4, 13], ["The 18f virus", "TREATMENT", 0, 13], ["the degradation of RNA", "TREATMENT", 156, 178], ["its replication", "TREATMENT", 201, 216], ["apoptosis in the host cell", "PROBLEM", 241, 267], ["host cell", "OBSERVATION", 258, 267]]]], "f24d3b4b4af138be06b7452b7acefc8948bc1056": [["IntroductionThe 2019 new coronavirus, \"2019-nCoV\", was discovered from Wuhan Viral Pneumonia cases in December 2019, and was named by the World Health Organization on January 12, 2020.", [["coronavirus", "DISEASE", 25, 36], ["Viral Pneumonia", "DISEASE", 77, 92], ["coronavirus", "ORGANISM", 25, 36]]], ["In the early stage, people knows little about the 2019-nCoV virus was not clear, and the spread period was encountering China's annual spring migration, which made the epidemic spread rapidly from Wuhan to almost all provinces in China.IntroductionAs of 20:30 on January 27, 2020, 2844 cases were confirmed nationwide, 5794 were suspected, 58 were cured, and 81 died.", [["people", "ORGANISM", 20, 26], ["2019-nCoV virus", "ORGANISM", 50, 65], ["people", "SPECIES", 20, 26], ["nCoV virus", "PROBLEM", 55, 65], ["early stage", "OBSERVATION_MODIFIER", 7, 18]]], ["Such a major epidemic is a serious challenge to people's lives and an important test of public health emergency management capabilities.IntroductionIn recent days, domestic and foreign scholars have published research results about new coronaviruses online, and some of them are non-medical scholars who use mathematics and computer technology to simulate and predict disease transmission.", [["people", "ORGANISM", 48, 54], ["coronaviruses", "ORGANISM", 236, 249], ["people", "SPECIES", 48, 54]]], ["Scholars from the field of public health present a timely evaluation of the Chinese 2019-nCov epidemic in its initial phase [1] .", [["a timely evaluation", "TEST", 49, 68]]], ["Different from the existing studies, this study taking into account the new characteristics of new coronaviruses and the current epidemic prevention and control measures in China, and constructing a SEIRD model that considers the movement of people across regions.", [["coronaviruses", "ORGANISM", 99, 112], ["people", "ORGANISM", 242, 248], ["people", "SPECIES", 242, 248], ["the existing studies", "TEST", 15, 35], ["this study", "TEST", 37, 47], ["new coronaviruses", "PROBLEM", 95, 112], ["a SEIRD model", "TREATMENT", 197, 210], ["new", "OBSERVATION_MODIFIER", 72, 75], ["new", "OBSERVATION_MODIFIER", 95, 98], ["coronaviruses", "OBSERVATION", 99, 112]]], ["The purpose of this study is to reveal the role of the three most important current measures to control the spread of the epidemic, such as quarantine of infected persons, reduction of human mobility, and improvement of treatment.ModelThe warehouse model was proposed by Kermack and McKendrick in 1927.", [["persons", "ORGANISM", 163, 170], ["human", "ORGANISM", 185, 190], ["persons", "SPECIES", 163, 170], ["human", "SPECIES", 185, 190], ["human", "SPECIES", 185, 190], ["this study", "TEST", 15, 25], ["human mobility", "TREATMENT", 185, 199], ["treatment", "TREATMENT", 220, 229], ["human mobility", "OBSERVATION_MODIFIER", 185, 199]]], ["The two most basic states are Susceptible (S) and Infected (Infected, I).ModelAccording to the types of individual states included in the model, classic warehouse models such as SI model [2] , SIS model [3] , SIR model [4] , and SEIR model [5] .", [["ModelAccording", "TREATMENT", 73, 87], ["SIS model", "TEST", 193, 202], ["SIR model", "TEST", 209, 218], ["SEIR model", "TEST", 229, 239], ["Susceptible", "OBSERVATION_MODIFIER", 30, 41], ["Infected", "OBSERVATION_MODIFIER", 50, 58], ["Infected", "OBSERVATION", 60, 68]]], ["CC-BY-NC-ND 4.0 International license author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["The SEIR model considers Exposed, that is, vulnerable individuals are infected, but they cannot infect other vulnerable individuals within a certain incubation period.ModelOn the basis of the SIR model, considering that 2019-nCoV is an infectious disease with a latent period, the E (Exposed) state and D (Death) state are added to construct the SEIRD propagation model.", [["individuals", "ORGANISM", 54, 65], ["infected", "PROBLEM", 70, 78], ["an infectious disease", "PROBLEM", 233, 254], ["infected", "OBSERVATION", 70, 78], ["infectious", "OBSERVATION", 236, 246]]], ["The schematic diagram of the SEIRD propagation model is shown in figure 1 .", [["The schematic diagram", "TEST", 0, 21]]], ["The members in this model mainly have the following four conversion methods.Model\uf06c First, S \u2192 E. Relevant evidence shows that during the 2019-nCoV infection process, not only confirmed patients have infectious capacity, but also those asymptomatic transmission individuals also have the ability to infect others.", [["infection", "DISEASE", 147, 156], ["patients", "ORGANISM", 185, 193], ["individuals", "ORGANISM", 261, 272], ["patients", "SPECIES", 185, 193], ["nCoV infection process", "PROBLEM", 142, 164], ["infectious capacity", "PROBLEM", 199, 218], ["infection", "OBSERVATION", 147, 156], ["infectious", "OBSERVATION", 199, 209]]], ["The Exposed status (E) may be transformed into an infected status (I) after the incubation period.Model\uf06c Third, I \u2192 R. The infected individual (I) will be isolated and treated with a certain probability in hospital and will change to the R status.", [["infected", "OBSERVATION", 50, 58], ["infected", "OBSERVATION", 123, 131]]], ["The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.01.28.923169 doi: bioRxiv preprint different regions / communities / urbans.", [["The copyright holder", "TREATMENT", 0, 20], ["bioRxiv", "TREATMENT", 125, 132]]], ["Suppose there are NU members in a twodimensional space.", [["NU", "OBSERVATION", 18, 20]]], ["In the initial stage, NU members are randomly and uniformly distributed in NC * NC communities (also can be understood as cities), that is, each community has NU / (NC * NC) people.", [["people", "SPECIES", 174, 180]]], ["Therefore, for individuals in different Table 1 .Simulation of infected isolation measuresIn this study, the isolation measures refer to that from the time of publication TI, individuals in I-status stop moving and are isolated and treated by the hospital.", [["infected isolation measures", "TREATMENT", 63, 90], ["this study", "TEST", 93, 103], ["the isolation measures", "TREATMENT", 105, 127], ["infected isolation", "OBSERVATION", 63, 81]]], ["It can be found that with the isolation measures implemented at four time points, the Estatus user changes are not obvious.", [["the isolation measures", "TREATMENT", 26, 48], ["not obvious", "UNCERTAINTY", 111, 122]]], ["The possible reason is that this isolation is only implemented for I-status users, but one of the characteristics of 2019-nCoV is that not only I-status is contagious, but E-status is also contagious.", [["this isolation", "TREATMENT", 28, 42], ["contagious", "PROBLEM", 156, 166], ["possible", "UNCERTAINTY", 4, 12]]], ["Although the I-status is being treated in isolation, there are still many members of the E-status in the incubation period.Simulation of infected isolation measuresThese members make the disease likely to continue to spread.", [["E-status", "DNA", 89, 97], ["infected isolation measures", "TREATMENT", 137, 164], ["the disease", "PROBLEM", 183, 194], ["infected isolation", "OBSERVATION", 137, 155]]], ["CC-BY-NC-ND 4.0 International license author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["It is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.01.28.923169 doi: bioRxiv preprint government requires that people who share a bus, a flight, or a train with the infected person need to isolate themselves.", [["people", "ORGANISM", 196, 202], ["people", "SPECIES", 196, 202], ["person", "SPECIES", 259, 265]]], ["These individuals may have changed to the E-status because they had been in the same space with the I-status individuals.Simulation of infected isolation measuresIt can be found that with the implementation of isolation measures at four time points, the I-status user has changed significantly.", [["infected isolation measures", "TREATMENT", 135, 162], ["isolation measures", "TREATMENT", 210, 228], ["infected isolation", "OBSERVATION", 135, 153]]], ["The change is reflected in that the sooner the isolation measures are implemented, the lower the proportion of I-status users remains, and the shorter the time it takes for the proportion of I-status users to decrease to zero.Simulation of infected isolation measuresFor example, the peak value of I-status personnel is 10% at TI = 10, and the peak value of I-status personnel is 95% at TI = 40 and decreases to 0 at t = 45. .", [["infected isolation measures", "TREATMENT", 240, 267], ["the peak value", "TEST", 280, 294], ["TI", "TEST", 327, 329], ["the peak value", "TEST", 340, 354], ["TI", "TEST", 387, 389], ["lower", "OBSERVATION_MODIFIER", 87, 92], ["infected isolation", "OBSERVATION", 240, 258]]], ["CC-BY-NC-ND 4.0 International license author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["It is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.01.28.923169 doi: bioRxiv preprint Due to the implementation of prevention and control measures, it will eventually enter a steady state, that is, there will no longer be new D-status users in all communities.", [["bioRxiv", "TREATMENT", 154, 161], ["prevention and control measures", "TREATMENT", 200, 231]]], ["It can be found that the implementation of population mobility control at two points in time, and the difference in the degree of population mobility control, the proportion of I-status users has changed significantly.", [["population mobility control", "TREATMENT", 43, 70], ["population mobility control", "TREATMENT", 130, 157]]], ["A conclusion similar to that of the E-status is obtained, that is, in order to reduce the proportion of the I-status users, measures to reduce population mobility should be implemented as soon as possible. .", [["the E-status", "TEST", 32, 44]]], ["CC-BY-NC-ND 4.0 International license author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["It is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.01.28.923169 doi: bioRxiv preprint 30, compared with the low-measure group, the proportion of D-status in the highmeasure group (MU = 0.01, MT = 10) was lower.", [["MT", "TEST", 276, 278]]], ["When t = 50, compared with the lowmeasure group (the percentage of D-status in almost all communities exceeds 50%), the range of the D-status ratio in the high-measure group is [0.5-1].", [["the D-status ratio", "TEST", 129, 147], ["high", "OBSERVATION_MODIFIER", 155, 159]]], ["Areas above 100% (gray) appear at t = 50, which is because the random flow of people makes the number of people in some communities higher than the initial stage.", [["people", "ORGANISM", 78, 84], ["people", "ORGANISM", 105, 111], ["people", "SPECIES", 78, 84], ["people", "SPECIES", 105, 111], ["Areas", "TEST", 0, 5]]], ["This result further validates that \"the sooner, the higher the degree of implementation of the measures to reduce the movement of people, the better the effect of controlling the spread of the epidemic.\"", [["people", "ORGANISM", 130, 136], ["people", "SPECIES", 130, 136]]], ["This study further validates the concerns of international and domestic experts regarding asymptomatic transmission (ie, E-status in this article).", [["This study", "TEST", 0, 10], ["asymptomatic transmission", "PROBLEM", 90, 115]]], ["This article suggests that as long as medical resources are available, E-status individuals or potential E-status individuals should be included in the scope of isolation and treatment.", [["isolation", "TREATMENT", 161, 170], ["treatment", "TREATMENT", 175, 184]]], ["The government should promptly release information on the epidemic situation, as well as information on the areas and vehicles used by the infected people, to further encourage those who have been in contact with individuals in the I or E-status to go to nearby hospitals for timely inspection.", [["people", "ORGANISM", 148, 154], ["people", "SPECIES", 148, 154]]]], "PMC7269887": [["IntroductionSince December, 2019, an increasing number of atypical pneumonia cases caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported in Wuhan, a city in the Chinese province of Hubei.1 As of Feb 17, 2020, 72 436 cases of coronavirus disease 2019 (COVID-19), including 1868 deaths, had been reported in mainland China.2 The outbreak has now spread to 198 countries, areas, or territories beyond China.3 On Jan 30, 2020, WHO declared the COVID-19 outbreak a public health emergency of international concern.4", [["pneumonia", "DISEASE", 67, 76], ["acute respiratory syndrome coronavirus", "DISEASE", 100, 138], ["coronavirus disease", "DISEASE", 261, 280], ["deaths", "DISEASE", 313, 319], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 93, 140], ["SARS-CoV-2", "ORGANISM", 142, 152], ["coronavirus", "ORGANISM", 261, 272], ["severe acute respiratory syndrome coronavirus", "SPECIES", 93, 138], ["SARS-CoV-2", "SPECIES", 142, 152], ["atypical pneumonia cases", "PROBLEM", 58, 82], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 93, 138], ["coronavirus disease", "PROBLEM", 261, 280], ["COVID", "TEST", 287, 292], ["atypical", "OBSERVATION_MODIFIER", 58, 66], ["pneumonia", "OBSERVATION", 67, 76], ["severe", "OBSERVATION_MODIFIER", 93, 99], ["acute", "OBSERVATION_MODIFIER", 100, 105], ["respiratory syndrome", "OBSERVATION", 106, 126], ["coronavirus disease", "OBSERVATION", 261, 280]]]], "PMC7185104": [["INTRODUCTIONSince the end of 2019, a novel coronavirus with person-to-person transmission has spread to many other countries worldwide [1\u20135].", [["coronavirus", "DISEASE", 43, 54], ["coronavirus", "ORGANISM", 43, 54], ["person", "SPECIES", 60, 66], ["person", "SPECIES", 70, 76]]], ["Previous epidemiology report uncovered that the epidemic of coronavirus disease 2019 (COVID-19) has doubled every 7.4 day in its early stage, with an average serial interval of 7.5 days [3].", [["coronavirus disease", "DISEASE", 60, 79], ["coronavirus", "ORGANISM", 60, 71], ["coronavirus disease", "PROBLEM", 60, 79], ["COVID", "TEST", 86, 91], ["coronavirus disease", "OBSERVATION", 60, 79]]], ["Early information estimated that the basic reproductive number R0 was estimated to be 1.4 \u2013 2.5 reported by WHO [2].", [["the basic reproductive number R0", "PROBLEM", 33, 65]]], ["The mortality of coronavirus disease 2019 (COVID-19) patients in China is approximately 2.3%, compared with 9.6% of severe acute respiratory syndrome (SARS) and 34.4% of middle east respiratory syndrome (MERS) reported by WHO [6].", [["coronavirus disease", "DISEASE", 17, 36], ["acute respiratory syndrome", "DISEASE", 123, 149], ["SARS", "DISEASE", 151, 155], ["middle east respiratory syndrome", "DISEASE", 170, 202], ["MERS", "DISEASE", 204, 208], ["coronavirus", "ORGANISM", 17, 28], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["coronavirus disease", "PROBLEM", 17, 36], ["COVID", "TEST", 43, 48], ["severe acute respiratory syndrome", "PROBLEM", 116, 149], ["SARS", "PROBLEM", 151, 155], ["middle east respiratory syndrome", "PROBLEM", 170, 202], ["coronavirus disease", "OBSERVATION", 17, 36], ["severe", "OBSERVATION_MODIFIER", 116, 122], ["acute", "OBSERVATION_MODIFIER", 123, 128], ["respiratory syndrome", "OBSERVATION", 129, 149], ["middle", "ANATOMY_MODIFIER", 170, 176], ["respiratory syndrome", "OBSERVATION", 182, 202]]], ["Even this virus is not as fetal as people thought, the transmissibility is far exceeding that of SARS and MERS [7].", [["fetal", "ANATOMY", 26, 31], ["SARS", "DISEASE", 97, 101], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 26, 31], ["people", "ORGANISM", 35, 41], ["people", "SPECIES", 35, 41], ["SARS", "PROBLEM", 97, 101]]], ["Although many clinical and epidemiological literatures have been published [3\u20136, 8\u201310], the spread in still ongoing and the early warning parameters for disease progression remain incomplete.INTRODUCTIONCompared to symptoms, chest CT findings were more rapid and frequent [11, 12].", [["chest", "ANATOMY", 225, 230], ["disease progression", "PROBLEM", 153, 172], ["symptoms", "PROBLEM", 215, 223], ["chest CT", "TEST", 225, 233], ["chest", "ANATOMY", 225, 230]]], ["The imaging performance on chest CT scans from COVID-19 patients mainly manifested as bilateral ground-glass opacities (GGOs) in the lung periphery [13].", [["chest", "ANATOMY", 27, 32], ["lung periphery", "ANATOMY", 133, 147], ["patients", "ORGANISM", 56, 64], ["lung", "ORGAN", 133, 137], ["patients", "SPECIES", 56, 64], ["The imaging performance", "TEST", 0, 23], ["chest CT scans", "TEST", 27, 41], ["COVID", "TEST", 47, 52], ["bilateral ground-glass opacities (GGOs) in the lung periphery", "PROBLEM", 86, 147], ["chest", "ANATOMY", 27, 32], ["bilateral", "ANATOMY_MODIFIER", 86, 95], ["glass opacities", "OBSERVATION", 103, 118], ["lung", "ANATOMY", 133, 137], ["periphery", "ANATOMY_MODIFIER", 138, 147]]], ["In a retrospective cohort, chest CTs of 121 symptomatic COVID-19 patients have been reviewed.", [["chest", "ANATOMY", 27, 32], ["chest CTs", "CANCER", 27, 36], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["chest CTs", "TEST", 27, 36], ["symptomatic COVID", "TEST", 44, 61], ["chest", "ANATOMY", 27, 32]]], ["Bilateral lung involvement was observed in 10/36 early patients (28%), 25/33 intermediate patients (76%), and 22/25 late patients (88%) [11].", [["lung", "ANATOMY", 10, 14], ["lung", "ORGAN", 10, 14], ["patients", "ORGANISM", 55, 63], ["patients", "ORGANISM", 90, 98], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 55, 63], ["patients", "SPECIES", 90, 98], ["patients", "SPECIES", 121, 129], ["Bilateral lung involvement", "PROBLEM", 0, 26], ["lung", "ANATOMY", 10, 14], ["involvement", "OBSERVATION", 15, 26]]], ["Currently, chest CT is used to assess the severity of lung involvement in COVID-19 pneumonia [14].", [["chest", "ANATOMY", 11, 16], ["lung", "ANATOMY", 54, 58], ["pneumonia", "DISEASE", 83, 92], ["chest", "ORGAN", 11, 16], ["lung", "ORGAN", 54, 58], ["chest CT", "TEST", 11, 19], ["lung involvement", "PROBLEM", 54, 70], ["COVID", "TEST", 74, 79], ["pneumonia", "PROBLEM", 83, 92], ["chest", "ANATOMY", 11, 16], ["lung", "ANATOMY", 54, 58], ["involvement", "OBSERVATION", 59, 70], ["pneumonia", "OBSERVATION", 83, 92]]], ["In a cohort study, 85.7% (54/63) confirmed COVID-19 patients developed imaging progression including enlarged and increased extent of GGOs and consolidation at early follow-up chest CT scans [12].", [["GGOs", "DISEASE", 134, 138], ["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["a cohort study", "TEST", 3, 17], ["COVID", "TEST", 43, 48], ["imaging progression", "TEST", 71, 90], ["enlarged and increased extent of GGOs", "PROBLEM", 101, 138], ["consolidation", "PROBLEM", 143, 156], ["chest CT scans", "TEST", 176, 190], ["enlarged", "OBSERVATION_MODIFIER", 101, 109], ["increased", "OBSERVATION_MODIFIER", 114, 123], ["extent", "OBSERVATION_MODIFIER", 124, 130], ["consolidation", "OBSERVATION", 143, 156], ["chest", "ANATOMY", 176, 181]]], ["That is, short-term imaging progression on chest CT from COVID-19 patients should be early predicted and intervened.INTRODUCTIONIn this analysis, we summarized the baseline characteristics and investigated the potential predictive parameters for imaging progression on chest CT scans at first week after admission of COVID-19 patients, in the hope that the data may provide novel biomarker candidates as well as useful insights into the pathogenesis and progression of COVID-19 patients.Imaging performance of progression and progression-free patients ::: RESULTSAs shown in Figure 1, most mild type COVID-19 patients had bilateral and peripheral GGOs, consolidation and linear opacities imaging involvements on chest CT at the first admission day.", [["chest", "ANATOMY", 43, 48], ["peripheral GGOs", "ANATOMY", 636, 651], ["chest", "ANATOMY", 712, 717], ["COVID", "DISEASE", 469, 474], ["peripheral GGOs", "DISEASE", 636, 651], ["opacities", "DISEASE", 678, 687], ["chest", "ORGAN", 43, 48], ["patients", "ORGANISM", 66, 74], ["patients", "ORGANISM", 326, 334], ["patients", "ORGANISM", 478, 486], ["patients", "ORGANISM", 543, 551], ["patients", "ORGANISM", 609, 617], ["patients", "SPECIES", 66, 74], ["patients", "SPECIES", 326, 334], ["patients", "SPECIES", 478, 486], ["patients", "SPECIES", 543, 551], ["patients", "SPECIES", 609, 617], ["short-term imaging progression", "PROBLEM", 9, 39], ["chest CT", "TEST", 43, 51], ["COVID", "TEST", 57, 62], ["this analysis", "TEST", 131, 144], ["imaging progression", "TEST", 246, 265], ["chest CT scans", "TEST", 269, 283], ["COVID", "TEST", 469, 474], ["Imaging performance", "TEST", 487, 506], ["most mild type COVID", "PROBLEM", 585, 605], ["bilateral and peripheral GGOs", "PROBLEM", 622, 651], ["consolidation", "PROBLEM", 653, 666], ["linear opacities imaging involvements", "PROBLEM", 671, 708], ["chest CT", "TEST", 712, 720], ["chest", "ANATOMY", 43, 48], ["chest", "ANATOMY", 269, 274], ["bilateral", "ANATOMY_MODIFIER", 622, 631], ["peripheral", "ANATOMY_MODIFIER", 636, 646], ["GGOs", "ANATOMY", 647, 651], ["consolidation", "OBSERVATION", 653, 666], ["linear", "OBSERVATION_MODIFIER", 671, 677], ["opacities", "OBSERVATION", 678, 687], ["chest", "ANATOMY", 712, 717]]], ["Some patients had no remarkable hallmarks.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["remarkable hallmarks", "PROBLEM", 21, 41], ["no", "UNCERTAINTY", 18, 20], ["remarkable", "OBSERVATION_MODIFIER", 21, 31], ["hallmarks", "OBSERVATION", 32, 41]]], ["At the first six (\u00b11) day, enlarged and increased GGOs, consolidation, solid nodules and fibrous stripes were observed for patients suffered from imaging progression on chest CT scans.", [["GGOs", "ANATOMY", 50, 54], ["solid nodules", "ANATOMY", 71, 84], ["fibrous stripes", "ANATOMY", 89, 104], ["solid nodules", "CANCER", 71, 84], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["enlarged and increased GGOs", "PROBLEM", 27, 54], ["consolidation", "PROBLEM", 56, 69], ["solid nodules", "PROBLEM", 71, 84], ["fibrous stripes", "PROBLEM", 89, 104], ["imaging progression", "TEST", 146, 165], ["chest CT scans", "TEST", 169, 183], ["enlarged", "OBSERVATION_MODIFIER", 27, 35], ["increased", "OBSERVATION_MODIFIER", 40, 49], ["GGOs", "OBSERVATION", 50, 54], ["consolidation", "OBSERVATION", 56, 69], ["solid", "OBSERVATION_MODIFIER", 71, 76], ["nodules", "OBSERVATION", 77, 84], ["fibrous stripes", "OBSERVATION", 89, 104], ["chest", "ANATOMY", 169, 174]]], ["On the contrary, the GGOs, consolidation and linear opacities were partly resolved and decreased for imaging progression-free patients.Baseline characteristics and inflammatory model comparisons between imaging progression and progression-free patients ::: RESULTSIn total, 71 COVID-19 patients suffered from imaging progression on chest CT at first week after admission, and the other 202 patients were imaging progression-free on chest CT.", [["chest", "ANATOMY", 432, 437], ["patients", "ORGANISM", 126, 134], ["patients", "ORGANISM", 244, 252], ["patients", "ORGANISM", 286, 294], ["chest", "ORGAN", 332, 337], ["patients", "ORGANISM", 390, 398], ["chest", "ORGANISM_SUBDIVISION", 432, 437], ["patients", "SPECIES", 126, 134], ["patients", "SPECIES", 244, 252], ["patients", "SPECIES", 286, 294], ["patients", "SPECIES", 390, 398], ["consolidation", "PROBLEM", 27, 40], ["linear opacities", "PROBLEM", 45, 61], ["imaging progression", "TEST", 101, 120], ["inflammatory model comparisons", "TEST", 164, 194], ["imaging progression", "TEST", 203, 222], ["COVID", "TEST", 277, 282], ["imaging progression", "TEST", 309, 328], ["chest CT", "TEST", 332, 340], ["imaging progression", "TEST", 404, 423], ["chest CT", "TEST", 432, 440], ["consolidation", "OBSERVATION", 27, 40], ["linear", "OBSERVATION_MODIFIER", 45, 51], ["opacities", "OBSERVATION", 52, 61], ["resolved", "OBSERVATION_MODIFIER", 74, 82], ["decreased", "OBSERVATION_MODIFIER", 87, 96], ["inflammatory", "OBSERVATION_MODIFIER", 164, 176], ["chest", "ANATOMY", 332, 337], ["chest", "ANATOMY", 432, 437]]], ["As summarized in Table 1, the patients in imaging progression group were significantly older than those in imaging progression-free group (p = 0.006, Table 1).", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["imaging progression", "TEST", 107, 126]]], ["More patients were treated with gamma globulin and thymosin in imaging progression group compared to those without imaging progression (p = 0.022 and p = 0.001, respectively, Table 1).", [["gamma globulin", "CHEMICAL", 32, 46], ["patients", "ORGANISM", 5, 13], ["gamma globulin", "GENE_OR_GENE_PRODUCT", 32, 46], ["thymosin", "GENE_OR_GENE_PRODUCT", 51, 59], ["gamma globulin", "PROTEIN", 32, 46], ["thymosin", "PROTEIN", 51, 59], ["patients", "SPECIES", 5, 13], ["gamma globulin", "TREATMENT", 32, 46], ["thymosin", "TREATMENT", 51, 59], ["imaging progression", "TEST", 115, 134], ["p", "TEST", 136, 137]]], ["In blood routine tests, the white blood cells (WBC), platelets and neutrophils were significantly lower in imaging progression patients than those in imaging progression-free ones (p = 0.025, p = 0.044 and p = 0.014, respectively, Table 1), while the monocytes were significantly higher in imaging progression patients (p = 0.025, Table 1).", [["blood", "ANATOMY", 3, 8], ["white blood cells", "ANATOMY", 28, 45], ["WBC", "ANATOMY", 47, 50], ["platelets", "ANATOMY", 53, 62], ["neutrophils", "ANATOMY", 67, 78], ["monocytes", "ANATOMY", 251, 260], ["blood", "ORGANISM_SUBSTANCE", 3, 8], ["white blood cells", "CELL", 28, 45], ["WBC", "CELL", 47, 50], ["platelets", "CELL", 53, 62], ["neutrophils", "CELL", 67, 78], ["patients", "ORGANISM", 127, 135], ["monocytes", "CELL", 251, 260], ["patients", "ORGANISM", 310, 318], ["white blood cells", "CELL_TYPE", 28, 45], ["WBC", "CELL_TYPE", 47, 50], ["platelets", "CELL_TYPE", 53, 62], ["neutrophils", "CELL_TYPE", 67, 78], ["monocytes", "CELL_TYPE", 251, 260], ["patients", "SPECIES", 127, 135], ["patients", "SPECIES", 310, 318], ["blood routine tests", "TEST", 3, 22], ["the white blood cells", "TEST", 24, 45], ["WBC", "TEST", 47, 50], ["platelets", "TEST", 53, 62], ["neutrophils", "TEST", 67, 78], ["imaging progression", "TEST", 107, 126], ["imaging progression", "TEST", 150, 169], ["p", "TEST", 181, 182], ["p", "TEST", 192, 193], ["p", "TEST", 206, 207], ["the monocytes", "TEST", 247, 260], ["p", "TEST", 320, 321], ["monocytes", "ANATOMY", 251, 260]]], ["Additionally, acid glycoprotein was significantly lower in imaging progression patients (p = 0.037, Table 1).", [["patients", "ORGANISM", 79, 87], ["acid glycoprotein", "PROTEIN", 14, 31], ["patients", "SPECIES", 79, 87], ["acid glycoprotein", "TREATMENT", 14, 31]]], ["In liver function tests, gamma-glutamyl transferase (GGT) levels were significantly higher in imaging progression-free patients (p = 0.045, Table 1), while homocysteine levels were significantly higher in imaging progression patients (p = 0.006, Table1).", [["liver", "ANATOMY", 3, 8], ["homocysteine", "CHEMICAL", 156, 168], ["gamma-glutamyl", "CHEMICAL", 25, 39], ["homocysteine", "CHEMICAL", 156, 168], ["liver", "ORGAN", 3, 8], ["gamma-glutamyl transferase", "GENE_OR_GENE_PRODUCT", 25, 51], ["GGT", "GENE_OR_GENE_PRODUCT", 53, 56], ["patients", "ORGANISM", 119, 127], ["homocysteine", "SIMPLE_CHEMICAL", 156, 168], ["patients", "ORGANISM", 225, 233], ["gamma-glutamyl transferase", "PROTEIN", 25, 51], ["GGT", "PROTEIN", 53, 56], ["patients", "SPECIES", 119, 127], ["patients", "SPECIES", 225, 233], ["liver function tests", "TEST", 3, 23], ["gamma-glutamyl transferase (GGT) levels", "TEST", 25, 64], ["imaging progression", "TEST", 94, 113], ["homocysteine levels", "TEST", 156, 175], ["liver", "ANATOMY", 3, 8]]], ["In kidney function tests, urea, creatinine and serum cystatin C levels were significantly higher in imaging progression patients compared to those in imaging progression-free ones (p = 0.011, p = 0.007, respectively, Table 1).", [["kidney", "ANATOMY", 3, 9], ["serum", "ANATOMY", 47, 52], ["urea", "CHEMICAL", 26, 30], ["creatinine", "CHEMICAL", 32, 42], ["urea", "CHEMICAL", 26, 30], ["creatinine", "CHEMICAL", 32, 42], ["kidney", "ORGAN", 3, 9], ["urea", "SIMPLE_CHEMICAL", 26, 30], ["creatinine", "SIMPLE_CHEMICAL", 32, 42], ["serum", "ORGANISM_SUBSTANCE", 47, 52], ["cystatin C", "GENE_OR_GENE_PRODUCT", 53, 63], ["patients", "ORGANISM", 120, 128], ["serum cystatin C", "PROTEIN", 47, 63], ["patients", "SPECIES", 120, 128], ["kidney function tests", "TEST", 3, 24], ["urea", "TEST", 26, 30], ["creatinine", "TEST", 32, 42], ["serum cystatin C levels", "TEST", 47, 70], ["imaging progression", "TEST", 100, 119], ["imaging progression", "TEST", 150, 169], ["p", "TEST", 192, 193], ["kidney", "ANATOMY", 3, 9]]], ["As we expected, the estimated glomerular filtration rate (eGFR) levels were significantly decreased in imaging progression patients (p < 0.001, Table 1).", [["glomerular", "ANATOMY", 30, 40], ["glomerular", "TISSUE", 30, 40], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["the estimated glomerular filtration rate", "TEST", 16, 56], ["eGFR) levels", "TEST", 58, 70], ["imaging progression", "TEST", 103, 122], ["decreased", "OBSERVATION_MODIFIER", 90, 99]]], ["No differences were found in cardiac markers and coagulation function tests.Baseline characteristics and inflammatory model comparisons between imaging progression and progression-free patients ::: RESULTSSix inflammatory models were compared between imaging progression and progression-free patients.", [["cardiac", "ANATOMY", 29, 36], ["cardiac", "ORGAN", 29, 36], ["patients", "ORGANISM", 185, 193], ["patients", "ORGANISM", 292, 300], ["patients", "SPECIES", 185, 193], ["patients", "SPECIES", 292, 300], ["cardiac markers", "TEST", 29, 44], ["coagulation function tests", "TEST", 49, 75], ["inflammatory model comparisons", "TEST", 105, 135], ["imaging progression", "TEST", 144, 163], ["RESULTSSix inflammatory models", "TEST", 198, 228], ["imaging progression", "TEST", 251, 270], ["cardiac", "ANATOMY", 29, 36], ["inflammatory", "OBSERVATION_MODIFIER", 105, 117], ["progression", "OBSERVATION_MODIFIER", 275, 286]]], ["As shown in Figure 2, monocyte-lymphocyte ratio (MLR) levels were significantly higher in imaging progression patients than those in imaging progression-free ones (p < 0.001, Figure 2C), while no differences were found among aspartate aminotransferase-lymphocyte ratio index (ALRI), aspartate aminotransferase-platelet ratio index (APRI), neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and systemic immune-inflammation index (SII) between these two groups (Figure 2A, 2B, 2D\u20132F).Co-manifestations on chest CT and outcomes ::: RESULTSAs summarized in Table 2, except for common manifestations on chest CT, chronic inflammatory manifestation, chronic bronchitis / emphysema, pericardial effusion, pleural effusion, bullae of lung and obsolete tuberculosis were the most frequent imaging co-manifestations in COVID-19 patients.", [["neutrophil-lymphocyte", "ANATOMY", 339, 360], ["platelet-lymphocyte", "ANATOMY", 374, 393], ["chest", "ANATOMY", 520, 525], ["chest", "ANATOMY", 615, 620], ["pericardial", "ANATOMY", 693, 704], ["pleural", "ANATOMY", 715, 722], ["bullae", "ANATOMY", 733, 739], ["lung", "ANATOMY", 743, 747], ["aspartate", "CHEMICAL", 225, 234], ["aspartate", "CHEMICAL", 283, 292], ["bronchitis", "DISEASE", 669, 679], ["emphysema", "DISEASE", 682, 691], ["pericardial effusion", "DISEASE", 693, 713], ["pleural effusion", "DISEASE", 715, 731], ["tuberculosis", "DISEASE", 761, 773], ["aspartate", "CHEMICAL", 225, 234], ["aspartate", "CHEMICAL", 283, 292], ["monocyte", "CELL", 22, 30], ["lymphocyte", "CELL", 31, 41], ["patients", "ORGANISM", 110, 118], ["aspartate aminotransferase-lymphocyte", "GENE_OR_GENE_PRODUCT", 225, 262], ["aspartate aminotransferase-platelet", "GENE_OR_GENE_PRODUCT", 283, 318], ["neutrophil", "CELL", 339, 349], ["platelet", "CELL", 374, 382], ["chest", "ORGAN", 520, 525], ["pericardial", "PATHOLOGICAL_FORMATION", 693, 704], ["pleural effusion", "PATHOLOGICAL_FORMATION", 715, 731], ["bullae", "PATHOLOGICAL_FORMATION", 733, 739], ["lung", "ORGAN", 743, 747], ["patients", "ORGANISM", 835, 843], ["aspartate aminotransferase", "PROTEIN", 225, 251], ["aspartate aminotransferase", "PROTEIN", 283, 309], ["NLR", "PROTEIN", 368, 371], ["patients", "SPECIES", 110, 118], ["patients", "SPECIES", 835, 843], ["Figure", "TEST", 12, 18], ["monocyte-lymphocyte ratio", "TEST", 22, 47], ["MLR) levels", "TEST", 49, 60], ["imaging progression", "TEST", 133, 152], ["aspartate aminotransferase", "TEST", 225, 251], ["lymphocyte ratio index", "TEST", 252, 274], ["ALRI", "TEST", 276, 280], ["aspartate aminotransferase", "TEST", 283, 309], ["platelet ratio index", "TEST", 310, 330], ["APRI", "TEST", 332, 336], ["neutrophil", "TEST", 339, 349], ["lymphocyte ratio", "TEST", 350, 366], ["NLR", "TEST", 368, 371], ["platelet", "TEST", 374, 382], ["lymphocyte ratio", "TEST", 383, 399], ["PLR", "TEST", 401, 404], ["systemic immune", "TEST", 410, 425], ["inflammation index", "PROBLEM", 426, 444], ["chest CT", "TEST", 520, 528], ["common manifestations", "PROBLEM", 590, 611], ["chest CT", "TEST", 615, 623], ["chronic inflammatory manifestation", "PROBLEM", 625, 659], ["chronic bronchitis", "PROBLEM", 661, 679], ["emphysema", "PROBLEM", 682, 691], ["pericardial effusion", "PROBLEM", 693, 713], ["pleural effusion", "PROBLEM", 715, 731], ["bullae of lung", "PROBLEM", 733, 747], ["obsolete tuberculosis", "PROBLEM", 752, 773], ["chest", "ANATOMY", 520, 525], ["chest", "ANATOMY", 615, 620], ["chronic", "OBSERVATION_MODIFIER", 625, 632], ["inflammatory", "OBSERVATION", 633, 645], ["chronic", "OBSERVATION_MODIFIER", 661, 668], ["bronchitis", "OBSERVATION", 669, 679], ["emphysema", "OBSERVATION", 682, 691], ["pericardial", "ANATOMY", 693, 704], ["effusion", "OBSERVATION", 705, 713], ["pleural", "ANATOMY", 715, 722], ["effusion", "OBSERVATION", 723, 731], ["bullae", "OBSERVATION", 733, 739], ["lung", "ANATOMY", 743, 747], ["obsolete", "OBSERVATION_MODIFIER", 752, 760], ["tuberculosis", "OBSERVATION", 761, 773]]], ["COVID-19 patients with imaging progression had significantly higher frequency of chronic inflammatory manifestation than those without imaging progression (12.7% vs. 3.5%, p = 0.005, Table 2).", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["COVID", "TEST", 0, 5], ["imaging progression", "TEST", 23, 42], ["chronic inflammatory manifestation", "PROBLEM", 81, 115], ["imaging progression", "TEST", 135, 154], ["p", "TEST", 172, 173], ["chronic", "OBSERVATION_MODIFIER", 81, 88], ["inflammatory", "OBSERVATION", 89, 101]]], ["No differences were found in distributions of chronic bronchitis / emphysema, pericardial effusion, pleural effusion, bullae of lung and obsolete tuberculosis between these two groups (Table 2).Co-manifestations on chest CT and outcomes ::: RESULTSMoreover, no acute bacterial or other viral co-infection performances on chest CT were found in these COVID-19 patients.Co-manifestations on chest CT and outcomes ::: RESULTSAll these COVID-19 patients did not develop severe conditions, no one died during our follow up.Parameters associated with imaging progression on chest CT ::: RESULTSVariables including age, gender, disease history, epidemiology, chest CT imaging, therapeutic strategies, period from onset to admission, ALRI, APRI, MLR, NLR, PLR, SII, WBC, neutrophils, lymphocytes, monocytes, platelet, red blood cells (RBC), hemoglobin, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), procalcitonin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), GGT, lactate dehydrogenase (LDH), total bilirubin (TBiL), albumin, globulin, urea, creatinine, eGFR, lactic acid, haptoglobin, acid glycoprotein, cystatin C, homocysteine, retinol-binding protein, cardiac troponin (cTnI), myoglobin, brain natriuretic peptide prohormone (pro-BNP), prothrombin time, prothrombin activity (PTA), international normalized ratio (INR), D-dimer were included in the univariate analysis.", [["pericardial", "ANATOMY", 78, 89], ["pleural", "ANATOMY", 100, 107], ["bullae", "ANATOMY", 118, 124], ["lung", "ANATOMY", 128, 132], ["chest", "ANATOMY", 215, 220], ["chest", "ANATOMY", 321, 326], ["chest", "ANATOMY", 389, 394], ["chest", "ANATOMY", 568, 573], ["WBC", "ANATOMY", 758, 761], ["neutrophils", "ANATOMY", 763, 774], ["lymphocytes", "ANATOMY", 776, 787], ["monocytes", "ANATOMY", 789, 798], ["platelet", "ANATOMY", 800, 808], ["red blood cells", "ANATOMY", 810, 825], ["RBC", "ANATOMY", 827, 830], ["bronchitis", "DISEASE", 54, 64], ["emphysema", "DISEASE", 67, 76], ["pericardial effusion", "DISEASE", 78, 98], ["pleural effusion", "DISEASE", 100, 116], ["tuberculosis", "DISEASE", 146, 158], ["ALRI", "DISEASE", 726, 730], ["alanine", "CHEMICAL", 924, 931], ["aspartate", "CHEMICAL", 956, 965], ["lactate", "CHEMICAL", 995, 1002], ["bilirubin", "CHEMICAL", 1030, 1039], ["urea", "CHEMICAL", 1067, 1071], ["creatinine", "CHEMICAL", 1073, 1083], ["lactic acid", "CHEMICAL", 1091, 1102], ["homocysteine", "CHEMICAL", 1148, 1160], ["retinol", "CHEMICAL", 1162, 1169], ["alanine", "CHEMICAL", 924, 931], ["aspartate", "CHEMICAL", 956, 965], ["lactate", "CHEMICAL", 995, 1002], ["bilirubin", "CHEMICAL", 1030, 1039], ["urea", "CHEMICAL", 1067, 1071], ["creatinine", "CHEMICAL", 1073, 1083], ["lactic acid", "CHEMICAL", 1091, 1102], ["homocysteine", "CHEMICAL", 1148, 1160], ["retinol", "CHEMICAL", 1162, 1169], ["pericardial effusion", "PATHOLOGICAL_FORMATION", 78, 98], ["pleural effusion", "PATHOLOGICAL_FORMATION", 100, 116], ["bullae", "PATHOLOGICAL_FORMATION", 118, 124], ["lung", "ORGAN", 128, 132], ["chest", "ORGAN", 215, 220], ["chest", "ORGANISM_SUBDIVISION", 321, 326], ["patients", "ORGANISM", 359, 367], ["chest", "ORGAN", 389, 394], ["patients", "ORGANISM", 441, 449], ["neutrophils", "CELL", 763, 774], ["lymphocytes", "CELL", 776, 787], ["monocytes", "CELL", 789, 798], ["platelet", "CELL", 800, 808], ["red blood cells", "CELL", 810, 825], ["RBC", "CELL", 827, 830], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 833, 843], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 845, 863], ["CRP", "GENE_OR_GENE_PRODUCT", 865, 868], ["erythrocyte", "CELL", 871, 882], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 909, 922], ["alanine aminotransferase", "GENE_OR_GENE_PRODUCT", 924, 948], ["ALT", "SIMPLE_CHEMICAL", 950, 953], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 956, 982], ["AST", "SIMPLE_CHEMICAL", 984, 987], ["GGT", "SIMPLE_CHEMICAL", 990, 993], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 995, 1016], ["LDH", "SIMPLE_CHEMICAL", 1018, 1021], ["bilirubin", "SIMPLE_CHEMICAL", 1030, 1039], ["TBiL", "SIMPLE_CHEMICAL", 1041, 1045], ["albumin", "GENE_OR_GENE_PRODUCT", 1048, 1055], ["globulin", "GENE_OR_GENE_PRODUCT", 1057, 1065], ["urea", "SIMPLE_CHEMICAL", 1067, 1071], ["creatinine", "SIMPLE_CHEMICAL", 1073, 1083], ["eGFR", "SIMPLE_CHEMICAL", 1085, 1089], ["lactic acid", "SIMPLE_CHEMICAL", 1091, 1102], ["haptoglobin", "GENE_OR_GENE_PRODUCT", 1104, 1115], ["cystatin C", "GENE_OR_GENE_PRODUCT", 1136, 1146], ["homocysteine", "SIMPLE_CHEMICAL", 1148, 1160], ["retinol-binding protein", "GENE_OR_GENE_PRODUCT", 1162, 1185], ["cardiac troponin", "GENE_OR_GENE_PRODUCT", 1187, 1203], ["cTnI", "GENE_OR_GENE_PRODUCT", 1205, 1209], ["myoglobin", "GENE_OR_GENE_PRODUCT", 1212, 1221], ["brain natriuretic peptide prohormone", "GENE_OR_GENE_PRODUCT", 1223, 1259], ["pro-BNP", "GENE_OR_GENE_PRODUCT", 1261, 1268], ["prothrombin", "GENE_OR_GENE_PRODUCT", 1271, 1282], ["prothrombin", "GENE_OR_GENE_PRODUCT", 1289, 1300], ["D-dimer", "GENE_OR_GENE_PRODUCT", 1355, 1362], ["APRI", "PROTEIN", 732, 736], ["NLR", "PROTEIN", 743, 746], ["PLR", "PROTEIN", 748, 751], ["SII", "PROTEIN", 753, 756], ["WBC", "PROTEIN", 758, 761], ["neutrophils", "CELL_TYPE", 763, 774], ["lymphocytes", "CELL_TYPE", 776, 787], ["monocytes", "CELL_TYPE", 789, 798], ["platelet", "CELL_TYPE", 800, 808], ["red blood cells", "CELL_TYPE", 810, 825], ["RBC", "CELL_TYPE", 827, 830], ["hemoglobin", "PROTEIN", 833, 843], ["C-reactive protein", "PROTEIN", 845, 863], ["CRP", "PROTEIN", 865, 868], ["procalcitonin", "PROTEIN", 909, 922], ["alanine aminotransferase", "PROTEIN", 924, 948], ["ALT", "PROTEIN", 950, 953], ["aspartate aminotransferase", "PROTEIN", 956, 982], ["AST", "PROTEIN", 984, 987], ["GGT", "PROTEIN", 990, 993], ["lactate dehydrogenase", "PROTEIN", 995, 1016], ["LDH", "PROTEIN", 1018, 1021], ["total bilirubin", "PROTEIN", 1024, 1039], ["TBiL", "PROTEIN", 1041, 1045], ["albumin", "PROTEIN", 1048, 1055], ["globulin", "PROTEIN", 1057, 1065], ["eGFR", "PROTEIN", 1085, 1089], ["haptoglobin", "PROTEIN", 1104, 1115], ["acid glycoprotein", "PROTEIN", 1117, 1134], ["cystatin C", "PROTEIN", 1136, 1146], ["retinol-binding protein", "PROTEIN", 1162, 1185], ["cardiac troponin", "PROTEIN", 1187, 1203], ["cTnI", "PROTEIN", 1205, 1209], ["myoglobin", "PROTEIN", 1212, 1221], ["brain natriuretic peptide prohormone", "PROTEIN", 1223, 1259], ["prothrombin", "PROTEIN", 1289, 1300], ["INR", "PROTEIN", 1349, 1352], ["patients", "SPECIES", 359, 367], ["patients", "SPECIES", 441, 449], ["chronic bronchitis", "PROBLEM", 46, 64], ["emphysema", "PROBLEM", 67, 76], ["pericardial effusion", "PROBLEM", 78, 98], ["pleural effusion", "PROBLEM", 100, 116], ["bullae of lung", "PROBLEM", 118, 132], ["obsolete tuberculosis", "PROBLEM", 137, 158], ["chest CT", "TEST", 215, 223], ["acute bacterial or other viral co-infection performances", "PROBLEM", 261, 317], ["chest CT", "TEST", 321, 329], ["these COVID", "TEST", 344, 355], ["chest CT", "TEST", 389, 397], ["severe conditions", "PROBLEM", 466, 483], ["imaging progression", "TEST", 545, 564], ["chest CT", "TEST", 568, 576], ["chest CT imaging", "TEST", 652, 668], ["ALRI", "TEST", 726, 730], ["APRI", "TEST", 732, 736], ["MLR", "TEST", 738, 741], ["NLR", "TEST", 743, 746], ["PLR", "TEST", 748, 751], ["SII", "TEST", 753, 756], ["WBC", "TEST", 758, 761], ["neutrophils", "TEST", 763, 774], ["lymphocytes", "TEST", 776, 787], ["monocytes", "TEST", 789, 798], ["platelet", "TEST", 800, 808], ["red blood cells", "TEST", 810, 825], ["RBC", "TEST", 827, 830], ["hemoglobin", "TEST", 833, 843], ["C-reactive protein", "TEST", 845, 863], ["CRP", "TEST", 865, 868], ["erythrocyte sedimentation rate", "TEST", 871, 901], ["ESR", "TEST", 903, 906], ["procalcitonin", "TEST", 909, 922], ["alanine aminotransferase", "TEST", 924, 948], ["ALT", "TEST", 950, 953], ["aspartate aminotransferase", "TEST", 956, 982], ["AST", "TEST", 984, 987], ["GGT", "TEST", 990, 993], ["lactate dehydrogenase", "TEST", 995, 1016], ["LDH", "TEST", 1018, 1021], ["total bilirubin", "TEST", 1024, 1039], ["TBiL", "TEST", 1041, 1045], ["albumin", "TEST", 1048, 1055], ["globulin", "TEST", 1057, 1065], ["urea", "TEST", 1067, 1071], ["creatinine", "TEST", 1073, 1083], ["eGFR", "TEST", 1085, 1089], ["lactic acid", "TEST", 1091, 1102], ["haptoglobin", "TEST", 1104, 1115], ["acid glycoprotein", "TEST", 1117, 1134], ["cystatin C", "TEST", 1136, 1146], ["homocysteine", "TEST", 1148, 1160], ["retinol-binding protein", "TEST", 1162, 1185], ["cardiac troponin", "TEST", 1187, 1203], ["cTnI", "TEST", 1205, 1209], ["myoglobin", "TEST", 1212, 1221], ["brain natriuretic peptide prohormone", "TEST", 1223, 1259], ["BNP", "TEST", 1265, 1268], ["prothrombin time", "TEST", 1271, 1287], ["prothrombin activity", "TEST", 1289, 1309], ["PTA", "TEST", 1311, 1314], ["international normalized ratio", "TEST", 1317, 1347], ["INR", "TEST", 1349, 1352], ["D-dimer", "TEST", 1355, 1362], ["the univariate analysis", "TEST", 1380, 1403], ["chronic", "OBSERVATION_MODIFIER", 46, 53], ["bronchitis", "OBSERVATION", 54, 64], ["emphysema", "OBSERVATION", 67, 76], ["pericardial", "ANATOMY", 78, 89], ["effusion", "OBSERVATION", 90, 98], ["pleural", "ANATOMY", 100, 107], ["effusion", "OBSERVATION", 108, 116], ["bullae", "OBSERVATION", 118, 124], ["lung", "ANATOMY", 128, 132], ["obsolete", "OBSERVATION_MODIFIER", 137, 145], ["tuberculosis", "OBSERVATION", 146, 158], ["chest", "ANATOMY", 215, 220], ["no", "UNCERTAINTY", 258, 260], ["acute", "OBSERVATION_MODIFIER", 261, 266], ["bacterial", "OBSERVATION_MODIFIER", 267, 276], ["viral", "OBSERVATION_MODIFIER", 286, 291], ["co-infection", "OBSERVATION", 292, 304], ["chest", "ANATOMY", 321, 326], ["chest", "ANATOMY", 389, 394], ["severe", "OBSERVATION_MODIFIER", 466, 472], ["conditions", "OBSERVATION", 473, 483], ["chest", "ANATOMY", 568, 573], ["chest", "ANATOMY", 652, 657], ["neutrophils", "ANATOMY", 763, 774], ["lymphocytes", "ANATOMY", 776, 787], ["cardiac", "ANATOMY", 1187, 1194]]], ["As presented in Table 3, age, gamma globulin therapy, thymosin therapy, MLR, serum cystatin C, homocysteine, eGFR and period from onset to admission were potential parameters associated with imaging progression (all p < 0.05, Table 3).", [["serum", "ANATOMY", 77, 82], ["gamma globulin", "CHEMICAL", 30, 44], ["homocysteine", "CHEMICAL", 95, 107], ["homocysteine", "CHEMICAL", 95, 107], ["gamma globulin", "GENE_OR_GENE_PRODUCT", 30, 44], ["thymosin", "GENE_OR_GENE_PRODUCT", 54, 62], ["serum", "ORGANISM_SUBSTANCE", 77, 82], ["cystatin C", "GENE_OR_GENE_PRODUCT", 83, 93], ["homocysteine", "SIMPLE_CHEMICAL", 95, 107], ["gamma globulin", "PROTEIN", 30, 44], ["thymosin", "PROTEIN", 54, 62], ["MLR", "PROTEIN", 72, 75], ["serum cystatin C", "PROTEIN", 77, 93], ["gamma globulin therapy", "TREATMENT", 30, 52], ["thymosin therapy", "TREATMENT", 54, 70], ["MLR", "TREATMENT", 72, 75], ["serum cystatin C", "TEST", 77, 93], ["homocysteine", "TEST", 95, 107], ["eGFR", "TEST", 109, 113], ["imaging progression", "TEST", 191, 210]]], ["When these parameters were included in the multivariate model, age, MLR and homocysteine were significantly correlated with imaging progression on chest CT from COVID-19 patients (RR = 2.28, 95%CI = 1.12 \u2013 4.34, p = 0.012; RR = 7.69, 95%CI = 1.67 \u2013 35.55, p = 0.009 and RR = 3.17, 95%CI = 1.01 \u2013 9.96, p = 0.048; respectively, Table 3).", [["chest", "ANATOMY", 147, 152], ["homocysteine", "CHEMICAL", 76, 88], ["homocysteine", "CHEMICAL", 76, 88], ["homocysteine", "SIMPLE_CHEMICAL", 76, 88], ["chest", "ORGAN", 147, 152], ["patients", "ORGANISM", 170, 178], ["patients", "SPECIES", 170, 178], ["these parameters", "TEST", 5, 21], ["homocysteine", "TEST", 76, 88], ["imaging progression", "TEST", 124, 143], ["chest CT", "TEST", 147, 155], ["COVID", "TEST", 161, 166], ["RR", "TEST", 180, 182], ["CI", "TEST", 194, 196], ["p", "TEST", 212, 213], ["RR", "TEST", 223, 225], ["CI", "TEST", 237, 239], ["p", "TEST", 256, 257], ["RR", "TEST", 270, 272], ["CI", "TEST", 284, 286], ["p", "TEST", 302, 303], ["chest", "ANATOMY", 147, 152]]], ["In addition, COVID-19 patients with period from onset to admission \u2265 4 days might have lower risk to develop imaging progression on chest CT at first week after admission (RR = 0.35, 95%CI = 0.19 \u2013 0.67, p = 0.001, Table 3).Predictive values of MLR and age for imaging progression on chest CT ::: RESULTSUsing OptimalCutpoints package in R program, we detected that the optimal cutoff of MLR was 0.51.", [["chest", "ANATOMY", 132, 137], ["chest", "ANATOMY", 284, 289], ["patients", "ORGANISM", 22, 30], ["chest", "ORGAN", 132, 137], ["patients", "SPECIES", 22, 30], ["imaging progression", "TEST", 109, 128], ["chest CT", "TEST", 132, 140], ["RR", "TEST", 172, 174], ["CI", "TEST", 186, 188], ["p", "TEST", 204, 205], ["Predictive values", "TEST", 224, 241], ["imaging progression", "TEST", 261, 280], ["chest CT", "TEST", 284, 292], ["the optimal cutoff of MLR", "TEST", 366, 391], ["chest", "ANATOMY", 132, 137], ["chest", "ANATOMY", 284, 289]]], ["The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of MLR for predicting imaging progression on chest CT were 0.44, 0.79, 0.42 and 0.80, respectively (Figure 3A and Table 4).", [["chest", "ANATOMY", 143, 148], ["chest", "ORGAN", 143, 148], ["The sensitivity", "TEST", 0, 15], ["PPV", "TEST", 57, 60], ["predicting imaging progression", "TEST", 109, 139], ["chest CT", "TEST", 143, 151], ["chest", "ANATOMY", 143, 148]]], ["And, the AUC of MLR for predicting imaging progression on chest CT was 0.63 (Figure 3A).Predictive values of MLR and age for imaging progression on chest CT ::: RESULTSThe optimal cutoff of age for predicting imaging progression on chest CT was 51 years.", [["chest", "ANATOMY", 58, 63], ["chest", "ANATOMY", 148, 153], ["chest", "ANATOMY", 232, 237], ["chest", "ORGAN", 58, 63], ["chest", "ORGAN", 232, 237], ["MLR", "PROTEIN", 16, 19], ["predicting imaging progression", "TEST", 24, 54], ["chest CT", "TEST", 58, 66], ["Predictive values", "TEST", 88, 105], ["imaging progression", "TEST", 125, 144], ["chest CT", "TEST", 148, 156], ["predicting imaging progression", "PROBLEM", 198, 228], ["chest CT", "TEST", 232, 240], ["chest", "ANATOMY", 58, 63], ["chest", "ANATOMY", 148, 153], ["chest", "ANATOMY", 232, 237]]], ["The sensitivity, specificity, PPV and NPV were 0.65, 0.58, 0.35 and 0.83 respectively (Figure 3B and Table 4).", [["The sensitivity", "TEST", 0, 15], ["specificity", "TEST", 17, 28], ["PPV", "TEST", 30, 33], ["NPV", "TEST", 38, 41]]], ["ROC curve revealed that the AUC of age in the prediction model was 0.6 (Figure 3B).Predictive values of MLR and age for imaging progression on chest CT ::: RESULTSIn addition, the optimal cutoff of homocysteine for predicting imaging progression on chest CT from COVID-19 patients was 10.58 \u03bcmol/L. The sensitivity, specificity, PPV and NPV were 0.42, 0.79, 0.41 and 0.80, respectively (Figure 3C and Table 4).Predictive values of MLR and age for imaging progression on chest CT ::: RESULTSWe performed ROC comparison in MLR, age and homocysteine using ROC regression.", [["chest", "ANATOMY", 143, 148], ["chest", "ANATOMY", 249, 254], ["chest", "ANATOMY", 470, 475], ["homocysteine", "CHEMICAL", 198, 210], ["homocysteine", "CHEMICAL", 534, 546], ["homocysteine", "CHEMICAL", 198, 210], ["homocysteine", "CHEMICAL", 534, 546], ["homocysteine", "SIMPLE_CHEMICAL", 198, 210], ["chest", "ORGAN", 249, 254], ["patients", "ORGANISM", 272, 280], ["homocysteine", "SIMPLE_CHEMICAL", 534, 546], ["patients", "SPECIES", 272, 280], ["ROC curve", "TEST", 0, 9], ["the AUC", "TEST", 24, 31], ["the prediction model", "TEST", 42, 62], ["Predictive values", "TEST", 83, 100], ["imaging progression", "TEST", 120, 139], ["chest CT", "TEST", 143, 151], ["homocysteine", "TREATMENT", 198, 210], ["predicting imaging progression", "TEST", 215, 245], ["chest CT", "TEST", 249, 257], ["COVID", "TEST", 263, 268], ["The sensitivity", "TEST", 299, 314], ["specificity", "TEST", 316, 327], ["PPV", "TEST", 329, 332], ["NPV", "TEST", 337, 340], ["Predictive values", "TEST", 410, 427], ["imaging progression", "TEST", 447, 466], ["chest CT", "TEST", 470, 478], ["MLR", "TEST", 521, 524], ["homocysteine", "TEST", 534, 546], ["ROC regression", "TEST", 553, 567], ["chest", "ANATOMY", 143, 148], ["chest", "ANATOMY", 249, 254], ["chest", "ANATOMY", 470, 475]]], ["As showed in Figure 3D, no difference among these three indexes was found (p = 0.834, Figure 3D).DISCUSSIONAccording to the Chinese guidelines, imaging progression-free on chest CT scans was one of discharge criteria for COVID-19 patients.", [["chest", "ORGAN", 172, 177], ["patients", "ORGANISM", 230, 238], ["patients", "SPECIES", 230, 238], ["imaging progression", "TEST", 144, 163], ["chest CT scans", "TEST", 172, 186], ["COVID", "TEST", 221, 226], ["chest", "ANATOMY", 172, 177]]], ["At present stage, the long-term imaging features of COVID-19 are not yet known [13, 15].", [["COVID-19", "CHEMICAL", 52, 60], ["COVID-19", "GENE_OR_GENE_PRODUCT", 52, 60], ["COVID", "TEST", 52, 57]]], ["Follow-up imaging in COVID-19 patients often demonstrated the disease progression.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["Follow-up imaging", "TEST", 0, 17], ["the disease progression", "PROBLEM", 58, 81], ["disease", "OBSERVATION", 62, 69]]], ["Generally, imaging manifestations are in line with the severity of COVID-19 [16].", [["COVID-19", "CHEMICAL", 67, 75], ["imaging manifestations", "TEST", 11, 33], ["COVID", "TEST", 67, 72]]], ["Hence, a short-term follow up with identification of imaging progression is of great importance for early warning of disease aggravation from COVID-19 patients, which could help clinicians to manage quickly and accurately [12].", [["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 151, 159], ["imaging progression", "TEST", 53, 72], ["disease aggravation", "PROBLEM", 117, 136]]], ["Considered that, we defined the imaging progression at first week on chest CT as the primary outcome.DISCUSSIONIn this outbreak, age was considered as one critical content during the disease occurrence and development.", [["chest", "ANATOMY", 69, 74], ["chest", "ORGAN", 69, 74], ["the imaging progression", "TEST", 28, 51], ["chest CT", "TEST", 69, 77], ["the disease occurrence", "PROBLEM", 179, 201], ["chest", "ANATOMY", 69, 74]]], ["Our results also revealed that the average age of patients with imaging progression was older than those without.", [["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["imaging progression", "TEST", 64, 83]]], ["Logistic model confirmed that age should be a risk factor for predicting imaging progression.", [["a risk factor", "PROBLEM", 44, 57]]], ["Previous reports suggested that COVID-19 is more susceptible to infect older adults [3, 8, 10].", [["COVID-19", "GENE_OR_GENE_PRODUCT", 32, 40], ["COVID-19", "DNA", 32, 40], ["COVID", "TEST", 32, 37]]], ["Research with small samples of 2019-nCoV infected infants have been reported [17].", [["2019-nCoV", "ORGANISM", 31, 40], ["infants", "ORGANISM", 50, 57], ["infants", "SPECIES", 50, 57], ["small samples", "TEST", 14, 27], ["small", "OBSERVATION_MODIFIER", 14, 19]]], ["In a study included 34 COVID-19 children, the authors concluded that the clinical manifestations in children with 2019-nCoV infection are non-specific and are milder than that in adults [18].", [["infection", "DISEASE", 124, 133], ["children", "ORGANISM", 32, 40], ["children", "ORGANISM", 100, 108], ["2019-nCoV", "ORGANISM", 114, 123], ["children", "SPECIES", 32, 40], ["children", "SPECIES", 100, 108], ["a study", "TEST", 3, 10], ["nCoV infection", "PROBLEM", 119, 133], ["infection", "OBSERVATION", 124, 133], ["non-specific", "OBSERVATION_MODIFIER", 138, 150]]], ["In a nationwide retrospective study, 2143 pediatric patients were included.", [["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["a nationwide retrospective study", "TEST", 3, 35]]], ["They found that more than 90% patients were asymptomatic, mild, or moderate, even though young children, particularly infants, were vulnerable to infection [19].", [["infection", "DISEASE", 146, 155], ["patients", "ORGANISM", 30, 38], ["children", "ORGANISM", 95, 103], ["infants", "ORGANISM", 118, 125], ["patients", "SPECIES", 30, 38], ["children", "SPECIES", 95, 103], ["infants", "SPECIES", 118, 125], ["asymptomatic", "PROBLEM", 44, 56], ["infection", "PROBLEM", 146, 155], ["mild", "OBSERVATION_MODIFIER", 58, 62], ["moderate", "OBSERVATION_MODIFIER", 67, 75]]], ["The first deaths of COVID-19 occurred frequently among elderly people, who may progress more faster [20].", [["deaths", "DISEASE", 10, 16], ["people", "ORGANISM", 63, 69], ["people", "SPECIES", 63, 69], ["COVID", "TEST", 20, 25]]], ["In a multicenter cohort study with 137 patients enrolled, age was shown to be associated with high risk of death in COVID-19 patients.", [["death", "DISEASE", 107, 112], ["patients", "ORGANISM", 39, 47], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 125, 133], ["a multicenter cohort study", "TEST", 3, 29], ["death", "PROBLEM", 107, 112]]], ["Middle-aged and elderly patients with underlying comorbidities are prone to respiratory failure and have a poorer prognosis [21, 22].", [["respiratory", "ANATOMY", 76, 87], ["respiratory failure", "DISEASE", 76, 95], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["underlying comorbidities", "PROBLEM", 38, 62], ["respiratory failure", "PROBLEM", 76, 95], ["failure", "OBSERVATION", 88, 95]]], ["Combined the previous literatures and our results, we assumed that age also should be a risk factor for imaging progression at the early stage of COVID-19.DISCUSSIONAmong the six inflammatory models, MLR was significantly higher in COVID-19 patients with imaging progression on chest CT scans, and correlated with imaging aggravation.", [["patients", "ORGANISM", 241, 249], ["patients", "SPECIES", 241, 249], ["imaging progression", "TEST", 104, 123], ["COVID", "TEST", 146, 151], ["MLR", "TEST", 200, 203], ["imaging progression", "TEST", 255, 274], ["chest CT scans", "TEST", 278, 292], ["imaging aggravation", "TEST", 314, 333], ["chest", "ANATOMY", 278, 283]]], ["Previous evidence demonstrated that monocytes/macrophages were susceptible to human coronavirus (HCoV) 229E infection, but strongly restricted OC43 replication [23].", [["monocytes", "ANATOMY", 36, 45], ["macrophages", "ANATOMY", 46, 57], ["infection", "DISEASE", 108, 117], ["monocytes", "CELL", 36, 45], ["macrophages", "CELL", 46, 57], ["human coronavirus (HCoV) 229E", "ORGANISM", 78, 107], ["OC43", "GENE_OR_GENE_PRODUCT", 143, 147], ["monocytes", "CELL_TYPE", 36, 45], ["macrophages", "CELL_TYPE", 46, 57], ["human", "SPECIES", 78, 83], ["coronavirus", "SPECIES", 84, 95], ["human coronavirus", "SPECIES", 78, 95], ["HCoV", "SPECIES", 97, 101], ["monocytes/macrophages", "PROBLEM", 36, 57], ["human coronavirus (HCoV) 229E infection", "PROBLEM", 78, 117], ["monocytes", "OBSERVATION", 36, 45], ["macrophages", "OBSERVATION", 46, 57]]], ["Differs from HCoV-229E, SARS-CoV poorly infects human purified monocytes/macrophages, and production of interferon-alpha by these cells further limits the infection [24].", [["monocytes", "ANATOMY", 63, 72], ["macrophages", "ANATOMY", 73, 84], ["cells", "ANATOMY", 130, 135], ["HCoV-229E", "CHEMICAL", 13, 22], ["infection", "DISEASE", 155, 164], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 13, 22], ["SARS-CoV", "ORGANISM", 24, 32], ["human", "ORGANISM", 48, 53], ["monocytes", "CELL", 63, 72], ["macrophages", "CELL", 73, 84], ["interferon-alpha", "GENE_OR_GENE_PRODUCT", 104, 120], ["cells", "CELL", 130, 135], ["human purified monocytes", "CELL_TYPE", 48, 72], ["macrophages", "CELL_TYPE", 73, 84], ["interferon-alpha", "PROTEIN", 104, 120], ["human", "SPECIES", 48, 53], ["HCoV-229E", "SPECIES", 13, 22], ["SARS-CoV", "SPECIES", 24, 32], ["human", "SPECIES", 48, 53], ["HCoV", "TEST", 13, 17], ["SARS", "PROBLEM", 24, 28], ["macrophages", "PROBLEM", 73, 84], ["interferon", "TREATMENT", 104, 114], ["alpha", "TREATMENT", 115, 120], ["the infection", "PROBLEM", 151, 164], ["macrophages", "ANATOMY", 73, 84]]], ["Following infection of monocytes/macrophages by HCoV-OC43, viability remained high over 6 days and no apoptosis was observed [25].", [["monocytes", "ANATOMY", 23, 32], ["macrophages", "ANATOMY", 33, 44], ["HCoV-OC43", "ANATOMY", 48, 57], ["infection", "DISEASE", 10, 19], ["monocytes", "CELL", 23, 32], ["macrophages", "CELL", 33, 44], ["HCoV-OC43", "CELL", 48, 57], ["monocytes", "CELL_TYPE", 23, 32], ["macrophages", "CELL_TYPE", 33, 44], ["HCoV", "SPECIES", 48, 52], ["monocytes", "TEST", 23, 32], ["macrophages", "PROBLEM", 33, 44], ["HCoV", "TEST", 48, 52], ["OC43", "PROBLEM", 53, 57], ["viability", "TEST", 59, 68], ["apoptosis", "PROBLEM", 102, 111], ["infection", "OBSERVATION", 10, 19], ["monocytes", "ANATOMY", 23, 32], ["macrophages", "OBSERVATION_MODIFIER", 33, 44], ["high", "OBSERVATION_MODIFIER", 78, 82], ["no", "UNCERTAINTY", 99, 101]]], ["These clues suggested that monocytes might be stable in function and quantity levels during HCoV infection like SARS and 2019-CoV.", [["monocytes", "ANATOMY", 27, 36], ["infection", "DISEASE", 97, 106], ["SARS", "DISEASE", 112, 116], ["monocytes", "CELL", 27, 36], ["HCoV", "GENE_OR_GENE_PRODUCT", 92, 96], ["2019-CoV", "ORGANISM", 121, 129], ["monocytes", "CELL_TYPE", 27, 36], ["HCoV", "SPECIES", 92, 96], ["2019-CoV", "SPECIES", 121, 129], ["monocytes", "PROBLEM", 27, 36], ["quantity levels", "TEST", 69, 84], ["HCoV infection", "PROBLEM", 92, 106], ["monocytes", "OBSERVATION", 27, 36], ["stable", "OBSERVATION_MODIFIER", 46, 52], ["infection", "OBSERVATION", 97, 106]]], ["Conversely, SARS-CoV frequently targets for cytotoxic T lymphocytes [26, 27].", [["cytotoxic T lymphocytes", "ANATOMY", 44, 67], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 12, 20], ["cytotoxic T lymphocytes", "CELL", 44, 67], ["cytotoxic T lymphocytes", "CELL_TYPE", 44, 67], ["SARS-CoV", "SPECIES", 12, 20], ["SARS", "PROBLEM", 12, 16], ["cytotoxic T lymphocytes", "TEST", 44, 67]]], ["Lymphopenia is one of hematological abnormalities during SARS-CoV infection, and lymphocyte counts could predict the severity and clinical outcomes [28].", [["hematological", "ANATOMY", 22, 35], ["lymphocyte", "ANATOMY", 81, 91], ["Lymphopenia", "DISEASE", 0, 11], ["SARS-CoV infection", "DISEASE", 57, 75], ["SARS-CoV", "ORGANISM", 57, 65], ["lymphocyte", "CELL", 81, 91], ["SARS-CoV", "SPECIES", 57, 65], ["Lymphopenia", "PROBLEM", 0, 11], ["hematological abnormalities", "PROBLEM", 22, 49], ["SARS", "PROBLEM", 57, 61], ["CoV infection", "PROBLEM", 62, 75], ["lymphocyte counts", "TEST", 81, 98], ["the severity", "PROBLEM", 113, 125], ["CoV", "OBSERVATION_MODIFIER", 62, 65], ["infection", "OBSERVATION", 66, 75]]], ["Previous study showed that lymphocytes and its subsets significantly decreased in SARS patients, while those with severe clinical illness or those who died had more remarkable CD4+ and CD8+ lymphopenia [28].", [["lymphocytes", "ANATOMY", 27, 38], ["CD4+", "ANATOMY", 176, 180], ["SARS", "DISEASE", 82, 86], ["lymphopenia", "DISEASE", 190, 201], ["lymphocytes", "CELL", 27, 38], ["patients", "ORGANISM", 87, 95], ["CD4", "GENE_OR_GENE_PRODUCT", 176, 179], ["CD8", "GENE_OR_GENE_PRODUCT", 185, 188], ["lymphocytes", "CELL_TYPE", 27, 38], ["CD4", "PROTEIN", 176, 179], ["CD8", "PROTEIN", 185, 188], ["patients", "SPECIES", 87, 95], ["Previous study", "TEST", 0, 14], ["lymphocytes", "PROBLEM", 27, 38], ["severe clinical illness", "PROBLEM", 114, 137], ["CD4", "TEST", 176, 179], ["lymphopenia", "PROBLEM", 190, 201], ["lymphocytes", "OBSERVATION", 27, 38], ["subsets", "OBSERVATION_MODIFIER", 47, 54], ["significantly", "OBSERVATION_MODIFIER", 55, 68], ["decreased", "OBSERVATION_MODIFIER", 69, 78], ["lymphopenia", "OBSERVATION", 190, 201]]], ["Also, MERS-CoV could efficiently infected T lymphocytes from the peripheral blood and from human lymphoid organs and induced apoptosis in T lymphocytes [29].", [["T lymphocytes", "ANATOMY", 42, 55], ["peripheral blood", "ANATOMY", 65, 81], ["lymphoid organs", "ANATOMY", 97, 112], ["T lymphocytes", "ANATOMY", 138, 151], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 6, 14], ["T lymphocytes", "CELL", 42, 55], ["peripheral blood", "ORGANISM_SUBSTANCE", 65, 81], ["human", "ORGANISM", 91, 96], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 97, 112], ["T lymphocytes", "CELL", 138, 151], ["MERS", "PROTEIN", 6, 10], ["T lymphocytes", "CELL_TYPE", 42, 55], ["T lymphocytes", "CELL_TYPE", 138, 151], ["human", "SPECIES", 91, 96], ["MERS-CoV", "SPECIES", 6, 14], ["human", "SPECIES", 91, 96], ["infected T lymphocytes", "PROBLEM", 33, 55], ["the peripheral blood", "TEST", 61, 81], ["human lymphoid organs", "PROBLEM", 91, 112], ["induced apoptosis in T lymphocytes", "PROBLEM", 117, 151], ["peripheral", "ANATOMY_MODIFIER", 65, 75], ["blood", "ANATOMY", 76, 81], ["human lymphoid organs", "OBSERVATION", 91, 112], ["apoptosis", "OBSERVATION_MODIFIER", 125, 134]]], ["Similar with SARS-CoV and MERS-CoV, 2019-nCoV infection also related with loss of lymphocytes, which was supported by Chinese guidelines [30, 31].", [["lymphocytes", "ANATOMY", 82, 93], ["SARS", "DISEASE", 13, 17], ["infection", "DISEASE", 46, 55], ["loss of lymphocytes", "DISEASE", 74, 93], ["SARS-CoV", "ORGANISM", 13, 21], ["MERS-CoV", "ORGANISM", 26, 34], ["2019-nCoV", "ORGANISM", 36, 45], ["lymphocytes", "CELL", 82, 93], ["lymphocytes", "CELL_TYPE", 82, 93], ["SARS-CoV", "SPECIES", 13, 21], ["MERS-CoV", "SPECIES", 26, 34], ["SARS", "PROBLEM", 13, 17], ["CoV", "PROBLEM", 31, 34], ["nCoV infection", "PROBLEM", 41, 55], ["loss of lymphocytes", "PROBLEM", 74, 93], ["SARS", "OBSERVATION", 13, 17], ["CoV", "OBSERVATION_MODIFIER", 18, 21], ["infection", "OBSERVATION", 46, 55]]], ["Thus, the MLR increased especially in patients with disease progression.DISCUSSIONHomocysteine is a potent toxic agent that involved in oxidative stress and neurotoxicity promotion, endothelial dysfunction, and acceleration of the atherosclerotic process [32\u201334].", [["endothelial", "ANATOMY", 182, 193], ["DISCUSSIONHomocysteine", "CHEMICAL", 72, 94], ["neurotoxicity", "DISEASE", 157, 170], ["endothelial dysfunction", "DISEASE", 182, 205], ["atherosclerotic", "DISEASE", 231, 246], ["DISCUSSIONHomocysteine", "CHEMICAL", 72, 94], ["patients", "ORGANISM", 38, 46], ["endothelial", "CELL", 182, 193], ["patients", "SPECIES", 38, 46], ["the MLR", "TEST", 6, 13], ["disease progression.", "PROBLEM", 52, 72], ["a potent toxic agent", "TREATMENT", 98, 118], ["oxidative stress", "PROBLEM", 136, 152], ["neurotoxicity promotion", "TREATMENT", 157, 180], ["endothelial dysfunction", "PROBLEM", 182, 205], ["acceleration of the atherosclerotic process", "PROBLEM", 211, 254], ["MLR", "OBSERVATION_MODIFIER", 10, 13], ["increased", "OBSERVATION_MODIFIER", 14, 23], ["endothelial dysfunction", "OBSERVATION", 182, 205], ["acceleration", "OBSERVATION_MODIFIER", 211, 223], ["atherosclerotic", "OBSERVATION_MODIFIER", 231, 246]]], ["Emerging evidences revealed that hyperhomocysteinemia contributed to a spectrum of disease development, including cardiovascular disease, diabetes, chronic kidney disease and fatty liver disease [35\u201337].", [["cardiovascular", "ANATOMY", 114, 128], ["kidney", "ANATOMY", 156, 162], ["fatty liver", "ANATOMY", 175, 186], ["hyperhomocysteinemia", "DISEASE", 33, 53], ["cardiovascular disease", "DISEASE", 114, 136], ["diabetes", "DISEASE", 138, 146], ["chronic kidney disease", "DISEASE", 148, 170], ["fatty liver disease", "DISEASE", 175, 194], ["kidney", "ORGAN", 156, 162], ["fatty", "CANCER", 175, 180], ["liver", "ORGAN", 181, 186], ["hyperhomocysteinemia", "PROBLEM", 33, 53], ["disease development", "PROBLEM", 83, 102], ["cardiovascular disease", "PROBLEM", 114, 136], ["diabetes", "PROBLEM", 138, 146], ["chronic kidney disease", "PROBLEM", 148, 170], ["fatty liver disease", "PROBLEM", 175, 194], ["hyperhomocysteinemia", "OBSERVATION", 33, 53], ["disease", "OBSERVATION", 83, 90], ["cardiovascular disease", "OBSERVATION", 114, 136], ["diabetes", "OBSERVATION", 138, 146], ["chronic", "OBSERVATION_MODIFIER", 148, 155], ["kidney", "ANATOMY", 156, 162], ["disease", "OBSERVATION", 163, 170], ["fatty", "OBSERVATION", 175, 180], ["liver", "ANATOMY", 181, 186]]], ["Previous reports uncovered that homocysteine concentrations were greater in many virus infections including human immunodeficiency virus, hepatitis virus and human papilloma virus [38\u201340].", [["homocysteine", "CHEMICAL", 32, 44], ["infections", "DISEASE", 87, 97], ["human immunodeficiency virus, hepatitis virus", "DISEASE", 108, 153], ["human papilloma virus", "DISEASE", 158, 179], ["homocysteine", "CHEMICAL", 32, 44], ["homocysteine", "SIMPLE_CHEMICAL", 32, 44], ["human immunodeficiency virus", "ORGANISM", 108, 136], ["hepatitis virus", "ORGANISM", 138, 153], ["human papilloma virus", "ORGANISM", 158, 179], ["human immunodeficiency virus", "SPECIES", 108, 136], ["hepatitis virus", "SPECIES", 138, 153], ["human", "SPECIES", 158, 163], ["papilloma virus", "SPECIES", 164, 179], ["human immunodeficiency virus", "SPECIES", 108, 136], ["hepatitis virus", "SPECIES", 138, 153], ["human papilloma virus", "SPECIES", 158, 179], ["homocysteine concentrations", "PROBLEM", 32, 59], ["many virus infections", "PROBLEM", 76, 97], ["human immunodeficiency virus", "PROBLEM", 108, 136], ["hepatitis virus", "PROBLEM", 138, 153], ["human papilloma virus", "PROBLEM", 158, 179], ["virus infections", "OBSERVATION", 81, 97], ["immunodeficiency virus", "OBSERVATION", 114, 136], ["hepatitis virus", "OBSERVATION", 138, 153]]], ["However, the roles of homocysteine in coronavirus infection have not been well illustrated.", [["homocysteine", "CHEMICAL", 22, 34], ["coronavirus infection", "DISEASE", 38, 59], ["homocysteine", "CHEMICAL", 22, 34], ["homocysteine", "SIMPLE_CHEMICAL", 22, 34], ["coronavirus", "ORGANISM", 38, 49], ["coronavirus", "SPECIES", 38, 49], ["homocysteine in coronavirus infection", "PROBLEM", 22, 59], ["coronavirus infection", "OBSERVATION", 38, 59]]], ["Based on our results, homocysteine concentrated in imaging progression patients and showed predictive value for imaging progression.DISCUSSIONOur results also demonstrated that COVID-19 patients with period from onset to admission \u2265 4 days had lower risk to develop imaging progression on chest CT at first week after admission.", [["chest", "ANATOMY", 289, 294], ["homocysteine", "CHEMICAL", 22, 34], ["homocysteine", "CHEMICAL", 22, 34], ["homocysteine", "SIMPLE_CHEMICAL", 22, 34], ["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 186, 194], ["chest", "ORGAN", 289, 294], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 186, 194], ["homocysteine", "TEST", 22, 34], ["imaging progression", "TEST", 51, 70], ["predictive value", "TEST", 91, 107], ["imaging progression", "TEST", 112, 131], ["imaging progression", "PROBLEM", 266, 285], ["chest CT", "TEST", 289, 297], ["chest", "ANATOMY", 289, 294]]], ["On the one hand, patients with period over 4 days might have mild clinical symptoms, which in line with mild or slow progression of this disease.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["mild clinical symptoms", "PROBLEM", 61, 83], ["this disease", "PROBLEM", 132, 144], ["mild", "OBSERVATION_MODIFIER", 61, 65], ["mild", "OBSERVATION_MODIFIER", 104, 108], ["slow", "OBSERVATION_MODIFIER", 112, 116], ["progression", "OBSERVATION_MODIFIER", 117, 128]]], ["On the other hand, the period from onset to admission should be counted in the natural process of 2019-nCoV infection.DISCUSSIONThis study has some limitations.", [["infection", "DISEASE", 108, 117], ["nCoV infection", "PROBLEM", 103, 117], ["DISCUSSIONThis study", "TEST", 118, 138], ["infection", "OBSERVATION", 108, 117]]], ["First, only mild type of COVID-19 patients was included, and severe type and life-threating types were excluded in this analysis.", [["COVID", "DISEASE", 25, 30], ["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["COVID", "TEST", 25, 30], ["severe type and life-threating types", "PROBLEM", 61, 97], ["this analysis", "TEST", 115, 128], ["mild", "OBSERVATION_MODIFIER", 12, 16], ["severe", "OBSERVATION_MODIFIER", 61, 67]]], ["Second, MLR and age did not have powerful prognostic values for imaging progression on chest CT in our study.", [["chest", "ORGAN", 87, 92], ["imaging progression", "TEST", 64, 83], ["chest CT", "TEST", 87, 95], ["our study", "TEST", 99, 108], ["chest", "ANATOMY", 87, 92]]], ["And, subgroup analysis of category manifestation of imaging progression on chest CT should also be considered.", [["chest", "ANATOMY", 75, 80], ["chest", "ORGAN", 75, 80], ["imaging progression", "TEST", 52, 71], ["chest CT", "TEST", 75, 83], ["chest", "ANATOMY", 75, 80]]], ["Even though, age, MLR model, homocysteine and period from onset to admission might be useful for evaluating disease progression in COVID-19 patients.Ethic statement ::: MATERIALS AND METHODSAll participants provided written informed consent during their admission.", [["homocysteine", "CHEMICAL", 29, 41], ["homocysteine", "CHEMICAL", 29, 41], ["homocysteine", "SIMPLE_CHEMICAL", 29, 41], ["patients", "ORGANISM", 140, 148], ["participants", "ORGANISM", 194, 206], ["patients", "SPECIES", 140, 148], ["participants", "SPECIES", 194, 206], ["homocysteine", "TEST", 29, 41], ["disease progression", "PROBLEM", 108, 127], ["COVID", "TEST", 131, 136]]], ["The study protocol and informed consent documents were reviewed and approved by the Ethics Committee of Shanghai Public Health Clinical Center, Fudan University.Patients ::: MATERIALS AND METHODSIn accordance to the 4th edition of \u201cDiagnosis and management program of novel coronavirus-infected pneumonia\u201d released by National Health Commission of The People\u2019s Republic of China [30], 273 diagnosed COVID-19 patients with mild category in Shanghai Public Health Clinical Center were included in this analysis.", [["coronavirus-infected pneumonia", "DISEASE", 274, 304], ["Patients", "ORGANISM", 161, 169], ["coronavirus", "ORGANISM", 274, 285], ["patients", "ORGANISM", 408, 416], ["Patients", "SPECIES", 161, 169], ["People", "SPECIES", 352, 358], ["patients", "SPECIES", 408, 416], ["The study protocol", "TEST", 0, 18], ["management program", "TREATMENT", 246, 264], ["novel coronavirus", "PROBLEM", 268, 285], ["infected pneumonia", "PROBLEM", 286, 304], ["mild category", "PROBLEM", 422, 435], ["this analysis", "TEST", 495, 508], ["infected", "OBSERVATION_MODIFIER", 286, 294], ["pneumonia", "OBSERVATION", 295, 304], ["mild", "OBSERVATION_MODIFIER", 422, 426]]], ["2019 novel coronavirus (2019-nCoV) nucleic acid of sputum samples from all participants were positive detected by real-time polymerase chain reaction.", [["sputum samples", "ANATOMY", 51, 65], ["nucleic acid", "CHEMICAL", 35, 47], ["coronavirus", "ORGANISM", 11, 22], ["sputum samples", "CANCER", 51, 65], ["participants", "ORGANISM", 75, 87], ["coronavirus", "SPECIES", 11, 22], ["participants", "SPECIES", 75, 87], ["novel coronavirus", "TEST", 5, 22], ["nucleic acid", "TEST", 35, 47], ["sputum samples", "TEST", 51, 65]]], ["The influenza A and B antigens of all participants were negative.", [["influenza A", "ORGANISM", 4, 15], ["B antigens", "GENE_OR_GENE_PRODUCT", 20, 30], ["participants", "ORGANISM", 38, 50], ["influenza A and B antigens", "PROTEIN", 4, 30], ["participants", "SPECIES", 38, 50], ["The influenza A and B antigens", "TEST", 0, 30]]], ["All participants had no other lymphatic system disorders or malignant hematologic diseases, ensuring that the whole blood parameters were representative of normal baseline values.", [["lymphatic system", "ANATOMY", 30, 46], ["malignant hematologic", "ANATOMY", 60, 81], ["blood", "ANATOMY", 116, 121], ["lymphatic system disorders", "DISEASE", 30, 56], ["malignant hematologic diseases", "DISEASE", 60, 90], ["lymphatic system", "MULTI-TISSUE_STRUCTURE", 30, 46], ["malignant hematologic", "CANCER", 60, 81], ["blood", "ORGANISM_SUBSTANCE", 116, 121], ["participants", "SPECIES", 4, 16], ["other lymphatic system disorders", "PROBLEM", 24, 56], ["malignant hematologic diseases", "PROBLEM", 60, 90], ["the whole blood parameters", "TEST", 106, 132], ["no other", "UNCERTAINTY", 21, 29], ["lymphatic system", "ANATOMY", 30, 46], ["malignant", "OBSERVATION_MODIFIER", 60, 69]]], ["Patients with renal and/or hepatic failure, acute coronary syndromes, valvular heart diseases, autoimmune thyroid diseases, or systematic inflammatory diseases were excluded from our study.Study design ::: MATERIALS AND METHODSThis was a prospective single-center cohort study.", [["renal", "ANATOMY", 14, 19], ["hepatic", "ANATOMY", 27, 34], ["coronary", "ANATOMY", 50, 58], ["valvular", "ANATOMY", 70, 78], ["heart", "ANATOMY", 79, 84], ["thyroid", "ANATOMY", 106, 113], ["renal and/or hepatic failure", "DISEASE", 14, 42], ["acute coronary syndromes", "DISEASE", 44, 68], ["valvular heart diseases", "DISEASE", 70, 93], ["autoimmune thyroid diseases", "DISEASE", 95, 122], ["inflammatory diseases", "DISEASE", 138, 159], ["Patients", "ORGANISM", 0, 8], ["renal", "ORGAN", 14, 19], ["hepatic", "ORGAN", 27, 34], ["coronary", "MULTI-TISSUE_STRUCTURE", 50, 58], ["heart", "ORGAN", 79, 84], ["thyroid", "ORGAN", 106, 113], ["Patients", "SPECIES", 0, 8], ["renal and/or hepatic failure", "PROBLEM", 14, 42], ["acute coronary syndromes", "PROBLEM", 44, 68], ["valvular heart diseases", "PROBLEM", 70, 93], ["autoimmune thyroid diseases", "PROBLEM", 95, 122], ["systematic inflammatory diseases", "PROBLEM", 127, 159], ["our study", "TEST", 179, 188], ["cohort study", "TEST", 264, 276], ["renal", "ANATOMY", 14, 19], ["hepatic", "ANATOMY", 27, 34], ["failure", "OBSERVATION", 35, 42], ["acute", "OBSERVATION_MODIFIER", 44, 49], ["coronary", "ANATOMY", 50, 58], ["syndromes", "OBSERVATION", 59, 68], ["valvular", "ANATOMY", 70, 78], ["heart", "ANATOMY", 79, 84], ["diseases", "OBSERVATION", 85, 93], ["autoimmune", "OBSERVATION_MODIFIER", 95, 105], ["thyroid", "ANATOMY", 106, 113], ["systematic", "OBSERVATION_MODIFIER", 127, 137], ["inflammatory", "OBSERVATION_MODIFIER", 138, 150]]], ["The baseline characteristics, including demographics, treatment strategies, routine blood tests, liver-kidney function parameters, coagulation function tests, cardiac markers and chest CT imaging, were all collected at the first admission day.", [["blood", "ANATOMY", 84, 89], ["liver", "ANATOMY", 97, 102], ["kidney", "ANATOMY", 103, 109], ["cardiac", "ANATOMY", 159, 166], ["blood", "ORGANISM_SUBSTANCE", 84, 89], ["liver", "ORGAN", 97, 102], ["kidney", "ORGAN", 103, 109], ["treatment strategies", "TREATMENT", 54, 74], ["routine blood tests", "TEST", 76, 95], ["liver-kidney function parameters", "TEST", 97, 129], ["coagulation function tests", "TEST", 131, 157], ["cardiac markers", "TEST", 159, 174], ["chest CT imaging", "TEST", 179, 195], ["liver", "ANATOMY", 97, 102], ["kidney", "ANATOMY", 103, 109], ["chest", "ANATOMY", 179, 184]]], ["Chest CT imaging were also performed at the (7 \u00b1 2) day during their admission.", [["Chest CT imaging", "TEST", 0, 16]]], ["All the tests and examines were conducted in the Department of Medical Laboratory and the Department of Radiology in Shanghai Public Health Clinical Center, Fudan University.Definition ::: MATERIALS AND METHODSThe primary outcome was defined as imaging progression on chest CT at first week.", [["chest", "ANATOMY", 268, 273], ["chest", "ORGAN", 268, 273], ["All the tests", "TEST", 0, 13], ["imaging progression", "TEST", 245, 264], ["chest CT", "TEST", 268, 276], ["chest", "ANATOMY", 268, 273]]], ["Any one of the following criteria was considered as imaging progression on chest CT: 1) Increased ground-glass lesions in the underlying involvements; 2) Newly occurred lesions beyond underlying involvements.", [["ground-glass lesions", "ANATOMY", 98, 118], ["lesions", "ANATOMY", 169, 176], ["glass lesions", "PATHOLOGICAL_FORMATION", 105, 118], ["lesions", "PATHOLOGICAL_FORMATION", 169, 176], ["imaging progression", "TEST", 52, 71], ["chest CT", "TEST", 75, 83], ["Increased ground-glass lesions", "PROBLEM", 88, 118], ["Newly occurred lesions", "PROBLEM", 154, 176], ["underlying involvements", "PROBLEM", 184, 207], ["chest", "ANATOMY", 75, 80], ["Increased", "OBSERVATION_MODIFIER", 88, 97], ["ground", "OBSERVATION_MODIFIER", 98, 104], ["-glass", "OBSERVATION_MODIFIER", 104, 110], ["lesions", "OBSERVATION", 111, 118], ["occurred", "OBSERVATION_MODIFIER", 160, 168], ["lesions", "OBSERVATION", 169, 176]]], ["The chest CT imaging performance was diagnosed by two radiologists independently and inconsistency was discussed and determined by the director of Department of Radiology who acted as an arbiter.Definition ::: MATERIALS AND METHODSSix inflammatory models, including ALRI, APRI, MLR, NLR, PLR and SII were included in this analysis.", [["chest", "ANATOMY", 4, 9], ["ALRI", "DISEASE", 266, 270], ["chest", "ORGAN", 4, 9], ["NLR", "GENE_OR_GENE_PRODUCT", 283, 286], ["APRI", "PROTEIN", 272, 276], ["MLR", "PROTEIN", 278, 281], ["NLR", "PROTEIN", 283, 286], ["PLR", "PROTEIN", 288, 291], ["SII", "PROTEIN", 296, 299], ["The chest CT imaging performance", "TEST", 0, 32], ["METHODSSix inflammatory models", "TEST", 224, 254], ["ALRI", "TEST", 266, 270], ["APRI", "TEST", 272, 276], ["MLR", "TEST", 278, 281], ["NLR", "TEST", 283, 286], ["PLR", "TEST", 288, 291], ["this analysis", "TEST", 317, 330], ["chest", "ANATOMY", 4, 9]]], ["The definitions of these models are as follows: ALRI = AST / L; APRI = AST / P; MLR = M / L; NLR = N / L; PLR = P / L; and SII = P \u00d7 N / L, where M, L, N and P are the peripheral monocyte, lymphocyte, neutrophil and platelet counts, respectively.Statistical analysis ::: MATERIALS AND METHODSDifferences of variables between the individual groups were analyzed using student t test and Chi-square test based on variables types.", [["peripheral monocyte", "ANATOMY", 168, 187], ["lymphocyte", "ANATOMY", 189, 199], ["neutrophil", "ANATOMY", 201, 211], ["platelet", "ANATOMY", 216, 224], ["ALRI", "DISEASE", 48, 52], ["peripheral monocyte", "CELL", 168, 187], ["lymphocyte", "CELL", 189, 199], ["neutrophil", "CELL", 201, 211], ["platelet", "CELL", 216, 224], ["APRI", "PROTEIN", 64, 68], ["AST", "PROTEIN", 71, 74], ["MLR", "PROTEIN", 80, 83], ["NLR", "PROTEIN", 93, 96], ["PLR", "PROTEIN", 106, 109], ["SII", "PROTEIN", 123, 126], ["peripheral monocyte", "CELL_TYPE", 168, 187], ["lymphocyte", "CELL_TYPE", 189, 199], ["neutrophil", "CELL_TYPE", 201, 211], ["ALRI", "TEST", 48, 52], ["AST", "TEST", 55, 58], ["APRI", "TEST", 64, 68], ["AST", "TEST", 71, 74], ["P", "TEST", 77, 78], ["MLR", "TEST", 80, 83], ["NLR", "TEST", 93, 96], ["PLR", "TEST", 106, 109], ["P", "TEST", 112, 113], ["SII", "TEST", 123, 126], ["the peripheral monocyte", "TEST", 164, 187], ["lymphocyte", "TEST", 189, 199], ["neutrophil", "TEST", 201, 211], ["platelet counts", "TEST", 216, 231], ["Statistical analysis", "TEST", 246, 266], ["student t test", "TEST", 367, 381], ["Chi-square test", "TEST", 386, 401], ["peripheral monocyte", "ANATOMY", 168, 187], ["lymphocyte", "ANATOMY", 189, 199], ["platelet counts", "OBSERVATION", 216, 231]]], ["Only variables significantly associated with the outcome at univariate analysis (two-sided p < 0.05) included in the multivariate model.", [["univariate analysis", "TEST", 60, 79]]], ["Results were reported as risk ratios (RR) with 95% confidence intervals (CI).", [["RR", "TEST", 38, 40], ["CI", "TEST", 73, 75]]], ["OptimalCutpoints package [41] in R program was used to perform ROC analysis to evaluate predictive values of potential factors for the outcome.", [["OptimalCutpoints package", "TREATMENT", 0, 24], ["ROC analysis", "TEST", 63, 75]]], ["Stata software version 16.0 (Stata Corp LLC, Texas, USA) was used for other statistics.", [["Stata software version", "TEST", 0, 22]]], ["A two-tailed p < 0.05 were considered significant for all tests.", [["all tests", "TEST", 54, 63]]]], "PMC7257353": [["IntroductionQuarantine is the separation and restriction of movement of people who have potentially been exposed to a contagious disease.", [["IntroductionQuarantine", "CHEMICAL", 0, 22], ["people", "ORGANISM", 72, 78], ["people", "SPECIES", 72, 78], ["IntroductionQuarantine", "TREATMENT", 0, 22], ["the separation", "TREATMENT", 26, 40], ["a contagious disease", "PROBLEM", 116, 136], ["contagious", "OBSERVATION_MODIFIER", 118, 128], ["disease", "OBSERVATION", 129, 136]]], ["The primary purpose of quarantine is to prevent transmission of an infectious agent from those potentially incubating it.", [["quarantine", "TREATMENT", 23, 33], ["an infectious agent", "TREATMENT", 64, 83], ["infectious", "OBSERVATION", 67, 77]]], ["Persons are usually quarantined in their homes but they may also be quarantined in community based facilities [1].", [["Persons", "ORGANISM", 0, 7], ["Persons", "SPECIES", 0, 7]]], ["The scientific use of quarantine was began by United Kingdom in response to Plague, but this word was first used by Venice, Italy in 1127 with regard to Leprosy [2].", [["Plague", "DISEASE", 76, 82], ["Leprosy", "DISEASE", 153, 160], ["quarantine", "TREATMENT", 22, 32]]], ["Most recently quarantine has been widely used worldwide as a tool to prevent transmission of coronavirus disease 2019 (Covid-19).IntroductionIndia is using quarantine as a tool to fight Covid-19 since the first case of Covid-19 was diagnosed in January 2020.", [["coronavirus disease", "DISEASE", 93, 112], ["coronavirus", "ORGANISM", 93, 104], ["coronavirus disease", "PROBLEM", 93, 112], ["Covid", "TEST", 119, 124], ["Covid", "TEST", 186, 191], ["Covid", "TEST", 219, 224], ["coronavirus", "OBSERVATION", 93, 104]]], ["In view of rising number of cases, Government of India imposed nationwide lockdown since 25th March 2020 to break the transmission chain [3].", [["rising", "OBSERVATION_MODIFIER", 11, 17]]], ["With the enforcement of lockdown, a very large number of migrant workers from cities along with their families started to return back to their homes.", [["very", "OBSERVATION_MODIFIER", 36, 40], ["large", "OBSERVATION_MODIFIER", 41, 46]]], ["Such susceptible and exposed individuals may act as super-spreaders at their native places.", [["Such susceptible and exposed individuals", "PROBLEM", 0, 40]]], ["The quarantine requirements following exposure to Covid-19 were designed to minimise transmission to the community as well as to protect household members.IntroductionFor normal psychological development and wellbeing of children, companionship and social interaction is an essential component.", [["Covid-19", "CHEMICAL", 50, 58], ["children", "ORGANISM", 221, 229], ["children", "SPECIES", 221, 229], ["essential", "OBSERVATION_MODIFIER", 274, 283], ["component", "OBSERVATION_MODIFIER", 284, 293]]], ["There is an increased risk of psychiatric disorders whenever there is separation of children from their caregivers [5, 6].", [["psychiatric disorders", "DISEASE", 30, 51], ["children", "ORGANISM", 84, 92], ["children", "SPECIES", 84, 92], ["psychiatric disorders", "PROBLEM", 30, 51], ["increased", "OBSERVATION_MODIFIER", 12, 21], ["psychiatric disorders", "OBSERVATION", 30, 51]]], ["It has been realised that quarantine like measures might have adverse psychological effect on children.IntroductionThere are many articles which compare adult and healthcare workers under quarantined to those who were not quarantined.", [["children", "ORGANISM", 94, 102], ["children", "SPECIES", 94, 102]]], ["But there are very few comparable studies on children and adolescents regarding their quarantine experiences, especially from India.", [["children", "ORGANISM", 45, 53], ["children", "SPECIES", 45, 53], ["adolescents", "SPECIES", 58, 69], ["very", "OBSERVATION_MODIFIER", 14, 18], ["few", "OBSERVATION_MODIFIER", 19, 22]]], ["This study describes understanding, compliance and psychological impact of quarantine on children and adolescents in the age group of 9 y to 18 y during Covid-19 outbreak.Material and MethodsDuring Covid-19 outbreak, Ministry of Health and Family Welfare released its guidelines regarding quarantine at home and at facilities /centres.", [["children", "ORGANISM", 89, 97], ["children", "SPECIES", 89, 97], ["adolescents", "SPECIES", 102, 113], ["This study", "TEST", 0, 10], ["Covid", "TEST", 153, 158]]], ["Local public health units were responsible for identification and quarantine of contacts of potential Covid-19 cases.", [["potential Covid", "TEST", 92, 107]]], ["Complying with the Government order, all persons placed under quarantine were to be provided with mask, thermometer (if necessary) and instructions about quarantine requirements.", [["persons", "ORGANISM", 41, 48], ["persons", "SPECIES", 41, 48], ["mask", "TREATMENT", 98, 102]]], ["All quarantined adolescents were to undergo daily medical examination for appearance of symptoms suggestive of Covid-19.", [["adolescents", "ORGANISM", 16, 27], ["adolescents", "SPECIES", 16, 27], ["daily medical examination", "TEST", 44, 69], ["symptoms", "PROBLEM", 88, 96], ["Covid", "TEST", 111, 116]]], ["Quarantined persons were encouraged to remain in contact with their family members through phone to avoid anxiety [1, 4].Material and MethodsChildren and adolescents in the age range of 9 y to 18 y who were placed either at home quarantine or facility quarantine, who remained well and were followed by healthcare workers after discharge from quarantine centres, were included in the study.", [["anxiety", "DISEASE", 106, 113], ["persons", "ORGANISM", 12, 19], ["Children", "ORGANISM", 141, 149], ["adolescents", "ORGANISM", 154, 165], ["persons", "SPECIES", 12, 19], ["Children", "SPECIES", 141, 149], ["adolescents", "SPECIES", 154, 165], ["anxiety", "PROBLEM", 106, 113], ["the study", "TEST", 380, 389]]], ["With these criteria, 121 children and adolescents were eligible to participate.", [["children", "ORGANISM", 25, 33], ["adolescents", "ORGANISM", 38, 49], ["children", "SPECIES", 25, 33], ["adolescents", "SPECIES", 38, 49]]], ["Comparable groups were taken from the neighbourhood of quarantined children and adolescents with the same family background (Number = 131).", [["children", "ORGANISM", 67, 75], ["children", "SPECIES", 67, 75], ["adolescents", "SPECIES", 80, 91]]], ["All children and adolescents were attending either government or private school before this period.", [["children", "ORGANISM", 4, 12], ["adolescents", "ORGANISM", 17, 28], ["children", "SPECIES", 4, 12], ["adolescents", "SPECIES", 17, 28]]], ["Children and adolescents were interviewed in detail along with their parents regarding their knowledge of quarantine facility, compliance during quarantine and psychological effect of quarantine.", [["Children", "ORGANISM", 0, 8], ["adolescents", "ORGANISM", 13, 24], ["Children", "SPECIES", 0, 8], ["adolescents", "SPECIES", 13, 24], ["quarantine", "TREATMENT", 184, 194]]], ["This interview was based on a preformed questionnaire which assessed adolescents\u2019 understanding of rationale of quarantine, quarantine behaviors as well as socioeconomic and psychological impacts.", [["adolescents", "SPECIES", 69, 80]]], ["During quarantine, required behaviors included mask usage, living in separate room with door closed and restriction of activities designed to prevent Covid-19 transmission to the household and to the community.Material and MethodsEthical approval was taken from the institute\u2019s Ethics committee.", [["mask usage", "TREATMENT", 47, 57], ["MethodsEthical approval", "TREATMENT", 223, 246]]], ["Written informed consent was taken from children and their parents.", [["children", "ORGANISM", 40, 48], ["children", "SPECIES", 40, 48]]], ["In statistical methods, first descriptive analysis was done which includes frequency, percent, mean and standard deviation.", [["first descriptive analysis", "TEST", 24, 50]]], ["Student\u2019s t test for continuous variables and Pearson\u2019s Chi square test for categorical variables were used to compare quarantined and non-quarantined groups.", [["Chi square test", "TEST", 56, 71], ["categorical variables", "TEST", 76, 97]]], ["Data entry and statistical analysis were performed using the Statistical Package for Social Science (SPSS) version 26.0.ResultsThe age range of children and adolescents was between 9 y to 18 y with a mean age of 15.4 y.", [["children", "ORGANISM", 144, 152], ["children", "SPECIES", 144, 152], ["adolescents", "SPECIES", 157, 168], ["Data entry", "TEST", 0, 10], ["statistical analysis", "TEST", 15, 35]]], ["Most of the adolescents were males (85.12%).", [["adolescents", "ORGANISM", 12, 23], ["adolescents", "SPECIES", 12, 23]]], ["Thirty seven (30.57%) were quarantined at home and rest (77.68%) at quarantine centres.ResultsMost adolescents (73.55%) identified correctly that quarantine had been imposed to protect the community, whereas only 51.23% of adolescents understood that the use of quarantine restrictions was also to protect members of the household.", [["adolescents", "ORGANISM", 223, 234], ["adolescents", "SPECIES", 99, 110], ["quarantine restrictions", "TREATMENT", 262, 285]]], ["Only 16.52% of adolescents were able to understand all rationale based questions (Table 1).", [["adolescents", "ORGANISM", 15, 26], ["adolescents", "SPECIES", 15, 26]]], ["The proportion of adolescents who adhered and were compliant with all the household protective measures was only 10.71% (N = 13), whereas compliance with all the community protecting measures combined was higher (17.35%).", [["adolescents", "ORGANISM", 18, 29], ["adolescents", "SPECIES", 18, 29]]], ["It means only 9 (7.43%) children and adolescents were correctly following all the instructions related to quarantine.", [["children", "ORGANISM", 24, 32], ["adolescents", "ORGANISM", 37, 48], ["children", "SPECIES", 24, 32], ["adolescents", "SPECIES", 37, 48]]], ["The most difficult (65.26%) activity for children and adolescents to comply with was not going out of the house to socialise (to visit friends and relatives).ResultsThis study also assessed qualitative indicators (feelings) of psychological impact associated with quarantine.", [["children", "ORGANISM", 41, 49], ["children", "SPECIES", 41, 49], ["adolescents", "SPECIES", 54, 65], ["This study", "TEST", 165, 175], ["psychological impact", "PROBLEM", 227, 247]]], ["Worry (68.59%), helplessness (66.11%) and fear (61.98%) were the most common feelings experienced during quarantine.", [["helplessness", "DISEASE", 16, 28], ["helplessness", "PROBLEM", 16, 28]]], ["Children and adolescents who were under quarantine had statistically significant more psychological problems than those who were not quarantined.", [["Children", "ORGANISM", 0, 8], ["adolescents", "ORGANISM", 13, 24], ["Children", "SPECIES", 0, 8], ["adolescents", "SPECIES", 13, 24]]], ["Fear (p \u02c20.0001), nervousness (p \u02c20.0001) and annoyance (p \u02c20.001) were most significantly seen in the quarantined group.", [["nervousness", "DISEASE", 18, 29], ["Fear", "PROBLEM", 0, 4], ["nervousness", "PROBLEM", 18, 29], ["annoyance", "PROBLEM", 46, 55]]], ["Anxiety related insomnia, isolation, boredom (not statistically significant) and sadness was also more common in the quarantine group.ResultsWhen asked in detail, these high levels of psychological problems like worry, helplessness and fear were mainly associated with loss of father\u2019s job, financial losses of family and unavailability of basic life needs.", [["Anxiety", "DISEASE", 0, 7], ["insomnia", "DISEASE", 16, 24], ["boredom", "DISEASE", 37, 44], ["helplessness", "DISEASE", 219, 231], ["Anxiety", "PROBLEM", 0, 7], ["insomnia", "PROBLEM", 16, 24], ["sadness", "PROBLEM", 81, 88], ["psychological problems", "PROBLEM", 184, 206], ["helplessness", "PROBLEM", 219, 231]]], ["Some children and adolescents were concerned about infecting others whereas a few thought that they had Covid-19 (p \u02c20.05).", [["children", "ORGANISM", 5, 13], ["adolescents", "ORGANISM", 18, 29], ["children", "SPECIES", 5, 13], ["adolescents", "SPECIES", 18, 29], ["Covid-", "TEST", 104, 110]]], ["It was very surprising that children and adolescents who were quarantined felt that people reacted differently to them than the non-quarantined group with statistically significant difference (p \u02c20.0001).", [["children", "ORGANISM", 28, 36], ["adolescents", "ORGANISM", 41, 52], ["people", "ORGANISM", 84, 90], ["children", "SPECIES", 28, 36], ["adolescents", "SPECIES", 41, 52], ["people", "SPECIES", 84, 90]]], ["These children and adolescents also avoided people having fever and cough (p \u02c20.05).DiscussionPandemics, like other disasters, have been a part of human history for centuries.", [["fever", "DISEASE", 58, 63], ["cough", "DISEASE", 68, 73], ["children", "ORGANISM", 6, 14], ["adolescents", "ORGANISM", 19, 30], ["people", "ORGANISM", 44, 50], ["human", "ORGANISM", 147, 152], ["children", "SPECIES", 6, 14], ["adolescents", "SPECIES", 19, 30], ["people", "SPECIES", 44, 50], ["human", "SPECIES", 147, 152], ["human", "SPECIES", 147, 152], ["fever", "PROBLEM", 58, 63], ["cough", "PROBLEM", 68, 73]]], ["However, response to pandemics necessarily differs as it requires separation, isolation and quarantine.", [["pandemics", "TREATMENT", 21, 30], ["isolation", "TREATMENT", 78, 87], ["quarantine", "TREATMENT", 92, 102]]], ["Beyond the potential community protective effects attributed to quarantine, the risk to quarantined individuals needs to be identified [8].DiscussionThis study in children and adolescents raises important concerns regarding the effectiveness and applicability of quarantine in recent era.", [["children", "ORGANISM", 163, 171], ["children", "SPECIES", 163, 171], ["adolescents", "SPECIES", 176, 187], ["quarantine", "TREATMENT", 64, 74], ["This study", "TEST", 149, 159]]], ["Ministry of Health and Family Welfare of India directed in its advisory that asymptomatic contacts of potential Covid-19 patients were required to remain in quarantine for 14 d after their last exposure [1, 4].", [["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129]]], ["It is obvious that implementation of quarantine for preventing transmission at community level will be only effective when we adhere to its compliance.", [["quarantine", "TREATMENT", 37, 47]]], ["As this study shows, compliance with all requirements was as low as 7.43%, indicating that quarantine in its present form would be of limited value in controlling transmission.", [["this study", "TEST", 3, 13]]], ["As a whole, most of the children and adolescents were non-compliant, potentially putting their family and community at risk.", [["children", "ORGANISM", 24, 32], ["adolescents", "ORGANISM", 37, 48], ["children", "SPECIES", 24, 32], ["adolescents", "SPECIES", 37, 48]]], ["Results of present study in relation to compliance of quarantine requirements are lower than the previous studies [9, 10].", [["present study", "TEST", 11, 24], ["quarantine requirements", "TREATMENT", 54, 77], ["the previous studies", "TEST", 93, 113]]], ["This can be achieved by improved knowledge about the disease and a better understanding of quarantine measures.", [["the disease", "PROBLEM", 49, 60], ["quarantine measures", "TREATMENT", 91, 110]]], ["A previous study reported that when asked about specific problems related to quarantine, the two most frequently cited \u201cmajor\u201d problems were emotional difficulties related to the confinement and not getting paid because they had to miss their duty [9].", [["A previous study", "TEST", 0, 16], ["emotional difficulties", "PROBLEM", 141, 163]]], ["In the present study the most common difficulty for children and adolescents was not going out to socialise.DiscussionChildren who were quarantined at facility/centre might be more susceptible to mental health problems than children who were quarantined at home because of their higher risk of infection and fear caused by parental separation [11, 12], however, the authors did not analyse these relationship in their study.", [["infection", "DISEASE", 294, 303], ["children", "ORGANISM", 52, 60], ["Children", "ORGANISM", 118, 126], ["children", "ORGANISM", 224, 232], ["children", "SPECIES", 52, 60], ["adolescents", "SPECIES", 65, 76], ["Children", "SPECIES", 118, 126], ["children", "SPECIES", 224, 232], ["infection", "PROBLEM", 294, 303], ["their study", "TEST", 412, 423], ["infection", "OBSERVATION", 294, 303]]], ["So beyond the potential community protecting effects attributed to quarantine, the risk of quarantined children needs to be identified.DiscussionThe consistency of the psychological problem in children and adolescents is very high in the present study group.", [["children", "ORGANISM", 103, 111], ["children", "ORGANISM", 193, 201], ["children", "SPECIES", 103, 111], ["children", "SPECIES", 193, 201], ["quarantine", "TREATMENT", 67, 77]]], ["In this study, most (around 68%) of quarantined children showed some or other form of psychological distress which is much higher than the non-quarantined group with statistically significant difference in most of the feelings (Table 2).", [["psychological distress", "DISEASE", 86, 108], ["children", "ORGANISM", 48, 56], ["children", "SPECIES", 48, 56], ["this study", "TEST", 3, 13], ["psychological distress", "PROBLEM", 86, 108]]], ["Other studies related to psychological impact in quarantined adults generally reported a high prevalence of symptoms of psychological distress like the present study.", [["psychological distress", "DISEASE", 120, 142], ["Other studies", "TEST", 0, 13], ["symptoms", "PROBLEM", 108, 116], ["psychological distress", "PROBLEM", 120, 142], ["the present study", "TEST", 148, 165]]], ["These studies reported emotional disturbance, depression, stress, low mood, irritability, insomnia, posttraumatic stress symptoms, anger and emotional exhaustion.", [["emotional disturbance", "DISEASE", 23, 44], ["depression", "DISEASE", 46, 56], ["low mood", "DISEASE", 66, 74], ["irritability", "DISEASE", 76, 88], ["insomnia", "DISEASE", 90, 98], ["posttraumatic stress symptoms", "DISEASE", 100, 129], ["anger and emotional exhaustion", "DISEASE", 131, 161], ["These studies", "TEST", 0, 13], ["emotional disturbance", "PROBLEM", 23, 44], ["depression", "PROBLEM", 46, 56], ["stress", "PROBLEM", 58, 64], ["low mood", "PROBLEM", 66, 74], ["irritability", "PROBLEM", 76, 88], ["insomnia", "PROBLEM", 90, 98], ["posttraumatic stress symptoms", "PROBLEM", 100, 129], ["emotional exhaustion", "PROBLEM", 141, 161]]], ["Quarantine studies also found a range of other feelings such as, confusion, fear, anger, grief, numbness and anxiety related insomnia [8, 9, 13, 14].", [["confusion", "DISEASE", 65, 74], ["grief", "DISEASE", 89, 94], ["numbness", "DISEASE", 96, 104], ["anxiety", "DISEASE", 109, 116], ["insomnia", "DISEASE", 125, 133], ["Quarantine studies", "TEST", 0, 18], ["confusion", "PROBLEM", 65, 74], ["grief", "PROBLEM", 89, 94], ["numbness", "PROBLEM", 96, 104], ["anxiety", "PROBLEM", 109, 116], ["insomnia", "PROBLEM", 125, 133]]], ["A study on children also found that the mean post-traumatic stress scores were four times higher in children who had been quarantined to those who were not quarantined [8].", [["children", "ORGANISM", 11, 19], ["children", "ORGANISM", 100, 108], ["children", "SPECIES", 11, 19], ["children", "SPECIES", 100, 108], ["A study", "TEST", 0, 7], ["the mean post-traumatic stress scores", "PROBLEM", 36, 73]]], ["Long term behavior changes after the quarantine period, such as vigilant hand washing and avoidance of crowds have been reported [15].DiscussionHowever, point to be noted here is that non-quarantined children also show a higher level of stress during Covid-19 period.", [["hand", "ANATOMY", 73, 77], ["hand", "ORGANISM_SUBDIVISION", 73, 77], ["children", "ORGANISM", 200, 208], ["children", "SPECIES", 200, 208], ["Long term behavior changes", "PROBLEM", 0, 26], ["vigilant hand washing", "TREATMENT", 64, 85]]], ["Previous studies from India have reported psychological distress in 13 to 45% of school children and adolescents [16, 17].", [["psychological distress", "DISEASE", 42, 64], ["children", "ORGANISM", 88, 96], ["children", "SPECIES", 88, 96], ["adolescents", "SPECIES", 101, 112], ["Previous studies", "TEST", 0, 16], ["psychological distress", "PROBLEM", 42, 64]]], ["Higher level of psychological problems in these children can be attributed to restriction of activity, school closure and confinement at home due to nationwide lockdown.", [["children", "ORGANISM", 48, 56], ["children", "SPECIES", 48, 56], ["psychological problems", "PROBLEM", 16, 38]]], ["So, this study also provides comparable data of psychological impact of pandemic within the non-quarantined group.DiscussionThe distribution of different feelings and emotions in this study matches with previous studies [8, 9] though frequency of worry, helplessness and fear was much higher in the present study.", [["helplessness", "DISEASE", 254, 266], ["this study", "TEST", 4, 14], ["pandemic", "PROBLEM", 72, 80], ["this study", "TEST", 179, 189], ["previous studies", "TEST", 203, 219], ["helplessness", "PROBLEM", 254, 266]]], ["On detailed interview, the authors found that children and their parents were more concerned about financial loss, loss of father\u2019s job, future uncertainties and unavailability of daily needs like food and water.", [["children", "ORGANISM", 46, 54], ["children", "SPECIES", 46, 54]]], ["Here, most children were related to families of migrant workers.", [["children", "ORGANISM", 11, 19], ["children", "SPECIES", 11, 19]]], ["Financial loss, as a result of quarantine was found to be a risk factor for symptoms of psychological disorders, anger and anxiety [18, 19].DiscussionAlthough great efforts have been made by the Government of India across country, it is almost impossible to provide psychological interventions nationwide because most local support focuses only on meeting basic needs of children.", [["Financial loss", "DISEASE", 0, 14], ["psychological disorders", "DISEASE", 88, 111], ["anger", "DISEASE", 113, 118], ["anxiety", "DISEASE", 123, 130], ["children", "ORGANISM", 371, 379], ["children", "SPECIES", 371, 379], ["Financial loss", "PROBLEM", 0, 14], ["symptoms", "PROBLEM", 76, 84], ["psychological disorders", "PROBLEM", 88, 111], ["anger", "PROBLEM", 113, 118], ["anxiety", "PROBLEM", 123, 130], ["psychological interventions", "TREATMENT", 266, 293]]], ["In one study, inadequate basic supplies like food, water and clothes during quarantine was a source of frustration, anxiety and anger even after four to 6 mo after release [18].", [["anxiety", "DISEASE", 116, 123], ["anger", "DISEASE", 128, 133], ["one study", "TEST", 3, 12], ["frustration", "PROBLEM", 103, 114], ["anxiety", "PROBLEM", 116, 123]]], ["To minimise the psychological effects we should increase children\u2019s access to disease information via comic books and videos and timely referral to psychiatrist.", [["children", "ORGANISM", 57, 65], ["children", "SPECIES", 57, 65]]], ["Social media could play an important role, allowing people who are quarantined to update their loved ones about themselves.", [["people", "ORGANISM", 52, 58], ["people", "SPECIES", 52, 58]]], ["So, having a working mobile phone is now a necessity, not a luxury.DiscussionThere are several limitations of this study.", [["this study", "TEST", 110, 120]]], ["The sample size was small but it included wide range of adolescent age group.", [["The sample size", "TEST", 0, 15], ["size", "OBSERVATION_MODIFIER", 11, 15], ["small", "OBSERVATION_MODIFIER", 20, 25]]], ["This study relies on children\u2019s, adolescents\u2019 and their parents\u2019 retrospective perception of feelings and behaviors associated with stressful experiences which could be flawed due to recall bias and social desirability.DiscussionIn conclusion, this study suggests that understanding, compliance and knowledge regarding quarantine behavior is poor in the reported group; also the psychological impact of quarantine is wide ranging and substantial.", [["children", "ORGANISM", 21, 29], ["children", "SPECIES", 21, 29], ["adolescents", "SPECIES", 33, 44], ["This study", "TEST", 0, 10], ["this study", "TEST", 244, 254], ["substantial", "OBSERVATION_MODIFIER", 434, 445]]], ["Quarantine, in its present form, requires further research to its utility for assessing transmission of Covid-19 especially in a resource-limited country like ours.", [["Quarantine", "CHEMICAL", 0, 10], ["Quarantine", "CHEMICAL", 0, 10], ["Quarantine", "TREATMENT", 0, 10], ["Covid", "TEST", 104, 109]]], ["Revised requirements, improved preparation along with collaborative network of psychiatrists, psychotherapists, researchers and community volunteers can minimise the psychological impact of quarantine experiences.", [["volunteers", "ORGANISM", 138, 148]]]], "931f8eee65de146dfb47627deac4113a9115bfc3": [["Dear Editor,We read with interest, the article titled 'Cadaverless anatomy: Darkness in the times of pandemic Covid-19', which is published in Morphologie.", [["Darkness", "PROBLEM", 76, 84], ["pandemic Covid", "TEST", 101, 115]]], ["This article authored by Singal et al. [1] has discussed about the teaching of anatomy subject in the pre pandemic and post pandemic eras.", [["anatomy subject", "PROBLEM", 79, 94]]], ["The colleges and universities are closed due to COVID-19 to maintain the social distancing and prevention of spread of infection of this communicable disease.", [["infection", "DISEASE", 119, 128], ["communicable disease", "DISEASE", 137, 157], ["COVID", "TEST", 48, 53], ["infection", "PROBLEM", 119, 128], ["this communicable disease", "PROBLEM", 132, 157], ["infection", "OBSERVATION", 119, 128]]], ["Studying anatomy by dissecting the donated cadavers will not be possible in this period of pandemic COVID-19 [3] .", [["cadavers", "ANATOMY", 43, 51], ["cadavers", "ORGANISM", 43, 51], ["dissecting the donated cadavers", "TREATMENT", 20, 51], ["pandemic COVID", "TEST", 91, 105]]], ["It is true that, students also lost access to other modalities like anatomical models, museum specimens, dried bones and histology slides [1] .", [["specimens", "ANATOMY", 94, 103], ["bones", "ANATOMY", 111, 116], ["bones", "TISSUE", 111, 116], ["anatomical models", "TEST", 68, 85], ["museum specimens", "TEST", 87, 103]]], ["It is unfortunate that these questions are not answerable [4] .Dear Editor,Medical colleges may not accept the bodies during this pandemic and in the future as well, because suspicion arises if the donor is a carrier of COVID-19.", [["COVID-19", "CHEMICAL", 220, 228], ["COVID", "TEST", 220, 225]]], ["It is not possible to test the cadaver for COVID antigen, because the screening kits are not sufficient in the present scenario even for the living people [1] .", [["COVID antigen", "GENE_OR_GENE_PRODUCT", 43, 56], ["people", "ORGANISM", 148, 154], ["COVID antigen", "PROTEIN", 43, 56], ["people", "SPECIES", 148, 154], ["COVID antigen", "PROBLEM", 43, 56], ["the screening kits", "TEST", 66, 84], ["not possible", "UNCERTAINTY", 6, 18]]], ["It is also real that the negative laboratory test may not rule out the possibility of COVID-19 infection [5] .Dear Editor,In this situation of COVID-19, online platforms are helping the students to some extent.Dear Editor,The lecture classes and practical teaching are done with the workplace chat and video meetings, but still the teaching and learning are seriously affected.", [["COVID-19", "CHEMICAL", 86, 94], ["infection", "DISEASE", 95, 104], ["COVID-19", "CHEMICAL", 86, 94], ["COVID-19", "ORGANISM", 86, 94], ["laboratory test", "TEST", 34, 49], ["COVID-19 infection", "PROBLEM", 86, 104], ["COVID", "TEST", 143, 148], ["practical teaching", "TREATMENT", 246, 264]]], ["In 2003 pandemic, the severe acute respiratory syndrome also, the web-based learning was successful in providing the education which the students received [6] .", [["acute respiratory syndrome", "DISEASE", 29, 55], ["the severe acute respiratory syndrome", "PROBLEM", 18, 55], ["severe", "OBSERVATION_MODIFIER", 22, 28], ["acute", "OBSERVATION_MODIFIER", 29, 34], ["respiratory syndrome", "OBSERVATION", 35, 55]]], ["However, the absence of practical teaching due to COVID-19 will have long lasting impact in the knowledge of students.", [["COVID-19", "DNA", 50, 58], ["practical teaching", "TREATMENT", 24, 42]]], ["We are sharing some of the good practices that helped us overcome these limitations in anatomy teaching at our institution.", [["anatomy teaching", "TREATMENT", 87, 103]]], ["These The objective structured practical examination included uploading of cadaveric images in the google form, like images of testis with epididymis, sacral plexus, perineal body, uterus, rectouterine pouch of Douglas, ischial spine, female bony pelvis, suprarenal gland, thyroid gland, ovary, uterine tube, seminal vesicle, vas deferens, hypophyseal fossa, vaginal part of cervix, prostate gland and broad ligament of uterus.", [["testis", "ANATOMY", 127, 133], ["epididymis", "ANATOMY", 139, 149], ["sacral plexus", "ANATOMY", 151, 164], ["perineal body", "ANATOMY", 166, 179], ["uterus", "ANATOMY", 181, 187], ["rectouterine pouch", "ANATOMY", 189, 207], ["ischial spine", "ANATOMY", 220, 233], ["bony pelvis", "ANATOMY", 242, 253], ["suprarenal gland", "ANATOMY", 255, 271], ["thyroid gland", "ANATOMY", 273, 286], ["ovary", "ANATOMY", 288, 293], ["uterine tube", "ANATOMY", 295, 307], ["seminal vesicle", "ANATOMY", 309, 324], ["vas deferens", "ANATOMY", 326, 338], ["hypophyseal fossa", "ANATOMY", 340, 357], ["vaginal part", "ANATOMY", 359, 371], ["cervix", "ANATOMY", 375, 381], ["prostate gland", "ANATOMY", 383, 397], ["ligament", "ANATOMY", 408, 416], ["uterus", "ANATOMY", 420, 426], ["testis", "ORGAN", 127, 133], ["epididymis", "MULTI-TISSUE_STRUCTURE", 139, 149], ["sacral plexus", "MULTI-TISSUE_STRUCTURE", 151, 164], ["perineal body", "TISSUE", 166, 179], ["uterus", "ORGAN", 181, 187], ["rectouterine pouch", "TISSUE", 189, 207], ["ischial spine", "MULTI-TISSUE_STRUCTURE", 220, 233], ["bony pelvis", "MULTI-TISSUE_STRUCTURE", 242, 253], ["suprarenal gland", "ORGAN", 255, 271], ["thyroid gland", "MULTI-TISSUE_STRUCTURE", 273, 286], ["ovary", "ORGAN", 288, 293], ["uterine tube", "TISSUE", 295, 307], ["seminal vesicle", "MULTI-TISSUE_STRUCTURE", 309, 324], ["vas deferens", "MULTI-TISSUE_STRUCTURE", 326, 338], ["hypophyseal fossa", "MULTI-TISSUE_STRUCTURE", 340, 357], ["vaginal part", "MULTI-TISSUE_STRUCTURE", 359, 371], ["cervix", "MULTI-TISSUE_STRUCTURE", 375, 381], ["prostate gland", "MULTI-TISSUE_STRUCTURE", 383, 397], ["ligament", "TISSUE", 408, 416], ["uterus", "ORGAN", 420, 426], ["The objective structured practical examination", "TEST", 6, 52], ["cadaveric images", "TEST", 75, 91], ["sacral plexus, perineal body, uterus, rectouterine pouch of Douglas, ischial spine, female bony pelvis, suprarenal gland, thyroid gland, ovary, uterine tube, seminal vesicle, vas deferens, hypophyseal fossa, vaginal part of cervix, prostate gland and broad ligament of uterus", "PROBLEM", 151, 426], ["testis", "ANATOMY", 127, 133], ["epididymis", "ANATOMY", 139, 149], ["sacral plexus", "ANATOMY", 151, 164], ["perineal body", "ANATOMY", 166, 179], ["uterus", "ANATOMY", 181, 187], ["rectouterine pouch", "OBSERVATION", 189, 207], ["Douglas", "ANATOMY_MODIFIER", 211, 218], ["ischial", "ANATOMY_MODIFIER", 220, 227], ["spine", "ANATOMY", 228, 233], ["female", "ANATOMY_MODIFIER", 235, 241], ["bony", "ANATOMY_MODIFIER", 242, 246], ["pelvis", "ANATOMY", 247, 253], ["suprarenal gland", "ANATOMY", 255, 271], ["thyroid gland", "ANATOMY", 273, 286], ["ovary", "ANATOMY", 288, 293], ["uterine", "ANATOMY", 295, 302], ["tube", "OBSERVATION", 303, 307], ["seminal vesicle", "ANATOMY", 309, 324], ["vas deferens", "ANATOMY", 326, 338], ["hypophyseal fossa", "ANATOMY", 340, 357], ["vaginal", "ANATOMY", 359, 366], ["cervix", "ANATOMY", 375, 381], ["prostate gland", "ANATOMY", 383, 397], ["broad ligament", "ANATOMY", 402, 416], ["uterus", "ANATOMY", 420, 426]]], ["These cadaveric images had 2 questions each, the students should finish one question and then go to other questions.", [["These cadaveric images", "TEST", 0, 22]]], ["All the questions were compulsory and students can't go to next question without answering the initial question.Dear Editor,These assessments were successful in checking the student's knowledge about 'knows how' and 'shows how' competency levels.Dear Editor,Online learning allows the medical students to choice their self-directed learning at home in their convenient time [7] , since recordings are available.", [["These assessments", "TEST", 124, 141]]], ["The three dimensional anatomy can also be learnt by using the virtual dissection table like, the anatomage.", [["dissection", "OBSERVATION", 70, 80]]], ["But it may be difficult to provide perception of real structures in a virtual software or video, because the spatial orientation and visualization of neurovascular structures will not be as clear as in the routine cadaveric dissection [1] .", [["neurovascular structures", "ANATOMY", 150, 174], ["neurovascular structures", "MULTI-TISSUE_STRUCTURE", 150, 174], ["the routine cadaveric dissection", "TREATMENT", 202, 234], ["neurovascular", "ANATOMY", 150, 163], ["dissection", "OBSERVATION", 224, 234]]], ["Singal et al. [1] is correct that the cadaveric dissection skills the fingers and hands of students, who can may become surgeons in the future.", [["fingers", "ANATOMY", 70, 77], ["fingers", "ORGANISM_SUBDIVISION", 70, 77], ["cadaveric", "OBSERVATION_MODIFIER", 38, 47], ["dissection", "OBSERVATION", 48, 58], ["fingers", "ANATOMY", 70, 77]]]], "7c3c3601db52a76d934d57432cd634ea20d7f17b": [["Dear Editor, On March 11, 2020, the world health organization (WHO) declared COVID-19 a pandemic as the world faces unprecedented global health crisis.", [["health crisis", "OBSERVATION", 137, 150]]], ["COVID-19 has severely impacted public life and the global economy [1] .In response, governments aiming to minimize community spread adopted preventive strategies like closing schools and enforcing social distancing.", [["COVID-19", "CHEMICAL", 0, 8], ["COVID", "TEST", 0, 5], ["preventive strategies", "TREATMENT", 140, 161], ["severely", "OBSERVATION_MODIFIER", 13, 21], ["impacted", "OBSERVATION_MODIFIER", 22, 30]]], ["Such measures resulted in suspension of all elective dental care services and limited practice to emergency cases only; this also meant that oral cancer screening has almost entirely stopped.", [["oral cancer", "ANATOMY", 141, 152], ["cancer", "DISEASE", 146, 152], ["oral cancer", "CANCER", 141, 152], ["all elective dental care services", "TREATMENT", 40, 73], ["oral cancer screening", "PROBLEM", 141, 162], ["cancer", "OBSERVATION", 146, 152]]], ["In this letter, we would like to make a case for conducting oral cancer screening when individuals are tested for COVID-19, which, if given careful consideration, would likely improve population health on the long-run.", [["oral cancer", "ANATOMY", 60, 71], ["cancer", "DISEASE", 65, 71], ["oral cancer", "CANCER", 60, 71], ["individuals", "ORGANISM", 87, 98], ["conducting oral cancer screening", "TEST", 49, 81], ["COVID", "TEST", 114, 119]]]], "17141b66d2b8d467aa81af194c447e61d9c1e355": [["IntroductionCoxsackieviruses are members of the genus Enterovirus, family Picornaviridae, and are divided into two groups on the basis of pathogenicity in mice: 23 serotypes of Coxsackie A viruses (CAV) and 6 serotypes of Coxsackie B viruses (CVB).", [["Enterovirus", "DISEASE", 54, 65], ["Coxsackie A viruses", "DISEASE", 177, 196], ["Coxsackie B viruses", "DISEASE", 222, 241], ["Coxsackieviruses", "GENE_OR_GENE_PRODUCT", 12, 28], ["Enterovirus", "ORGANISM", 54, 65], ["mice", "ORGANISM", 155, 159], ["Coxsackie A viruses", "ORGANISM", 177, 196], ["CAV", "ORGANISM", 198, 201], ["Coxsackie B viruses", "ORGANISM", 222, 241], ["CVB", "CANCER", 243, 246], ["mice", "SPECIES", 155, 159], ["Coxsackie A viruses", "SPECIES", 177, 196], ["Coxsackie B viruses", "SPECIES", 222, 241], ["mice", "SPECIES", 155, 159], ["Coxsackie A viruses", "SPECIES", 177, 196], ["CAV", "SPECIES", 198, 201], ["Coxsackie B viruses", "SPECIES", 222, 241], ["IntroductionCoxsackieviruses", "PROBLEM", 0, 28], ["Picornaviridae", "TREATMENT", 74, 88], ["Coxsackie A viruses", "PROBLEM", 177, 196], ["Coxsackie B viruses", "PROBLEM", 222, 241]]], ["CVB had been implicated in childhood myocarditis by the end of the 1950s.", [["CVB", "CHEMICAL", 0, 3], ["myocarditis", "DISEASE", 37, 48], ["CVB", "CANCER", 0, 3], ["CVB", "PROBLEM", 0, 3], ["childhood myocarditis", "PROBLEM", 27, 48], ["myocarditis", "OBSERVATION", 37, 48]]], ["Since then, six CVB serotypes (CVB1-6) have been shown to cause not only myocarditis but also a wide variety of human diseases, including common colds, cardiomyopathy, diabetes, neurological disorders, and inflammation [1] [2] [3] [4] .", [["neurological", "ANATOMY", 178, 190], ["CVB1-6", "CHEMICAL", 31, 37], ["myocarditis", "DISEASE", 73, 84], ["human diseases", "DISEASE", 112, 126], ["colds", "DISEASE", 145, 150], ["cardiomyopathy", "DISEASE", 152, 166], ["diabetes", "DISEASE", 168, 176], ["neurological disorders", "DISEASE", 178, 200], ["inflammation", "DISEASE", 206, 218], ["CVB serotypes", "ORGANISM", 16, 29], ["CVB1-6", "ORGANISM", 31, 37], ["human", "ORGANISM", 112, 117], ["[1] [2] [3] [4]", "SIMPLE_CHEMICAL", 219, 234], ["human", "SPECIES", 112, 117], ["human", "SPECIES", 112, 117], ["six CVB serotypes", "TEST", 12, 29], ["CVB1", "TEST", 31, 35], ["myocarditis", "PROBLEM", 73, 84], ["human diseases", "PROBLEM", 112, 126], ["common colds", "PROBLEM", 138, 150], ["cardiomyopathy", "PROBLEM", 152, 166], ["diabetes", "PROBLEM", 168, 176], ["neurological disorders", "PROBLEM", 178, 200], ["inflammation", "PROBLEM", 206, 218], ["myocarditis", "OBSERVATION", 73, 84], ["cardiomyopathy", "OBSERVATION", 152, 166]]], ["Numerous outbreaks of CVB infections have been noted at the community level, but only Coxsackie virus B 5 (CVB 5 ) is known to have caused widespread nationwide epidemics in the United States, particularly in 1961, 1972, and 1983 [5] .", [["CVB infections", "DISEASE", 22, 36], ["Coxsackie virus B 5 (CVB 5", "CHEMICAL", 86, 112], ["CVB", "CANCER", 22, 25], ["Coxsackie virus B 5", "ORGANISM", 86, 105], ["CVB 5", "ORGANISM", 107, 112], ["Coxsackie virus B", "SPECIES", 86, 103], ["CVB", "SPECIES", 22, 25], ["Coxsackie virus", "SPECIES", 86, 101], ["CVB infections", "PROBLEM", 22, 36], ["Coxsackie virus B", "PROBLEM", 86, 103], ["outbreaks", "OBSERVATION_MODIFIER", 9, 18], ["CVB", "OBSERVATION_MODIFIER", 22, 25], ["infections", "OBSERVATION", 26, 36], ["widespread", "OBSERVATION_MODIFIER", 139, 149]]], ["Moreover, CVB 5 is associated with several human diseases, including encephalitis and myocarditis in immunocompromised children and CNS disease in older adults.IntroductionSince direct viral cytotoxicity is one possible cause of damage, targeting the causative agent should limit the extent of damage, especially with early treatment.", [["CNS", "ANATOMY", 132, 135], ["human diseases", "DISEASE", 43, 57], ["encephalitis", "DISEASE", 69, 81], ["myocarditis", "DISEASE", 86, 97], ["CNS disease", "DISEASE", 132, 143], ["CVB 5", "ORGANISM", 10, 15], ["human", "ORGANISM", 43, 48], ["children", "ORGANISM", 119, 127], ["CNS", "ANATOMICAL_SYSTEM", 132, 135], ["CVB 5", "PROTEIN", 10, 15], ["human", "SPECIES", 43, 48], ["children", "SPECIES", 119, 127], ["human", "SPECIES", 43, 48], ["several human diseases", "PROBLEM", 35, 57], ["encephalitis", "PROBLEM", 69, 81], ["myocarditis", "PROBLEM", 86, 97], ["CNS disease", "PROBLEM", 132, 143], ["direct viral cytotoxicity", "TEST", 178, 203], ["damage", "PROBLEM", 229, 235], ["the causative agent", "TREATMENT", 247, 266], ["damage", "PROBLEM", 294, 300], ["early treatment", "TREATMENT", 318, 333], ["diseases", "OBSERVATION", 49, 57], ["encephalitis", "OBSERVATION", 69, 81], ["myocarditis", "OBSERVATION", 86, 97], ["CNS", "ANATOMY", 132, 135], ["disease", "OBSERVATION", 136, 143], ["damage", "OBSERVATION", 229, 235], ["damage", "OBSERVATION", 294, 300]]], ["Until now, there has been no enterovirus-specific vaccine or therapeutic reagent available for clinical use [6] , although some reports have presented effective candidates for CVB 3 in a murine model [1, 7, 8] .", [["CVB 3", "GENE_OR_GENE_PRODUCT", 176, 181], ["murine", "ORGANISM", 187, 193], ["murine", "SPECIES", 187, 193], ["enterovirus", "PROBLEM", 29, 40], ["specific vaccine", "TREATMENT", 41, 57], ["therapeutic reagent", "TREATMENT", 61, 80], ["CVB", "PROBLEM", 176, 179]]], ["A great number of picornavirus replication inhibitors have been described in vitro, but few of them have shown effectiveness in vivo [9] , and none has been approved for clinical use.", [["picornavirus", "ORGANISM", 18, 30], ["picornavirus replication inhibitors", "TREATMENT", 18, 53], ["great", "OBSERVATION_MODIFIER", 2, 7], ["picornavirus replication", "OBSERVATION", 18, 42]]], ["Gancyclovir and cidofovir have been studied in myocarditis caused by cytomegalovirus in mice [10] , but there is no evidence that it also works for enterovirus-induced myocarditis.", [["Gancyclovir", "CHEMICAL", 0, 11], ["cidofovir", "CHEMICAL", 16, 25], ["myocarditis", "DISEASE", 47, 58], ["cytomegalovirus", "DISEASE", 69, 84], ["myocarditis", "DISEASE", 168, 179], ["Gancyclovir", "CHEMICAL", 0, 11], ["cidofovir", "CHEMICAL", 16, 25], ["Gancyclovir", "SIMPLE_CHEMICAL", 0, 11], ["cidofovir", "SIMPLE_CHEMICAL", 16, 25], ["cytomegalovirus", "ORGANISM", 69, 84], ["mice", "ORGANISM", 88, 92], ["enterovirus", "ORGANISM", 148, 159], ["mice", "SPECIES", 88, 92], ["mice", "SPECIES", 88, 92], ["Gancyclovir", "TREATMENT", 0, 11], ["cidofovir", "TREATMENT", 16, 25], ["myocarditis", "PROBLEM", 47, 58], ["cytomegalovirus", "PROBLEM", 69, 84], ["enterovirus", "PROBLEM", 148, 159], ["myocarditis", "PROBLEM", 168, 179], ["myocarditis", "OBSERVATION", 47, 58], ["cytomegalovirus", "OBSERVATION", 69, 84], ["no evidence", "UNCERTAINTY", 113, 124], ["myocarditis", "OBSERVATION", 168, 179]]], ["Acyclovir has been successfully used to treat myocarditis associated with Epstein-Barr virus [11, 12] and varicella [13] , but there are no reports demonstrating that acyclovir is effective in CVB myocarditis.IntroductionArbidol is an antiviral molecule first developed in Russia.", [["CVB", "ANATOMY", 193, 196], ["Acyclovir", "CHEMICAL", 0, 9], ["myocarditis", "DISEASE", 46, 57], ["Epstein-Barr virus", "DISEASE", 74, 92], ["varicella", "DISEASE", 106, 115], ["acyclovir", "CHEMICAL", 167, 176], ["myocarditis", "DISEASE", 197, 208], ["IntroductionArbidol", "CHEMICAL", 209, 228], ["Acyclovir", "CHEMICAL", 0, 9], ["acyclovir", "CHEMICAL", 167, 176], ["IntroductionArbidol", "CHEMICAL", 209, 228], ["Acyclovir", "SIMPLE_CHEMICAL", 0, 9], ["Epstein-Barr virus", "ORGANISM", 74, 92], ["acyclovir", "SIMPLE_CHEMICAL", 167, 176], ["IntroductionArbidol", "SIMPLE_CHEMICAL", 209, 228], ["Epstein-Barr virus", "SPECIES", 74, 92], ["CVB", "SPECIES", 193, 196], ["Acyclovir", "TREATMENT", 0, 9], ["myocarditis", "PROBLEM", 46, 57], ["Epstein-Barr virus", "PROBLEM", 74, 92], ["varicella", "PROBLEM", 106, 115], ["acyclovir", "TREATMENT", 167, 176], ["CVB myocarditis", "PROBLEM", 193, 208], ["IntroductionArbidol", "TREATMENT", 209, 228], ["an antiviral molecule", "TREATMENT", 232, 253], ["Barr virus", "OBSERVATION", 82, 92], ["myocarditis", "OBSERVATION", 197, 208], ["antiviral molecule", "OBSERVATION", 235, 253]]], ["Its chemical name is ethyl-6-bromo-4-[(dimethylamino)-methyl]-5-hydroxy-1-methyl-2-[(phenylthio) methyl] -indole-3-carboxylate hydrochloride monohydrate.", [["ethyl-6-bromo-4-[(dimethylamino)-methyl]-5-hydroxy-1-methyl-2-[(phenylthio) methyl] -indole-3-carboxylate", "CHEMICAL", 21, 126], ["ethyl-6-bromo-4-[(dimethylamino)-methyl]-5-hydroxy-1-methyl-2-[(phenylthio) methyl] -indole-3-carboxylate hydrochloride monohydrate", "CHEMICAL", 21, 152], ["ethyl-6-bromo-4-[(dimethylamino)-methyl]-5-hydroxy-1-methyl-2-[(phenylthio) methyl] -indole-3-carboxylate hydrochloride monohydrate", "SIMPLE_CHEMICAL", 21, 152], ["hydroxy-1-methyl-2-[(phenylthio) methyl] -indole", "TREATMENT", 64, 112], ["carboxylate hydrochloride monohydrate", "TREATMENT", 115, 152]]], ["Arbidol was first found to have wide-spectrum antiviral activity against human influenza virus.", [["Arbidol", "CHEMICAL", 0, 7], ["influenza virus", "DISEASE", 79, 94], ["Arbidol", "CHEMICAL", 0, 7], ["Arbidol", "SIMPLE_CHEMICAL", 0, 7], ["human", "ORGANISM", 73, 78], ["influenza virus", "ORGANISM", 79, 94], ["human", "SPECIES", 73, 78], ["influenza virus", "SPECIES", 79, 94], ["human influenza virus", "SPECIES", 73, 94], ["Arbidol", "TREATMENT", 0, 7], ["wide-spectrum antiviral activity", "TREATMENT", 32, 64], ["human influenza virus", "PROBLEM", 73, 94], ["antiviral activity", "OBSERVATION", 46, 64]]], ["It was shown to inhibit the reproduction of rimantadine-resistant human influenza virus A, avian viruses H5N1 and H9N2, and influenza viruses B and C [14] .", [["rimantadine", "CHEMICAL", 44, 55], ["influenza virus A", "DISEASE", 72, 89], ["avian viruses H5N1 and H9N2", "DISEASE", 91, 118], ["rimantadine", "CHEMICAL", 44, 55], ["rimantadine", "SIMPLE_CHEMICAL", 44, 55], ["human influenza virus A", "ORGANISM", 66, 89], ["avian viruses H5N1", "ORGANISM", 91, 109], ["H9N2", "ORGANISM", 114, 118], ["influenza viruses B", "ORGANISM", 124, 143], ["human", "SPECIES", 66, 71], ["influenza virus", "SPECIES", 72, 87], ["avian viruses H5N1", "SPECIES", 91, 109], ["H9N2", "SPECIES", 114, 118], ["human influenza virus A", "SPECIES", 66, 89], ["rimantadine", "TREATMENT", 44, 55], ["resistant human influenza virus A", "PROBLEM", 56, 89], ["H5N1", "PROBLEM", 105, 109], ["H9N2", "PROBLEM", 114, 118], ["influenza viruses", "PROBLEM", 124, 141], ["influenza virus", "OBSERVATION", 72, 87]]], ["In many studies, Arbidol also exhibited broad and potent antiviral activity against a number of viruses including respiratory syncytial virus [15] , adenovirus [16] , parainfluenza virus type 5, rhinovirus type 14, avian coronavirus, infectious bronchitis virus and Marek disease virus [17] , hepatitis B virus [18] , and hepatitis C virus [19] .", [["Arbidol", "CHEMICAL", 17, 24], ["respiratory syncytial virus", "DISEASE", 114, 141], ["adenovirus [16] , parainfluenza virus type 5, rhinovirus type 14,", "CHEMICAL", 149, 214], ["avian coronavirus", "DISEASE", 215, 232], ["infectious bronchitis virus", "DISEASE", 234, 261], ["Marek disease", "DISEASE", 266, 279], ["hepatitis B", "DISEASE", 293, 304], ["hepatitis C", "DISEASE", 322, 333], ["Arbidol", "CHEMICAL", 17, 24], ["Arbidol", "SIMPLE_CHEMICAL", 17, 24], ["respiratory syncytial virus", "ORGANISM", 114, 141], ["adenovirus [16] ,", "ORGANISM", 149, 166], ["parainfluenza virus type 5", "ORGANISM", 167, 193], ["rhinovirus type 14", "ORGANISM", 195, 213], ["avian coronavirus", "ORGANISM", 215, 232], ["infectious bronchitis virus", "ORGANISM", 234, 261], ["Marek disease virus [17", "ORGANISM", 266, 289], ["hepatitis B virus", "ORGANISM", 293, 310], ["hepatitis C virus", "ORGANISM", 322, 339], ["respiratory syncytial virus", "SPECIES", 114, 141], ["parainfluenza virus type 5", "SPECIES", 167, 193], ["avian coronavirus", "SPECIES", 215, 232], ["infectious bronchitis virus", "SPECIES", 234, 261], ["Marek disease virus", "SPECIES", 266, 285], ["hepatitis B virus", "SPECIES", 293, 310], ["hepatitis C virus", "SPECIES", 322, 339], ["respiratory syncytial virus", "SPECIES", 114, 141], ["adenovirus", "SPECIES", 149, 159], ["parainfluenza virus type 5", "SPECIES", 167, 193], ["rhinovirus type 14", "SPECIES", 195, 213], ["avian coronavirus", "SPECIES", 215, 232], ["infectious bronchitis virus", "SPECIES", 234, 261], ["Marek disease virus", "SPECIES", 266, 285], ["hepatitis B virus", "SPECIES", 293, 310], ["hepatitis C virus", "SPECIES", 322, 339], ["many studies", "TEST", 3, 15], ["Arbidol", "TREATMENT", 17, 24], ["broad and potent antiviral activity", "TREATMENT", 40, 75], ["viruses", "PROBLEM", 96, 103], ["respiratory syncytial virus", "PROBLEM", 114, 141], ["adenovirus", "PROBLEM", 149, 159], ["parainfluenza virus type", "PROBLEM", 167, 191], ["rhinovirus type 14", "PROBLEM", 195, 213], ["avian coronavirus", "PROBLEM", 215, 232], ["infectious bronchitis virus", "PROBLEM", 234, 261], ["Marek disease virus", "PROBLEM", 266, 285], ["hepatitis B virus", "PROBLEM", 293, 310], ["hepatitis C virus", "PROBLEM", 322, 339], ["potent antiviral activity", "OBSERVATION", 50, 75], ["infectious", "OBSERVATION_MODIFIER", 234, 244]]], ["In our previous study, Arbidol showed broad-spectrum antiviral activity against a number of respiratory viruses, including FLU-A, RSV, HRV 14, and CVB 3 in vitro [20] .", [["Arbidol", "CHEMICAL", 23, 30], ["respiratory viruses", "DISEASE", 92, 111], ["FLU", "CHEMICAL", 123, 126], ["Arbidol", "CHEMICAL", 23, 30], ["Arbidol", "SIMPLE_CHEMICAL", 23, 30], ["FLU-A", "ORGANISM", 123, 128], ["RSV", "ORGANISM", 130, 133], ["HRV 14", "ORGANISM", 135, 141], ["CVB 3", "CELL", 147, 152], ["FLU-A", "SPECIES", 123, 128], ["RSV", "SPECIES", 130, 133], ["our previous study", "TEST", 3, 21], ["Arbidol", "TREATMENT", 23, 30], ["broad-spectrum antiviral activity", "TREATMENT", 38, 71], ["respiratory viruses", "PROBLEM", 92, 111], ["FLU", "TEST", 123, 126], ["RSV", "TEST", 130, 133], ["HRV", "TEST", 135, 138], ["CVB", "TEST", 147, 150], ["antiviral activity", "OBSERVATION", 53, 71], ["respiratory viruses", "OBSERVATION", 92, 111]]], ["The extensive list of Arbidolsensitive viruses includes RNA and DNA viruses, enveloped and non-enveloped viruses, and pH-dependent and -independent viruses, emphasizing a broad spectrum of Arbidol antiviral activity.", [["Arbidol", "CHEMICAL", 189, 196], ["Arbidolsensitive viruses", "ORGANISM", 22, 46], ["DNA", "CELLULAR_COMPONENT", 64, 67], ["Arbidol", "SIMPLE_CHEMICAL", 189, 196], ["Arbidolsensitive viruses", "SPECIES", 22, 46], ["Arbidolsensitive viruses", "PROBLEM", 22, 46], ["RNA", "PROBLEM", 56, 59], ["DNA viruses", "PROBLEM", 64, 75], ["non-enveloped viruses", "PROBLEM", 91, 112], ["pH", "TEST", 118, 120], ["independent viruses", "PROBLEM", 136, 155], ["Arbidol antiviral activity", "TREATMENT", 189, 215], ["extensive", "OBSERVATION_MODIFIER", 4, 13], ["Arbidolsensitive viruses", "OBSERVATION", 22, 46], ["DNA viruses", "OBSERVATION", 64, 75], ["non-enveloped", "OBSERVATION_MODIFIER", 91, 104], ["viruses", "OBSERVATION", 105, 112], ["antiviral activity", "OBSERVATION", 197, 215]]], ["At the same time, the wide spectrum of Arbidol's activity suggests that Arbidol targets common critical step(s) in virus-cell interaction.", [["cell", "ANATOMY", 121, 125], ["Arbidol", "CHEMICAL", 39, 46], ["Arbidol", "CHEMICAL", 72, 79], ["Arbidol", "CHEMICAL", 39, 46], ["Arbidol", "CHEMICAL", 72, 79], ["Arbidol", "SIMPLE_CHEMICAL", 39, 46], ["Arbidol", "SIMPLE_CHEMICAL", 72, 79], ["cell", "CELL", 121, 125], ["Arbidol's activity", "TREATMENT", 39, 57], ["Arbidol targets", "TREATMENT", 72, 87]]], ["In this study, we systematically investigated the antiviral activity of Arbidol against CVB 5 in vitro and in vivo.Chemicals and reagentsArbidol was synthesized at Qianjiang Pharmaceutical Co. Ltd, Hubei, China.", [["Arbidol", "CHEMICAL", 72, 79], ["CVB 5", "CHEMICAL", 88, 93], ["Arbidol", "CHEMICAL", 137, 144], ["Arbidol", "CHEMICAL", 72, 79], ["Arbidol", "CHEMICAL", 137, 144], ["Arbidol", "SIMPLE_CHEMICAL", 72, 79], ["CVB 5", "ORGANISM", 88, 93], ["Arbidol", "SIMPLE_CHEMICAL", 137, 144], ["this study", "TEST", 3, 13], ["Arbidol", "TREATMENT", 72, 79], ["Arbidol", "TREATMENT", 137, 144], ["China", "ANATOMY", 205, 210]]], ["The compound was initially dissolved in dimethyl sulfoxide (DMSO) and further diluted with complete test medium.", [["dimethyl sulfoxide", "CHEMICAL", 40, 58], ["DMSO", "CHEMICAL", 60, 64], ["dimethyl sulfoxide", "CHEMICAL", 40, 58], ["DMSO", "CHEMICAL", 60, 64], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 40, 58], ["DMSO", "SIMPLE_CHEMICAL", 60, 64], ["dimethyl sulfoxide (DMSO", "TREATMENT", 40, 64], ["complete test medium", "TEST", 91, 111]]], ["The final maximum DMSO concentration was 0.05%, which showed no effect on cell cultures.", [["cell cultures", "ANATOMY", 74, 87], ["DMSO", "CHEMICAL", 18, 22], ["DMSO", "CHEMICAL", 18, 22], ["DMSO", "SIMPLE_CHEMICAL", 18, 22], ["cell cultures", "CELL", 74, 87], ["cell cultures", "CELL_LINE", 74, 87], ["The final maximum DMSO concentration", "TREATMENT", 0, 36], ["cell cultures", "TEST", 74, 87], ["no", "UNCERTAINTY", 61, 63]]], ["Therefore, 0.05% DMSO was also added to all no-compound control samples.", [["samples", "ANATOMY", 64, 71], ["DMSO", "CHEMICAL", 17, 21], ["DMSO", "CHEMICAL", 17, 21], ["DMSO", "SIMPLE_CHEMICAL", 17, 21], ["0.05% DMSO", "TREATMENT", 11, 21]]], ["For the in vivo experiment, the compound was dissolved in 0.5% methylcellulose solution.Cell cultures and virusesHEp-2 (human laryngeal carcinoma) cells were maintained in our laboratory and were routinely grown in Eagle's minimal essential medium plus nonessential amino acids (Eagle's MEM; Sigma) supplemented with 10% fetal bovine serum, 0.1% L-glutamine, 100 U/ml penicillin, and 0.1 mg/ml streptomycin.", [["Cell cultures", "ANATOMY", 88, 101], ["virusesHEp-2", "ANATOMY", 106, 118], ["laryngeal carcinoma) cells", "ANATOMY", 126, 152], ["fetal bovine serum", "ANATOMY", 321, 339], ["methylcellulose", "CHEMICAL", 63, 78], ["laryngeal carcinoma", "DISEASE", 126, 145], ["amino acids", "CHEMICAL", 266, 277], ["L-glutamine", "CHEMICAL", 346, 357], ["penicillin", "CHEMICAL", 368, 378], ["streptomycin", "CHEMICAL", 394, 406], ["methylcellulose", "CHEMICAL", 63, 78], ["amino acids", "CHEMICAL", 266, 277], ["L-glutamine", "CHEMICAL", 346, 357], ["penicillin", "CHEMICAL", 368, 378], ["streptomycin", "CHEMICAL", 394, 406], ["methylcellulose", "SIMPLE_CHEMICAL", 63, 78], ["Cell cultures", "CELL", 88, 101], ["virusesHEp-2", "CELL", 106, 118], ["human", "ORGANISM", 120, 125], ["laryngeal carcinoma) cells", "CELL", 126, 152], ["amino acids", "AMINO_ACID", 266, 277], ["bovine", "ORGANISM", 327, 333], ["serum", "ORGANISM_SUBSTANCE", 334, 339], ["L-glutamine", "SIMPLE_CHEMICAL", 346, 357], ["penicillin", "SIMPLE_CHEMICAL", 368, 378], ["streptomycin", "SIMPLE_CHEMICAL", 394, 406], ["virusesHEp-2 (human laryngeal carcinoma) cells", "CELL_LINE", 106, 152], ["human", "SPECIES", 120, 125], ["bovine", "SPECIES", 327, 333], ["human", "SPECIES", 120, 125], ["bovine", "SPECIES", 327, 333], ["0.5% methylcellulose solution", "TREATMENT", 58, 87], ["Cell cultures", "TEST", 88, 101], ["virusesHEp", "TEST", 106, 116], ["human laryngeal carcinoma) cells", "PROBLEM", 120, 152], ["nonessential amino acids", "TEST", 253, 277], ["Eagle's MEM", "TEST", 279, 290], ["10% fetal bovine serum", "TREATMENT", 317, 339], ["L-glutamine", "TREATMENT", 346, 357], ["penicillin", "TREATMENT", 368, 378], ["streptomycin", "TREATMENT", 394, 406], ["laryngeal", "ANATOMY", 126, 135], ["carcinoma", "OBSERVATION", 136, 145]]], ["The test medium used for the cytotoxic assay as well as for antiviral assays contained 2% of the appropriate serum.Cell cultures and virusesCVB 5 was maintained in our laboratory and propagated in HEp-2 cells.", [["serum", "ANATOMY", 109, 114], ["Cell cultures", "ANATOMY", 115, 128], ["HEp-2 cells", "ANATOMY", 197, 208], ["serum", "ORGANISM_SUBSTANCE", 109, 114], ["Cell cultures", "CELL", 115, 128], ["virusesCVB 5", "CELL", 133, 145], ["HEp-2 cells", "CELL", 197, 208], ["virusesCVB 5", "CELL_LINE", 133, 145], ["HEp-2 cells", "CELL_LINE", 197, 208], ["The test medium", "TEST", 0, 15], ["the cytotoxic assay", "TEST", 25, 44], ["antiviral assays", "TEST", 60, 76], ["Cell cultures", "TEST", 115, 128], ["virusesCVB", "TEST", 133, 143], ["HEp", "TEST", 197, 200], ["HEp", "ANATOMY", 197, 200]]], ["The virus was stored in small aliquots at -80\u00b0C until use.Virus titrationVirus titration was performed by the limited dilution method, using a 96-well plate with six wells per dilution.", [["Virus", "ORGANISM", 58, 63], ["The virus", "PROBLEM", 0, 9], ["Virus titrationVirus titration", "TREATMENT", 58, 88], ["virus", "OBSERVATION", 4, 9], ["small", "OBSERVATION_MODIFIER", 24, 29]]], ["The virus titer was estimated from cytopathogenicity of cells induced by viral infection and expressed as 50% tissue culture infectious doses/ml (TCID 50 /ml) [21] .MTT assaysThe cytotoxicity and antiviral activity of the compound were determined by quantitative colorimetric MTT [(3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide)] assay [13, 22] .", [["cells", "ANATOMY", 56, 61], ["tissue culture", "ANATOMY", 110, 124], ["viral infection", "DISEASE", 73, 88], ["3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide", "CHEMICAL", 282, 344], ["MTT", "CHEMICAL", 165, 168], ["MTT", "CHEMICAL", 276, 279], ["(3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide)", "CHEMICAL", 281, 345], ["cells", "CELL", 56, 61], ["(3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide", "SIMPLE_CHEMICAL", 281, 344], ["The virus titer", "TEST", 0, 15], ["cytopathogenicity of cells", "PROBLEM", 35, 61], ["viral infection", "PROBLEM", 73, 88], ["MTT assays", "TEST", 165, 175], ["The cytotoxicity", "TEST", 175, 191], ["dimethylthiazol", "TREATMENT", 290, 305], ["diphenyl tetrazolium bromide", "TREATMENT", 316, 344], ["virus", "OBSERVATION", 4, 9], ["cells", "OBSERVATION", 56, 61], ["viral infection", "OBSERVATION", 73, 88]]], ["Briefly, HEp-2 cells were seeded at 2 9 10 4 cells per well in 96-well plates and grown to subconfluence.", [["HEp-2 cells", "ANATOMY", 9, 20], ["cells", "ANATOMY", 45, 50], ["HEp-2 cells", "CELL", 9, 20], ["cells", "CELL", 45, 50], ["HEp-2 cells", "CELL_LINE", 9, 20], ["HEp-2 cells", "TREATMENT", 9, 20], ["HEp", "ANATOMY", 9, 12]]], ["After removal of the growth medium, serial twofold dilutions of the compound in 200 ll test medium were added.", [["removal", "TREATMENT", 6, 13], ["the growth medium", "TREATMENT", 17, 34], ["serial twofold dilutions", "TREATMENT", 36, 60], ["the compound in 200 ll test medium", "TREATMENT", 64, 98], ["growth", "OBSERVATION_MODIFIER", 21, 27], ["medium", "OBSERVATION_MODIFIER", 28, 34]]], ["At each dilution, four wells were infected with 100 TCID 50 /0.1 ml of virus, while four wells were left uninfected for toxicity determination.", [["toxicity", "DISEASE", 120, 128], ["virus", "PROBLEM", 71, 76], ["toxicity determination", "PROBLEM", 120, 142]]], ["The same dose of Arbidol was added to the plate daily, since its halflife in cultured cells is about 18 h [23] .", [["cells", "ANATOMY", 86, 91], ["Arbidol", "CHEMICAL", 17, 24], ["Arbidol", "CHEMICAL", 17, 24], ["Arbidol", "SIMPLE_CHEMICAL", 17, 24], ["cells", "CELL", 86, 91], ["cultured cells", "CELL_LINE", 77, 91], ["Arbidol", "TREATMENT", 17, 24], ["its halflife in cultured cells", "TEST", 61, 91]]], ["The plates were incubated at 37\u00b0C, and the development of cytopathic effect (CPE) was monitored daily by light microscopy until the virus-infected, untreated cells showed CPE up to 80%.", [["cells", "ANATOMY", 158, 163], ["cells", "CELL", 158, 163], ["untreated cells", "CELL_TYPE", 148, 163], ["The plates", "TEST", 0, 10], ["cytopathic effect (CPE", "PROBLEM", 58, 80], ["light microscopy", "TEST", 105, 121], ["the virus", "TEST", 128, 137], ["infected", "PROBLEM", 138, 146], ["untreated cells", "PROBLEM", 148, 163], ["CPE", "TEST", 171, 174], ["plates", "OBSERVATION_MODIFIER", 4, 10], ["cytopathic", "OBSERVATION_MODIFIER", 58, 68]]], ["At this time point, the culture medium was removed and 25 ll of the MTT solution (5 mg/ml in phosphatebuffered saline, PBS) was added to each well.", [["MTT", "CHEMICAL", 68, 71], ["MTT", "CHEMICAL", 68, 71], ["MTT", "SIMPLE_CHEMICAL", 68, 71], ["saline", "SIMPLE_CHEMICAL", 111, 117], ["the culture medium", "TEST", 20, 38], ["the MTT solution", "TREATMENT", 64, 80], ["phosphatebuffered saline", "TREATMENT", 93, 117], ["PBS", "TREATMENT", 119, 122]]], ["The plate was further incubated for 4 h to allow MTT formazan formation.", [["MTT formazan", "CHEMICAL", 49, 61], ["MTT formazan", "CHEMICAL", 49, 61], ["MTT formazan", "SIMPLE_CHEMICAL", 49, 61], ["The plate", "TREATMENT", 0, 9], ["MTT formazan formation", "TREATMENT", 49, 71], ["plate", "OBSERVATION_MODIFIER", 4, 9]]], ["After removal of the supernatant, 50 ll of DMSO was added for solubilization of formazan crystals, which were homogenized on a microplate shaker for 15 min.", [["supernatant", "ANATOMY", 21, 32], ["DMSO", "CHEMICAL", 43, 47], ["formazan", "CHEMICAL", 80, 88], ["DMSO", "CHEMICAL", 43, 47], ["formazan", "CHEMICAL", 80, 88], ["DMSO", "SIMPLE_CHEMICAL", 43, 47], ["formazan crystals", "SIMPLE_CHEMICAL", 80, 97], ["removal", "TREATMENT", 6, 13], ["the supernatant", "TREATMENT", 17, 32], ["50 ll of DMSO", "TREATMENT", 34, 47], ["solubilization of formazan crystals", "TREATMENT", 62, 97], ["a microplate shaker", "TREATMENT", 125, 144], ["formazan crystals", "OBSERVATION", 80, 97]]], ["The optical densities (ODs) were then read using a microplate spectrophotometer at double wavelengths of 540 and 690 nm.", [["a microplate spectrophotometer", "TREATMENT", 49, 79], ["optical", "OBSERVATION_MODIFIER", 4, 11], ["densities", "OBSERVATION", 12, 21], ["690 nm", "OBSERVATION_MODIFIER", 113, 119]]], ["Results were expressed as a percentage of OD value of treated cell cultures with respect to untreated ones.", [["cell cultures", "ANATOMY", 62, 75], ["cell cultures", "CELL", 62, 75], ["treated cell cultures", "CELL_LINE", 54, 75], ["treated cell cultures", "PROBLEM", 54, 75]]], ["All data were analyzed with SPSS 11.5, and the 50% cytotoxic (CC 50 ) and 50% inhibitory (IC 50 ) concentrations of the agent were determined.", [["CC", "CHEMICAL", 62, 64], ["All data", "TEST", 0, 8], ["SPSS", "TEST", 28, 32], ["CC", "TEST", 62, 64], ["the agent", "TREATMENT", 116, 125]]], ["Thus, the therapeutic index (TI) for the compound was also determined from CC 50 /IC 50 .", [["CC", "CHEMICAL", 75, 77]]], ["Each dilution was tested in triplicate, and in each set of experiments, three control wells without drug were included.Compound treatment before virus infectionSerial twofold dilutions of the compound were dissolved in MEM and incubated with HEp-2 cells in 96-well microtiter plates for 24 h at 37\u00b0C in a 5% CO 2 atmosphere.", [["HEp-2 cells", "ANATOMY", 242, 253], ["MEM", "CHEMICAL", 219, 222], ["CO", "CHEMICAL", 308, 310], ["HEp-2 cells", "CELL", 242, 253], ["HEp-2 cells", "CELL_LINE", 242, 253], ["Each dilution", "TREATMENT", 0, 13], ["drug", "TREATMENT", 100, 104], ["Compound treatment", "TREATMENT", 119, 137], ["virus infectionSerial twofold dilutions", "TREATMENT", 145, 184], ["the compound", "PROBLEM", 188, 200], ["HEp-2 cells", "TREATMENT", 242, 253]]], ["After removal of the compound, the cells were washed twice with PBS and challenged with 100 TCID 50 /0.1 ml of CVB 5 .", [["cells", "ANATOMY", 35, 40], ["cells", "CELL", 35, 40], ["removal", "TREATMENT", 6, 13], ["the cells", "TREATMENT", 31, 40], ["PBS", "TREATMENT", 64, 67], ["compound", "OBSERVATION_MODIFIER", 21, 29]]], ["After a 1-h incubation, the cells were washed twice with PBS and further incubated with test medium until typical CPE was visible.", [["cells", "ANATOMY", 28, 33], ["cells", "CELL", 28, 33], ["a 1-h incubation", "TREATMENT", 6, 22], ["the cells", "TREATMENT", 24, 33], ["PBS", "TREATMENT", 57, 60], ["test medium", "TREATMENT", 88, 99], ["typical CPE", "PROBLEM", 106, 117]]], ["The inhibition of the virusinduced CPE was scored by light microscopy and measured by the MTT assay.", [["MTT", "CHEMICAL", 90, 93], ["the virusinduced CPE", "TEST", 18, 38], ["light microscopy", "TEST", 53, 69], ["the MTT assay", "TEST", 86, 99]]], ["Four untreated virus controls and four uninfected, untreated cell controls were included in all assays.", [["cell", "ANATOMY", 61, 65], ["cell", "CELL", 61, 65], ["Four untreated virus controls", "PROBLEM", 0, 29], ["untreated cell controls", "PROBLEM", 51, 74], ["virus", "OBSERVATION", 15, 20], ["cell controls", "OBSERVATION", 61, 74]]], ["All data presented are results of experiments performed in triplicate.Virucidal assayViral suspensions were cocultured with serial twofold dilutions of the compound at 37\u00b0C for 1 h and then added to confluent cells.", [["cells", "ANATOMY", 209, 214], ["cells", "CELL", 209, 214], ["Virucidal assayViral suspensions", "CELL_LINE", 70, 102], ["confluent cells", "CELL_LINE", 199, 214], ["All data", "TEST", 0, 8], ["Virucidal assayViral suspensions", "TREATMENT", 70, 102], ["serial twofold dilutions", "TEST", 124, 148], ["confluent cells", "PROBLEM", 199, 214], ["confluent cells", "OBSERVATION", 199, 214]]], ["After a 1-h incubation, the solutions containing both compound and viruses were removed; the cells were rinsed carefully with PBS and further incubated with test medium.", [["cells", "ANATOMY", 93, 98], ["cells", "CELL", 93, 98], ["a 1-h incubation", "TREATMENT", 6, 22], ["the solutions", "TREATMENT", 24, 37], ["viruses", "PROBLEM", 67, 74], ["the cells", "TREATMENT", 89, 98], ["PBS", "TREATMENT", 126, 129], ["test medium", "TEST", 157, 168]]], ["The assay was performed following the protocol described above.Compound treatment after virus infectionThe experiment was carried out as above with the following difference: confluent cell monolayers were infected with 100TCID 50 /0.1 ml viruses for 1 h.", [["cell monolayers", "ANATOMY", 184, 199], ["infection", "DISEASE", 94, 103], ["100TCID", "CHEMICAL", 219, 226], ["cell monolayers", "CELL", 184, 199], ["confluent cell monolayers", "CELL_LINE", 174, 199], ["The assay", "TEST", 0, 9], ["the protocol", "TREATMENT", 34, 46], ["Compound treatment", "TREATMENT", 63, 81], ["virus infection", "PROBLEM", 88, 103], ["confluent cell monolayers", "PROBLEM", 174, 199], ["confluent", "OBSERVATION_MODIFIER", 174, 183], ["cell monolayers", "OBSERVATION", 184, 199]]], ["The cell sheets were washed with PBS and overlaid with different doses of the compound in 200 ll test medium.Compound treatment after virus infectionSemi-quantitative detection of viral RNA by RT-PCR RNA was extracted from both supernatants and cells after compound treatment and virus infection using Trizol reagent (Invitrogen).", [["cell sheets", "ANATOMY", 4, 15], ["supernatants", "ANATOMY", 228, 240], ["cells", "ANATOMY", 245, 250], ["infection", "DISEASE", 286, 295], ["cell sheets", "CELL", 4, 15], ["cells", "CELL", 245, 250], ["viral RNA", "RNA", 180, 189], ["The cell sheets", "TREATMENT", 0, 15], ["PBS", "TREATMENT", 33, 36], ["Compound treatment", "TREATMENT", 109, 127], ["virus infection", "PROBLEM", 134, 149], ["viral RNA", "PROBLEM", 180, 189], ["PCR RNA", "TEST", 196, 203], ["compound treatment", "TREATMENT", 257, 275], ["virus infection", "PROBLEM", 280, 295], ["Trizol reagent (Invitrogen)", "TREATMENT", 302, 329], ["cell sheets", "OBSERVATION", 4, 15], ["viral RNA", "OBSERVATION", 180, 189]]], ["We also purified the RNA of the uninfected cells, the infected cells without treatment and the test medium as negative, positive and blank controls.", [["cells", "ANATOMY", 43, 48], ["cells", "ANATOMY", 63, 68], ["cells", "CELL", 43, 48], ["cells", "CELL", 63, 68], ["uninfected cells", "CELL_TYPE", 32, 48], ["infected cells", "CELL_TYPE", 54, 68], ["the infected cells", "PROBLEM", 50, 68], ["treatment", "TREATMENT", 77, 86], ["the test medium", "TEST", 91, 106], ["uninfected cells", "OBSERVATION", 32, 48], ["infected cells", "OBSERVATION", 54, 68]]], ["RNA was dissolved in RNase-free water, and the concentration was measured using a spectrophotometer (Bio-Rad).", [["RNase", "GENE_OR_GENE_PRODUCT", 21, 26], ["RNA", "RNA", 0, 3], ["RNase", "PROTEIN", 21, 26], ["RNase-free water", "TREATMENT", 21, 37], ["the concentration", "TREATMENT", 43, 60], ["a spectrophotometer (Bio-Rad)", "TREATMENT", 80, 109], ["dissolved", "OBSERVATION_MODIFIER", 8, 17]]], ["All samples were adjusted to 1 lg/ll according to the method of Yamamoto et al. [24] .", [["samples", "ANATOMY", 4, 11], ["All samples", "TEST", 0, 11]]], ["Random primers were used for the preparation of complementary DNA templates for PCR.", [["DNA", "CELLULAR_COMPONENT", 62, 65], ["complementary DNA templates", "DNA", 48, 75], ["Random primers", "TREATMENT", 0, 14], ["complementary DNA templates", "TREATMENT", 48, 75], ["PCR", "TEST", 80, 83]]], ["The forward and reverse primers used for RT-PCR were 5 0 -CCCCGGACTGAGTATCA ATA-3 0 (180-199) and 5 0 -GCAGTTAGGATTAGCCGC AT-3 0 (479-460), respectively.Compound treatment after virus infectionb-actin was used as internal control, and the sequences were 5 0 -GGCGGGACCACCATGTACCCT-3 0 and 5 0 -AGG GGCCGGACTCGTCATACT-3 0 .Compound treatment after virus infectionTwenty-eight cycles of PCR were carried out in 50-ll reaction mixtures containing 10 ll synthesized cDNA, 5 ll 10X PCR buffer, 10 ll 1 M dNTPs, 1 ll of primer 1, 1 ll of primer 2, 1 ll b-actin 220 P1, 1 ll b-actin 220 P2, 1 ll of Taq DNA polymerase, and 30 ll of mineral oil, which was placed on top of the PCR mixture to prevent evaporation.", [["oil", "ANATOMY", 633, 636], ["infection", "DISEASE", 353, 362], ["dNTPs", "CHEMICAL", 499, 504], ["dNTPs", "CHEMICAL", 499, 504], ["infectionb-actin", "GENE_OR_GENE_PRODUCT", 184, 200], ["DNA", "CELLULAR_COMPONENT", 596, 599], ["forward and reverse primers", "DNA", 4, 31], ["actin", "PROTEIN", 195, 200], ["AGG GGCCGGACTCGTCATACT-3 0", "DNA", 294, 320], ["ll synthesized cDNA", "DNA", 447, 466], ["primer 1", "DNA", 514, 522], ["primer 2", "DNA", 532, 540], ["ll b-actin 220 P1", "DNA", 544, 561], ["ll b-actin 220 P2", "DNA", 565, 582], ["Taq DNA polymerase", "DNA", 592, 610], ["reverse primers", "TREATMENT", 16, 31], ["RT-PCR", "TEST", 41, 47], ["CCCCGGACTGAGTATCA ATA", "TEST", 58, 79], ["GCAGTTAGGATTAGCCGC", "TEST", 103, 121], ["Compound treatment", "TREATMENT", 153, 171], ["virus infectionb", "PROBLEM", 178, 194], ["actin", "TREATMENT", 195, 200], ["the sequences", "TEST", 235, 248], ["-GGCGGGACCACCATGTACCCT", "TEST", 258, 280], ["Compound treatment", "TREATMENT", 322, 340], ["virus infection", "PROBLEM", 347, 362], ["PCR", "TEST", 385, 388], ["dNTPs", "TEST", 499, 504], ["primer", "TEST", 514, 520], ["primer", "TEST", 532, 538], ["Taq DNA polymerase", "TEST", 592, 610], ["mineral oil", "TREATMENT", 625, 636], ["the PCR mixture", "TREATMENT", 665, 680], ["evaporation", "OBSERVATION", 692, 703]]], ["A programmed thermal cycler was set as follows: 94\u00b0C for 300 s, 94\u00b0C for 300 s, and 53\u00b0C for 45 s, 72\u00b0C for 45 s, and 72\u00b0C for 5 min.", [["A programmed thermal cycler", "TREATMENT", 0, 27]]], ["Then, 5 ll of each PCR product was loaded onto an agarose gel containing ethidium bromide and separated by electrophoresis.", [["ethidium bromide", "CHEMICAL", 73, 89], ["ethidium bromide", "CHEMICAL", 73, 89], ["agarose", "SIMPLE_CHEMICAL", 50, 57], ["ethidium bromide", "SIMPLE_CHEMICAL", 73, 89], ["5 ll of each PCR product", "TREATMENT", 6, 30], ["an agarose gel", "TREATMENT", 47, 61], ["ethidium bromide", "TREATMENT", 73, 89]]], ["The gel was scanned using the SX-300 photoanalysis system and analyzed using Four Stars Bioimage software, which calculates the ratio of peak value adsorption of CVB to that of b-actin.Coxsackie virus B5 infections in miceSpecific-pathogen-free male BALB/c mice, 3-4 weeks old (13-15 g), obtained from Animal Center of Wuhan University, were used in all experiments.", [["infections", "DISEASE", 204, 214], ["b-actin", "CHEMICAL", 177, 184], ["CVB", "SIMPLE_CHEMICAL", 162, 165], ["b-actin", "GENE_OR_GENE_PRODUCT", 177, 184], ["Coxsackie virus B5", "ORGANISM", 185, 203], ["miceSpecific-pathogen-free", "ORGANISM", 218, 244], ["male", "ORGANISM", 245, 249], ["BALB/c mice", "ORGANISM", 250, 261], ["CVB", "PROTEIN", 162, 165], ["b-actin", "PROTEIN", 177, 184], ["Coxsackie virus B5", "SPECIES", 185, 203], ["mice", "SPECIES", 257, 261], ["Coxsackie virus B5", "SPECIES", 185, 203], ["mice", "SPECIES", 257, 261], ["the SX-300 photoanalysis system", "TREATMENT", 26, 57], ["b-actin", "TREATMENT", 177, 184], ["Coxsackie virus B5 infections", "PROBLEM", 185, 214]]], ["Sixty-four BALB/c mice (16 mice/group, four groups) were used in this experiment.", [["BALB/c mice", "ORGANISM", 11, 22], ["mice", "ORGANISM", 27, 31], ["mice", "SPECIES", 18, 22], ["mice", "SPECIES", 27, 31], ["mice", "SPECIES", 18, 22], ["mice", "SPECIES", 27, 31], ["BALB/c mice (16 mice/group, four groups)", "TREATMENT", 11, 51]]], ["Forty-eight mice were infected intraperitoneally with CVB 5 (10 5 TCID 50 /0.1 ml), and the remaining 16 were used as normal control and injected intraperitoneally with the same volume of PBS.", [["intraperitoneally", "ANATOMY", 31, 48], ["mice", "ORGANISM", 12, 16], ["mice", "SPECIES", 12, 16], ["mice", "SPECIES", 12, 16], ["CVB", "TREATMENT", 54, 57], ["the same volume of PBS", "TREATMENT", 169, 191]]], ["After infection for 24 hours, mice were treated by oral gavage (p.o.) with 0.1 ml Arbidol, corresponding to approximately 25 and 50 mg/kg body weight/day, and treatment was continued daily for 6 days unless otherwise indicated.", [["oral", "ANATOMY", 51, 55], ["body", "ANATOMY", 138, 142], ["infection", "DISEASE", 6, 15], ["Arbidol", "CHEMICAL", 82, 89], ["Arbidol", "CHEMICAL", 82, 89], ["mice", "ORGANISM", 30, 34], ["oral", "ORGANISM_SUBDIVISION", 51, 55], ["Arbidol", "SIMPLE_CHEMICAL", 82, 89], ["body", "ORGANISM_SUBDIVISION", 138, 142], ["mice", "SPECIES", 30, 34], ["mice", "SPECIES", 30, 34], ["infection", "PROBLEM", 6, 15], ["oral gavage", "TREATMENT", 51, 62], ["0.1 ml Arbidol", "TREATMENT", 75, 89], ["treatment", "TREATMENT", 159, 168], ["infection", "OBSERVATION", 6, 15]]], ["The virus control group and the normal (PBS) control group received 0.5% methylcellulose solution instead of the compound.Coxsackie virus B5 infections in miceEight mice from each group were sacrificed by cervical dislocation on day 6 after viral exposure.", [["cervical", "ANATOMY", 205, 213], ["methylcellulose", "CHEMICAL", 73, 88], ["infections", "DISEASE", 141, 151], ["cervical dislocation", "DISEASE", 205, 225], ["methylcellulose", "CHEMICAL", 73, 88], ["methylcellulose", "SIMPLE_CHEMICAL", 73, 88], ["Coxsackie virus B5", "ORGANISM", 122, 140], ["miceEight mice", "ORGANISM", 155, 169], ["cervical", "ORGAN", 205, 213], ["Coxsackie virus B5", "SPECIES", 122, 140], ["mice", "SPECIES", 165, 169], ["Coxsackie virus B5", "SPECIES", 122, 140], ["mice", "SPECIES", 165, 169], ["The virus control group", "TREATMENT", 0, 23], ["0.5% methylcellulose solution", "TREATMENT", 68, 97], ["Coxsackie virus B5 infections", "PROBLEM", 122, 151], ["cervical dislocation", "PROBLEM", 205, 225], ["viral exposure", "PROBLEM", 241, 255], ["virus", "OBSERVATION", 4, 9], ["normal", "OBSERVATION", 32, 38], ["cervical", "ANATOMY", 205, 213], ["dislocation", "OBSERVATION", 214, 225]]], ["The body weights of the mice were recorded daily until the animals were killed.", [["body", "ANATOMY", 4, 8], ["body", "ORGANISM_SUBDIVISION", 4, 8], ["mice", "ORGANISM", 24, 28], ["mice", "SPECIES", 24, 28], ["mice", "SPECIES", 24, 28]]], ["The lungs and hearts were harvested and weighed.", [["lungs", "ANATOMY", 4, 9], ["hearts", "ANATOMY", 14, 20], ["lungs", "ORGAN", 4, 9], ["hearts", "ORGAN", 14, 20], ["lungs", "ANATOMY", 4, 9], ["hearts", "ANATOMY", 14, 20], ["harvested", "OBSERVATION", 26, 35]]], ["The organs from four mice of each group were subsequently homogenized to 10% (weight/volume) suspensions in test medium.", [["organs", "ANATOMY", 4, 10], ["organs", "ORGAN", 4, 10], ["mice", "ORGANISM", 21, 25], ["mice", "SPECIES", 21, 25], ["mice", "SPECIES", 21, 25], ["weight/volume) suspensions", "TREATMENT", 78, 104], ["organs", "ANATOMY", 4, 10]]], ["The homogenates were frozen and thawed twice to release the virus and centrifuged at 3,000 rpm for 10 min.", [["homogenates", "ANATOMY", 4, 15]]], ["Virus titration was determined by plaque assay, and the organs from another four mice were used for pathological examination (HE staining).The lung index was expressed as the ratio of mean lung weights to mean body weights [25] .", [["plaque", "ANATOMY", 34, 40], ["organs", "ANATOMY", 56, 62], ["lung", "ANATOMY", 143, 147], ["lung", "ANATOMY", 189, 193], ["body", "ANATOMY", 210, 214], ["Virus", "ORGANISM", 0, 5], ["organs", "ORGAN", 56, 62], ["mice", "ORGANISM", 81, 85], ["lung", "ORGAN", 143, 147], ["lung", "ORGAN", 189, 193], ["body", "ORGANISM_SUBDIVISION", 210, 214], ["mice", "SPECIES", 81, 85], ["mice", "SPECIES", 81, 85], ["Virus titration", "TREATMENT", 0, 15], ["plaque assay", "TEST", 34, 46], ["pathological examination", "TEST", 100, 124], ["The lung index", "TEST", 139, 153], ["mean lung weights", "TEST", 184, 201], ["mean body weights", "TEST", 205, 222], ["organs", "ANATOMY", 56, 62], ["lung", "ANATOMY", 143, 147], ["index", "OBSERVATION", 148, 153]]], ["The remaining eight animals of each group were observed daily for changes in body weight and for any deaths.Viral plaque assay of lung and heart samplesThe titers of infectious virus particles were determined by the standard plaque formation assay.", [["body", "ANATOMY", 77, 81], ["plaque", "ANATOMY", 114, 120], ["lung", "ANATOMY", 130, 134], ["heart samples", "ANATOMY", 139, 152], ["plaque", "ANATOMY", 225, 231], ["deaths", "DISEASE", 101, 107], ["animals", "ORGANISM", 20, 27], ["body", "ORGANISM_SUBDIVISION", 77, 81], ["lung", "ORGAN", 130, 134], ["heart samples", "CANCER", 139, 152], ["plaque", "PATHOLOGICAL_FORMATION", 225, 231], ["changes in body weight", "PROBLEM", 66, 88], ["Viral plaque assay of lung and heart samples", "PROBLEM", 108, 152], ["infectious virus particles", "PROBLEM", 166, 192], ["remaining", "OBSERVATION_MODIFIER", 4, 13], ["eight", "OBSERVATION_MODIFIER", 14, 19], ["animals", "OBSERVATION_MODIFIER", 20, 27], ["plaque", "OBSERVATION", 114, 120], ["lung", "ANATOMY", 130, 134], ["heart", "ANATOMY", 139, 144], ["infectious", "OBSERVATION_MODIFIER", 166, 176], ["plaque", "OBSERVATION", 225, 231]]], ["Replicate aliquots (500 ll/well) of serial 10-fold dilutions were inoculated onto HEp-2 cell monolayers in 6-well plates and incubated at 37\u00b0C in 5% CO 2 .", [["HEp-2 cell monolayers", "ANATOMY", 82, 103], ["CO 2", "CHEMICAL", 149, 153], ["HEp-2 cell monolayers", "CELL", 82, 103], ["HEp-2 cell monolayers", "CELL_LINE", 82, 103], ["serial 10-fold dilutions", "TREATMENT", 36, 60], ["HEp", "TEST", 82, 85], ["cell monolayers", "TEST", 88, 103], ["cell monolayers", "OBSERVATION", 88, 103]]], ["Two days later, the CPE was read; results were expressed as PFUs.Antiviral effect of Arbidol against Coxsackie virus B5 in vitroArbidol showed significant inhibitory activity against CVB 5 when added after infection, with an IC 50 of 6.62 lg/ml, TI of 12.45, and mild inhibitory activity against CVB when added before infection, with an IC 50 of 30.34 lg/ml, which is close to the CC 50 of the compound (82.12 lg/ml), and TI of 2.7 (see Table 1 ).Antiviral effect of Arbidol against Coxsackie virus B5 in vitroTo investigate the direct inactivating effect of Arbidol, virus was treated for 1 h with concentrations of Arbidol ranging from 0.5 to 20 lg/ml.", [["Arbidol", "CHEMICAL", 85, 92], ["Coxsackie virus B5", "CHEMICAL", 101, 119], ["vitroArbidol", "CHEMICAL", 123, 135], ["CVB 5", "CHEMICAL", 183, 188], ["infection", "DISEASE", 206, 215], ["CVB", "CHEMICAL", 296, 299], ["infection", "DISEASE", 318, 327], ["CC", "CHEMICAL", 381, 383], ["Arbidol", "CHEMICAL", 467, 474], ["Coxsackie virus B5", "CHEMICAL", 483, 501], ["Arbidol", "CHEMICAL", 559, 566], ["Arbidol", "CHEMICAL", 617, 624], ["Arbidol", "CHEMICAL", 85, 92], ["vitroArbidol", "CHEMICAL", 123, 135], ["Arbidol", "CHEMICAL", 467, 474], ["Arbidol", "CHEMICAL", 559, 566], ["Arbidol", "CHEMICAL", 617, 624], ["Arbidol", "SIMPLE_CHEMICAL", 85, 92], ["Coxsackie virus B5", "ORGANISM", 101, 119], ["vitroArbidol", "SIMPLE_CHEMICAL", 123, 135], ["CVB 5", "ORGANISM", 183, 188], ["CVB", "SIMPLE_CHEMICAL", 296, 299], ["Arbidol", "SIMPLE_CHEMICAL", 467, 474], ["Coxsackie virus B5", "ORGANISM", 483, 501], ["Arbidol", "SIMPLE_CHEMICAL", 559, 566], ["Arbidol", "SIMPLE_CHEMICAL", 617, 624], ["Coxsackie virus B5", "SPECIES", 101, 119], ["Coxsackie virus B5", "SPECIES", 483, 501], ["Coxsackie virus B5", "SPECIES", 101, 119], ["CVB", "SPECIES", 183, 186], ["CVB", "SPECIES", 296, 299], ["Coxsackie virus B5", "SPECIES", 483, 501], ["the CPE", "TEST", 16, 23], ["PFUs", "TEST", 60, 64], ["Antiviral effect", "TREATMENT", 65, 81], ["Arbidol", "TREATMENT", 85, 92], ["Coxsackie virus B5", "TREATMENT", 101, 119], ["vitroArbidol", "TREATMENT", 123, 135], ["infection", "PROBLEM", 206, 215], ["an IC", "TEST", 222, 227], ["TI", "TEST", 246, 248], ["mild inhibitory activity against CVB", "PROBLEM", 263, 299], ["infection", "PROBLEM", 318, 327], ["an IC", "TEST", 334, 339], ["TI", "TEST", 422, 424], ["Antiviral effect", "TREATMENT", 447, 463], ["Arbidol", "TREATMENT", 467, 474], ["Coxsackie virus B5", "TREATMENT", 483, 501], ["Arbidol, virus", "TREATMENT", 559, 573], ["Arbidol", "TREATMENT", 617, 624], ["significant", "OBSERVATION_MODIFIER", 143, 154], ["inhibitory activity", "OBSERVATION", 155, 174], ["infection", "OBSERVATION", 206, 215], ["mild", "OBSERVATION_MODIFIER", 263, 267], ["inhibitory activity", "OBSERVATION", 268, 287], ["infection", "OBSERVATION", 318, 327]]], ["As shown in Table 1 , Arbidol was virucidal for CVB 5 , with an IC 50 of 2.66, and it inhibited the CPE of CVB 5 on HEp-2 cells, with a TI of 27.56.Semiquantitative detection of viral RNA by RT-PCRRNA was extracted from the supernatants and cells in each well of the plates that were treated with the compound after virus infection, using Trizol (Invitrogen) according to the manufacturer's protocol.", [["HEp-2 cells", "ANATOMY", 116, 127], ["supernatants", "ANATOMY", 224, 236], ["cells", "ANATOMY", 241, 246], ["Arbidol", "CHEMICAL", 22, 29], ["infection", "DISEASE", 322, 331], ["Arbidol", "CHEMICAL", 22, 29], ["Arbidol", "SIMPLE_CHEMICAL", 22, 29], ["HEp-2 cells", "CELL", 116, 127], ["cells", "CELL", 241, 246], ["HEp-2 cells", "CELL_LINE", 116, 127], ["viral RNA", "RNA", 178, 187], ["PCRRNA", "PROTEIN", 194, 200], ["Arbidol", "TREATMENT", 22, 29], ["CVB", "TEST", 48, 51], ["an IC", "TEST", 61, 66], ["the CPE of CVB", "PROBLEM", 96, 110], ["HEp", "TEST", 116, 119], ["a TI", "TEST", 134, 138], ["viral RNA", "PROBLEM", 178, 187], ["PCRRNA", "TEST", 194, 200], ["virus infection", "PROBLEM", 316, 331], ["Trizol (Invitrogen", "TREATMENT", 339, 357], ["the manufacturer's protocol", "TREATMENT", 372, 399], ["viral RNA", "OBSERVATION", 178, 187]]], ["Specific amplified products of CVB 5 (280 bp) and b-actin (220 bp) by the two pairs of primers were identified as described in ''Materials and methods''.", [["CVB 5", "GENE_OR_GENE_PRODUCT", 31, 36], ["b-actin", "GENE_OR_GENE_PRODUCT", 50, 57], ["CVB 5", "DNA", 31, 36], ["b-actin", "DNA", 50, 57], ["CVB", "TEST", 31, 34], ["bp", "TEST", 42, 44], ["b-actin", "TEST", 50, 57], ["bp", "TEST", 63, 65]]], ["Figure 1a is the gel picture of the PCR products.", [["the PCR products", "TREATMENT", 32, 48]]], ["The gel was scanned using the SX-300 photoanalysis system and analyzed using Four Stars Bioimage software.", [["the SX-300 photoanalysis system", "TREATMENT", 26, 57]]], ["The ratio of peak value adsorption of CVB to that of b-actin was calculated by the software (shown in Fig. 1b) .", [["CVB", "SIMPLE_CHEMICAL", 38, 41], ["b-actin", "GENE_OR_GENE_PRODUCT", 53, 60], ["CVB", "PROTEIN", 38, 41], ["b-actin", "PROTEIN", 53, 60], ["The ratio", "TEST", 0, 9], ["peak value adsorption of CVB", "PROBLEM", 13, 41], ["peak", "OBSERVATION_MODIFIER", 13, 17]]], ["There was a quantitative relationship between the ratio and dose of Arbidol.", [["Arbidol", "CHEMICAL", 68, 75], ["Arbidol", "CHEMICAL", 68, 75], ["Arbidol", "SIMPLE_CHEMICAL", 68, 75], ["Arbidol", "TREATMENT", 68, 75]]], ["The ratio decreased with increasing dose of Arbidol, suggesting that the synthesis of CVB 5 RNA decreased with the increasing dose of compound when treatment was done after infection.Clinical observationsIn the viral control group, animals showed a tendency to huddle; diminished vitality, ruffled fur, and weight loss (Fig. 2a) were observed on day 6 after infection.", [["Arbidol", "CHEMICAL", 44, 51], ["infection", "DISEASE", 173, 182], ["weight loss", "DISEASE", 307, 318], ["infection", "DISEASE", 358, 367], ["Arbidol", "CHEMICAL", 44, 51], ["Arbidol", "SIMPLE_CHEMICAL", 44, 51], ["CVB 5", "ORGANISM", 86, 91], ["animals", "ORGANISM", 232, 239], ["CVB 5 RNA", "RNA", 86, 95], ["The ratio", "TEST", 0, 9], ["Arbidol", "TREATMENT", 44, 51], ["the synthesis of CVB 5 RNA", "PROBLEM", 69, 95], ["treatment", "TREATMENT", 148, 157], ["infection", "PROBLEM", 173, 182], ["Clinical observations", "TEST", 183, 204], ["a tendency to huddle", "PROBLEM", 247, 267], ["diminished vitality", "PROBLEM", 269, 288], ["ruffled fur", "PROBLEM", 290, 301], ["weight loss", "PROBLEM", 307, 318], ["infection", "PROBLEM", 358, 367], ["ratio", "OBSERVATION_MODIFIER", 4, 9], ["decreased", "OBSERVATION_MODIFIER", 10, 19], ["viral", "OBSERVATION_MODIFIER", 211, 216], ["diminished", "OBSERVATION_MODIFIER", 269, 279], ["ruffled fur", "OBSERVATION", 290, 301], ["infection", "OBSERVATION", 358, 367]]], ["On day 8, this group of animals began to die, and by 18 day, all of them had died (Fig. 2b) .", [["animals", "ORGANISM", 24, 31]]], ["In the compound-treated group, the animals receiving 25 mg/kg body weight/day began to show behavior changes and lose weight by day 9 (Fig. 2a) and began to die on day 12 after challenge.", [["body", "ANATOMY", 62, 66], ["animals", "ORGANISM", 35, 42], ["body", "ORGANISM_SUBDIVISION", 62, 66], ["behavior changes", "PROBLEM", 92, 108]]], ["The animals receiving 50 mg/kg body weight/day and the normal control animals did not show abnormalities during the 30-day period, except that the former group had a slight weight loss (Fig. 2a) .", [["body", "ANATOMY", 31, 35], ["weight loss", "DISEASE", 173, 184], ["animals", "ORGANISM", 4, 11], ["body", "ORGANISM_SUBDIVISION", 31, 35], ["animals", "ORGANISM", 70, 77], ["abnormalities", "PROBLEM", 91, 104], ["a slight weight loss", "PROBLEM", 164, 184], ["abnormalities", "OBSERVATION", 91, 104], ["slight", "OBSERVATION_MODIFIER", 166, 172], ["weight loss", "OBSERVATION", 173, 184]]], ["The i.p. infection with CVB 5 led to an increase in mean lung weight and a decrease in mean body weight on day 8 after virus exposure.", [["lung", "ANATOMY", 57, 61], ["body", "ANATOMY", 92, 96], ["infection", "DISEASE", 9, 18], ["CVB 5", "CHEMICAL", 24, 29], ["CVB 5", "CHEMICAL", 24, 29], ["CVB 5", "ORGANISM", 24, 29], ["lung", "ORGAN", 57, 61], ["body", "ORGANISM_SUBDIVISION", 92, 96], ["The i.p. infection", "PROBLEM", 0, 18], ["CVB", "PROBLEM", 24, 27], ["an increase in mean lung weight", "PROBLEM", 37, 68], ["a decrease in mean body weight", "PROBLEM", 73, 103], ["virus exposure", "PROBLEM", 119, 133], ["infection", "OBSERVATION", 9, 18], ["increase", "OBSERVATION_MODIFIER", 40, 48], ["mean lung weight", "OBSERVATION", 52, 68], ["decrease", "OBSERVATION_MODIFIER", 75, 83], ["mean body", "OBSERVATION_MODIFIER", 87, 96]]], ["Lung indexes of the 25-and 50mg/kg body weight/day groups were significantly lower than that of the viral control group, with the 50-mg group almost the same as the normal group.", [["Lung", "ANATOMY", 0, 4], ["body", "ANATOMY", 35, 39], ["Lung", "ORGAN", 0, 4], ["body", "ORGANISM_SUBDIVISION", 35, 39], ["Lung indexes", "TEST", 0, 12], ["indexes", "OBSERVATION_MODIFIER", 5, 12], ["normal", "OBSERVATION", 165, 171]]], ["There was no significant difference between the 50-mg and normal group in lung index (Fig. 4c) , and there was no significant difference among the groups of animals in mean heart weight (data not shown).Pathological evaluationFour animals of each group were sacrificed on day 8 after viral exposure, and tissue samples were obtained from the lungs, kidneys, liver, heart, and spleen for pathological examination.", [["lung", "ANATOMY", 74, 78], ["heart", "ANATOMY", 173, 178], ["tissue samples", "ANATOMY", 304, 318], ["lungs", "ANATOMY", 342, 347], ["kidneys", "ANATOMY", 349, 356], ["liver", "ANATOMY", 358, 363], ["heart", "ANATOMY", 365, 370], ["spleen", "ANATOMY", 376, 382], ["lung", "ORGAN", 74, 78], ["heart", "ORGAN", 173, 178], ["tissue samples", "CANCER", 304, 318], ["lungs", "ORGAN", 342, 347], ["kidneys", "ORGAN", 349, 356], ["liver", "ORGAN", 358, 363], ["heart", "ORGAN", 365, 370], ["spleen", "ORGAN", 376, 382], ["mean heart weight", "TEST", 168, 185], ["viral exposure", "TEST", 284, 298], ["tissue samples", "TEST", 304, 318], ["pathological examination", "TEST", 387, 411], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35], ["lung", "ANATOMY", 74, 78], ["index", "OBSERVATION", 79, 84], ["no", "UNCERTAINTY", 111, 113], ["significant", "OBSERVATION_MODIFIER", 114, 125], ["difference", "OBSERVATION_MODIFIER", 126, 136], ["heart", "ANATOMY", 173, 178], ["lungs", "ANATOMY", 342, 347], ["kidneys", "ANATOMY", 349, 356], ["liver", "ANATOMY", 358, 363], ["heart", "ANATOMY", 365, 370], ["spleen", "ANATOMY", 376, 382]]], ["As shown microscopically, the lungs of the viral control animals had thickened alveoli walls due to edema of alveolar epithelia, proliferation of interstitial cells, interstitial lymphocytes and macrophage inflammatory infiltration, and hemorrhage (Fig. 3a) .", [["lungs", "ANATOMY", 30, 35], ["alveoli walls", "ANATOMY", 79, 92], ["edema", "ANATOMY", 100, 105], ["alveolar epithelia", "ANATOMY", 109, 127], ["interstitial cells", "ANATOMY", 146, 164], ["interstitial lymphocytes", "ANATOMY", 166, 190], ["macrophage", "ANATOMY", 195, 205], ["edema", "DISEASE", 100, 105], ["hemorrhage", "DISEASE", 237, 247], ["lungs", "ORGAN", 30, 35], ["alveoli walls", "PATHOLOGICAL_FORMATION", 79, 92], ["edema", "PATHOLOGICAL_FORMATION", 100, 105], ["alveolar epithelia", "TISSUE", 109, 127], ["interstitial cells", "CELL", 146, 164], ["interstitial lymphocytes", "CELL", 166, 190], ["macrophage", "CELL", 195, 205], ["interstitial cells", "CELL_TYPE", 146, 164], ["interstitial lymphocytes", "CELL_TYPE", 166, 190], ["thickened alveoli walls", "PROBLEM", 69, 92], ["edema", "PROBLEM", 100, 105], ["alveolar epithelia", "PROBLEM", 109, 127], ["interstitial cells", "PROBLEM", 146, 164], ["interstitial lymphocytes", "PROBLEM", 166, 190], ["macrophage inflammatory infiltration", "PROBLEM", 195, 231], ["hemorrhage", "PROBLEM", 237, 247], ["microscopically", "OBSERVATION", 9, 24], ["lungs", "ANATOMY", 30, 35], ["viral", "OBSERVATION", 43, 48], ["thickened", "OBSERVATION", 69, 78], ["alveoli walls", "OBSERVATION", 79, 92], ["due to", "UNCERTAINTY", 93, 99], ["edema", "OBSERVATION", 100, 105], ["alveolar epithelia", "ANATOMY", 109, 127], ["proliferation", "OBSERVATION_MODIFIER", 129, 142], ["interstitial cells", "OBSERVATION", 146, 164], ["interstitial", "ANATOMY_MODIFIER", 166, 178], ["lymphocytes", "ANATOMY", 179, 190], ["macrophage", "OBSERVATION_MODIFIER", 195, 205], ["inflammatory infiltration", "OBSERVATION", 206, 231], ["hemorrhage", "OBSERVATION", 237, 247]]], ["The hearts of the viral control animals had denaturation of cardiac muscle cells (Fig. 3c) .", [["hearts", "ANATOMY", 4, 10], ["cardiac muscle cells", "ANATOMY", 60, 80], ["hearts", "ORGAN", 4, 10], ["animals", "ORGANISM", 32, 39], ["cardiac muscle cells", "CELL", 60, 80], ["cardiac muscle cells", "CELL_TYPE", 60, 80], ["denaturation of cardiac muscle cells", "PROBLEM", 44, 80], ["hearts", "ANATOMY", 4, 10], ["viral", "OBSERVATION", 18, 23], ["cardiac muscle", "ANATOMY", 60, 74], ["cells", "OBSERVATION", 75, 80]]], ["Tissue samples from the remaining animals did not have changes, except that the lungs of animals receiving 25 mg/kg body weight/day showed local hemorrhage (data not shown).Virological evaluationFour animals of each group were sacrificed on day 8 after viral exposure, and tissue samples were obtained from the lungs and hearts for virological examination.", [["Tissue samples", "ANATOMY", 0, 14], ["lungs", "ANATOMY", 80, 85], ["body", "ANATOMY", 116, 120], ["tissue samples", "ANATOMY", 273, 287], ["lungs", "ANATOMY", 311, 316], ["hearts", "ANATOMY", 321, 327], ["hemorrhage", "DISEASE", 145, 155], ["Tissue samples", "CANCER", 0, 14], ["animals", "ORGANISM", 34, 41], ["lungs", "ORGAN", 80, 85], ["animals", "ORGANISM", 89, 96], ["body", "ORGANISM_SUBDIVISION", 116, 120], ["animals", "ORGANISM", 200, 207], ["tissue samples", "CANCER", 273, 287], ["lungs", "ORGAN", 311, 316], ["hearts", "ORGAN", 321, 327], ["Tissue samples", "TEST", 0, 14], ["local hemorrhage", "PROBLEM", 139, 155], ["Virological evaluationFour animals", "TEST", 173, 207], ["viral exposure", "TEST", 253, 267], ["tissue samples", "TEST", 273, 287], ["virological examination", "TEST", 332, 355], ["lungs", "ANATOMY", 80, 85], ["hemorrhage", "OBSERVATION", 145, 155], ["lungs", "ANATOMY", 311, 316], ["hearts", "ANATOMY", 321, 327]]], ["The virus titers of lung and heart were significantly lower in mice receiving oral administration of Arbidol daily for 6 days than in the viral control group.", [["lung", "ANATOMY", 20, 24], ["heart", "ANATOMY", 29, 34], ["oral", "ANATOMY", 78, 82], ["Arbidol", "CHEMICAL", 101, 108], ["Arbidol", "CHEMICAL", 101, 108], ["lung", "ORGAN", 20, 24], ["heart", "ORGAN", 29, 34], ["mice", "ORGANISM", 63, 67], ["oral", "ORGANISM_SUBDIVISION", 78, 82], ["Arbidol", "SIMPLE_CHEMICAL", 101, 108], ["mice", "SPECIES", 63, 67], ["mice", "SPECIES", 63, 67], ["The virus titers", "TEST", 0, 16], ["Arbidol", "TREATMENT", 101, 108], ["the viral control group", "TREATMENT", 134, 157], ["virus", "OBSERVATION", 4, 9], ["lung", "ANATOMY", 20, 24], ["heart", "ANATOMY", 29, 34], ["significantly", "OBSERVATION_MODIFIER", 40, 53], ["lower", "OBSERVATION_MODIFIER", 54, 59]]], ["In the groups treated with Arbidol at 25 and 50 mg/kg body weight/day, the mean virus yields of lungs were around 10 2 and 10 1 viral plaques/ lung, respectively, whereas the yields in virus control mice were 10 4 viral plaques/lung (Fig. 4a) .", [["body", "ANATOMY", 54, 58], ["lungs", "ANATOMY", 96, 101], ["plaques", "ANATOMY", 134, 141], ["lung", "ANATOMY", 143, 147], ["plaques", "ANATOMY", 220, 227], ["lung", "ANATOMY", 228, 232], ["Arbidol", "CHEMICAL", 27, 34], ["Arbidol", "CHEMICAL", 27, 34], ["Arbidol", "SIMPLE_CHEMICAL", 27, 34], ["body", "ORGANISM_SUBDIVISION", 54, 58], ["lungs", "ORGAN", 96, 101], ["lung", "ORGAN", 143, 147], ["mice", "ORGANISM", 199, 203], ["lung", "ORGAN", 228, 232], ["mice", "SPECIES", 199, 203], ["mice", "SPECIES", 199, 203], ["Arbidol", "TREATMENT", 27, 34], ["the mean virus", "TEST", 71, 85], ["1 viral plaques/ lung", "PROBLEM", 126, 147], ["4 viral plaques", "PROBLEM", 212, 227], ["lungs", "ANATOMY", 96, 101], ["viral", "OBSERVATION_MODIFIER", 128, 133], ["plaques", "OBSERVATION", 134, 141], ["lung", "ANATOMY", 143, 147], ["viral", "OBSERVATION_MODIFIER", 214, 219], ["plaques", "OBSERVATION", 220, 227], ["lung", "ANATOMY", 228, 232]]], ["The mean virus yields of hearts were reduced to 10 3 and 10 2 viral plaques/heart, respectively, whereas the yields in viruscontrol mice were 10 5 viral plaques/heart (Fig. 4b) .DiscussionArbidol is a Russian-made broad-spectrum antiviral compound that has been shown to inhibit the fusion of influenza A and B viruses within endosomes [26] .", [["hearts", "ANATOMY", 25, 31], ["plaques", "ANATOMY", 68, 75], ["heart", "ANATOMY", 76, 81], ["plaques", "ANATOMY", 153, 160], ["heart", "ANATOMY", 161, 166], ["endosomes", "ANATOMY", 326, 335], ["DiscussionArbidol", "CHEMICAL", 178, 195], ["hearts", "ORGAN", 25, 31], ["heart", "ORGAN", 76, 81], ["viruscontrol", "ORGANISM", 119, 131], ["mice", "ORGANISM", 132, 136], ["heart", "ORGAN", 161, 166], ["DiscussionArbidol", "SIMPLE_CHEMICAL", 178, 195], ["influenza A", "ORGANISM", 293, 304], ["B viruses", "ORGANISM", 309, 318], ["endosomes", "CELLULAR_COMPONENT", 326, 335], ["mice", "SPECIES", 132, 136], ["mice", "SPECIES", 132, 136], ["B viruses", "SPECIES", 309, 318], ["2 viral plaques/heart", "PROBLEM", 60, 81], ["5 viral plaques", "PROBLEM", 145, 160], ["broad-spectrum antiviral compound", "TREATMENT", 214, 247], ["influenza A", "PROBLEM", 293, 304], ["mean virus", "OBSERVATION", 4, 14], ["hearts", "ANATOMY", 25, 31], ["plaques", "OBSERVATION", 68, 75], ["heart", "ANATOMY", 76, 81], ["plaques", "OBSERVATION", 153, 160], ["heart", "ANATOMY", 161, 166]]], ["Influenza-virusinduced fusion needs an acidic environment (pH 5.0).", [["Influenza", "PROBLEM", 0, 9], ["virusinduced fusion", "TREATMENT", 10, 29], ["pH", "TEST", 59, 61]]], ["A slight increase in pH can abolish the fusion process [27] .", [["A slight increase in pH", "PROBLEM", 0, 23], ["slight", "OBSERVATION_MODIFIER", 2, 8], ["increase", "OBSERVATION_MODIFIER", 9, 17], ["fusion", "OBSERVATION", 40, 46]]], ["Since Arbidol is a weak base, it may elevate endosomal pH and abrogate virus-endosome fusion.", [["endosomal", "ANATOMY", 45, 54], ["endosome", "ANATOMY", 77, 85], ["Arbidol", "CHEMICAL", 6, 13], ["Arbidol", "CHEMICAL", 6, 13], ["Arbidol", "SIMPLE_CHEMICAL", 6, 13], ["endosomal", "CELLULAR_COMPONENT", 45, 54], ["endosome", "CELLULAR_COMPONENT", 77, 85], ["a weak base", "PROBLEM", 17, 28], ["endosomal pH", "PROBLEM", 45, 57], ["abrogate virus", "PROBLEM", 62, 76], ["endosome fusion", "TREATMENT", 77, 92], ["endosomal pH", "OBSERVATION", 45, 57], ["endosome fusion", "OBSERVATION", 77, 92]]], ["Arbidol has also been shown to exert antiviral activity against other pH-dependent viruses, such as hepatitis B virus [18] and rhinovirus 14 [17] .DiscussionMoreover, Arbidol has demonstrated low toxicity upon single-dose oral administration in many animal models.", [["oral", "ANATOMY", 222, 226], ["Arbidol", "CHEMICAL", 0, 7], ["hepatitis B", "DISEASE", 100, 111], ["Arbidol", "CHEMICAL", 167, 174], ["toxicity", "DISEASE", 196, 204], ["Arbidol", "CHEMICAL", 0, 7], ["Arbidol", "CHEMICAL", 167, 174], ["Arbidol", "SIMPLE_CHEMICAL", 0, 7], ["hepatitis B virus", "ORGANISM", 100, 117], ["rhinovirus 14", "ORGANISM", 127, 140], ["Arbidol", "SIMPLE_CHEMICAL", 167, 174], ["oral", "ORGANISM_SUBDIVISION", 222, 226], ["hepatitis B virus", "SPECIES", 100, 117], ["hepatitis B virus", "SPECIES", 100, 117], ["Arbidol", "TREATMENT", 0, 7], ["antiviral activity", "TREATMENT", 37, 55], ["other pH-dependent viruses", "PROBLEM", 64, 90], ["hepatitis B virus", "PROBLEM", 100, 117], ["rhinovirus", "PROBLEM", 127, 137], ["Arbidol", "TREATMENT", 167, 174], ["low toxicity", "PROBLEM", 192, 204], ["single-dose oral administration", "TREATMENT", 210, 241], ["antiviral activity", "OBSERVATION", 37, 55], ["dependent", "OBSERVATION_MODIFIER", 73, 82], ["viruses", "OBSERVATION", 83, 90], ["low toxicity", "OBSERVATION_MODIFIER", 192, 204]]], ["The animal LD50 (50% lethal dose) was 687 mg/kg for mice, 3,000 mg/kg for rats, and 4,000 mg/kg for guinea pigs [28] .", [["mice", "ORGANISM", 52, 56], ["rats", "ORGANISM", 74, 78], ["guinea pigs", "ORGANISM", 100, 111], ["mice", "SPECIES", 52, 56], ["rats", "SPECIES", 74, 78], ["guinea pigs", "SPECIES", 100, 111], ["mice", "SPECIES", 52, 56], ["The animal LD50", "TREATMENT", 0, 15]]], ["A long-term Arbidol intake study also did not show pathologic changes in animals, as confirmed by clinical, hematological, biochemical, and pathological data.", [["Arbidol", "CHEMICAL", 12, 19], ["Arbidol", "CHEMICAL", 12, 19], ["Arbidol", "SIMPLE_CHEMICAL", 12, 19], ["A long-term Arbidol intake study", "TEST", 0, 32], ["pathologic changes in animals", "PROBLEM", 51, 80]]], ["At therapeutic doses, Arbidol possessed no mutagenic or teratogenic activity [28] .DiscussionIn this study, we tested the antiviral activity of Arbidol against CVB 5 , both in vitro and in vivo.", [["Arbidol", "CHEMICAL", 22, 29], ["Arbidol", "CHEMICAL", 144, 151], ["CVB 5", "CHEMICAL", 160, 165], ["Arbidol", "CHEMICAL", 22, 29], ["Arbidol", "CHEMICAL", 144, 151], ["Arbidol", "SIMPLE_CHEMICAL", 22, 29], ["Arbidol", "SIMPLE_CHEMICAL", 144, 151], ["CVB 5", "ORGANISM", 160, 165], ["Arbidol", "TREATMENT", 22, 29], ["mutagenic or teratogenic activity", "PROBLEM", 43, 76], ["this study", "TEST", 96, 106], ["Arbidol against CVB", "TREATMENT", 144, 163]]], ["Like other enteroviruses, CVB is a small RNA virus that replicates at 37\u00b0C, lacks a lipid envelope, and is stable at acid pH.", [["CVB", "CHEMICAL", 26, 29], ["CVB", "GENE_OR_GENE_PRODUCT", 26, 29], ["CVB", "SPECIES", 26, 29], ["other enteroviruses", "PROBLEM", 5, 24], ["CVB", "PROBLEM", 26, 29], ["a small RNA virus", "PROBLEM", 33, 50], ["a lipid envelope", "PROBLEM", 82, 98], ["enteroviruses", "OBSERVATION", 11, 24], ["small", "OBSERVATION_MODIFIER", 35, 40], ["RNA virus", "OBSERVATION", 41, 50], ["stable", "OBSERVATION_MODIFIER", 107, 113]]], ["When primarily cultured HEp-2 cells infected with CVB 3 were treated with Arbidol by different methods, arbidol was found to present potent antiviral activity against CVB 5 when added before and after infection.", [["HEp-2 cells", "ANATOMY", 24, 35], ["Arbidol", "CHEMICAL", 74, 81], ["arbidol", "CHEMICAL", 104, 111], ["CVB 5", "CHEMICAL", 167, 172], ["infection", "DISEASE", 201, 210], ["Arbidol", "CHEMICAL", 74, 81], ["arbidol", "CHEMICAL", 104, 111], ["HEp-2 cells", "CELL", 24, 35], ["CVB 3", "CELL", 50, 55], ["Arbidol", "SIMPLE_CHEMICAL", 74, 81], ["arbidol", "SIMPLE_CHEMICAL", 104, 111], ["CVB 5", "ORGANISM", 167, 172], ["HEp-2 cells", "CELL_LINE", 24, 35], ["CVB", "SPECIES", 50, 53], ["CVB", "SPECIES", 167, 170], ["HEp", "TEST", 24, 27], ["CVB", "TEST", 50, 53], ["Arbidol", "TREATMENT", 74, 81], ["arbidol", "TREATMENT", 104, 111], ["infection", "PROBLEM", 201, 210], ["potent", "OBSERVATION_MODIFIER", 133, 139], ["antiviral activity", "OBSERVATION", 140, 158], ["infection", "OBSERVATION", 201, 210]]], ["In a virucidal assay, Arbidol exhibited a strong effect against CVB 5 , and inhibited the CPE of CVB 5 on HEp-2 cells with a TI of 27.56, which is higher than other treatments.", [["HEp-2 cells", "ANATOMY", 106, 117], ["Arbidol", "CHEMICAL", 22, 29], ["Arbidol", "CHEMICAL", 22, 29], ["Arbidol", "SIMPLE_CHEMICAL", 22, 29], ["CVB 5", "ORGANISM", 64, 69], ["HEp-2 cells", "CELL", 106, 117], ["HEp-2 cells", "CELL_LINE", 106, 117], ["a virucidal assay", "TEST", 3, 20], ["Arbidol", "TREATMENT", 22, 29], ["CVB", "TEST", 64, 67], ["the CPE of CVB", "PROBLEM", 86, 100], ["HEp", "TEST", 106, 109], ["a TI", "TEST", 123, 127], ["higher", "OBSERVATION_MODIFIER", 147, 153]]], ["Those data suggested that Arbidol had a strong antiviral effect against CVB 5 during the adsorption step.", [["Arbidol", "CHEMICAL", 26, 33], ["CVB 5", "CHEMICAL", 72, 77], ["Arbidol", "CHEMICAL", 26, 33], ["Arbidol", "SIMPLE_CHEMICAL", 26, 33], ["CVB 5", "ORGANISM", 72, 77], ["Arbidol", "TREATMENT", 26, 33], ["CVB", "PROBLEM", 72, 75]]], ["We also cocultured HEp-2 cells with different doses of Arbidol after infection to study whether it still had an antiviral effect after virus entry into the host cell.", [["HEp-2 cells", "ANATOMY", 19, 30], ["cell", "ANATOMY", 161, 165], ["Arbidol", "CHEMICAL", 55, 62], ["infection", "DISEASE", 69, 78], ["Arbidol", "CHEMICAL", 55, 62], ["HEp-2 cells", "CELL", 19, 30], ["Arbidol", "SIMPLE_CHEMICAL", 55, 62], ["host cell", "CELL", 156, 165], ["HEp-2 cells", "CELL_LINE", 19, 30], ["host cell", "CELL_TYPE", 156, 165], ["HEp-2 cells", "TREATMENT", 19, 30], ["Arbidol", "TREATMENT", 55, 62], ["infection", "PROBLEM", 69, 78], ["an antiviral effect", "PROBLEM", 109, 128], ["infection", "OBSERVATION", 69, 78], ["antiviral effect", "OBSERVATION", 112, 128], ["host cell", "OBSERVATION", 156, 165]]], ["The MTT assay showed that Arbidol had inhibitory activity against CVB 5 , with an IC 50 of 6.62 lg/ml and a TI of 12.45 (see Table 1 ).", [["Arbidol", "CHEMICAL", 26, 33], ["MTT", "CHEMICAL", 4, 7], ["Arbidol", "CHEMICAL", 26, 33], ["Arbidol", "SIMPLE_CHEMICAL", 26, 33], ["CVB 5", "ORGANISM", 66, 71], ["The MTT assay", "TEST", 0, 13], ["CVB", "TEST", 66, 69], ["an IC", "TEST", 79, 84], ["a TI", "TEST", 106, 110]]], ["Semiquantitative RT-PCR data suggested that Arbidol prevented the synthesis of CVB 5 RNA in a dose-dependent manner.", [["Arbidol", "CHEMICAL", 44, 51], ["Arbidol", "CHEMICAL", 44, 51], ["Arbidol", "SIMPLE_CHEMICAL", 44, 51], ["CVB 5 RNA", "RNA", 79, 88], ["Semiquantitative RT-PCR data", "TEST", 0, 28], ["Arbidol", "TREATMENT", 44, 51], ["the synthesis of CVB 5 RNA", "TREATMENT", 62, 88]]], ["In short, our data demonstrate that Arbidol can induce durable antiviral activity in host cells, not only blocking the adsorption of viral particles onto cells but also inhibiting the late stage of the viral replication cycle.DiscussionTo study further whether Arbidol has antiviral ability against CVB 5 in vivo, we established a mouse model of infection.", [["cells", "ANATOMY", 90, 95], ["cells", "ANATOMY", 154, 159], ["Arbidol", "CHEMICAL", 36, 43], ["Arbidol", "CHEMICAL", 261, 268], ["infection", "DISEASE", 346, 355], ["Arbidol", "CHEMICAL", 36, 43], ["Arbidol", "CHEMICAL", 261, 268], ["Arbidol", "SIMPLE_CHEMICAL", 36, 43], ["host cells", "CELL", 85, 95], ["cells", "CELL", 154, 159], ["Arbidol", "SIMPLE_CHEMICAL", 261, 268], ["CVB 5", "ORGANISM", 299, 304], ["mouse", "ORGANISM", 331, 336], ["host cells", "CELL_TYPE", 85, 95], ["mouse", "SPECIES", 331, 336], ["CVB", "SPECIES", 299, 302], ["mouse", "SPECIES", 331, 336], ["Arbidol", "TREATMENT", 36, 43], ["durable antiviral activity in host cells", "PROBLEM", 55, 95], ["viral particles onto cells", "PROBLEM", 133, 159], ["DiscussionTo study", "TEST", 226, 244], ["Arbidol", "TREATMENT", 261, 268], ["antiviral ability", "TREATMENT", 273, 290], ["CVB", "PROBLEM", 299, 302], ["infection", "PROBLEM", 346, 355], ["durable", "OBSERVATION_MODIFIER", 55, 62], ["antiviral activity", "OBSERVATION", 63, 81], ["host cells", "OBSERVATION", 85, 95], ["viral particles", "OBSERVATION", 133, 148], ["late stage", "OBSERVATION_MODIFIER", 184, 194], ["viral replication cycle", "OBSERVATION", 202, 225], ["infection", "OBSERVATION", 346, 355]]], ["Mice infected with CVB 5 had some symptoms of circulatory failure such as cyanosis and lack of blood perfusion in the tail and auricle, and there was evidence of virus replication in the heart and lungs.", [["blood", "ANATOMY", 95, 100], ["tail", "ANATOMY", 118, 122], ["auricle", "ANATOMY", 127, 134], ["heart", "ANATOMY", 187, 192], ["lungs", "ANATOMY", 197, 202], ["circulatory failure", "DISEASE", 46, 65], ["cyanosis", "DISEASE", 74, 82], ["Mice", "ORGANISM", 0, 4], ["CVB 5", "ORGANISM", 19, 24], ["blood", "ORGANISM_SUBSTANCE", 95, 100], ["tail", "ORGANISM_SUBDIVISION", 118, 122], ["auricle", "ORGAN", 127, 134], ["heart", "ORGAN", 187, 192], ["lungs", "ORGAN", 197, 202], ["Mice", "SPECIES", 0, 4], ["some symptoms", "PROBLEM", 29, 42], ["circulatory failure", "PROBLEM", 46, 65], ["cyanosis", "PROBLEM", 74, 82], ["blood perfusion in the tail and auricle", "PROBLEM", 95, 134], ["virus replication in the heart and lungs", "PROBLEM", 162, 202], ["circulatory failure", "OBSERVATION", 46, 65], ["cyanosis", "OBSERVATION", 74, 82], ["blood perfusion", "OBSERVATION", 95, 110], ["tail", "ANATOMY", 118, 122], ["auricle", "ANATOMY", 127, 134], ["evidence of", "UNCERTAINTY", 150, 161], ["virus replication", "OBSERVATION", 162, 179], ["heart", "ANATOMY", 187, 192], ["lungs", "ANATOMY", 197, 202]]], ["Pathological findings were consistent with the results from virus isolation, and all viral control mice died by day 18 after infection.", [["infection", "DISEASE", 125, 134], ["mice", "ORGANISM", 99, 103], ["mice", "SPECIES", 99, 103], ["mice", "SPECIES", 99, 103], ["virus isolation", "TREATMENT", 60, 75], ["infection", "PROBLEM", 125, 134], ["consistent with", "UNCERTAINTY", 27, 42], ["infection", "OBSERVATION", 125, 134]]], ["Thus, CVB 5 infection in BALB/c mice is a suitable in vivo model to study in vivo antiviral activity.DiscussionOrally administered Arbidol at 50 mg/kg body weight/ day (once a day) after infection with Coxsackievirus B 5 for 6 days significantly enhanced survival rate, reduced virus yields and released pathological abnormalities in lungs and hearts.DiscussionIn summary, our results suggest that Arbidol can elicit protective antiviral activity against CVB 5 in vitro and in vivo.", [["body", "ANATOMY", 151, 155], ["lungs", "ANATOMY", 334, 339], ["hearts", "ANATOMY", 344, 350], ["infection", "DISEASE", 12, 21], ["Arbidol", "CHEMICAL", 131, 138], ["infection", "DISEASE", 187, 196], ["Coxsackievirus B 5", "CHEMICAL", 202, 220], ["Arbidol", "CHEMICAL", 398, 405], ["Arbidol", "CHEMICAL", 131, 138], ["Arbidol", "CHEMICAL", 398, 405], ["CVB 5", "ORGANISM", 6, 11], ["BALB/c mice", "ORGANISM", 25, 36], ["Arbidol", "SIMPLE_CHEMICAL", 131, 138], ["body", "ORGANISM_SUBDIVISION", 151, 155], ["Coxsackievirus B 5", "ORGANISM", 202, 220], ["lungs", "ORGAN", 334, 339], ["hearts", "ORGAN", 344, 350], ["Arbidol", "SIMPLE_CHEMICAL", 398, 405], ["CVB 5", "ORGANISM", 455, 460], ["mice", "SPECIES", 32, 36], ["mice", "SPECIES", 32, 36], ["Coxsackievirus B 5", "SPECIES", 202, 220], ["CVB", "SPECIES", 455, 458], ["CVB 5 infection in BALB", "PROBLEM", 6, 29], ["vivo antiviral activity", "TREATMENT", 77, 100], ["Arbidol", "TREATMENT", 131, 138], ["infection", "PROBLEM", 187, 196], ["Coxsackievirus B 5", "TREATMENT", 202, 220], ["survival rate", "TEST", 255, 268], ["reduced virus yields", "PROBLEM", 270, 290], ["released pathological abnormalities in lungs and hearts", "PROBLEM", 295, 350], ["Arbidol", "TREATMENT", 398, 405], ["protective antiviral activity", "TREATMENT", 417, 446], ["CVB", "PROBLEM", 455, 458], ["infection", "OBSERVATION", 12, 21], ["antiviral activity", "OBSERVATION", 82, 100], ["infection", "OBSERVATION", 187, 196], ["lungs", "ANATOMY", 334, 339], ["hearts", "ANATOMY", 344, 350]]], ["The exact antiviral mechanism of Arbidol is still Arbidol prevents the increase of both lung index and viral titer in CBV 5 -infected mice.", [["lung", "ANATOMY", 88, 92], ["Arbidol", "CHEMICAL", 33, 40], ["Arbidol", "CHEMICAL", 50, 57], ["Arbidol", "CHEMICAL", 33, 40], ["Arbidol", "CHEMICAL", 50, 57], ["Arbidol", "SIMPLE_CHEMICAL", 33, 40], ["Arbidol", "SIMPLE_CHEMICAL", 50, 57], ["lung", "ORGAN", 88, 92], ["CBV 5", "ORGANISM", 118, 123], ["mice", "ORGANISM", 134, 138], ["mice", "SPECIES", 134, 138], ["mice", "SPECIES", 134, 138], ["Arbidol", "TREATMENT", 33, 40], ["Arbidol", "TREATMENT", 50, 57], ["both lung index", "PROBLEM", 83, 98], ["viral titer", "TEST", 103, 114], ["CBV", "TEST", 118, 121], ["increase", "OBSERVATION_MODIFIER", 71, 79], ["both", "ANATOMY_MODIFIER", 83, 87], ["lung", "ANATOMY", 88, 92], ["index", "OBSERVATION", 93, 98], ["viral titer", "OBSERVATION", 103, 114]]], ["Four mice from each group were sacrificed on day 6 post-infection, and body weight and lung weight were used to calculate lung index (a).", [["body", "ANATOMY", 71, 75], ["lung", "ANATOMY", 87, 91], ["lung", "ANATOMY", 122, 126], ["infection", "DISEASE", 56, 65], ["mice", "ORGANISM", 5, 9], ["body", "ORGANISM_SUBDIVISION", 71, 75], ["lung", "ORGAN", 87, 91], ["lung", "ORGAN", 122, 126], ["mice", "SPECIES", 5, 9], ["mice", "SPECIES", 5, 9], ["infection", "PROBLEM", 56, 65], ["body weight", "TEST", 71, 82], ["lung weight", "TEST", 87, 98], ["lung index", "TEST", 122, 132], ["infection", "OBSERVATION", 56, 65], ["lung", "ANATOMY", 87, 91], ["lung", "ANATOMY", 122, 126], ["index", "OBSERVATION", 127, 132]]], ["Viral titer of lungs (b) and hearts (c) were determined by plaque assay.", [["lungs", "ANATOMY", 15, 20], ["hearts", "ANATOMY", 29, 35], ["plaque", "ANATOMY", 59, 65], ["Viral", "ORGANISM", 0, 5], ["lungs", "ORGAN", 15, 20], ["hearts", "ORGAN", 29, 35], ["Viral titer", "TEST", 0, 11], ["plaque assay", "TEST", 59, 71], ["lungs", "ANATOMY", 15, 20], ["hearts", "ANATOMY", 29, 35], ["plaque", "OBSERVATION", 59, 65]]], ["Asterisk means P \u00a00.05, NS no statistical difference unknown.", [["Asterisk", "TEST", 0, 8], ["P", "TEST", 15, 16], ["NS", "TREATMENT", 24, 26]]], ["Arbidol may play a significant role in medical countermeasures against CVB 5 infections.", [["Arbidol", "CHEMICAL", 0, 7], ["infections", "DISEASE", 77, 87], ["Arbidol", "CHEMICAL", 0, 7], ["Arbidol", "SIMPLE_CHEMICAL", 0, 7], ["CVB 5", "ORGANISM", 71, 76], ["Arbidol", "TREATMENT", 0, 7], ["medical countermeasures", "TREATMENT", 39, 62], ["CVB 5 infections", "PROBLEM", 71, 87]]]]}